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Preamble
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the detection, management, or prevention of
disease states. Rigorous and expert analysis of the available
data documenting absolute and relative benefits and risks of
those procedures and therapies can produce helpful guide-
lines that improve the effectiveness of care, optimize patient
outcomes, and favorably affect the overall cost of care by
focusing resources on the most effective strategies.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the production of such guidelines in the area of
cardiovascular disease since 1980. The American College of
Cardiology (ACC)/AHA Task Force on Practice Guidelines,
whose charge is to develop, update, or revise practice
guidelines for important cardiovascular diseases and pro-
cedures, directs this effort. Writing committees are
charged with the task of performing an assessment of the
evidence and acting as an independent group of authors to
develop, update, or revise written recommendations for
clinical practice.
Experts in the subject under consideration have been
selected from both organizations to examine subject-specific
data and write guidelines. The process includes additional
representatives from other medical practitioner and specialty
groups when appropriate. Writing committees are specifically
charged to perform a formal literature review, weigh the
strength of evidence for or against a particular treatment or
procedure, and include estimates of expected health
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outcomes where data exist. Patient-speciﬁc modiﬁers, co-
morbidities, and issues of patient preference that might
inﬂuence the choice of particular tests or therapies are
considered, as well as frequency of follow-up and cost
effectiveness. When available, information from studies on
cost will be considered; however, review of data on efﬁcacy
and clinical outcomes will constitute the primary basis for
preparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines
makes every effort to avoid any actual, potential, or per-
ceived conﬂict of interest that may arise as a result of an
industry relationship or personal interest of a member of the
Writing Committee. Speciﬁcally, all members of the Writ-
ing Committee, as well as peer reviewers of the document,
were asked to provide disclosure statements of all such
relationships that may be perceived as real or potential
conﬂicts of interest. Writing Committee members are also
strongly encouraged to declare a previous relationship with
industry that may be perceived as relevant to guideline
development. If a Writing Committee member develops a
new relationship with industry during their tenure, they are
required to notify guideline staff in writing. The continued
participation of the Writing Committee member will be
reviewed. These statements are reviewed by the parent task
force, reported orally to all members of the Writing Com-
mittee at each meeting, and updated and reviewed by the
Writing Committee as changes occur. Please refer to the
methodology manual for ACC/AHA Guideline Writing
Committees further description of relationships with indus-
try policy, available on the ACC and AHA World Wide
Web sites (http://www.acc.org/qualityandscience/clinical/
manual/manual%5Fi.htm and http://www.circ.ahajournals.
org/manual/). See Appendix 1 for a list of Writing Committee
member relationships with industry and Appendix 2 for a
listing of peer reviewer relationships with industry that are
pertinent to this guideline.
These practice guidelines are intended to assist health
care providers in clinical decision making by describing a
range of generally acceptable approaches for the diagnosis,
management, and prevention of speciﬁc diseases or condi-
tions. Clinical decision making should consider the quality
and availability of expertise in the area where care is
provided. These guidelines attempt to deﬁne practices that
meet the needs of most patients in most circumstances.
These guideline recommendations reﬂect a consensus of
expert opinion after a thorough review of the available,
current scientiﬁc evidence and are intended to improve
patient care.
Patient adherence to prescribed and agreed upon medical
regimens and lifestyles is an important aspect of treatment.
Prescribed courses of treatment in accordance with these
recommendations will only be effective if they are followed.
Since lack of patient understanding and adherence may
adversely affect treatment outcomes, physicians and other
health care providers should make every effort to engage the
patient in active participation with prescribed medical reg-
imens and lifestyles.
If these guidelines are used as the basis for regulatory/
payer decisions, the ultimate goal is quality of care and
serving the patient’s best interests. The ultimate judgment
regarding care of a particular patient must be made by the
health care provider and patient in light of all the circum-
stances presented by that patient. There are circumstances
in which deviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/
AHA Task Force on Practice Guidelines and will be
considered current unless they are updated, revised, or
sunsetted and withdrawn from distribution. The executive
summary and recommendations are published in the August
7, 2007, issue of the Journal of the American College of
Cardiology and August 7, 2007, issue of Circulation. The
full- text guidelines are e-published in the same issue of the
journals noted above, as well as posted on the ACC
(www.acc.org) and AHA (www.americanheart.org) World
Wide Web sites. Copies of the full text and the executive
summary are available from both organizations.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Organization of Committee and
Evidence Review
The ACC/AHA Task Force on Practice Guidelines was
formed to make recommendations regarding the diagnosis and
treatment of patients with known or suspected cardiovascular
disease (CVD). Coronary artery disease (CAD) is the leading
cause of death in the United States. Unstable angina (UA) and
the closely related condition of non–ST-segment elevation
myocardial infarction (NSTEMI) are very common manifes-
tations of this disease.
The committee members reviewed and compiled pub-
lished reports through a series of computerized literature
searches of the English-language literature since 2002 and a
ﬁnal manual search of selected articles. Details of the
speciﬁc searches conducted for particular sections are pro-
vided when appropriate. Detailed evidence tables were
developed whenever necessary with the speciﬁc criteria
outlined in the individual sections. The recommendations
made were based primarily on these published data. The
weight of the evidence was ranked highest (A) to lowest
(C). The ﬁnal recommendations for indications for a diag-
nostic procedure, a particular therapy, or an intervention in
patients with UA/NSTEMI summarize both clinical evi-
dence and expert opinion.
Classiﬁcation of Recommendations
The schema for classiﬁcation of recommendations and level
of evidence is summarized in Table 1, which also illustrates
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how the grading system provides an estimate of the size of
the treatment effect and an estimate of the certainty of the
treatment effect.
A complete list of the thousands of publications on
various aspects of this subject is beyond the scope of these
guidelines; only selected references are included. The
Committee consisted of acknowledged experts in general
internal medicine representing the American College of
Physicians (ACP), family medicine from the American
Academy of Family Physicians (AAFP), emergency med-
icine from the American College of Emergency Physi-
cians (ACEP), thoracic surgery from the Society of
Thoracic Surgeons (STS), interventional cardiology from
the Society for Cardiovascular Angiography and Inter-
ventions (SCAI), and general and critical care cardiology,
as well as individuals with recognized expertise in more
specialized areas, including noninvasive testing, preven-
tive cardiology, coronary intervention, and cardiovascular
surgery. Both the academic and private practice sectors
were represented. This document was reviewed by 2
outside reviewers nominated by each of the ACC and
AHA and by 49 peer reviewers. These guidelines will be
considered current unless the Task Force revises them or
withdraws them from distribution.
These guidelines overlap several previously published ACC/
AHA practice guidelines, including the ACC/AHA Guide-
lines for the Management of Patients With ST-Elevation
Myocardial Infarction (1), the ACC/AHA/SCAI 2005
Guideline Update for Percutaneous Coronary Intervention (2),
the AHA/ACC Guidelines for Secondary Prevention for
Patients With Coronary and Other Atherosclerotic Vascular
Disease: 2006 Update (3), and the ACC/AHA 2002 Guide-
line Update for the Management of Patients With Chronic
Stable Angina (4).
Table 1. Applying Classiﬁcation of Recommendations and Level of Evidence†
Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not
lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline recommendations have been written in full sentences that express
a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the
full intent of the recommendation. It is hoped that this will increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
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1.2. Purpose of These Guidelines
These guidelines address the diagnosis and management of
patients with UA and the closely related condition of
NSTEMI. These life-threatening disorders are a major
cause of emergency medical care and hospitalization in the
United States. In 2004, the National Center for Health
Statistics reported 1,565,000 hospitalizations for primary or
secondary diagnosis of an acute coronary syndrome (ACS),
669,000 for UA and 896,000 for myocardial infarction (MI)
(5). The average age of a person having a ﬁrst heart attack
is 65.8 years for men and 70.4 years for women, and 43% of
ACS patients of all ages are women. In 2003, there were
4,497,000 visits to US emergency departments (EDs) for
primary diagnosis of CVD (5). The prevalence of this
presentation of CVD ensures that many health care provid-
ers who are not cardiovascular specialists will encounter
patients with UA/NSTEMI in the course of the treatment
of other diseases, especially in outpatient and ED settings.
These guidelines are intended to assist both cardiovascular
specialists and nonspecialists in the proper evaluation and
management of patients with an acute onset of symptoms
suggestive of these conditions. These clinical practice guide-
lines also provide recommendations and supporting evi-
dence for the continued management of patients with these
conditions in both inpatient and outpatient settings. The
diagnostic and therapeutic strategies that are recommended
are supported by the best available evidence and expert
opinion. The application of these principles with carefully
reasoned clinical judgment reduces but does not eliminate
the risk of cardiac damage and death in patients who present
with symptoms suggestive of UA/NSTEMI.
1.3. Overview of the Acute Coronary Syndromes
1.3.1. Deﬁnition of Terms
Unstable angina/NSTEMI constitutes a clinical syndrome
subset of the ACS that is usually, but not always, caused by
atherosclerotic CAD and is associated with an increased risk
of cardiac death and subsequent MI. In the spectrum of
ACS, UA/NSTEMI is deﬁned by electrocardiographic
(ECG) ST-segment depression or prominent T-wave in-
version and/or positive biomarkers of necrosis (e.g., tropo-
nin) in the absence of ST-segment elevation and in an
appropriate clinical setting (chest discomfort or anginal
equivalent) (Table 2, Fig. 1). The results of angiographic
Table 2. Guidelines for the Identiﬁcation of ACS Patients by ED Registration Clerks or Triage Nurses
Registration/clerical staff
Patients with the following chief complaints require immediate assessment by the triage nurse and should be referred for further evaluation:
•Chest pain, pressure, tightness, or heaviness; pain that radiates to neck, jaw, shoulders, back, or 1 or both arms
•Indigestion or “heartburn”; nausea and/or vomiting associated with chest discomfort
•Persistent shortness of breath
•Weakness, dizziness, lightheadedness, loss of consciousness
Triage nurse
Patients with the following symptoms and signs require immediate assessment by the triage nurse for the initiation of the ACS protocol:
•Chest pain or severe epigastric pain, nontraumatic in origin, with components typical of myocardial ischemia or MI:
X Central/substernal compression or crushing chest pain
X Pressure, tightness, heaviness, cramping, burning, aching sensation
X Unexplained indigestion, belching, epigastric pain
X Radiating pain in neck, jaw, shoulders, back, or 1 or both arms
•Associated dyspnea
•Associated nausea and/or vomiting
•Associated diaphoresis
If these symptoms are present, obtain stat ECG.
Medical history
The triage nurse should take a brief, targeted, initial history with an assessment of current or past history of:
•CABG, PCI, CAD, angina on effort, or MI
•NTG use to relieve chest discomfort
•Risk factors, including smoking, hyperlipidemia, hypertension, diabetes mellitus, family history, and cocaine or methamphetamine use
•Regular and recent medication use
The brief history must not delay entry into the ACS protocol.
Special considerations
Women may present more frequently than men with atypical chest pain and symptoms.
Diabetic patients may have atypical presentations due to autonomic dysfunction.
Elderly patients may have atypical symptoms such as generalized weakness, stroke, syncope, or a change in mental status.
Adapted from National Heart Attack Alert Program. Emergency Department: rapid identiﬁcation and treatment of patients with acute myocardial infarction. Bethesda, MD: US Department of Health and
Human Services. US Public Health Service. National Institutes of Health. National Heart, Lung and Blood Institute, September 1993. NIH Publication No. 93-3278 (6).
ACS acute coronary syndrome; CABG coronary artery bypass graft surgery; CAD coronary artery disease; ECG electrocardiogram; ED emergency department; MImyocardial infarction; NTG
 nitroglycerin; PCI  percutaneous coronary intervention.
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Figure 1. Acute Coronary Syndromes
The top half of the ﬁgure illustrates the chronology of the interface between the patient and the clinician through the progression of plaque formation, onset, and complica-
tions of UA/NSTEMI, along with relevant management considerations at each stage. The longitudinal section of an artery depicts the “timeline” of atherogenesis from (1) a
normal artery to (2) lesion initiation and accumulation of extracellular lipid in the intima, to (3) the evolution to the ﬁbrofatty stage, to (4) lesion progression with procoagu-
lant expression and weakening of the ﬁbrous cap. An acute coronary syndrome (ACS) develops when the vulnerable or high-risk plaque undergoes disruption of the ﬁbrous
cap (5); disruption of the plaque is the stimulus for thrombogenesis. Thrombus resorption may be followed by collagen accumulation and smooth muscle cell growth (6).
After disruption of a vulnerable or high-risk plaque, patients experience ischemic discomfort that results from a reduction of ﬂow through the affected epicardial coronary
artery. The ﬂow reduction may be caused by a completely occlusive thrombus (bottom half, right side) or subtotally occlusive thrombus (bottom half, left side). Patients with
ischemic discomfort may present with or without ST-segment elevation on the ECG. Among patients with ST-segment elevation, most (thick white arrow in bottom panel) ulti-
mately develop a Q-wave MI (QwMI), although a few (thin white arrow) develop a non–Q-wave MI (NQMI). Patients who present without ST-segment elevation are suffering
from either unstable angina (UA) or a non–ST-segment elevation MI (NSTEMI) (thick red arrows), a distinction that is ultimately made on the basis of the presence or
absence of a serum cardiac marker such as CK-MB or a cardiac troponin detected in the blood. Most patients presenting with NSTEMI ultimately develop a NQMI on the
ECG; a few may develop a QwMI. The spectrum of clinical presentations ranging from UA through NSTEMI and STEMI is referred to as the acute coronary syndromes. This
UA/NSTEMI guideline, as diagrammed in the upper panel, includes sections on initial management before UA/NSTEMI, at the onset of UA/NSTEMI, and during the hospital
phase. Secondary prevention and plans for long-term management begin early during the hospital phase of treatment. *Positive serum cardiac marker. Modiﬁed with permis-
sion from Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365 (7); © 2001 Lippincott, Williams & Wilkins; The Lancet,
358, Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines, 1553–8. Copyright 2001, with permission from
Elsevier (8); and Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000;83:361–6 (9). © 2000 Lippincott, Williams & Wilkins. CK-MB  MB fraction of
creatine kinase; Dx  diagnosis; ECG  electrocardiogram.
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and angioscopic studies suggest that UA/NSTEMI often
results from the disruption or erosion of an atherosclerotic
plaque and a subsequent cascade of pathological processes
that decrease coronary blood ﬂow. Most patients who die
during UA/NSTEMI do so because of sudden death or the
development (or recurrence) of acute MI. The efﬁcient
diagnosis and optimal management of these patients must
derive from information readily available at the time of the
initial clinical presentation. The clinical presentation of
patients with a life-threatening ACS often overlaps that of
patients subsequently found not to have CAD. Moreover,
some forms of MI cannot always be differentiated from UA
at the time of initial presentation.
“Acute coronary syndrome” has evolved as a useful
operational term to refer to any constellation of clinical
symptoms that are compatible with acute myocardial isch-
emia (Fig. 1). It encompasses MI (ST-segment elevation
and depression, Q wave and non-Q wave) and UA. These
guidelines focus on 2 components of this syndrome: UA and
NSTEMI. In practice, the term “possible ACS” is often
assigned ﬁrst by ancillary personnel, such as emergency
medical technicians and triage nurses, early in the evaluation
process. A guideline of the National Heart Attack Alert
Program (6) summarizes the clinical information needed to
make the diagnosis of possible ACS at the earliest phase of
clinical evaluation (Table 2). The implication of this early
diagnosis for clinical management is that a patient who is
considered to have an ACS should be placed in an environ-
ment with continuous ECG monitoring and deﬁbrillation
capability, where a 12-lead ECG can be obtained expeditiously
and deﬁnitively interpreted, ideally within 10 min of arrival in
the ED. The most urgent priority of early evaluation is to
identify patients with ST-elevation MI (STEMI) who should
be considered for immediate reperfusion therapy and to rec-
ognize other potentially catastrophic causes of patient symp-
toms, such as aortic dissection.
Patients diagnosed as having STEMI are excluded from
management according to these guidelines and should be
managed as indicated according to the ACC/AHA Guide-
lines for the Management of Patients With ST-Elevation
Myocardial Infarction (1,10). Similarly, management of
electrocardiographic true posterior MI, which can masquer-
ade as NSTEMI, is covered in the STEMI guidelines (1).
The management of patients who experience periprocedural
myocardial damage, as reﬂected in the release of biomarkers
of necrosis, such as the MB isoenzyme of creatine kinase
(CK-MB) or troponin, also is not considered here.
Patients with MI and with deﬁnite ischemic ECG changes
for whom acute reperfusion therapy is not suitable should be
diagnosed and managed as patients with UA. The residual
group of patients with an initial diagnosis of ACS will include
many patients who will ultimately be proven to have a
noncardiac cause for the initial clinical presentation that was
suggestive of ACS. Therefore, at the conclusion of the initial
evaluation, which is frequently performed in the ED but
sometimes occurs during the initial hours of inpatient hospi-
talization, each patient should have a provisional diagnosis of
1) ACS (Fig. 1), which in turn is classiﬁed as a) STEMI, a
condition for which immediate reperfusion therapy (ﬁbrinoly-
sis or percutaneous coronary intervention [PCI]) should be
considered, b) NSTEMI, or c) UA (deﬁnite, probable, or
possible); 2) a non-ACS cardiovascular condition (e.g., acute
pericarditis); 3) a noncardiac condition with another speciﬁc
disease (e.g., chest pain secondary to esophageal spasm); or 4)
a noncardiac condition that is undeﬁned. In addition, the
initial evaluation should be used to determine risk and to treat
life-threatening events.
In these guidelines, UA and NSTEMI are considered to be
closely related conditions whose pathogenesis and clinical
presentations are similar but of differing severity; that is, they
differ primarily in whether the ischemia is severe enough to
cause sufﬁcient myocardial damage to release detectable quan-
tities of a marker of myocardial injury, most commonly
troponin I (TnI), troponin T (TnT), or CK-MB. Once it has
been established that no biomarker of myocardial necrosis has
been released (based on 2 or more samples collected at least 6 h
apart, with a reference limit of the 99th percentile of the
normal population) (11), the patient with ACS may be
considered to have experienced UA, whereas the diagnosis of
NSTEMI is established if a biomarker has been released.
Markers of myocardial injury can be detected in the blood-
stream with a delay of up to several hours after the onset of
ischemic chest pain, which then allows the differentiation
between UA (i.e., no biomarkers in circulation; usually tran-
sient, if any, ECG changes of ischemia) and NSTEMI (i.e.,
elevated biomarkers). Thus, at the time of presentation, pa-
tients with UA and NSTEMI can be indistinguishable and
therefore are considered together in these guidelines.
1.3.2. Pathogenesis of UA/NSTEMI
These conditions are characterized by an imbalance between
myocardial oxygen supply and demand. They are not a
speciﬁc disease, such as pneumococcal pneumonia, but
rather a syndrome, analogous to hypertension. A relatively
few nonexclusive causes are recognized (12) (Table 3).
The most common mechanisms involve an imbalance
that is caused primarily by a reduction in oxygen supply to
the myocardium, whereas with the ﬁfth mechanism noted
below, the imbalance is principally due to increased myo-
cardial oxygen requirements, usually in the presence of a
ﬁxed, restricted oxygen supply:
• The most common cause of UA/NSTEMI is reduced
myocardial perfusion that results from coronary artery
narrowing caused by a thrombus that developed on a
disrupted atherosclerotic plaque and is usually nonocclu-
sive. Microembolization of platelet aggregates and com-
ponents of the disrupted plaque are believed to be
responsible for the release of myocardial markers in many
of these patients. An occlusive thrombus/plaque also can
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cause this syndrome in the presence of an extensive
collateral blood supply.
• The most common underlying molecular and cellular
pathophysiology of disrupted atherosclerotic plaque is
arterial inﬂammation, caused by noninfectious (e.g., ox-
idized lipids) and, possibly, infectious stimuli, which can
lead to plaque expansion and destabilization, rupture or
erosion, and thrombogenesis. Activated macrophages
and T lymphocytes located at the shoulder of a plaque
increase the expression of enzymes such as metallopro-
teinases that cause thinning and disruption of the plaque,
which in turn can lead to UA/NSTEMI.
• A less common cause is dynamic obstruction, which may
be triggered by intense focal spasm of a segment of an
epicardial coronary artery (Prinzmetal’s angina) (see Sec-
tion 6.7). This local spasm is caused by hypercontractility
of vascular smooth muscle and/or by endothelial dysfunc-
tion. Large-vessel spasm can occur on top of obstructive
or destabilized plaque, resulting in angina of “mixed”
origin or UA/NSTEMI. Dynamic coronary obstruction
can also be caused by diffuse microvascular dysfunction;
for example, due to endothelial dysfunction or the ab-
normal constriction of small intramural resistance vessels.
Coronary spasm also is the presumed mechanism under-
lying cocaine-induced UA/NSTEMI.
• A third cause of UA/NSTEMI is severe narrowing without
spasm or thrombus. This occurs in some patients with
progressive atherosclerosis or with restenosis after a PCI.
• A fourth cause of UA/NSTEMI is coronary artery
dissection (e.g., as a cause of ACS in peripartal women).
• The ﬁfth mechanism is secondary UA, in which the
precipitating condition is extrinsic to the coronary arterial
bed. Patients with secondary UA usually, but not always,
have underlying coronary atherosclerotic narrowing that
limits myocardial perfusion, and they often have chronic
stable angina. Secondary UA is precipitated by conditions
that 1) increase myocardial oxygen requirements, such as
fever, tachycardia, or thyrotoxicosis; 2) reduce coronary
blood ﬂow, such as hypotension; or 3) reduce myocardial
oxygen delivery, such as anemia or hypoxemia.
These causes of UA/NSTEMI are not mutually exclusive.
1.3.3. Presentations of UA and NSTEMI
There are 3 principal presentations of UA: 1) rest angina
(angina commencing when the patient is at rest), 2) new-
onset (less than 2 months) severe angina, and 3) increasing
angina (increasing in intensity, duration, and/or frequency)
(Table 4) (14). Criteria for the diagnosis of UA are based on
the duration and intensity of angina as graded according to
the Canadian Cardiovascular Society classiﬁcation (Table 5)
(15). Non–ST-elevation MI generally presents as pro-
longed, more intense rest angina or angina equivalent.
1.4. Management Before UA/NSTEMI and Onset of
UA/NSTEMI
The ACS spectrum (UA/MI) has a variable but potentially
serious prognosis. The major risk factors for development of
coronary heart disease (CHD) and UA/NSTEMI are well
established. Clinical trials have demonstrated that modiﬁ-
Table 3. Causes of UA/NSTEMI*
Thrombus or thromboembolism, usually arising on disrupted or eroded plaque
● Occlusive thrombus, usually with collateral vessels†
● Subtotally occlusive thrombus on pre-existing plaque
● Distal microvascular thromboembolism from plaque-associated thrombus
Thromboembolism from plaque erosion
● Non–plaque-associated coronary thromboembolism
Dynamic obstruction (coronary spasm‡ or vasoconstriction) of epicardial and/
or microvascular vessels
Progressive mechanical obstruction to coronary ﬂow
Coronary arterial inﬂammation
Secondary UA
Coronary artery dissection§
*These causes are not mutually exclusive; some patients have 2 or more causes. †DeWood MA,
Stifter WF, Simpson CS, et al. Coronary arteriographic ﬁndings soon after non–Q-wave myocardial
infarction. N Engl J Med 1986;315:417–23 (13). ‡May occur on top of an atherosclerotic plaque,
producingmissed-etiology angina or UA/NSTEMI. §Rare. Modiﬁed with permission fromBraunwald E.
Unstable angina: an etiologic approach to management. Circulation 1998;98:2219–22 (12).
UA  unstable angina; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.
Table 4. Three Principal Presentations of UA
Class Presentation
Rest angina* Angina occurring at rest and prolonged, usually greater
than 20 min
New-onset angina New-onset angina of at least CCS class III severity
Increasing angina Previously diagnosed angina that has become
distinctly more frequent, longer in duration, or lower
in threshold (i.e., increased by 1 or more CCS class
to at least CCS class III severity)
*Patients with non–ST-elevated myocardial infarction usually present with angina at rest. Adapted
with permission from Braunwald E. Unstable angina: a classiﬁcation. Circulation 1989;80:410–4
(14).
CCS  Canadian Cardiovascular Society classiﬁcation; UA  unstable angina.
Table 5. Grading of Angina Pectoris
According to CCS Classiﬁcation
Class Description of Stage
I “Ordinary physical activity does not cause . . . angina,” such as
walking or climbing stairs. Angina occurs with strenuous, rapid,
or prolonged exertion at work or recreation.
II “Slight limitation of ordinary activity.” Angina occurs on walking or
climbing stairs rapidly; walking uphill; walking or stair climbing
after meals; in cold, in wind, or under emotional stress; or only
during the few hours after awakening. Angina occurs on
walking more than 2 blocks on the level and climbing more
than 1 ﬂight of ordinary stairs at a normal pace and under
normal conditions.
III “Marked limitations of ordinary physical activity.” Angina occurs
on walking
1 to 2 blocks on the level and climbing 1 ﬂight of stairs under
normal conditions and at a normal pace.
IV “Inability to carry on any physical activity without discomfort—
anginal symptoms may be present at rest.”
Adapted with permission from Campeau L. Grading of angina pectoris (letter). Circulation
1976;54:522–3 (15).
CCS  Canadian Cardiovascular Society.
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cation of those risk factors can prevent the development of
CHD (primary prevention) or reduce the risk of experienc-
ing UA/NSTEMI in patients who have CHD (secondary
prevention). All practitioners should emphasize prevention
and refer patients to primary care providers for appropriate
long-term preventive care. In addition to internists and
family physicians, cardiologists have an important leader-
ship role in primary (and secondary) prevention efforts.
1.4.1. Identiﬁcation of Patients at Risk of UA/NSTEMI
CLASS I
1. Primary care providers should evaluate the presence and status of
control of major risk factors for CHD for all patients at regular
intervals (approximately every 3 to 5 years). (Level of Evidence: C)
2. Ten-year risk (National Cholesterol Education Program [NCEP]
global risk) of developing symptomatic CHD should be calculated
for all patients who have 2 or more major risk factors to assess
the need for primary prevention strategies (16,17). (Level of
Evidence: B)
3. Patients with established CHD should be identiﬁed for secondary
prevention efforts, and patients with a CHD risk equivalent (e.g.,
atherosclerosis in other vascular beds, diabetes mellitus, chronic
kidney disease, or 10-year risk greater than 20% as calculated by
Framingham equations) should receive equally intensive risk factor
intervention as those with clinically apparent CHD. (Level of Evi-
dence: A)
Major risk factors for developing CHD (i.e., smoking,
family history, adverse lipid proﬁles, diabetes mellitus, and
elevated blood pressure) have been established from large,
long-term epidemiological studies (18,19). These risk fac-
tors are predictive for most populations in the United States.
Primary and secondary prevention interventions aimed at
these risk factors are effective when used properly. They can
also be costly in terms of primary care provider time,
diversion of attention from other competing and important
health care needs, and expense, and they may not be
effective unless targeted at higher-risk patients (20). It is
therefore important for primary care providers to make the
identiﬁcation of patients at risk, who are most likely to
beneﬁt from primary prevention, a routine part of everyone’s
health care. The Third Report of the NCEP provides
guidance on identifying such patients (18). Furthermore,
the Writing Committee supports public health efforts to
reach all adults at risk, not just those under the care of a
primary care physician.
Patients with 2 or more risk factors who are at increased
10-year and lifetime risk will have the greatest beneﬁt from
primary prevention, but any individual with a single elevated
risk factor is a candidate for primary prevention (19). Waiting
until the patient develops multiple risk factors and increased
10-year risk contributes to the high prevalence of CHD in
the United States (18,21). Such patients should have their
risk speciﬁcally calculated by any of the several valid prog-
nostic tools available in print (18,22), on the Internet (23),
or for use on a personal computer or personal digital
assistant (PDA) (18). Patients’ speciﬁc risk levels determine
the absolute risk reductions they can obtain from preventive
interventions and guide selection and prioritization of those
interventions. For example, target levels for lipid lowering
and for antihypertensive therapy vary by patients’ baseline
risk. A speciﬁc risk number can also serve as a powerful
educational intervention to motivate lifestyle changes (24).
The detection of subclinical atherosclerosis by noninva-
sive imaging represents a new, evolving approach for reﬁn-
ing individual risk in asymptomatic individuals beyond
traditional risk factor assessment alone. A recent AHA
scientiﬁc statement indicates that it may be reasonable to
measure atherosclerosis burden using electron-beam or mul-
tidetector computed tomography (CT) in clinically selected
intermediate-CAD-risk individuals (e.g., those with a 10%
to 20% Framingham 10-year risk estimate) to reﬁne clinical
risk prediction and to select patients for aggressive target
values for lipid-lowering therapies (Class IIb, Level of
Evidence: B) (25).
1.4.2. Interventions to Reduce Risk of UA/NSTEMI
The beneﬁts of prevention of UA/NSTEMI in patients
with CHD are well documented and of large magnitude
(3,21,26–28). Patients with established CHD should be
identiﬁed for secondary prevention efforts, and patients with
a CHD risk equivalent should receive equally intensive risk
factor intervention for high-risk primary prevention regard-
less of sex (29). Patients with diabetes mellitus and periph-
eral vascular disease have baseline risks of UA/NSTEMI
similar to patients with known CHD, as do patients with
multiple risk factors that predict a calculated risk of greater
than 20% over 10 years as estimated by the Framingham
equations (18). Such patients should be considered to have
the risk equivalents of CHD, and they can be expected to
have an absolute beneﬁt similar to those with established
CHD.
All patients who use tobacco should be encouraged to
quit and should be provided with help in quitting at every
opportunity (30). Recommendations by a clinician to avoid
tobacco can have a meaningful impact on the rate of
cessation of tobacco use. The most effective strategies for
encouraging quitting are those that identify the patient’s
level or stage of readiness and provide information, support,
and, if necessary, pharmacotherapy targeted at the individ-
ual’s readiness and speciﬁc needs (26,31). Pharmacotherapy
may include nicotine replacement or withdrawal-relieving
medication such as bupropion. Varenicline, a nicotine ace-
tylcholine receptor partial antagonist, is a newly approved
nonnicotine replacement therapy for tobacco avoidance
(32–35). Many patients require several attempts before they
succeed in quitting permanently (36,37). Additional discus-
sion in this area can be found in other contemporary
documents (e.g., the ACC/AHA 2002 Guideline Update
for the Management of Patients With Chronic Stable
Angina [4]).
All patients should be instructed in and encouraged to
maintain appropriate low-saturated-fat, low-trans-fat, and
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low-cholesterol diets high in soluble (viscous) ﬁber and rich
in vegetables, fruits, and whole grains. All patients also
should be encouraged to be involved with a regular aerobic
exercise program, including 30 to 60 min of moderate-
intensity physical activity (such as brisk walking) on most
and preferably all days of the week (3,38). For those who
need to weigh less, an appropriate balance of increased
physical activity (i.e., 60 to 90 min daily), caloric restriction,
and formal behavioral programs is encouraged to achieve
and maintain a body mass index between 18.5 and 24.9
kg/m2 and a waist circumference of less than or equal to 35
inches in women and less than or equal to 40 inches in men.
For those who need lipid lowering beyond lifestyle mea-
sures, the statin drugs have the best outcome evidence
supporting their use and should be the mainstay of phar-
macological intervention (21). The appropriate levels for
lipid management are dependent on baseline risk; the reader
is referred to the NCEP report (http://www.nhlbi.nih.gov/
guidelines/cholesterol/index.htm) for details (17,18,39–41).
Primary prevention patients with high blood pressure
should be treated according to the recommendations of the
Seventh Joint National Committee on High Blood Pressure
(JNC 7) (42,43). Speciﬁc treatment recommendations are
based on the level of hypertension and the patient’s other
risk factors. A diet low in salt and rich in vegetables, fruits,
and low-fat dairy products should be encouraged for all
hypertensive patients, as should a regular aerobic exercise
program (44–47). Most patients will require more than 1
medication to achieve blood pressure control, and pharma-
cotherapy should begin with known outcome-improving
medications (primarily thiazide diuretics as ﬁrst choice, with
the addition of beta blockers, angiotensin-converting en-
zyme [ACE] inhibitors, angiotensin receptor blockers,
and/or long-acting calcium channel blockers) (42,48). Sys-
tolic hypertension is a powerful predictor of adverse out-
come, particularly among the elderly, and it should be
treated even if diastolic pressures are normal (49).
Detection of hyperglycemic risk (e.g., metabolic syn-
drome) and diabetes mellitus should be pursued as part of
risk assessment. Lifestyle changes and pharmacotherapy are
indicated in individuals with diabetes mellitus to achieve a
glycosylated hemoglobin [HbA1c] level less than 7% but to
avoid hypoglycemia (3,50,51).
Aspirin prophylaxis can uncommonly result in hemor-
rhagic complications and should only be used in primary
prevention when the level of risk justiﬁes it. Patients whose
10-year risk of CHD is 10% or more are most likely to
beneﬁt, and 75 to 162 mg of aspirin (ASA) per day as
primary prophylaxis should be discussed with such patients
(29,38,52–55).
1.5. Onset of UA/NSTEMI
1.5.1. Recognition of Symptoms by Patient
Early recognition of symptoms of UA/NSTEMI by the
patient or someone with the patient is the ﬁrst step that
must occur before evaluation and life-saving treatment can
be obtained. Although many laypersons are generally aware
that chest pain is a presenting symptom of UA/NSTEMI,
they are unaware of the other common symptoms, such as
arm pain, lower jaw pain, shortness of breath (56), and
diaphoresis (57) or anginal equivalents, such as dyspnea or
extreme fatigue (56,58). The average patient with NSTEMI
or prolonged rest UA (e.g., longer than 20 min) does not
seek medical care for approximately 2 h after symptom
onset, and this pattern appears unchanged over the last
decade (58–60). A baseline analysis from the Rapid Early
Action for Coronary Treatment (REACT) research pro-
gram demonstrated longer delay times among non-Hispanic
blacks, older patients, and Medicaid-only recipients and
shorter delay times among Medicare recipients (compared
with privately insured patients) and patients who came to
the hospital by ambulance (58). In the majority of studies
examined to date, women in both univariate- and
multivariate-adjusted analyses (in which age and other
potentially confounding variables have been controlled)
exhibit more prolonged delay patterns than men (61).
A number of studies have provided insight into why
patients delay in seeking early care for heart symptoms
(62). Focus groups conducted for the REACT research
program (63,64) revealed that patients commonly hold a
preexisting expectation that a heart attack would present
dramatically with severe, crushing chest pain, such that
there would be no doubt that one was occurring. This was
in contrast to their actual reported symptom experience
of a gradual onset of discomfort involving midsternal
chest pressure or tightness, with other associated symp-
toms often increasing in intensity. The ambiguity of
these symptoms, due to this disconnect between prior
expectations and actual experience, resulted in uncer-
tainty about the origin of symptoms and thus a “wait-
and-see” posture by patients and those around them (62).
Other reported reasons for delay were that patients
thought the symptoms were self-limited and would go
away or were not serious (65–67); that they attributed
symptoms to other preexisting chronic conditions, espe-
cially among older adults with multiple chronic condi-
tions (e.g., arthritis), or sometimes to a common illness
such as inﬂuenza; that they were afraid of being embar-
rassed if symptoms turned out to be a “false alarm”; that
they were reluctant to trouble others (e.g., health care
providers, Emergency Medical Services [EMS]) unless
they were “really sick” (65–67); that they held stereotypes
of who is at risk for a heart attack; and that they lacked
awareness of the importance of rapid action, knowledge
of reperfusion treatment, or knowledge of the beneﬁts of
calling EMS/9-1-1 to ensure earlier treatment (62). Notably,
women did not perceive themselves to be at risk (69).
1.5.2. Silent and Unrecognized Events
Patients experiencing UA/NSTEMI do not always present
with chest discomfort (70). The Framingham Study was the
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ﬁrst to show that as many as half of all MIs may be clinically
silent and unrecognized by the patient (71). Canto et al.
(72) found that one third of the 434,877 patients with
conﬁrmed MI in the National Registry of Myocardial
Infarction presented to the hospital with symptoms other
than chest discomfort. Compared with MI patients with
chest discomfort, MI patients without chest discomfort
were more likely to be older, to be women, to have diabetes,
and/or to have prior heart failure [HF]. Myocardial infarc-
tion patients without chest discomfort delayed longer before
they went to the hospital (mean 7.9 vs. 5.3 h) and were less
likely to be diagnosed as having an MI when admitted
(22.2% vs. 50.3%). They also were less likely to receive
ﬁbrinolysis or primary PCI, ASA, beta blockers, or heparin.
Silent MI patients were 2.2 times more likely to die during
the hospitalization (in-hospital mortality rate 23.3% vs.
9.3%). Unexplained dyspnea, even without angina, is a
particularly worrisome symptom, with more than twice the
risk of death than for typical angina in patients undergoing
cardiovascular evaluation (56). Recently, the prognostic
signiﬁcance of dyspnea has been emphasized in patients
undergoing cardiac evaluation. Self-reported dyspnea alone
among 17,991 patients undergoing stress perfusion testing
was an independent predictor of cardiac and total mortality
and increased the risk of sudden cardiac death 4-fold even in
those with no prior history of CAD (56).
Health care providers should maintain a high index of
suspicion for UA/NSTEMI when evaluating women, pa-
tients with diabetes mellitus, older patients, those with
unexplained dyspnea (56), and those with a history of HF or
stroke, as well as those patients who complain of chest
discomfort but who have a permanent pacemaker that may
confound recognition of UA/NSTEMI on their 12-lead
ECG (73).
2. Initial Evaluation and Management
2.1. Clinical Assessment
Because symptoms are similar and the differentiation of
UA/NSTEMI and STEMI requires medical evaluation, we
will refer to prediagnostic clinical presentation as ACS,
deﬁned as UA or MI (NSTEMI or STEMI) (Fig. 2).
RECOMMENDATIONS
CLASS I
1. Patients with symptoms that may represent ACS (Table 2) should
not be evaluated solely over the telephone but should be referred to
a facility that allows evaluation by a physician and the recording of
Figure 2. Algorithm for Evaluation and Management of Patients Suspected of Having ACS
To facilitate interpretation of this algorithm and a more detailed discussion in the text, each box is assigned a letter code that reﬂects its level in the algorithm and a num-
ber that is allocated from left to right across the diagram on a given level. ACC/AHA  American College of Cardiology/American Heart Association; ACS  acute coronary
syndrome; ECG  electrocardiogram; LV  left ventricular.
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a 12-lead ECG and biomarker determination (e.g., an ED or other
acute care facility). (Level of Evidence: C)
2. Patients with symptoms of ACS (chest discomfort with or without
radiation to the arm[s], back, neck, jaw or epigastrium; shortness of
breath; weakness; diaphoresis; nausea; lightheadedness) should
be instructed to call 9-1-1 and should be transported to the hospital
by ambulance rather than by friends or relatives. (Level of Evidence: B)
3. Health care providers should actively address the following issues
regarding ACS with patients with or at risk for CHD and their
families or other responsible caregivers:
a. The patient’s heart attack risk; (Level of Evidence: C)
b. How to recognize symptoms of ACS; (Level of Evidence: C)
c. The advisability of calling 9-1-1 if symptoms are unimproved or
worsening after 5 min, despite feelings of uncertainty about the
symptoms and fear of potential embarrassment; (Level of Evi-
dence: C)
d. A plan for appropriate recognition and response to a potential
acute cardiac event, including the phone number to access
EMS, generally 9-1-1 (74). (Level of Evidence: C)
4. Prehospital EMS providers should administer 162 to 325 mg of
ASA (chewed) to chest pain patients suspected of having ACS
unless contraindicated or already taken by the patient. Although
some trials have used enteric-coated ASA for initial dosing, more
rapid buccal absorption occurs with non–enteric-coated formula-
tions. (Level of Evidence: C)
5. Health care providers should instruct patients with suspected ACS
for whom nitroglycerin [NTG] has been prescribed previously to take
not more than 1 dose of NTG sublingually in response to chest
discomfort/pain. If chest discomfort/pain is unimproved or is wors-
ening 5 min after 1 NTG dose has been taken, it is recommended
that the patient or family member/friend/caregiver call 9-1-1
immediately to access EMS before taking additional NTG. In pa-
tients with chronic stable angina, if symptoms are signiﬁcantly
improved by 1 dose of NTG, it is appropriate to instruct the patient
or family member/friend/caregiver to repeat NTG every 5 min for a
maximum of 3 doses and call 9-1-1 if symptoms have not resolved
completely. (Level of Evidence: C)
6. Patients with a suspected ACS with chest discomfort or other
ischemic symptoms at rest for greater than 20 min, hemodynamic
instability, or recent syncope or presyncope should be referred
immediately to an ED. Other patients with suspected ACS who are
experiencing less severe symptoms and who have none of the
above high-risk features, including those who respond to an NTG
dose, may be seen initially in an ED or an outpatient facility able to
provide an acute evaluation. (Level of Evidence: C)
CLASS IIa
1. It is reasonable for health care providers and 9-1-1 dispatchers to
advise patients without a history of ASA allergy who have symptoms
of ACS to chew ASA (162 to 325 mg) while awaiting arrival of
prehospital EMS providers. Although some trials have used enteric-
coated ASA for initial dosing, more rapid buccal absorption occurs
with non–enteric-coated formulations. (Level of Evidence: B)
2. It is reasonable for health care providers and 9-1-1 dispatchers to
advise patients who tolerate NTG to repeat NTG every 5 min for a
maximum of 3 doses while awaiting ambulance arrival. (Level of
Evidence: C)
3. It is reasonable that all prehospital EMS providers perform and
evaluate 12-lead ECGs in the ﬁeld (if available) on chest pain
patients suspected of ACS to assist in triage decisions. Electrocar-
diographs with validated computer-generated interpretation algo-
rithms are recommended for this purpose. (Level of Evidence: B)
4. If the 12-lead ECG shows evidence of acute injury or ischemia, it is
reasonable that prehospital ACLS providers relay the ECG to a
predetermined medical control facility and/or receiving hospital.
(Level of Evidence: B)
Patients with suspected ACS must be evaluated rapidly.
Decisions made on the basis of the initial evaluation have
substantial clinical and economic consequences (75). The
ﬁrst triage decision is made by the patient, who must decide
whether to access the health care system. Media campaigns
such as “Act in Time,” sponsored by the National Heart,
Lung, and Blood Institute (NHLBI), provide patient edu-
cation regarding this triage decision (www.nhlbi.nih.gov/
actintime). The campaign urges both men and women who
feel heart attack symptoms or observe the signs in others to
wait no more than a few minutes, 5 min at most, before
calling 9-1-1 (76,77). Campaign materials point out that
patients can increase their chance of surviving a heart attack
by learning the symptoms and ﬁlling out a survival plan.
They also are advised to talk with their doctor about heart
attacks and how to reduce their risk of having one. The
patient materials include a free brochure about symptoms
and recommended actions for survival, in English (78) and
Spanish (79), as well as a free wallet card that can be ﬁlled
in with emergency medical information (80). Materials
geared directly to providers include a Patient Action Plan
Tablet (81), which contains the heart attack warning symp-
toms and steps for developing a survival plan, individualized
with the patient’s name; a quick reference card for address-
ing common patient questions about seeking early treatment
to survive a heart attack (82), including a PDA version (83);
and a warning signs wall chart (84). These materials and
others are available on the “Act in Time” Web page
(www.nhlbi.nih.gov/health/public/heart/mi/core_bk.pdf)
(77).
When the patient ﬁrst makes contact with the medical
care system, a critical decision must be made about where
the evaluation will take place. The health care provider then
must place the evaluation in the context of 2 critical
questions: Are the symptoms a manifestation of an ACS? If
so, what is the prognosis? The answers to these 2 questions
lead logically to a series of decisions about where the patient
will be best managed, what medications will be prescribed,
and whether an angiographic evaluation will be required.
Given the large number of patients with symptoms
compatible with ACS, the heterogeneity of the population,
and a clustering of events shortly after the onset of symp-
toms, a strategy for the initial evaluation and management is
essential. Health care providers may be informed about
signs and symptoms of ACS over the telephone or in person
by the patient or family members. The objectives of the
initial evaluation are ﬁrst to identify signs of immediate
life-threatening instability and then to ensure that the
patient is moved rapidly to the most appropriate environ-
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ment for the level of care needed based on diagnostic criteria
and an estimation of the underlying risk of speciﬁc negative
outcomes.
Health practitioners frequently receive telephone calls
from patients or family members/friends/caregivers who are
concerned that their symptoms could reﬂect heart disease.
Most such calls regarding chest discomfort of possible
cardiac origin in patients without known CAD do not
represent an emergency; rather, these patients usually seek
reassurance that they do not have heart disease or that there
is little risk due to their symptoms. Despite the frequent
inclination to dismiss such symptoms over the telephone,
health care providers, EMS dispatchers, and staff positioned
to receive these calls should advise patients with possible
accelerating angina or angina at rest that an evaluation
cannot be performed solely via the telephone. This advice is
essential because of the need for timely evaluation, including
a physical examination, ECG, and appropriate blood tests
to measure cardiac biomarkers.
Patients with known CAD—including those with
chronic stable angina, recent MI, or prior intervention (i.e.,
coronary artery bypass graft surgery [CABG] or PCI)—who
contact a physician or other appropriate member of the
health care team because of worsening or recurrent symp-
toms should be instructed to proceed rapidly to an ED,
preferably one equipped to perform prompt reperfusion
therapy. When the discomfort is moderate to severe or
sustained, they should be instructed to access the EMS
system directly by calling 9-1-1. Patients who have been
evaluated recently and who are calling for advice regarding
modiﬁcation of medications as part of an ongoing treatment
plan represent exceptions.
Even in the most urgent subgroup of patients who
present with acute-onset chest pain, there usually is ade-
quate time for transport to an environment in which they
can be evaluated and treated (85). In a large study of
consecutive patients with chest pain suspected to be of
cardiac origin who were transported to the ED via ambu-
lance, one third had a ﬁnal diagnosis of MI, one third had
a ﬁnal diagnosis of UA, and one third had a ﬁnal diagnosis
of a noncardiac cause; 1.5% of these patients developed
cardiopulmonary arrest before arrival at the hospital or in
the ED (86).
Every community should have a written protocol that
guides EMS system personnel in determining where to take
patients with suspected or conﬁrmed ACS. Active involve-
ment of local health care providers, particularly cardiologists
and emergency physicians, is needed to formulate local
EMS destination protocols for these patients. In general,
patients with suspected ACS should be taken to the nearest
appropriate hospital; however, patients with known STEMI
and/or cardiogenic shock should be sent as directly as
possible to hospitals with interventional and surgical capa-
bility (1).
The advent of highly effective, time-dependent treatment
for ACS, coupled with the need to reduce health care costs,
adds further incentive for clinicians to get the right answer
quickly and to reduce unnecessary admissions and length of
hospital stay. Investigators have tried various diagnostic
tools, such as clinical decision algorithms, cardiac biomar-
kers, serial ECGs, echocardiography, myocardial perfusion
imaging, and multidetector (e.g., 64-slice) coronary CT
angiography (CCTA), in an attempt to avoid missing
patients with MI or UA. The most successful strategies to
emerge thus far are designed to identify MI patients and,
when clinically appropriate, screen for UA and underlying
CAD. Most strategies use a combination of cardiac biomar-
kers, short-term observation, diagnostic imaging, and pro-
vocative stress testing. An increasing number of high-
quality centers now use structured protocols, checklists, or
critical pathways to screen patients with suspected MI or
UA (87–99). It does not appear to matter whether the
institution designates itself a chest pain center; rather, it is
the multifaceted, multidisciplinary, standardized, and struc-
tured approach to the problem that appears to provide
clinical, cost-effective beneﬁt (100,101). One randomized
trial has conﬁrmed the safety, efﬁcacy, and cost-effectiveness
of the structured decision-making approach compared with
standard, unstructured care (102).
Regardless of the approach used, all patients presenting to
the ED with chest discomfort or other symptoms suggestive
of MI or UA should be considered high-priority triage cases
and should be evaluated and treated on the basis of a
predetermined, institution-speciﬁc chest pain protocol. The
protocol should include several diagnostic possibilities (Fig.
2) (103). The patient should be placed on a cardiac monitor
immediately, with emergency resuscitation equipment, in-
cluding a deﬁbrillator, nearby. An ECG also should be
performed immediately and evaluated by an experienced
emergency medicine physician, with a goal of within 10 min
of ED arrival. If STEMI is present, the decision as to
whether the patient will be treated with ﬁbrinolytic therapy
or primary PCI should be made within the next 10 min (1).
For cases in which the initial diagnosis and treatment plan
are unclear to the emergency medicine physician or are not
covered directly by an institutionally agreed-upon protocol,
immediate cardiology consultation is advisable.
Morbidity and mortality from ACS can be reduced
signiﬁcantly if patients and bystanders recognize symptoms
early, activate the EMS system, and thereby shorten the
time to deﬁnitive treatment. Patients with possible symp-
toms of MI should be transported to the hospital by
ambulance rather than by friends or relatives, because there
is a signiﬁcant association between arrival at the ED by
ambulance and early reperfusion therapy in STEMI patients
(104–107). In addition, emergency medical technicians and
paramedics can provide life-saving interventions (e.g., early
cardiopulmonary resuscitation [CPR] and deﬁbrillation) if
the patient develops cardiac arrest. Approximately 1 in every
300 patients with chest pain transported to the ED by
private vehicle goes into cardiac arrest en route (108).
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Several studies have conﬁrmed that patients with ACS
frequently do not call 9-1-1 and are not transported to the
hospital by ambulance. A follow-up survey of chest pain
patients presenting to participating EDs in 20 US commu-
nities who were either released or admitted to the hospital
with a conﬁrmed coronary event revealed that the average
proportion of patients who used EMS was 23%, with
signiﬁcant geographic difference (range 10% to 48%). Most
patients were driven by someone else (60%) or drove
themselves to the hospital (16%) (109). In the National
Registry of Myocardial Infarction 2, just over half (53%) of
all patients with MI were transported to the hospital by
ambulance (105).
Even in areas of the country that have undertaken
substantial public education campaigns about the warning
signs of ACS and the need to activate the EMS system
rapidly, either there were no increases in EMS use (58,110–
113) or EMS use increased (as a secondary outcome
measure) but was still suboptimal, with a 20% increase from
a baseline of 33% in all 20 communities in the REACT
study (63) and an increase from 27% to 41% in southern
Minnesota after a community campaign (114). Given the
importance of patients using EMS for possible acute cardiac
symptoms, communities, including medical providers, EMS
systems, health care insurers, hospitals, and policy makers at
the state and local level, need to have agreed-upon emer-
gency protocols to ensure patients with possible heart attack
symptoms will be able to access 9-1-1 without barriers, to
secure their timely evaluation and treatment (115).
As part of making a plan with the patient for timely
recognition and response to an acute event, providers should
review instructions for taking NTG in response to chest
discomfort/pain (Fig. 3). If a patient has previously been
prescribed NTG, it is recommended that the patient be
advised to take 1 NTG dose sublingually promptly for chest
discomfort/pain. If symptoms are unimproved or worsening
5 min after 1 NTG dose has been taken, it also is
recommended that the patient be instructed to call 9-1-1
immediately to access EMS. Although the traditional rec-
ommendation is for patients to take 1 NTG dose sublin-
gually, 5 min apart, for up to 3 doses before calling for
emergency evaluation, this recommendation has been mod-
iﬁed by the UA/NSTEMI Writing Committee to encour-
age earlier contacting of EMS by patients with symptoms
suggestive of ACS. While awaiting ambulance arrival,
patients tolerating NTG can be instructed by health care
providers or 9-1-1 dispatchers to take additional NTG every
5 min up to 3 doses. Self-treatment with prescription
medication, including nitrates, and with nonprescription
medication (e.g., antacids) has been documented as a
frequent cause of delay among patients with ACS, including
those with a history of MI or angina (65,116). Both the rate
Figure 3. Patient (Advance) Instructions for NTG Use and EMS Contact in the Setting of Non–Trauma-Related Chest Discomfort/Pain
If patients experience chest discomfort/pain and have been previously prescribed NTG and have it available (right side of algorithm), it is recommended that they be
instructed (in advance) to take 1 dose of NTG immediately in response to symptoms. If chest discomfort/pain is unimproved or worsening 5 min after taking 1 NTG sublin-
gually, it is recommended that the patient call 9-1-1 immediately to access EMS. In patients with chronic stable angina, if the symptoms are signiﬁcantly improved after tak-
ing 1 NTG, it is appropriate to instruct the patient or family member/friend/caregiver to repeat NTG every 5 min for a maximum of 3 doses and call 9-1-1 if symptoms have
not totally resolved. If patients are not previously prescribed NTG (left side of algorithm), it is recommended that they call 9-1-1 if chest discomfort/pain is unimproved or
worsening 5 min after it starts. If the symptoms subside within 5 min of when they began, patients should notify their physician of the episode. (For those patients with new-
onset chest discomfort who have not been prescribed NTG, it is appropriate to discourage them from seeking someone else’s NTG [e.g., from a neighbor, friend, or rela-
tive].) *Although some trials have used enteric-coated aspirin for initial dosing, more rapid buccal absorption occurs with non–enteric-coated formulations. EMS  emergency
medical services; NTG  nitroglycerin.
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of use of these medications and the number of doses taken
were positively correlated with delay time to hospital arrival
(65).
Family members, close friends, caregivers, or advocates
should be included in these discussions and enlisted as
reinforcement for rapid action when the patient experiences
symptoms of a possible ACS (74,117,118) (Fig. 3). For
patients known to their providers to have frequent angina,
physicians may consider a selected, more tailored message
that takes into account the frequency and character of the
patient’s angina and their typical time course of response to
NTG. In many of these patients with chronic stable angina,
if chest pain is signiﬁcantly improved by 1 NTG, it is still
appropriate to instruct the patient or family member/friend/
caregiver to repeat NTG every 5 min for a maximum of 3
doses and to call 9-1-1 if symptoms have not resolved
completely. Avoidance of patient delay associated with
self-medication and prolonged reevaluation of symptoms
are paramount. An additional consideration in high-risk
CHD patients is to train family members in CPR and/or to
have home access to an automatic external deﬁbrillator, now
available commercially to the public.
The taking of aspirin by patients in response to acute
symptoms has been reported to be associated with a delay in
calling EMS (109). Patients should focus on calling 9-1-1,
which activates the EMS system, where they may receive
instructions from emergency medical dispatchers to chew
aspirin (162 to 325 mg) while emergency personnel are en
route, or emergency personnel can give an aspirin while
transporting the patient to the hospital (119). Alternatively,
patients may receive an aspirin as part of their early
treatment once they arrive at the hospital if it has not been
given in the prehospital setting (117).
Providers should target those patients at increased risk for
ACS, focusing on patients with known CHD, peripheral
vascular disease, or cerebral vascular disease, those with
diabetes, and patients with a 10-year Framingham risk of
CHD of more than 20% (120). They should stress that the
chest discomfort will usually not be dramatic, such as is
commonly misrepresented on television or in the movies as
a “Hollywood heart attack.” Providers also should describe
anginal equivalents and the commonly associated symptoms
of ACS (e.g., shortness of breath, a cold sweat, nausea, or
lightheadedness) in both men and women (56,106), as well
as the increased frequency of atypical symptoms in elderly
patients (72).
2.1.1. Emergency Department or Outpatient Facility
Presentation
It is recommended that patients with a suspected ACS with
chest discomfort or other ischemic symptoms at rest for
more than 20 min, hemodynamic instability, or recent
syncope or presyncope to be referred immediately to an ED
or a specialized chest pain unit. For other patients with a
suspected ACS who are experiencing less severe symptoms
and are having none of the above high-risk features, the
recommendation is to be seen initially in an ED, a chest
pain unit, or an appropriate outpatient facility. Outcomes
data that ﬁrmly support these recommendations are not
available; however, these recommendations are of practical
importance because differing ACS presentations require
differing levels of emergent medical interventions, such as
ﬁbrinolytics or emergency coronary angiography leading to
PCI or surgery, or sophisticated diagnostic evaluation such
as nuclear stress testing or CCTA. When symptoms have
been unremitting for more than 20 min, the possibility of
MI must be considered. Given the strong evidence for a
relationship between delay in treatment and death (121–
123), an immediate assessment that includes a 12-lead
ECG is essential. Patients who present with hemodynamic
instability require an environment in which therapeutic
interventions can be provided, and for those with presyn-
cope or syncope, the major concern is the risk of sudden
death. Such patients should be encouraged to seek emer-
gency transportation when it is available. Transport as a
passenger in a private vehicle is an acceptable alternative
only if the wait for an emergency vehicle would impose a
delay of greater than 20 to 30 min.
2.1.2. Questions to Be Addressed at the Initial Evaluation
The initial evaluation should be used to provide information
about the diagnosis and prognosis. The attempt should be
made to simultaneously answer 2 questions:
• What is the likelihood that the signs and symptoms
represent ACS secondary to obstructive CAD (Table 6)?
• What is the likelihood of an adverse clinical outcome
(Table 7)? Outcomes of concern include death, MI (or
recurrent MI), stroke, HF, recurrent symptomatic isch-
emia, and serious arrhythmia.
For the most part, the answers to these questions form a
sequence of contingent probabilities. Thus, the likelihood that
the signs and symptoms represent ACS is contingent on the
likelihood that the patient has underlying CAD. Similarly, the
prognosis is contingent on the likelihood that the symptoms
represent acute ischemia. However, in patients with symptoms
of possible ACS, traditional risk factors for CAD are less
important than are symptoms, ECG ﬁndings, and cardiac
biomarkers. Therefore, the presence or absence of these tradi-
tional risk factors ordinarily should not be heavily weighed in
determining whether an individual patient should be admitted
or treated for ACS.
2.2. Early Risk Stratiﬁcation
RECOMMENDATIONS FOR EARLY RISK STRATIFICATION
CLASS I
1. A rapid clinical determination of the likelihood risk of obstructive
CAD (i.e., high, intermediate, or low) should be made in all
patients with chest discomfort or other symptoms suggestive of
an ACS and considered in patient management. (Level of Evi-
dence: C)
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2. Patients who present with chest discomfort or other ischemic
symptoms should undergo early risk stratiﬁcation for the risk of
cardiovascular events (e.g., death or [re]MI) that focuses on history,
including anginal symptoms, physical ﬁndings, ECG ﬁndings, and
biomarkers of cardiac injury, and results should be considered in
patient management. (Level of Evidence: C)
3. A 12-lead ECG should be performed and shown to an experienced
emergency physician as soon as possible after ED arrival, with a
Table 6. Likelihood That Signs and Symptoms Represent an ACS Secondary to CAD
Feature
High Likelihood Intermediate Likelihood Low Likelihood
Any of the following:
Absence of high-likelihood features and
presence of any of the following:
Absence of high- or intermediate-
likelihood features but may have:
History Chest or left arm pain or discomfort as chief
symptom reproducing prior documented
angina
Known history of CAD, including MI
Chest or left arm pain or discomfort as chief
symptom
Age greater than 70 years
Male sex
Diabetes mellitus
Probable ischemic symptoms in absence
of any of the intermediate likelihood
characteristics
Recent cocaine use
Examination Transient MR murmur, hypotension,
diaphoresis, pulmonary edema, or rales
Extracardiac vascular disease Chest discomfort reproduced by palpation
ECG New, or presumably new, transient ST-segment
deviation (1 mm or greater) or T-wave
inversion in multiple precordial leads
Fixed Q waves
ST depression 0.5 to 1 mm or T-wave inversion
greater than 1 mm
T-wave ﬂattening or inversion less than
1 mm in leads with dominant R waves
Normal ECG
Cardiac
markers
Elevated cardiac TnI, TnT, or CK-MB Normal Normal
Modiﬁed with permission from Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Rockville, MD: Agency for Health Care Policy and Research and the National Heart,
Lung, and Blood Institute, U.S. Public Health Service, U.S. Department of Health and Human Service, 1994. AHCPR publication no. 94-0602 (124).
ACS  acute coronary syndrome; CAD  coronary artery disease; CK-MB  MB fraction of creatine kinase; ECG  electrocardiogram; MI  myocardial infarction; MR  mitral regurgitation; TnI 
troponin I; TnT  troponin T.
Table 7. Short-Term Risk of Death or Nonfatal MI in Patients With UA/NSTEMI*
Feature
High Risk Intermediate Risk Low Risk
At least 1 of the following features must
be present:
No high-risk feature, but must have 1 of the
following:
No high- or intermediate-risk feature but
may have any of the following features:
History Accelerating tempo of ischemic symptoms
in preceding 48 h
Prior MI, peripheral or cerebrovascular disease,
or CABG; prior aspirin use
Character of pain Prolonged ongoing (greater than 20 min)
rest pain
Prolonged (greater than 20 min) rest angina,
now resolved, with moderate or high
likelihood of CAD
Rest angina (greater than 20 min) or relieved
with rest or sublingual NTG
Nocturnal angina
New-onset or progressive CCS class III or IV
angina in the past 2 weeks without
prolonged (greater than 20 min) rest pain
but with intermediate or high likelihood of
CAD (see Table 6)
Increased angina frequency, severity, or
duration
Angina provoked at a lower threshold
New onset angina with onset 2 weeks to
2 months prior to presentation
Clinical ﬁndings Pulmonary edema, most likely due to
ischemia
New or worsening MR murmur
S3 or new/worsening rales
Hypotension, bradycardia, tachycardia
Age greater than 75 years
Age greater than 70 years
ECG Angina at rest with transient ST-segment
changes greater than 0.5 mm
Bundle-branch block, new or presumed
new
Sustained ventricular tachycardia
T-wave changes
Pathological Q waves or resting ST-depression
less than 1 mm in multiple lead groups
(anterior, inferior, lateral)
Normal or unchanged ECG
Cardiac markers Elevated cardiac TnT, TnI, or CK-MB (e.g.,
TnT or TnI greater than 0.1 ng per ml)
Slightly elevated cardiac TnT, TnI, or CK-MB
(e.g., TnT greater than 0.01 but less than
0.1 ng per ml)
Normal
*Estimation of the short-term risks of death and nonfatal cardiac ischemic events in UA (or NSTEMI) is a complex multivariable problem that cannot be fully speciﬁed in a table such as this; therefore,
this table is meant to offer general guidance and illustration rather than rigid algorithms. Adapted from AHCPR Clinical Practice Guidelines No. 10, Unstable Angina: Diagnosis and Management, May
1994 (124).
CABG  coronary artery bypass graft surgery; CAD  coronary artery disease; CCS  Canadian Cardiovascular Society; CK-MB  creatine kinase, MB fraction; ECG  electrocardiogram; MI 
myocardial infarction; MR  mitral regurgitation; NTG  nitroglycerin; TnI  troponin I; TnT  troponin T; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.
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goal of within 10 min of ED arrival for all patients with chest
discomfort (or anginal equivalent) or other symptoms suggestive of
ACS. (Level of Evidence: B)
4. If the initial ECG is not diagnostic but the patient remains symptom-
atic and there is high clinical suspicion for ACS, serial ECGs, initially
at 15- to 30-min intervals, should be performed to detect the
potential for development of ST-segment elevation or depression.
(Level of Evidence: B)
5. Cardiac biomarkers should be measured in all patients who present
with chest discomfort consistent with ACS. (Level of Evidence: B)
6. A cardiac-speciﬁc troponin is the preferred marker, and if available,
it should be measured in all patients who present with chest
discomfort consistent with ACS. (Level of Evidence: B)
7. Patients with negative cardiac biomarkers within 6 h of the onset of
symptoms consistent with ACS should have biomarkers remea-
sured in the time frame of 8 to 12 h after symptom onset. (The exact
timing of serum marker measurement should take into account the
uncertainties often present with the exact timing of onset of pain
and the sensitivity, precision, and institutional norms of the assay
being utilized as well as the release kinetics of the marker being
measured.) (Level of Evidence: B)
8. The initial evaluation of the patient with suspected ACS should
include the consideration of noncoronary causes for the develop-
ment of unexplained symptoms. (Level of Evidence: C)
CLASS IIa
1. Use of risk-stratiﬁcation models, such as the Thrombolysis In Myo-
cardial Infarction (TIMI) or Global Registry of Acute Coronary Events
(GRACE) risk score or the Platelet Glycoprotein IIb/IIIa in Unstable
Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT)
risk model, can be useful to assist in decision making with regard to
treatment options in patients with suspected ACS. (Level of Evi-
dence: B)
2. It is reasonable to remeasure positive biomarkers at 6- to 8-h
intervals 2 to 3 times or until levels have peaked, as an index of
infarct size and dynamics of necrosis. (Level of Evidence: B)
3. It is reasonable to obtain supplemental ECG leads V7 through V9 in
patients whose initial ECG is nondiagnostic to rule out MI due to left
circumﬂex occlusion. (Level of Evidence: B)
4. Continuous 12-lead ECG monitoring is a reasonable alternative to
serial 12-lead recordings in patients whose initial ECG is nondiag-
nostic. (Level of Evidence: B)
CLASS IIb
1. For patients who present within 6 h of the onset of symptoms
consistent with ACS, assessment of an early marker of cardiac
injury (e.g., myoglobin) in conjunction with a late marker (e.g.,
troponin) may be considered. (Level of Evidence: B)
2. For patients who present within 6 h of symptoms suggestive of ACS,
a 2-h delta CK-MB mass in conjunction with 2-h delta troponin may
be considered. (Level of Evidence: B)
3. For patients who present within 6 h of symptoms suggestive of ACS,
myoglobin in conjunction with CK-MB mass or troponin when mea-
sured at baseline and 90 min may be considered. (Level of Evi-
dence: B)
4. Measurement of B-type natriuretic peptide (BNP) or NT-pro-BNP
may be considered to supplement assessment of global risk in
patients with suspected ACS. (Level of Evidence: B)
CLASS III
Total CK (without MB), aspartate aminotransferase (AST, SGOT), ala-
nine transaminase, beta-hydroxybutyric dehydrogenase, and/or lactate
dehydrogenase should not be utilized as primary tests for the detection
of myocardial injury in patients with chest discomfort suggestive of
ACS. (Level of Evidence: C)
2.2.1. Estimation of the Level of Risk
The medical history, physical examination, ECG, assess-
ment of renal function, and cardiac biomarker measure-
ments in patients with symptoms suggestive of ACS at the
time of the initial presentation can be integrated into an
estimation of the risk of death and nonfatal cardiac ischemic
events. The latter include new or recurrent MI, recurrent
UA, disabling angina that requires hospitalization, and
urgent coronary revascularization. Estimation of the level of
risk is a multivariable problem that cannot be accurately
quantiﬁed with a simple table; therefore, Tables 6 and 7 are
meant to be illustrative of the general relationships between
history, clinical and ECG ﬁndings, and the categorization
of patients into those at low, intermediate, or high risk of
the presence of obstructive CAD and the short-term risk of
cardiovascular events, respectively. Optimal risk stratiﬁca-
tion requires accounting for multiple prognostic factors
simultaneously by a multivariable approach (e.g., the TIMI
and GRACE risk score algorithms [see below]).
2.2.2. Rationale for Risk Stratiﬁcation
Because patients with ischemic discomfort at rest as a group
are heterogeneous in terms of risk of cardiac death and
nonfatal ischemic events, an assessment of the prognosis
guides the initial evaluation and treatment. An estimation of
risk is useful in 1) selection of the site of care (coronary care
unit, monitored step-down unit, or outpatient setting) and
2) selection of therapy, including platelet glycoprotein (GP)
IIb/IIIa inhibitors (see Section 3.2) and invasive manage-
ment strategy (see Section 3.3). For all modes of presenta-
tion of an ACS, a strong relationship exists between
indicators of the likelihood of ischemia due to CAD and
prognosis (Tables 6 and 7). Patients with a high likelihood
of ischemia due to CAD are at a greater risk of an untoward
cardiac event than are patients with a lower likelihood of
CAD. Therefore, an assessment of the likelihood of CAD
is the starting point for the determination of prognosis in
patients who present with symptoms suggestive of ACS.
Other important elements for prognostic assessment are the
tempo of the patient’s clinical course, which relates to the
short-term risk of future cardiac events, principally MI, and
the patient’s likelihood of survival should an MI occur.
Patients can present with ischemic discomfort but with-
out ST-segment deviation on the 12-lead ECG in a variety
of clinical scenarios, including no known prior history of
CAD, a prior history of stable CAD, soon after MI, and
after myocardial revascularization with CABG or PCI
(12,125,126). As a clinical syndrome, ischemic discomfort
without ST-segment elevation (UA and NSTEMI) shares
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ill-deﬁned borders with severe chronic stable angina, a
condition associated with lower immediate risk, and
STEMI, a presentation with a higher risk of early death and
cardiac ischemic events. The risk is highest at the time of
presentation and subsequently declines. Yet, the risk re-
mains high past the acute phase. By 6 months, UA/
NSTEMI mortality rates higher than that after STEMI can
be seen (127); and by 12 months, the rates of death, MI, and
recurrent instability in contemporary randomized controlled
trials and registry studies exceed 10% and are often related
to speciﬁc risk factors such as age, diabetes mellitus, renal
failure, and impairment of left ventricular (LV) function.
Whereas the early events are related to the activity of 1
culprit coronary plaque that has ruptured and is the site of
thrombus formation, events that occur later are more related
to the underlying pathophysiological mechanisms that trig-
ger plaque activity and that mark active atherosclerosis
(128–134).
A few risk scores have been developed that regroup
markers of the acute thrombotic process and other markers
of high risk to identify high-risk patients with UA/
NSTEMI. The TIMI, GRACE, and PURSUIT risk scores
are discussed in detail in Section 2.2.6.
2.2.3. History
Patients with suspected UA/NSTEMI may be divided into
those with and those without a history of documented
CAD. Particularly when the patient does not have a known
history of CAD, the physician must determine whether the
patient’s presentation, with its constellation of speciﬁc
symptoms and signs, is most consistent with chronic isch-
emia, acute ischemia, or an alternative disease process. The
5 most important factors derived from the initial history
that relate to the likelihood of ischemia due to CAD, ranked
in the order of importance, are 1) the nature of the anginal
symptoms, 2) prior history of CAD, 3) sex, 4) age, and 5)
the number of traditional risk factors present (135–139). In
patients with suspected ACS but without preexisting clin-
ical CHD, older age appears to be the most important
factor. One study found that for males, age younger than 40
years, 40 to 55 years, and older than 55 years and for
females, age younger than 50 years, 50 to 65 years, and older
than 65 years was correlated with low, intermediate, and
high risk for CAD, respectively (138). Another study found
that the risk of CAD increased in an incremental fashion for
each decade above age 40 years, with male sex being
assigned an additional risk point (139,140). In these studies,
being a male older than 55 years or a female older than 65
years outweighed the importance of all historical factors,
including the nature of the chest pain (138,139).
2.2.4. Anginal Symptoms and Anginal Equivalents
The characteristics of angina, which are thoroughly de-
scribed in the ACC/AHA 2002 Guideline Update for the
Management of Patients With Chronic Stable Angina (4),
include deep, poorly localized chest or arm discomfort that
is reproducibly associated with physical exertion or emo-
tional stress and is relieved promptly (i.e., in less than 5 min)
with rest and/or the use of sublingual NTG. Patients with
UA/NSTEMI may have discomfort that has all of the
qualities of typical angina except that the episodes are more
severe and prolonged, may occur at rest, or may be precip-
itated by less exertion than in the past. Although it is
traditional to use the simple term “chest pain” to refer to the
discomfort of ACS, patients often do not perceive these
symptoms to be true pain, especially when they are mild or
atypical. Terms such as “ischemic-type chest discomfort” or
“symptoms suggestive of ACS” have been proposed to more
precisely capture the character of ischemic symptoms. Al-
though “chest discomfort” or “chest press” is frequently used
in these guidelines for uniformity and brevity, the following
caveats should be kept clearly in mind. Some patients may
have no chest discomfort but present solely with jaw, neck,
ear, arm, shoulder, back, or epigastric discomfort or with
unexplained dyspnea without discomfort (56,141,142). If
these symptoms have a clear relationship to exertion or
stress or are relieved promptly with NTG, they should be
considered equivalent to angina. Occasionally, such “anginal
equivalents” that occur at rest are the mode of presentation
of a patient with UA/NSTEMI, but without the exertional
history or known prior history of CAD, it may be difﬁcult to
recognize their cardiac origin. Other difﬁcult presentations
of the patient with UA/NSTEMI include those without any
chest (or equivalent) discomfort. Isolated unexplained new-
onset or worsened exertional dyspnea is the most common
anginal equivalent symptom, especially in older patients; less
common isolated presentations, primarily in older adults,
include nausea and vomiting, diaphoresis, and unexplained
fatigue. Indeed, older adults and women with ACS not
infrequently present with atypical angina or nonanginal
symptoms. Rarely do patients with ACS present with syncope
as the primary symptom or with other nonanginal symptoms.
Features that are not characteristic of myocardial isch-
emia include the following:
• Pleuritic pain (i.e., sharp or knifelike pain brought on by
respiratory movements or cough)
• Primary or sole location of discomfort in the middle or
lower abdominal region
• Pain that may be localized at the tip of 1 ﬁnger,
particularly over the left ventricular apex or a costochon-
dral junction
• Pain reproduced with movement or palpation of the
chest wall or arms
• Very brief episodes of pain that last a few seconds or less
• Pain that radiates into the lower extremities
Documentation of the evaluation of a patient with sus-
pected UA/NSTEMI should include the physician’s opin-
ion of whether the discomfort is in 1 of 3 categories: high,
intermediate, or low likelihood of acute ischemia caused by
CAD (Table 6).
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Although typical characteristics substantially increase the
probability of CAD, features not characteristic of typical
angina, such as sharp stabbing pain or reproduction of pain
on palpation, do not entirely exclude the possibility of ACS.
In the Multicenter Chest Pain Study, acute ischemia was
diagnosed in 22% of patients who presented to the ED with
sharp or stabbing pain and in 13% of patients with pain with
pleuritic qualities. Furthermore, 7% of patients whose pain
was fully reproduced with palpation were ultimately recog-
nized to have ACS (143). The Acute Cardiac Ischemia
Time-Insensitive Predictive Instrument (ACI-TIPI)
project (144,145) found that older age, male sex, the
presence of chest or left arm pain, and the identiﬁcation of
chest pain or pressure as the most important presenting
symptom all increased the likelihood that the patient was
experiencing acute ischemia.
The relief of chest pain by administration of sublingual
NTG in the ED setting is not always predictive of ACS.
One study reported that sublingual NTG relieved symp-
toms in 35% of patients with active CAD (deﬁned as
elevated cardiac biomarkers, coronary vessel with at least
70% stenosis on coronary angiography, or positive stress
test) compared with 41% of patients without active CAD
(146). Furthermore, the relief of chest pain by the admin-
istration of a “GI cocktail” (e.g., a mixture of liquid antacid,
viscous lidocaine, and anticholinergic agent) does not pre-
dict the absence of ACS (147).
2.2.5. Demographics and History in Diagnosis and
Risk Stratiﬁcation
In most studies of ACS, a prior history of MI has been
associated not only with a high risk of obstructive CAD
(148) but also with an increased risk of multivessel CAD.
There are differences in the presentations of men and
women with ACS (see Section 6.1). A smaller percentage of
women than men present with STEMI, and of the patients
who present without ST-segment elevation, fewer women
than men have MIs (149). Women with suspected ACS are
less likely to have obstructive CAD than are men with a
similar clinical presentation, and when CAD is present in
women, it tends to be less severe. On the other hand, when
STEMI is present, the outcome in women tends to be worse
even when adjustment is made for the older age and greater
comorbidity of women. However, the outcome for women
with UA is signiﬁcantly better than the outcome for men,
and the outcomes are similar for men and women with
NSTEMI (150,151).
Older adults (see Section 6.4) have increased risks of both
underlying CAD (152,153) and multivessel CAD; further-
more, they are at higher risk for an adverse outcome than are
younger patients. The slope of the increased risk is steepest
beyond age 70 years. This increased risk is related in part to the
greater extent and severity of underlying CAD and the more
severe LV dysfunction in older patients; however, age itself
exerts a strong, independent prognostic risk as well, perhaps at
least in part because of comorbidities. Older adults also are
more likely to have atypical symptoms on presentation.
In patients with symptoms of possible ACS, some of the
traditional risk factors for CAD (e.g., hypertension, hypercho-
lesterolemia, and cigarette smoking) are only weakly predictive
of the likelihood of acute ischemia (145,154) and are far less
important than are symptoms, ECG ﬁndings, and cardiac
biomarkers. Therefore, the presence or absence of these tradi-
tional risk factors ordinarily should not be used to determine
whether an individual patient should be admitted or treated for
ACS. However, the presence of these risk factors does appear
to relate to poor outcomes in patients with established ACS.
Although not as well investigated as the traditional risk factors,
a family history of premature CAD has been demonstrated to
be associated with increased coronary artery calcium scores
greater than the 75th age percentile in asymptomatic individ-
uals (155) and increased risk of 30-d cardiac events in patients
admitted for UA/NSTEMI (156). Of special interest is that
sibling history of premature CAD has a stronger relationship
than parental history (157). However, several of these risk
factors have important prognostic and therapeutic implica-
tions. Diabetes and the presence of extracardiac (carotid, aortic,
or peripheral) vascular disease are major risk factors for poor
outcome in patients with ACS (see Section 6.2). For both
STEMI (158) and UA/NSTEMI (128), patients with these
conditions have a signiﬁcantly higher mortality rate and risk of
acute HF. For the most part, this increase in risk is due to a
greater extent of underlying CAD and LV dysfunction, but in
many studies, diabetes carries prognostic signiﬁcance over and
above these ﬁndings. Similarly, a history of hypertension is
associated with an increased risk of a poor outcome.
The current or prior use of ASA at the time and
presentation of ACS has been associated in 1 database with
increased cardiovascular event risk (159). Although the
rationale is not fully elucidated, it appears those taking prior
ASA therapy have more multivessel CAD, are more likely
to present with thrombus present, may present later in the
evolution of ACS, or may be ASA resistant. Surprisingly,
current smoking is associated with a lower risk of death in
the setting of ACS (159–161), primarily because of the
younger age of smokers with ACS and less severe underly-
ing CAD. This “smokers’ paradox” seems to represent a
tendency for smokers to develop thrombi on less severe
plaques and at an earlier age than nonsmokers.
Being overweight and/or obese at the time of ACS
presentation is associated with lower short-term risk of
death; however, this “obesity paradox” is primarily a func-
tion of younger age at time of presentation, referral for
angiography at an earlier stage of disease, and more aggres-
sive ACS management (160). Although short-term risk
may be lower for overweight/obese individuals, these pa-
tients have a higher long-term total mortality risk (161–
165). Increased long-term cardiovascular risk appears to be
primarily limited to severe obesity (166).
Cocaine use has been implicated as a cause of ACS,
presumably owing to the ability of this drug to cause
Anderson et al ACC/AHA UA/NSTEMI Guideline Revision e167
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
coronary vasospasm and thrombosis in addition to its direct
effects on heart rate and arterial pressure and its myocardial
toxic properties (see Section 6.6) (167). Recently, the use of
methamphetamine has grown, and its association with ACS
also should be considered. It is important to inquire about
the use of cocaine and methamphetamine in patients with
suspected ACS, especially in younger patients (age less than
40 years) and others with few risk factors for CAD. Urine
toxicology should be considered when substance abuse is
suspected as a cause of or contributor to ACS.
2.2.6. Estimation of Early Risk at Presentation
A number of risk assessment tools have been developed to
assist in assessing risk of death and ischemic events in
patients with UA/NSTEMI, thereby providing a basis for
therapeutic decision making (Table 8; Fig. 4) (158,168,169).
It should be recognized that the predictive ability of these
commonly used risk assessment scores for nonfatal CHD
risk is only moderate.
Antman et al. developed the TIMI risk score (159), a
simple tool composed of 7 (1-point) risk indicators rated on
presentation (Table 8). The composite end points (all-cause
mortality, new or recurrent MI, or severe recurrent ischemia
prompting urgent revascularization within 14 d) increase as
the TIMI risk score increases. The TIMI risk score has been
validated internally within the TIMI 11B trial and 2
separate cohorts of patients from the Efﬁcacy and Safety of
Subcutaneous Enoxaparin in Unstable Angina and Non-Q-
Wave Myocardial Infarction (ESSENCE) trial (169). The
model remained a signiﬁcant predictor of events and ap-
peared relatively insensitive to missing information, such as
knowledge of previously documented coronary stenosis of
50% or more. The model’s predictive ability remained intact
with a cutoff of 65 years of age. The TIMI risk score was
recently studied in an unselected ED population with chest
pain syndrome; its performance was similar to that in the
ACS population in which it was derived and validated (170).
The TIMI risk calculator is available at www.timi.org. The
TIMI risk index, a modiﬁcation of the TIMI risk score that
uses the variables age, systolic blood pressure, and heart rate,
has not only been shown to predict short-term mortality in
STEMI but has also been useful in the prediction of 30-d and
1-year mortality across the spectrum of patients with ACS,
including UA/NSTEMI (171).
The PURSUIT risk model, developed by Boersma et al.
(172), based on patients enrolled in the PURSUIT trial, is
another useful tool to guide the clinical decision-making
process when the patient is admitted to the hospital. In the
PURSUIT risk model, critical clinical features associated with
an increased 30-d incidence of death and the composite of
death or myocardial (re)infarction were (in order of strength)
age, heart rate, systolic blood pressure, ST-segment depression,
signs of HF, and cardiac biomarkers (172).
The GRACE risk model, which predicts in-hospital
mortality (and death or MI), can be useful to clinicians to
guide treatment type and intensity (168,173). The GRACE
risk tool was developed on the basis of 11,389 patients in
GRACE, validated in subsequent GRACE and GUSTO
IIb cohorts, and predicts in-hospital death in patients with
STEMI, NSTEMI, or UA (C statistic  0.83). The 8
variables used in the GRACE risk model are older age (odds
ratio [OR] 1.7 per 10 years), Killip class (OR 2.0 per class),
systolic blood pressure (OR 1.4 per 20 mm Hg decrease),
ST-segment deviation (OR 2.4), cardiac arrest during pre-
sentation (OR 4.3), serum creatinine level (OR 1.2 per
1-mg per dL increase), positive initial cardiac biomarkers
(OR 1.6), and heart rate (OR 1.3 per 30-beat per min
increase). The sum of scores is applied to a reference
monogram to determine the corresponding all-cause mor-
tality from hospital discharge to 6 mo. The GRACE clinical
application tool can be downloaded to a handheld PDA to be
used at the bedside and is available at www.outcomes-
umassmed.org/grace (Fig. 4) (173). An analysis comparing the
3 risk scores (TIMI, GRACE, and PURSUIT) concluded that
all 3 demonstrated good predictive accuracy for death and MI
at 1 year, thus identifying patients who might be likely to
beneﬁt from aggressive therapy, including early myocardial
revascularization (174).
The ECG provides unique and important diagnostic and
prognostic information (see also Section 2.2.6.1 below).
Accordingly, ECG changes have been incorporated into
quantitative decision aids for the triage of patients present-
ing with chest discomfort (175). Although ST elevation
carries the highest early risk of death, ST depression on the
presenting ECG portends the highest risk of death at 6
months, with the degree of ST depression showing a strong
relationship to outcome (176).
Dynamic risk modeling is a new frontier in modeling that
accounts for the common observation that levels and pre-
dictors of risk constantly evolve as patients pass through
their disease process. Excellent models have been developed
based on presenting features, but information the next day
Table 8. TIMI Risk Score for
Unstable Angina/Non–ST-Elevation MI
TIMI Risk
Score
All-Cause Mortality, New or Recurrent MI, or Severe
Recurrent Ischemia Requiring Urgent Revascularization
Through 14 d After Randomization, %
0–1 4.7
2 8.3
3 13.2
4 19.9
5 26.2
6–7 40.9
The TIMI risk score is determined by the sum of the presence of 7 variables at admission; 1 point
is given for each of the following variables: age 65 y or older; at least 3 risk factors for CAD; prior
coronary stenosis of 50% or more; ST-segment deviation on ECG presentation; at least 2 anginal
events in prior 24 h; use of aspirin in prior 7 d; elevated serum cardiac biomarkers. Prior coronary
stenosis of 50% or more remained relatively insensitive to missing information and remained a
signiﬁcant predictor of events. Reprinted with permission from Antman EM, Cohen M, Bernink PJ,
et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication
and therapeutic decision making. JAMA 2000;284:835–42 (159). Copyright © 2000 American
Medical Association.
CAD  coronary artery disease; ECG  electrocardiogram; MI  myocardial infarction; y 
year.
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about clinical (e.g., complications), laboratory (e.g., biomar-
ker evolution), and ECG (e.g., ST resolution for STEMI)
changes provides additional data relevant to decisions at key
“decision-node” points in care (177). Dynamic modeling
concepts promise more sophisticated, adaptive, and individ-
ually predictive modeling of risk in the future.
Renal impairment has been recognized as an additional
high-risk feature in patients with ACS (178). Mild to
moderate renal dysfunction is associated with moderately
increased short- and long-term risks, and severe renal
dysfunction is associated with severely increased short- and
long-term mortality risks. Patients with renal dysfunction
Figure 4. GRACE Prediction Score Card and Nomogram for All-Cause Mortality From Discharge to 6 Months
Reprinted with permission from Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month
postdischarge death in an international registry. JAMA 2004;291:2727–33 (168). Copyright © 2004 American Medical Association.
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experience increased bleeding risks, have higher rates of HF
and arrhythmias, have been underrepresented in cardiovas-
cular trials, and may not enjoy the same magnitude of
beneﬁt with some therapies observed in patients with
normal renal function (179) (see also Section 6.5).
Among patients with UA/NSTEMI, there is a progres-
sively greater beneﬁt from newer, more aggressive therapies
such as low-molecular-weight heparin (LMWH) (169,180),
platelet GP IIb/IIIa inhibition (181), and an invasive
strategy (182) with increasing risk score.
2.2.6.1. ELECTROCARDIOGRAM
The ECG is critical not only to add support to the clinical
suspicion of CAD but also to provide prognostic informa-
tion based on the pattern and magnitude of the abnormal-
ities (127,175,183,184). A recording made during an epi-
sode of the presenting symptoms is particularly valuable.
Importantly, transient ST-segment changes (greater than or
equal to 0.05 mV [i.e., 0.5 mm]) that develop during a
symptomatic episode at rest and that resolve when the
patient becomes asymptomatic strongly suggest acute isch-
emia and a very high likelihood of underlying severe CAD.
Patients whose current ECG suggests ischemia can be
assessed with greater diagnostic accuracy if a prior ECG is
available for comparison (Table 6) (185).
Although it is imperfect, the 12-lead ECG lies at the
center of the decision pathway for the evaluation and
management of patients with acute ischemic discomfort
(Fig. 1; Table 6). The diagnosis of MI is conﬁrmed with
serial cardiac biomarkers in more than 90% of patients who
present with ST-segment elevation of greater than or equal
to 1 mm (0.1 mV) in at least 2 contiguous leads, and such
patients should be considered candidates for acute reperfu-
sion therapy. Patients who present with ST-segment de-
pression are initially considered to have either UA or
NSTEMI; the distinction between the 2 diagnoses is
ultimately based on the detection of markers of myocardial
necrosis in the blood (11,126,186).
Up to 25% of patients with NSTEMI and elevated
CK-MB go on to develop Q-wave MI during their hospital
stay, whereas the remaining 75% have non–Q-wave MI.
Acute ﬁbrinolytic therapy is contraindicated for ACS pa-
tients without ST-segment elevation, except for those with
electrocardiographic true posterior MI manifested as ST-
segment depression in 2 contiguous anterior precordial leads
and/or isolated ST-segment elevation in posterior chest
leads (187–189). Inverted T waves may also indicate UA/
NSTEMI. In patients suspected of having ACS on clinical
grounds, marked (greater than or equal to 2 mm [0.2 mV])
symmetrical precordial T-wave inversion strongly suggests
acute ischemia, particularly that due to a critical stenosis of
the left anterior descending coronary artery (LAD) (190).
Patients with this ECG ﬁnding often exhibit hypokinesis of
the anterior wall and are at high risk if given medical
treatment alone (191). Revascularization will often reverse
both the T-wave inversion and wall-motion disorder (192).
Nonspeciﬁc ST-segment and T-wave changes, usually de-
ﬁned as ST-segment deviation of less than 0.5 mm (0.05
mV) or T-wave inversion of less than or equal to 2 mm (0.2
mV), are less diagnostically helpful than the foregoing
ﬁndings. Established Q waves greater than or equal to 0.04 s
are also less helpful in the diagnosis of UA, although by
suggesting prior MI, they do indicate a high likelihood of
signiﬁcant CAD. Isolated Q waves in lead III may be a
normal ﬁnding, especially in the absence of repolarization
abnormalities in any of the inferior leads. A completely
normal ECG in a patient with chest pain does not exclude
the possibility of ACS, because 1% to 6% of such patients
eventually are proved to have had an MI (by deﬁnition, an
NSTEMI), and at least 4% will be found to have UA
(184,193,194).
The common alternative causes of ST-segment and
T-wave changes must be considered. In patients with
ST-segment elevation, the diagnoses of LV aneurysm,
pericarditis, myocarditis, Prinzmetal’s angina, early repolar-
ization (e.g., in young black males), apical LV ballooning
syndrome (Takotsubo cardiomyopathy; see Section 6.9),
and Wolff-Parkinson-White syndrome represent several
examples to be considered. Central nervous system events
and drug therapy with tricyclic antidepressants or phe-
nothiazines can cause deep T-wave inversion.
Acute MI due to occlusion of the left circumﬂex coronary
artery can present with a nondiagnostic 12-lead ECG.
Approximately 4% of acute MI patients show the presence
ST elevation isolated to the posterior chest leads V7 through
V9 and “hidden” from the standard 12 leads (187,195,196).
The presence of posterior ST elevation is diagnostically
important because it qualiﬁes the patient for acute reperfu-
sion therapy as an acute STEMI (1,197). The presence or
absence of ST-segment elevation in the right ventricular
(V4R through V6R) or posterior chest leads (V7 through V9)
also adds prognostic information in the presence of inferior
ST-segment elevation, predicting high and low rates of
in-hospital life-threatening complications, respectively
(196).
With reference to electrocardiographic true posterior
MI, new terminology recently has been proposed based
on the standard of cardiac magnetic resonance (CMR)
imaging localization. CMR studies indicate that abnor-
mally increased R waves, the Q-wave equivalent in leads
V1 and V2, indicate an MI localized to the lateral LV wall
and that abnormal Q waves in I and VL (but not V6)
indicate a mid-anterior wall MI. Thus, the electrocardio-
graphic terms “posterior” and “high lateral MI” refer to
anatomic “lateral wall MI” and “mid-anterior wall MI”
(198). The impact of these ﬁndings and recommenda-
tions for standard electrocardiographic terminology are
unresolved as of this writing.
Several investigators have shown that a gradient of risk of
death and cardiac ischemic events can be established based
on the nature of the ECG abnormality (183,199,200).
Patients with ACS and confounding ECG patterns such as
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bundle-branch block, paced rhythm, or LV hypertrophy are
at the highest risk for death, followed by patients with
ST-segment deviation (ST-segment elevation or depres-
sion); at the lowest risk are patients with isolated T-wave
inversion or normal ECG patterns. Importantly, the prog-
nostic information contained within the ECG pattern
remains an independent predictor of death even after
adjustment for clinical ﬁndings and cardiac biomarker
measurements (199–202).
In addition to the presence or absence of ST-segment
deviation or T-wave inversion patterns as noted earlier,
there is evidence that the magnitude of the ECG abnor-
mality provides important prognostic information. Thus,
Lloyd-Jones et al. (203) reported that the diagnosis of acute
non–Q-wave MI was 3 to 4 times more likely in patients
with ischemic discomfort who had at least 3 ECG leads that
showed ST-segment depression and maximal ST depression
of greater than or equal to 0.2 mV. Investigators from the
TIMI III Registry (199) reported that the 1-year incidence
of death or new MI in patients with at least 0.5 mm (0.05
mV) of ST-segment deviation was 16.3% compared with
6.8% for patients with isolated T-wave changes and 8.2%
for patients with no ECG changes.
Physicians frequently seek out a previous ECG for
comparison in patients with suspected ACS. Studies have
demonstrated that patients with an unchanged ECG
have a reduced risk of MI and a very low risk of
in-hospital life-threatening complications even in the
presence of confounding ECG patterns such as LV
hypertrophy (204–206).
Because a single 12-lead ECG recording provides only a
snapshot view of a dynamic process (207), the usefulness of
obtaining serial ECG tracings or performing continuous
ST-segment monitoring has been studied (175,208). Al-
though serial ECGs increase the ability to diagnose UA and
MI (208–212), the yield is higher with serial cardiac
biomarker measurements (212–214). However, identiﬁca-
tion of new injury on serial 12-lead ECG (and not elevated
cardiac biomarkers) is the principal eligibility criterion for
emergency reperfusion therapy, so that monitoring of both
is recommended. Continuous 12-lead ECG monitoring to
detect ST-segment shifts, both symptomatic and asymp-
tomatic, also can be performed with microprocessor-
controlled programmable devices. An injury current was
detected in an additional 16% of chest pain patients in 1
study (213). The identiﬁcation of ischemic ECG changes
on serial or continuous ECG recordings frequently alters
therapy and provides independent prognostic information
(212,215,216).
2.2.6.2. PHYSICAL EXAMINATION
The major objectives of the physical examination are to
identify potential precipitating causes of myocardial isch-
emia, such as uncontrolled hypertension, thyrotoxicosis, or
gastrointestinal bleeding, and comorbid conditions that
could impact therapeutic risk and decision making, such as
pulmonary disease and malignancies, as well as to assess the
hemodynamic impact of the ischemic event. Every patient
with suspected ACS should have his or her vital signs
measured (blood pressure in both arms if dissection is
suspected, as well as heart rate and temperature) and should
undergo a thorough cardiovascular and chest examination.
Patients with evidence of LV dysfunction on examination
(rales, S3 gallop) or with acute mitral regurgitation have a
higher likelihood of severe underlying CAD and are at a
high risk of a poor outcome. Just as the history of extracar-
diac vascular disease is important, the physical examination
of the peripheral vessels can also provide important prog-
nostic information. The presence of bruits or pulse deﬁcits
that suggest extracardiac vascular disease identiﬁes patients
with a higher likelihood of signiﬁcant CAD.
Elements of the physical examination can be critical in
making an important alternative diagnosis in patients with
chest pain. In particular, several disorders carry a signiﬁcant
threat to life and function if not diagnosed acutely. Aortic
dissection is suggested by pain in the back, unequal pulses,
or a murmur of aortic regurgitation. Acute pericarditis is
suggested by a pericardial friction rub, and cardiac tampon-
ade can be evidenced by pulsus paradoxus. Pneumothorax is
suspected when acute dyspnea, pleuritic chest pain, and
differential breath sounds are present.
The importance of cardiogenic shock in patients with
NSTEMI should be emphasized. Although most literature
on cardiogenic shock has focused on STEMI, the SHould
we emergently revascularize Occluded Coronaries for car-
diogenic shocK (SHOCK) study (217) found that approx-
imately 20% of all cardiogenic shock complicating MI was
associated with NSTEMI. The Global Use of Strategies to
Open Occluded Coronary Arteries (GUSTO)-II (218) and
PURSUIT (128) trials found that cardiogenic shock occurs
in up to 5% of patients with NSTEMI and that mortality
rates are greater than 60%. Thus, hypotension and evidence
of organ hypoperfusion can occur and constitute a medical
emergency in NSTEMI.
2.2.7. Noncardiac Causes of Symptoms and Secondary
Causes of Myocardial Ischemia
Information from the initial history, physical examination,
and ECG (Table 6) can enable the physician to classify and
exclude from further assessment patients “not having isch-
emic discomfort.” This includes patients with noncardiac
pain (e.g., pulmonary embolism, musculoskeletal pain, or
esophageal discomfort) or cardiac pain not caused by myo-
cardial ischemia (e.g., acute pericarditis). The remaining
patients should undergo a more complete evaluation of the
secondary causes of UA that might alter management. This
evaluation should include a physical examination for evi-
dence of other cardiac disease, an ECG to screen for
arrhythmias, measurement of body temperature and blood
pressure, and determination of hemoglobin or hematocrit.
Cardiac disorders other than CAD that can cause myocar-
dial ischemia include aortic stenosis and hypertrophic car-
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diomyopathy. Factors that increase myocardial oxygen de-
mand or decrease oxygen delivery to the heart can provoke
or exacerbate ischemia in the presence of signiﬁcant under-
lying CAD or secondary angina; previously unrecognized
gastrointestinal bleeding that causes anemia is a common
secondary cause of worsening angina or the development of
symptoms of ACS. Acute worsening of chronic obstructive
pulmonary disease (with or without superimposed infection)
can lower oxygen saturation levels sufﬁciently to intensify
ischemic symptoms in patients with CAD. Evidence of
increased cardiac oxygen demand can be suspected in the
presence of fever, signs of hyperthyroidism, sustained tachy-
arrhythmias, or markedly elevated blood pressure. Another
cause of increased myocardial oxygen demand is arterio-
venous ﬁstula in patients receiving dialysis.
The majority of patients seen in the ED with symptoms
of possible ACS will be judged after their workup not to
have a cardiac problem. One clinical trial of a predictive
instrument evaluated 10,689 patients with suspected ACS
(75). To participate, patients were required to be greater
than 30 years of age with a chief symptom of chest, left arm,
jaw, or epigastric pain or discomfort; shortness of breath;
dizziness; palpitations; or other symptoms suggestive of
acute ischemia. After evaluation, 7,996 patients (75%) were
deemed not to have acute ischemia.
2.2.8. Cardiac Biomarkers of Necrosis and the
Redeﬁnition of AMI
Cardiac biomarkers have proliferated over recent years to
address various facets of the complex pathophysiology of
ACS. Some, like the cardiac troponins, have become essen-
tial for risk stratiﬁcation of patients with UA/NSTEMI and
for the diagnosis of MI. Others, such as the inﬂammatory
markers, are opening new perspectives on pathophysiology
and risk stratiﬁcation, and the use in clinical practice of
selected new markers may be recommended for clinical use
in the near future. Still other promising markers are being
developed as part of translational research and await pro-
spective validation in various populations. New develop-
ments are expected in the ﬁelds of proteomic and genomics,
cell markers and circulating microparticles, and microtech-
nology and nanotechnology imaging.
Current markers of necrosis leak from cardiomyocytes
after the loss of membrane integrity and diffuse into the
cardiac interstitium, then into the lymphatics and cardiac
microvasculature. Eventually, these macromolecules, collec-
tively referred to as cardiac biomarkers, are detectable in the
peripheral circulation. Features that favor their diagnostic
performance are high concentrations in the myocardium
and absence in nonmyocardial tissue, release into the blood
within a convenient diagnostic time window and in propor-
tion to the extent of myocardial injury, and quantiﬁcation
with reproducible, inexpensive, and rapid and easily applied
assays (11). The cardiac troponins possess many of these
features and have gained wide acceptance as the biomarkers
of choice in the evaluation of patients with ACS for
diagnosis, risk stratiﬁcation, and treatment selection.
The traditional deﬁnitions of MI were revisited in 2000
in a consensus document of a joint committee of the
European Society of Cardiology (ESC) and ACC (219) and
at the time of publication is being updated by an expanded
joint task force of the ESC, ACC, AHA, World Heart
Federation (WHF), and World Health Organization. The
new deﬁnitions are inspired by the emergence of new highly
sensitive and speciﬁc diagnostic methods that allow the
detection of areas of cell necrosis as small as 1 g. Myocardial
necrosis in the task force document is deﬁned by an
elevation of troponin above the 99th percentile of normal.
Myocardial infarction, which is necrosis related to ischemia,
is further deﬁned by the addition to the troponin elevation
of at least 1 of the following criteria: ischemic ST and
T-wave changes, new left bundle-branch block, new Q
waves, PCI-related marker elevation, or positive imaging for
a new loss of viable myocardium. Myocardial infarction can
still be diagnosed in the absence of measurement of tropo-
nin when there is evidence of a new loss of viable myocar-
dium, ST-segment elevation, or new left bundle-branch
block with sudden cardiac death within 1 h of symptoms, or
a postmortem pathological diagnosis. Coronary artery by-
pass graft-related MI is diagnosed by an increase of cardiac
biomarkers to more than 5 to 10-fold the 99th percentile of
normal, new Q waves or new left bundle-branch block on
the ECG, or a positive imaging test. The task force further
recommended further deﬁning MI by the circumstances
that cause it (spontaneous or in the setting of a diagnostic or
therapeutic procedure), by the amount of cell loss (infarct
size), and by the timing of MI (evolving, healing, or healed)
(219,220). Providing fold-elevations above normal for di-
agnostic biomarkers, to allow for meaningful comparisons
among clinical trials, is also endorsed.
At the present time, the implications of using the new
ESC/ACC redeﬁnition of MI have not been fully explored;
much of the present database for UA/NSTEMI derives
from CK/CK-MB–based deﬁnitions of MI. Moreover,
troponin assays have rapidly evolved through several gener-
ations over the past decade, becoming increasingly more
sensitive and speciﬁc. Thus, it is important to recognize that
the recommendations in this section are formulated from
studies that frequently utilize modiﬁed World Health Or-
ganization criteria or deﬁnitions of MI based on earlier-
generation troponin assays.
2.2.8.1. CREATINE KINASE-MB
Creatine kinase-MB, a cytosolic carrier protein for high-
energy phosphates, has long been the standard marker for
the diagnosis of MI. Creatine kinase-MB, however, is less
sensitive and less speciﬁc for MI than the cardiac troponins.
Low levels of CK-MB can be found in the blood of healthy
persons, and elevated levels occur with damage to skeletal
muscle (221).
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When a cardiac troponin is available, the determination
of CK-MB remains useful in a few speciﬁc clinical situa-
tions. One is the diagnosis of early infarct extension (rein-
farction), because the short half-life of CK-MB compared
with troponin permits the detection of a diagnostic new
increase after initial peak. Although routine determination
of CK-MB has been suggested for the diagnosis of an
eventual infarct extension, a single CK-MB determination
obtained when symptoms recur may serve as the baseline
value for comparison with samples obtained 6 to 12 h later.
Another situation is the diagnosis of a periprocedural MI,
because the diagnostic and prognostic value of CK-MB in
these situations has been extensively validated. When as-
sessed, CK-MB should be measured by mass immunoassays
and not by other methods previously used (222). The use of
other, older biochemistry assays of nonspeciﬁc markers such
as alanine transaminase, aspartate transaminase, and lactate
dehydrogenase should generally be avoided in contemporary
practice.
2.2.8.2. CARDIAC TROPONINS
The troponin complex consists of 3 subunits: T (TnT), I
(TnI), and C (TnC) (223). The latter is expressed by both
cardiac and skeletal muscle, whereas TnT and TnI are
derived from heart-speciﬁc genes. Therefore, the term
“cardiac troponins” (cTn) in these guidelines refers speciﬁ-
cally to either cTnT or cTnI. Cardiac troponin as a
biomarker provides robust results that are highly sensitive
and speciﬁc in detecting cell necrosis; an early release is
attributable to a cytosolic pool and a late release to the
structural pool (219,224).
Because cTnT and cTnI generally are not detected in the
blood of healthy persons, the cutoff value for elevated cTnT
and cTnI levels may be set to slightly above the upper limit
of the performance characteristics of the assay for a normal
healthy population. High-quality analytic methods are
needed to achieve these high standards (225). One issue
with the use of cTnI is the multiplicity of existing assays
that have different analytical sensitivities, some being unable
to detect the lower values with a reasonable precision (226).
Physicians therefore need to know the sensitivity of the tests
used for TnI in their hospitals at the cutoff concentrations
used for clinical decisions. Such heterogeneity does not exist
for cTnT, which exists as a single test; this test is now a
third-generation immunoassay that uses recombinant
monoclonal human antibodies (224). Rare patients may
have blocking antibodies to part of the troponin molecule,
which would result in false-negative results (227).
2.2.8.2.1. CLINICAL USE
Although troponins can be detected in blood as early as 2 to
4 h after the onset of symptoms, elevation can be delayed for
up to 8 to 12 h. This timing of elevation is similar to that of
CK-MB but persists longer, for up to 5 to 14 d (Fig. 5). An
increasing pattern in serial levels best helps determine
whether the event is acute, distinct from a previous event,
subacute, or chronic.
The proportion of patients showing a positive cTn value
depends on the population of patients under evaluation.
Approximately 30% of patients with typical rest chest
discomfort without ST-segment elevation who would be
diagnosed as having UA because of a lack of CK-MB
elevation actually have NSTEMI when assessed with
cardiac-speciﬁc troponin assays. The diagnosis of MI in the
community at large when cTn is used results in a large
increase in the incidence of MIs, by as much as 41%
compared with use of only CK-MB alone, and a change in
the case mix, with a survival rate that is better than that of
MI identiﬁed by the previous criteria (228). Troponin
elevation conveys prognostic information beyond that sup-
plied by the clinical characteristics of the patient, the ECG
at presentation, and the predischarge exercise test
(200,201,229–231). Furthermore, a quantitative relation-
ship exists between the amount of elevation of cTn and the
risk of death (200,201) (Fig. 6). The incremental risk of
death or MI in troponin-positive versus troponin-negative
patients is summarized in Table 9. It should be cautioned,
however, that cTn should not be used as the sole marker of
risk, because patients without troponin elevations can still
have a substantial risk of an adverse outcome.
Figure 5. Timing of Release of Various Biomarkers
After Acute Myocardial Infarction
The biomarkers are plotted showing the multiples of the cutoff for acute myocardial
infarction (AMI) over time. The dashed horizontal line shows the upper limit of nor-
mal (ULN; deﬁned as the 99th percentile from a normal reference population with-
out myocardial necrosis; the coefﬁcient of variation of the assay should be 10% or
less). The earliest rising biomarkers are myoglobin and CK isoforms (leftmost
curve). CKMB (dashed curve) rises to a peak of 2 to 5 times the ULN and typically
returns to the normal range within 2 to 3 d after AMI. The cardiac-speciﬁc troponins
show small elevations above the ULN in small infarctions (e.g., as is often the
case with NSTEMI) but rise to 20 to 50 times the ULN in the setting of large infarc-
tions (e.g., as is typically the case in STEMI). The troponin levels may stay elevated
above the ULN for 7 d or more after AMI. Modiﬁed from Shapiro BP, Jaffe AS. Car-
diac biomarkers. In: Murphy JG, Lloyd MA, editors. Mayo Clinic Cardiology: Concise
Textbook. 3rd ed. Rochester, MN: Mayo Clinic Scientiﬁc Press and New York:
Informa Healthcare USA, 2007:773–80 (70). Used with permission of Mayo Foun-
dation for Medical Education and Research. CK  creatine kinase; CKMB  MB
fraction of creatine kinase; CV  coefﬁcient of variation; MI  myocardial infarc-
tion; NSTEMI  non–ST-elevation myocardial infarction; UA/NSTEMI  unstable
angina/non–ST-elevation myocardial infarction.
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Although cTn accurately identiﬁes myocardial necrosis, it
does not inform as to the cause or causes of necrosis; these
can be multiple (224) and include noncoronary causes such
as tachyarrhythmia, cardiac trauma by interventions, chest
trauma from motor vehicle accidents, HF, LV hypertrophy,
myocarditis, and pericarditis, as well as severe noncardiac
conditions such as sepsis, burns, respiratory failure, acute
neurological diseases, pulmonary embolism, pulmonary hy-
pertension, drug toxicity, cancer chemotherapy, and renal
insufﬁciency (230). Therefore, in making the diagnosis of
NSTEMI, cTns should be used in conjunction with other
criteria of MI, including characteristics of the ischemic
symptoms and the ECG.
In all of these situations, equivalent information is gen-
erally obtained with cTnI and cTnT, except in patients with
renal dysfunction, in whom cTnI assessment appears to
have a speciﬁc role (227). Among patients with end-stage
renal disease and no clinical evidence of acute myocardial
necrosis, 15% to 53% show increased cTnT, but fewer than
10% have increased cTnI; dialysis generally increases cTnT
but decreases cTnI. The exact reasons for the high rates of
elevation in the cTn, especially cTnT, in renal failure are not
clear; they can relate to cardiac damage, differential clear-
ance, or to other biochemical or metabolic abnormalities (227).
Whatever the reasons and the sources, an elevation of cTn,
including cTnT, in patients with renal insufﬁciency is associ-
ated with a higher risk of morbidity regardless of the presence
of cardiac symptoms or documented CAD. Among 7,033
patients enrolled in the GUSTO IV trial with suspected ACS,
TnT level was independently predictive of risk across the entire
spectrum of renal function enrolled (233).
Aggressive preventive measures for patients with renal
insufﬁciency have been suggested, because most deaths in
renal failure are of cardiac origin (227). Unfortunately, some
standard therapies, such as lipid lowering with statins or PCI,
have been less effective in improving survival in certain patient
populations with advanced renal insufﬁciency (234,235). Fur-
thermore, patients with suspected UA/NSTEMI have partic-
ularly unfavorable outcomes when in renal failure, with an
event rate that correlates with the decrease in creatinine
clearance (236–239). A sequential change in cTn levels in the
ﬁrst 24 h of observation for a suspected ACS supports new
myocardial injury, whereas unchanging levels are more consis-
tent with a chronic disease state without ACS.
Figure 6. Troponin I Levels to Predict the Risk
of Mortality in Acute Coronary Syndromes
Mortality rates are at 42 d (without adjustment for baseline characteristics) in
patients with acute coronary syndrome. The numbers at the bottom of each bar are
the numbers of patients with cardiac troponin I levels in each range, and the num-
bers above the bars are percentages. p less than 0.001 for the increase in the
mortality rate (and the risk ratio for mortality) with increasing levels of cardiac tro-
ponin I at enrollment. Reprinted with permission from Antman EM, Tanasijevic MJ,
Thompson B, et al. Cardiac-speciﬁc troponin I levels to predict the risk of mortality
in patients with acute coronary syndromes. N Engl J Med 1996;335:1342–9 (201).
Copyright © 1996 Massachusetts Medical Society. All rights reserved.
Table 9. Risk of Death Associated With a Positive Troponin Test in Patients With Suspected ACS
Subgroup
Events/Total
Summary RR 95% CI No. of StudiesNegative Troponin Positive Troponin
TnT
Total death 32/1,187 46/473 3.1 2.0 to 4.9 5
Cardiac death 31/1,689 52/744 3.8 2.4 to 6.0 7
UA patients* 21/397 26/198 2.5 1.4 to 4.5 5
Chest pain patients* 43/2,479 73/1,019 4.0 2.7 to 5.9 7
TnI
Total death 34/1,451 49/815 3.1 2.0 to 4.9 3
Cardiac death 3/905 26/384 25.0 11 to 55 2
UA patients* 2/70 2/22 3.2 0.3 to 40 1
Chest pain patients* 35/2,286 73/1,177 5.1 3.4 to 7.6 4
TnT and TnI combined†
Total death 42/2,088 69/1,068 3.3 2.2 to 4.8 7
Cardiac death 28/1,641 55/792 5.0 3.2 to 7.9 7
*Outcomes of cardiac death and total death are pooled. †Some studies provided both troponin T (TnT) and I (TnI) data. For the combined analysis, data from 1 marker were chosen randomly. Reprinted
with permission from Heidenreich PA, Go A, Melsop KA, et al. Prediction of risk for patients with unstable angina. Evidence Report/Technology Assessment No. 31 (prepared by the UCSF-Stanford
Evidence-Based Practice Center under contract no. 290-97-0013). AHRQ publication no. 01-E001. Rockville, MD: Agency for Healthcare Research and Quality, December 2000. Available at:
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?ridhstat1.chapter.45627. Accessed August 10, 2006 (232).
ACS  acute coronary syndrome; CI  conﬁdence interval; RR  relative risk; UA  unstable angina.
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Troponin elevation has important therapeutic implica-
tions. It permits the identiﬁcation of high-risk patients and
of subsets of patients who will beneﬁt from speciﬁc thera-
pies. Thus, among patients with UA/NSTEMI, those with
elevated cTn beneﬁt from treatment with platelet GP
IIb/IIIa inhibitors, whereas those without such elevation
may not beneﬁt or may even experience a deleterious effect.
For example, in the c7E3 Fab Antiplatelet Therapy in
Unstable Refractory Angina (CAPTURE) trial, the rates of
death or nonfatal MI with cTnT elevation were 23.9% with
placebo versus 9.5% with abciximab (p  0.002) (240).
Similar results have been reported for cTnI and cTnT with
use of tiroﬁban (241). The beneﬁt of LMWH was also
greater in UA/NSTEMI patients with positive cTn. In the
Fragmin during Instability in Coronary Artery Disease
(FRISC) trial, the rates of death or nonfatal MI through 40
d increased progressively in the placebo group from 5.7% in
the lowest tertile to 12.6% and 15.7% in the second and
third tertiles, respectively, compared with rates of 4.7%,
5.7%, and 8.9%, respectively, in the dalteparin group, which
represents risk reductions in events by increasing tertiles of
17.5%, 43%, and 55% (242). Similar differential beneﬁts
were observed with enoxaparin versus unfractionated hepa-
rin (UFH) in the ESSENCE trial (169). By contrast and of
interest, patients with UA/NSTEMI but without elevated
cTnT in the Clopidogrel in Unstable angina to prevent
Recurrent ischemic Events (CURE) trial beneﬁted as much
from clopidogrel, a platelet P2Y12 adenosine diphosphate
(ADP) receptor inhibitor, as patients with elevated levels
(243). The placebo-controlled Intracoronary Stenting and
Antithrombotic Regimen–Rapid Early Action for Coronary
Treatment (ISAR-REACT)-2 trial compared triple-
antiplatelet therapy with ASA, clopidogrel, and abciximab
to double therapy with ASA and clopidogrel in patients
with UA/NSTEMI undergoing PCI; 52% of patients were
troponin positive, and 48% were troponin negative. The
30-d event rates were similar at 4.6% in patients with
normal cTnT levels but were reduced by close to 30% with
the triple therapy (13.1% vs. 18.3%) in patients with
elevated levels (244). The reasons for the differential beneﬁt
could pertain to a beneﬁt that does not emerge in the
low-risk patient, or that is overshadowed by complications
related to treatment.
Such also appears to be the case with the GP IIb/IIIa
antagonists and with an invasive management strategy that
includes application of interventional procedures. Indeed, in 2
trials that compared an early routine invasive strategy to a
routine noninvasive strategy, the FRISC-II and Treat Angina
with Aggrastat and determine Cost of Therapy with Invasive
or Conservative Strategy (TACTICS) TIMI-18 trials, patients
who proﬁted from the early invasive treatment strategy were
those at high risk as determined by cTnT levels and the
admission ECG. In the FRISC study, the invasive strategy
reduced the 12-month risk of death or MI by 40% (13.2% vs.
22.1%, p 0.001) in the cohort with both ST depression and
a cTnT level of 0.03 mcg per liter or greater, but the absolute
gain of the invasive strategy was insigniﬁcant in the cohorts
with either ST depression, cTnT level elevation, or neither of
these ﬁndings (245). In the TACTICS TIMI-28 study,
subgroups of patients with no ECG changes, a low TIMI
score, and no cTn elevation showed no beneﬁt from the
invasive strategy, whereas those with positive cTn, indepen-
dent of the presence of elevated CK-MB levels, showed
markedly reduced odds of adverse clinical events of 0.13 at 30
d (95% conﬁdence interval [CI]  0.04 to 0.39) and 0.29 at
180 d (95% CI  0.16 to 0.52) (246).
2.2.8.2.1.1. CLINICAL USE OF MARKER CHANGE SCORES. A
newer method to both identify and exclude MI within 6 h
of symptoms is to rely on changes in serum marker levels
(delta values) over an abbreviated time interval (e.g., 2 h) as
opposed to the traditional approach of performing serial
measurements over 6 to 8 h (212,214,247–250). Because
assays are becoming more sensitive and precise, this method
permits the identiﬁcation of increasing values while they are
still in the normal or indeterminate range of the assay. By
relying on delta values for the identiﬁcation or exclusion of
MI, higher-risk patients with positive delta values can be
selected earlier for more aggressive anti-ischemic therapy
(e.g., GP IIb/IIIa inhibitors), and lower-risk patients with
negative delta values can be considered for early stress
testing (212,214,249–251). One study of 1,042 patients
found the addition of a 3-h delta CK-MB to result in a
sensitivity of 93% and a speciﬁcity of 94% for MI (248). In
another study of 2,074 consecutive ED chest pain patients,
a 2-h delta CK-MB in conjunction with a 2-h delta
troponin I measurement had a sensitivity for acute MI of
93% and speciﬁcity of 94% in patients whose initial ECG
was nondiagnostic for injury. When combined with physi-
cian judgment and selective nuclear stress testing, the
sensitivity for MI was 100% with speciﬁcity of 82%, and the
sensitivity for 30-d ACS was 99.1% with speciﬁcity of 87%
(214). Because there are no manufacturer-recommended delta
cutoff values, the appropriate delta values for identiﬁcation
and exclusion of MI should take into account the sensitivity
and precision of the speciﬁc assay utilized and should be
conﬁrmed by in-house studies. It also is important for delta
values to be measured on the same instrument owing to
subtle variations in calibration among individual instru-
ments, even of the same model.
Another method to exclude MI within 6 h of symptom
onset is the multimarker approach, which utilizes the serial
measurement of myoglobin (i.e., a very early marker) in
combination with the serial measurements of cTn and/or
CK-MB (i.e., a later marker) (252–256). Studies have
reported that multimarker measurements at baseline and 90
min have a sensitivity for MI of approximately 95% with a
high negative predictive value, thus allowing for the early
exclusion of MI when combined with clinical judgment
(254,255). However, because of the low speciﬁcity of the
multimarker strategy (mainly due to the lower speciﬁcity of
myoglobin), a positive multimarker test is inadequate to
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diagnose MI and requires conﬁrmation with a later-
appearing deﬁnitive marker (254,257).
2.2.8.2.1.2. BEDSIDE TESTING FOR CARDIAC MARKERS. Car-
diac markers can be measured in the central chemistry
laboratory or with point-of-care instruments in the ED with
desktop devices or handheld bedside rapid qualitative assays
(229). When a central laboratory is used, results should be
available as soon as possible, with a goal of within 60 min.
Point-of-care systems, if implemented at the bedside, have
the advantage of reducing delays due to transportation and
processing in a central laboratory and can eliminate delays
due to the lack of availability of central laboratory assays at
all hours. Certain portable devices can simultaneously mea-
sure myoglobin, CK-MB, and troponin I (249). These
advantages of point-of-care systems must be weighed
against the need for stringent quality control and appropri-
ate training of ED personnel in assay performance and the
higher costs of point-of-care testing devices relative to
determinations in the central laboratory. In addition, these
point-of-care assays at present are qualitative or, at best,
semiquantitative. To date, bedside testing has not succeeded
in becoming widely accepted or applied.
2.2.8.3. MYOGLOBIN AND CK-MB SUBFORMS COMPARED WITH TROPONINS
Myoglobin, a low-molecular-weight heme protein found in
both cardiac and skeletal muscle, is not cardiac speciﬁc, but
it is released more rapidly from infarcted myocardium than
are CK-MB and cTn and can be detected as early as 2 h
after the onset of myocardial necrosis. However, the clinical
value of serial determinations of myoglobin for the diagnosis
of MI is limited by its brief duration of elevation of less than
24 h. Thus, an isolated early elevation in patients with a
nondiagnostic ECG should not be relied on to make the
diagnosis of MI but should be supplemented by a more
cardiac-speciﬁc marker (258). Creatine kinase-MB sub-
forms are also efﬁcient for the early diagnosis of MI and
have a similar speciﬁcity to that of CK-MB but require
special expertise, with no real advantage over better stan-
dardized and more easily applied cTn testing.
2.2.8.4. SUMMARY COMPARISON OF BIOMARKERS OF NECROSIS: SINGLY AND
IN COMBINATION
Table 10 compares the advantages and disadvantages of
cardiac biomarkers of necrosis that are currently used for the
evaluation and management of patients with suspected ACS
but without ST-segment elevation on the 12-lead ECG.
Given the overlapping time frame of the release pattern of
cardiac biomarkers, it is important that clinicians incorpo-
rate the time from the onset of the patient’s symptoms into
their assessment of the results of biomarker measurements
(11,252,259,260) (Fig. 5).
Many patients with suspected ACS have combined as-
sessments of troponin and CK-MB. When baseline tropo-
nin and CK-MB were used together for diagnostic and risk
assessment across the spectrum of chest pain syndromes in
a large database that consisted of several clinical trials, those
with positive results for both markers were at highest
short-term (24 h and 30 d) risk of death or MI (261).
However, those with baseline troponin elevation without
CK-MB elevation also were at increased 30-d risk, whereas
risk with isolated CK-MB elevation was lower and not
signiﬁcantly different than if both markers were negative
(261).
In summary, the cTns are currently the markers of choice
for the diagnosis of MI. They have a sensitivity and
speciﬁcity as yet unsurpassed, which allows for the recogni-
tion of very small amounts of myocardial necrosis. These
small areas of infarction are the consequence of severe
ischemia and/or distal microembolization of debris from an
unstable thrombogenic plaque. The unstable plaques are
likely responsible for the high-risk situation. Thus, cTns as
biomarkers are not only markers of cell necrosis but also of
an active thrombogenic plaque, and hence, they indicate
prognosis and are useful in guiding therapies. Although not
quite as sensitive or speciﬁc as the cTns, CK-MB by mass
assay is a second-choice marker that remains useful for the
diagnosis of MI extension and of periprocedural MI. Rou-
tine use of myoglobin and other markers is not generally
recommended.
Because many methods exist, many with multiple test
generations, for cardiac biomarker testing in practice and in
published reports, physicians should work with their clinical
laboratories to ensure use of and familiarity with contem-
porary test technology, with appropriate, accurate ranges of
normal and diagnostic cutoffs, speciﬁc to the assay used.
2.2.9. Other Markers and Multimarker Approaches
Besides markers of myocardial necrosis, markers of patho-
physiological mechanisms implicated in ACS are under
investigation and could become useful to determine patho-
physiology, individualize treatment, and evaluate therapeu-
tic effects. In considering the clinical application of new
biomarkers, it is important to determine that they provide
incremental value over existing biomarkers. A multimarker
approach to risk stratiﬁcation of UA/NSTEMI (e.g., simul-
taneous assessment of cTnI, C-reactive protein [CRP], and
BNP) has been advocated as a potential advance over single
biomarker assessment (262,263). Further evaluation of a
multimarker approach will be of interest.
2.2.9.1. ISCHEMIA
Other new biochemical markers for the detection of myo-
cardial necrosis are either less useful or have been less well
studied than those mentioned above. An example is
ischemia-modiﬁed albumin found soon after transient cor-
onary occlusion and preceding any signiﬁcant elevations in
myoglobin, CK-MB, or cTnI. This modiﬁed albumin
depends on a reduced capacity of human albumin to bind
exogenous cobalt during ischemia (264,265). Choline is
released upon the cleavage of phospholipids and could also
serve as a marker of ischemia. Growth-differentiation
factor-15 (GDF-15), a member of the transforming growth
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factor- cytokine superfamily that is induced after
ischemia-and-reperfusion injury, is a new biomarker that
has been reported to be of incremental prognostic value for
death in patients with UA/NSTEMI (265a).
2.2.9.2. COAGULATION
Markers of activity of the coagulation cascade, including
elevated plasma levels of ﬁbrinogen, the prothrombin
fragments, ﬁbrinopeptide, and D-dimers, are elevated in
ACS but have little discriminative ability for a speciﬁc patho-
physiology, diagnosis, or treatment assessments (266,267). In
experimental studies, markers of thrombin generation are
blocked by anticoagulants but reactivate after their discon-
tinuation (268) and are not affected by clopidogrel (269).
2.2.9.3. PLATELETS
Platelet activation currently is difﬁcult to assess directly in
vivo. New methods, however, are emerging that should
allow a better and more efﬁcient appraisal of their state of
activation and of drug effects (270–272). Alternative mark-
ers of platelet activity are also being studied, including
CD40L, platelet-neutrophil coaggregates, P-selectin, and
platelet microparticles.
2.2.9.4. INFLAMMATION
Systemic markers of inﬂammation are being widely studied
and show promise for providing additional insights into
pathophysiological mechanisms proximal to and triggering
thrombosis, as well as suggesting novel therapeutic ap-
proaches. White blood cell counts are elevated in patients
with MI, and this elevation has prognostic implications.
Patients without biochemical evidence of myocardial necro-
sis but who have elevated CRP levels on admission or past
the acute-phase reaction after 1 month and who have values
in the highest quartile are at an increased risk of an adverse
outcome (273–275). Elevated levels of interleukin-6, which
promotes the synthesis of CRP, and of other proinﬂamma-
Table 10. Biochemical Cardiac Markers for the Evaluation and Management of
Patients With Suspected ACS But Without ST-Segment Elevation on 12-Lead ECG
Marker Advantages Disadvantages
Point-of-Care
Test
Available? Comment
Clinical
Recommendation
Cardiac troponins 1. Powerful tool for risk stratiﬁcation
2. Greater sensitivity and speciﬁcity
than CK-MB
3. Detection of recent MI up to
2 weeks after onset
4. Useful for selection of therapy
5. Detection of reperfusion
1. Low sensitivity in very
early phase of MI
(less than 6 h after
symptom onset) and
requires repeat
measurement at 8 to
12 h, if negative
2. Limited ability to
detect late minor
reinfarction
Yes Data on diagnostic
performance and potential
therapeutic implications
increasingly available from
clinical trials
Useful as a single test
to efﬁciently
diagnose NSTEMI
(including minor
myocardial
damage), with
serial
measurements.
Clinicians should
familiarize
themselves with
diagnostic “cutoffs”
used in their local
hospital laboratory
CK-MB 1. Rapid, cost-efﬁcient, accurate
assays
2. Ability to detect early reinfarction
1. Loss of speciﬁcity
in setting of skeletal
muscle disease or
injury, including
surgery
2. Low sensitivity during
very early MI (less than
6 h after symptom
onset) or later after
symptom onset (more
than 36 h) and for
minor myocardial
damage (detectable
with troponins)
Yes Familiar to majority of
clinicians
Prior standard and
still acceptable
diagnostic test in
most clinical
circumstances
Myoglobin 1. High sensitivity
2. Useful in early detection of MI
3. Detection of reperfusion
4. Most useful in ruling out MI
1. Very low speciﬁcity in
setting of skeletal
muscle injury or
disease
2. Rapid return to normal
range limits sensitivity
for later presentations
Yes More convenient early marker
than CK-MB isoforms
because of greater
availability of assays for
myoglobin; rapid-release
kinetics make myoglobin
useful for noninvasive
monitoring of reperfusion
in patients with established
MI
ACS  acute coronary syndrome; CK-MB  MB fraction of creatine kinase; ECG  electrocardiogram; h  hours; MI  myocardial infarction; NSTEMI  non–ST-elevation MI.
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tory cytokines also have been studied for their prognostic
value (276). Other potentially useful markers are levels of
circulating soluble adhesion molecules, such as intercellular
adhesion molecule-1, vascular cell adhesion molecule-1, and
E-selectin (277); the pregnancy–associated plasma protein-A,
which is a zinc-binding matrix metalloproteinase released
with neorevascularization and believed to be a marker of
incipient plaque rupture (278); myeloperoxidase, a
leukocyte-derived protein that generates reactive oxidant
species that contribute to tissue damage, inﬂammation, and
immune processes within atherosclerotic lesions (279); and
others. At this writing, none of these have been adequately
studied or validated to be recommended for routine clinical
application in UA/NSTEMI.
2.2.9.5. B-TYPE NATRIURETIC PEPTIDES
One newer biomarker of considerable interest that now may
be considered in the guidelines recommendations is BNP.
B-type natriuretic peptide is a cardiac neurohormone re-
leased upon ventricular myocyte stretch as proBNP, which
is enzymatically cleaved to the N-terminal proBNP (NT-
proBNP) and, subsequently, to BNP. The usefulness of
assessing this neurohormone was ﬁrst shown for the diag-
nosis and evaluation of HF. Since then, numerous prospec-
tive studies and data from large data sets have documented
its powerful prognostic value independent of conventional
risk factors for mortality in patients with stable and unstable
CAD (263,280–284). A review of available studies in ACS
showed that when measured at ﬁrst patient contact or
during the hospital stay, the natriuretic peptides are strong
predictors of both short- and long-term mortality in pa-
tients with STEMI and UA/NSTEMI (280). Increasing
levels of NT-proBNP are associated with proportionally
higher short- and long-term mortality rates; at 1 year,
mortality rates with increasing quartiles were 1.8%, 3.9%,
7.7%, and 19.2%, respectively (p less than 0.001) in the
GUSTO-IV trial of 6,809 patients (284). This prognostic
value was independent of a previous history of HF and of
clinical or laboratory signs of LV dysfunction on admission
or during hospital stay (280). B-type natriuretic peptide and
NT-proBNP levels can now be measured easily and rapidly
in most hospital laboratories.
2.3. Immediate Management
RECOMMENDATIONS
CLASS I
1. The history, physical examination, 12-lead ECG, and initial cardiac
biomarker tests should be integrated to assign patients with chest
pain into 1 of 4 categories: a noncardiac diagnosis, chronic stable
angina, possible ACS, and deﬁnite ACS. (Level of Evidence: C)
2. Patients with probable or possible ACS but whose initial 12-lead
ECG and cardiac biomarker levels are normal should be observed in
a facility with cardiac monitoring (e.g., chest pain unit or hospital
telemetry ward), and repeat ECG (or continuous 12-lead ECG mon-
itoring) and repeat cardiac biomarker measurement(s) should be
obtained at predetermined, speciﬁed time intervals (see Section
2.2.8). (Level of Evidence: B)
3. In patients with suspected ACS in whom ischemic heart disease is
present or suspected, if the follow-up 12-lead ECG and cardiac
biomarkers measurements are normal, a stress test (exercise or
pharmacological) to provoke ischemia should be performed in the
ED, in a chest pain unit, or on an outpatient basis in a timely
fashion (within 72 h) as an alternative to inpatient admission.
Low-risk patients with a negative diagnostic test can be managed
as outpatients. (Level of Evidence: C)
4. In low-risk patients who are referred for outpatient stress testing
(see above), precautionary appropriate pharmacotherapy (e.g., ASA,
sublingual NTG, and/or beta blockers) should be given while await-
ing results of the stress test. (Level of Evidence: C)
5. Patients with deﬁnite ACS and ongoing ischemic symptoms, posi-
tive cardiac biomarkers, new ST-segment deviations, new deep
T-wave inversions, hemodynamic abnormalities, or a positive stress
test should be admitted to the hospital for further management.
Admission to the critical care unit is recommended for those with
active, ongoing ischemia/injury or hemodynamic or electrical insta-
bility. Otherwise, a telemetry step-down unit is reasonable. (Level of
Evidence: C)
6. Patients with possible ACS and negative cardiac biomarkers who
are unable to exercise or who have an abnormal resting ECG should
undergo a pharmacological stress test. (Level of Evidence: B)
7. Patients with deﬁnite ACS and ST-segment elevation in leads V7 to
V9 due to left circumﬂex occlusion should be evaluated for immedi-
ate reperfusion therapy. (Level of Evidence: A)
8. Patients discharged from the ED or chest pain unit should be given
speciﬁc instructions for activity, medications, additional testing, and
follow-up with a personal physician. (Level of Evidence: C)
CLASS IIa
In patients with suspected ACS with a low or intermediate probability of
CAD, in whom the follow-up 12-lead ECG and cardiac biomarkers
measurements are normal, performance of a noninvasive coronary
imaging test (i.e., CCTA) is reasonable as an alternative to stress
testing. (Level of Evidence: B)
By integrating information from the history, physical
examination, 12-lead ECG, and initial cardiac biomarker
tests, clinicians can assign patients to 1 of 4 categories:
noncardiac diagnosis, chronic stable angina, possible ACS,
and deﬁnite ACS (Fig. 2).
Patients who arrive at a medical facility in a pain-free
state, have unchanged or normal ECGs, are hemodynami-
cally stable, and do not have elevated cardiac biomarkers
represent more of a diagnostic than an urgent therapeutic
challenge. Evaluation begins in these patients by obtaining
information from the history, physical examination, and
ECG (Tables 6 and 7) to be used to conﬁrm or reject the
diagnosis of UA/NSTEMI.
Patients with a low likelihood of CAD should be evalu-
ated for other causes of the noncardiac presentation, includ-
ing musculoskeletal pain; gastrointestinal disorders, such as
esophageal spasm, gastritis, peptic ulcer disease, or chole-
cystitis; intrathoracic disease, such as musculoskeletal dis-
comfort, pneumonia, pleurisy, pneumothorax, pulmonary
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embolus, dissecting aortic aneurysm, myocarditis, or peri-
carditis; and neuropsychiatric disease, such as hyperventila-
tion or panic disorder (Fig. 2, B1). Patients who are found
to have evidence of 1 of these alternative diagnoses should
be excluded from management with these guidelines and
referred for appropriate follow-up care (Fig. 2, C1). Reas-
surance should be balanced with instructions to return for
further evaluation if symptoms worsen or if the patient fails
to respond to symptomatic treatment. Chronic stable angina
may also be diagnosed in this setting (Fig. 2, B2), and
patients with this diagnosis should be managed according to
the ACC/AHA 2002 Guideline Update for the Manage-
ment of Patients With Chronic Stable Angina (4).
Patients with possible ACS (Fig. 2, B3 and D1) are
candidates for additional observation in a specialized facility
(e.g., chest pain unit) (Fig. 2, E1). Patients with deﬁnite
ACS (Fig. 2, B4) are triaged on the basis of the pattern of
the 12-lead ECG. Patients with ST-segment elevation (Fig.
2, C3) are evaluated for immediate reperfusion therapy (Fig.
2, D3) and managed according to the ACC/AHA Guide-
lines for the Management of Patients With ST-Elevation
Myocardial Infarction (1), whereas those without ST-
segment elevation (Fig. 2, C2) are either managed by
additional observation (Fig. 2, E1) or admitted to the
hospital (Fig. 2, H3). Patients with low-risk ACS (Table 6)
without transient ST-segment depressions greater than or
equal to 0.05 mV (0.5 mm) or T-wave inversions greater
than or equal to 0.2 mV (2 mm), without positive cardiac
biomarkers, and with a negative stress test or CCTA (Fig.
2, H1) may be discharged and treated as outpatients (Fig. 2,
I1). Low-risk patients may have a stress test within 3 d of
discharge.
2.3.1. Chest Pain Units
To facilitate a more deﬁnitive evaluation while avoiding the
unnecessary hospital admission of patients with possible
ACS (Fig. 2, B3) and low-risk ACS (Fig. 2, F1), as well as
the inappropriate discharge of patients with active myocar-
dial ischemia without ST-segment elevation (Fig. 2, C2),
special units have been established that are variously referred
to as “chest pain units” and “short-stay ED coronary care
units.” Personnel in these units use critical pathways or
protocols designed to arrive at a decision about the presence
or absence of myocardial ischemia and, if present, to
characterize it further as UA or NSTEMI and to deﬁne the
optimal next step in the care of the patient (e.g., admission,
acute intervention) (87,214,285,286). The goal is to arrive at
such a decision after a ﬁnite amount of time, which usually
is between 6 and 12 h but may extend up to 24 h depending
on the policies in individual hospitals. Typically, the patient
undergoes a predetermined observation period with serial
cardiac biomarkers and ECGs. At the end of the observa-
tion period, the patient is reevaluated and then generally
undergoes functional cardiac testing (e.g., resting nuclear
scan or echocardiography) and/or stress testing (e.g., tread-
mill, stress echocardiography, or stress nuclear testing) or
noninvasive coronary imaging study (i.e., CCTA) (see
Section 2.3.2). Those patients who have a recurrence of
chest pain strongly suggestive of ACS, a positive biomarker
value, a signiﬁcant ECG change, or a positive functional/
stress test or CCTA are generally admitted for inpatient
evaluation and treatment. Although chest pain units are
useful, other appropriate observation areas in which patients
with chest pain can be evaluated may be used as well, such
as a section of the hospital’s cardiac telemetry ward.
The physical location of the chest pain unit or the site
where patients with chest pain are observed is variable,
ranging from a speciﬁcally designated area of the ED to a
separate hospital unit with the appropriate equipment to
observational status (24-h admission) on a regular hospital
telemetry ward (287). Similarly, the chest pain unit may be
administratively a part of the ED and staffed by emergency
physicians or may be administered and staffed separately or
as part of the hospital cardiovascular service. Capability of
chest pain units generally includes continuous monitoring of
the patient’s ECG, ready availability of cardiac resuscitation
equipment and medications, and appropriate stafﬁng with
nurses and physicians. The ACEP has published guidelines
that recommend a program for the continuous monitoring
of outcomes of patients evaluated in such units and the
impact on hospital resources (288). A consensus panel
statement from ACEP emphasized that chest pain units
should be considered as part of a multifaceted program that
includes efforts to minimize patient delays in seeking med-
ical care and delays in the ED itself (288).
It has been reported, both from studies with historical
controls and from randomized trials, that the use of chest
pain units is cost-saving compared with an in-hospital
evaluation to “rule out MI” (289,290). The potential cost
savings of a chest pain unit varies depending on the practice
pattern for the disposition of chest pain patients at individ-
ual hospitals (289). Hospitals with a high admission rate of
low-risk patients to rule out MI (70% to 80%) will experi-
ence the largest cost savings by implementing a chest pain
unit approach but will have the smallest impact on the
number of missed MI patients. In contrast, hospitals with
relatively low admission rates of such patients (30% to 40%)
will experience greater improvements in the quality of care
because fewer MI patients will be missed but will experience
a smaller impact on costs because of the low baseline
admission rate.
Farkouh et al. (102) extended the use of a chest pain unit
in a separate portion of the ED to include patients at an
intermediate risk of adverse clinical outcome on the basis of
the previously published Agency for Healthcare Research
and Quality guidelines for the management of UA (124)
(Table 7). They reported a 46% reduction in the ultimate
need for hospital admission in intermediate-risk patients
after a median stay of 9.2 h in the chest pain unit. Extension
of the use of chest pain units to intermediate-risk patients in
an effort to reduce inpatient costs is facilitated by making
available diagnostic testing modalities such as treadmill
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testing and stress imaging (echocardiographic, nuclear, or
magnetic resonance) or CCTA 7 d a week (291).
Patients with chest discomfort for whom a speciﬁc
diagnosis cannot be made after a review of the history,
physical examination, initial 12-lead ECG, and cardiac
biomarker data should undergo a more deﬁnitive evaluation.
Several categories of patients should be considered accord-
ing to the algorithm shown in Figure 2:
• Patients with possible ACS (Fig. 2, B3) are those who
had a recent episode of chest discomfort at rest not
entirely typical of ischemia but who are pain free when
initially evaluated, have a normal or unchanged ECG,
and have no elevations of cardiac biomarkers.
• Patients with a recent episode of typical ischemic dis-
comfort that either is of new onset or is severe or that
exhibits an accelerating pattern of previous stable angina
(especially if it has occurred at rest or is within 2 weeks of
a previously documented MI) should initially be consid-
ered to have a “deﬁnite ACS” (Fig. 2, B4). However,
such patients may be at a low risk if their ECG obtained
at presentation has no diagnostic abnormalities and the
initial serum cardiac biomarkers (especially cardiac-
speciﬁc troponins) are normal (Fig. 2, C2 and D1). As
indicated in the algorithm, patients with either “possible
ACS” (Fig. 2, B3) or “deﬁnite ACS” (Fig. 2, B4) but
with nondiagnostic ECGs and normal initial cardiac
markers (Fig. 2, D1) are candidates for additional obser-
vation in the ED or in a specialized area such as a chest
pain unit (Fig. 2, E1). In contrast, patients who present
without ST-segment elevation but who have features
indicative of active ischemia (ongoing pain, ST-segment
and/or T-wave changes, positive cardiac biomarkers, or
hemodynamic instability; Fig. 2, D2) should be admitted
to the hospital (Fig. 2, H3).
2.3.2. Discharge From ED or Chest Pain Unit
The initial assessment of whether a patient has UA/
NSTEMI and which triage option is most suitable generally
should be made immediately on the patient’s arrival at a
medical facility. Rapid assessment of a patient’s candidacy
for additional observation can be accomplished based on the
status of the symptoms, ECG ﬁndings, and initial serum
cardiac biomarker measurement.
Patients who experience recurrent ischemic discomfort,
evolve abnormalities on a follow-up 12-lead ECG or on
cardiac biomarker measurements, or develop hemodynamic
abnormalities such as new or worsening HF (Fig. 2, D2)
should be admitted to the hospital (Fig. 2, H3) and
managed as described in Section 3.
Patients who are pain free, have either a normal or
nondiagnostic ECG or one that is unchanged from previous
tracings, and have a normal set of initial cardiac biomarker
measurements are candidates for further evaluation to screen
for nonischemic discomfort (Fig. 2, B1) versus a low-risk
ACS (Fig. 2, D1). If the patient is low risk (Table 7) and
does not experience any further ischemic discomfort and a
follow-up 12-lead ECG and cardiac biomarker measure-
ments after 6 to 8 h of observation are normal (Fig. 2, F1),
the patient may be considered for an early stress test to
provoke ischemia or CCTA to assess for obstructive CAD
(Fig. 2, G1). This test can be performed before the
discharge and should be supervised by an experienced
physician. Alternatively, the patient may be discharged and
return for stress testing as an outpatient within 72 h. The
exact nature of the test may vary depending on the patient’s
ability to exercise on either a treadmill or bicycle and the
local expertise in a given hospital setting (e.g., availability of
different testing modalities at different times of the day or
different days of the week) (292). Patients who are capable
of exercise and who are free of confounding features on the
baseline ECG, such as bundle-branch block, LV hypertro-
phy, or paced rhythms, can be evaluated with routine
symptom-limited conventional exercise stress testing. Pa-
tients who are incapable of exercise or who have an
uninterpretable baseline ECG should be considered for
pharmacological stress testing with either nuclear perfusion
imaging or 2-dimensional echocardiography, or magnetic
resonance (175,293,294). Alternatively, it is reasonable to
perform a non-invasive coronary imaging test (i.e., CCTA).
An imaging-enhanced test also may be more predictive in
women than conventional ECG exercise stress testing (see
Section 6.1.).
Two imaging modalities, CMR and multidetector com-
puted tomography for coronary calciﬁcation and CCTA, are
increasingly becoming clinically validated and applied and
hold promise as alternative or supplementary imaging mo-
dalities for assessing patients who present with chest pain
syndromes (25,294,295). Cardiac magnetic resonance has
the capability of assessing cardiac function, perfusion, and
viability in the same setting. Its advantages are excellent
resolution (approximately 1 mm) of cardiac structures and
avoidance of exposure to radiation and iodinated contrast.
Disadvantages include long study time, conﬁned space
(claustrophobia), and (current) contraindication to the pres-
ence of pacemakers/deﬁbrillators. To evaluate for ischemic
heart disease, an adenosine ﬁrst-pass gadolinium perfusion
study is combined with assessment of regional and global
function and viability (gadolinium delayed study). Direct
coronary artery imaging is better assessed by CCTA (see
below). One study indicated a sensitivity of 89% and
speciﬁcity of 87% for combined adenosine stress and gado-
linium delayed enhancement (viability) CMR testing for
CAD (296). Dobutamine CMR stress testing can be used as
an alternative to adenosine perfusion CMR (e.g., in asth-
matic patients).
Coronary CT angiography with current multidetector
technology (i.e., 64 slices beginning in 2005) has been
reported to give 90% to 95% or greater sensitivity and
speciﬁcity for occlusive CAD in early clinical trial experi-
ence (297–299). For evaluation of potential UA/NSTEMI,
coronary artery calcium scoring followed by CCTA is
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typically done in the same sitting. The advantages of CCTA
are good to excellent resolution (approximately 0.6 mm) of
coronary artery anatomy and short study time (single breath
hold). Disadvantages are radiation dose (8 to 24 mSv),
contrast dye exposure, and necessity to achieve a slow,
regular heart rate (beta blockers are usually required). A lack
of large controlled comparative trials and reimbursement
issues are current limitations to these technologies. In
summary, the high negative predictive value of CCTA is its
greatest advantage: if no evidence of either calciﬁed or
noncalciﬁed (soft/ﬁbrous) plaque is found, then it is highly
unlikely that the patient’s symptoms are due to UA/
NSTEMI of an atherosclerotic origin. (Note that primary
[micro]vascular dysfunction causes of chest pain are not
excluded.) In contrast, the positive predictive value of
CCTA in determining whether a given plaque or stenosis is
causing the signs and symptoms of possible UA/NSTEMI
is less clear because although it gives valuable anatomic
information, it does not provide functional or physiological
assessment. Coronary CT angiography has been judged to
be useful for evaluation of obstructive CAD in symptomatic
patients (Class IIa, Level of Evidence: B) (25) and appro-
priate for acute chest pain evaluation for those with inter-
mediate and possibly low pretest probability of CAD when
serial ECG and biomarkers are negative (294). It may be
particularly appropriate for those with acute chest pain
syndromes with intermediate pretest probability of CAD in
the setting of nondiagnostic ECG and negative cardiac
biomarkers (294).
Because LV function is so integrally related to prognosis
and greatly affects therapeutic options, strong consideration
should be given to the assessment of LV function with
echocardiography or another modality (i.e., CMR, radionu-
clide, CCTA, or contrast angiography) in patients with
documented ischemia. In sites at which stress tests are not
available, low-risk patients may be discharged and referred
for outpatient stress testing in a timely fashion. Prescription
of precautionary anti-ischemic treatment (e.g., ASA, sub-
lingual NTG, and beta blockers) should be considered in
these patients while awaiting results of stress testing. Spe-
ciﬁc instructions also should be given on whether or not to
take these medications (e.g., beta blockers) before testing,
which may vary depending on the test ordered and patient-
speciﬁc factors. These patients also should be given speciﬁc
instructions on what to do and how to seek emergency care
for recurrence or worsening of symptoms while awaiting the
stress test.
Patients who develop recurrent symptoms during ob-
servation suggestive of ACS or in whom the follow-up
studies (12-lead ECG, cardiac biomarkers) show new
abnormalities (Fig. 2, F2) should be admitted to the
hospital (Fig. 2, H3). Patients in whom ACS has been
excluded should be reassessed for need for further eval-
uation of other potentially serious medical conditions
that may mimic ACS symptomatology (e.g., pulmonary
embolism and aortic dissection).
Because continuity of care is important in the overall
management of patients with a chest pain syndrome, the
patient’s primary physician (if not involved in the care of the
patient during the initial episode) should be notiﬁed of the
results of the evaluation and should receive a copy of the
relevant test results. Patients with a noncardiac diagnosis
and those with low risk or possible ACS with a negative
stress test should be counseled to make an appointment with
their primary care physician as outpatients for further
investigation into the cause of their symptoms (Fig. 2, I1).
They should be seen by a physician as soon after discharge
from the ED or chest pain unit as practical and appropriate,
that is, usually within 72 h.
Patients with possible ACS (Fig. 5, B3) and those with a
deﬁnite ACS but a nondiagnostic ECG and normal cardiac
biomarkers when they are initially seen (Fig. 2, D1) at
institutions without a chest pain unit (or equivalent facility)
should be admitted to an inpatient unit. The inpatient unit
to which such patients are to be admitted should have the
same provisions for continuous ECG monitoring, availabil-
ity of resuscitation equipment, and stafﬁng arrangements as
described above for the design of chest pain units.
3. Early Hospital Care
Patients with UA/NSTEMI, recurrent symptoms sugges-
tive of ACS and/or ECG ST-segment deviations, or posi-
tive cardiac biomarkers who are stable hemodynamically
should be admitted to an inpatient unit for bed rest with
continuous rhythm monitoring and careful observation for
recurrent ischemia (a step-down unit) and managed with
either an invasive or conservative strategy (Table 11).
Patients with continuing discomfort and/or hemodynamic
Table 11. Selection of Initial Treatment Strategy:
Invasive Versus Conservative Strategy
Preferred Strategy Patient Characteristics
Invasive Recurrent angina or ischemia at rest or with low-level
activities despite intensive medical therapy
Elevated cardiac biomarkers (TnT or TnI)
New or presumably new ST-segment depression
Signs or symptoms of HF or new or worsening mitral
regurgitation
High-risk ﬁndings from noninvasive testing
Hemodynamic instability
Sustained ventricular tachycardia
PCI within 6 months
Prior CABG
High risk score (e.g., TIMI, GRACE)
Reduced left ventricular function (LVEF less than 40%)
Conservative Low risk score (e.g., TIMI, GRACE)
Patient or physician preference in the absence of high-
risk features
CABG coronary artery bypass graft surgery; GRACE Global Registry of Acute Coronary Events;
HF  heart failure; LVEF  left ventricular ejection fraction; PCI  percutaneous coronary
intervention; TIMI  Thrombolysis In Myocardial Infarction; TnI  troponin I; TnT  troponin T.
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instability should be hospitalized for at least 24 h in a
coronary care unit characterized by a nursing-to-patient
ratio sufﬁcient to provide 1) continuous rhythm monitoring,
2) frequent assessment of vital signs and mental status, 3)
documented ability to perform deﬁbrillation quickly after
the onset of ventricular ﬁbrillation, and 4) adequate staff to
perform these functions. Patients should be maintained at
that level of care until they have been observed for an
adequate period of time, generally at least 24 h, without any
of the following major complications: sustained ventricular
tachycardia or ﬁbrillation, sinus tachycardia, high-degree
atrioventricular (AV) block, sustained hypotension, recur-
rent ischemia documented by symptoms or ST-segment
change, new mechanical defect (ventricular septal defect or
mitral regurgitation), or HF. Shorter periods of monitoring
might be appropriate for selected patients who are success-
fully reperfused and who have normal LV function and
minimal or no necrosis.
Once a patient with documented high-risk ACS is
admitted, standard medical therapy is indicated as dis-
cussed later. Unless a contraindication exists, these pa-
tients generally should be treated with ASA, a beta
blocker, anticoagulant therapy, a GP IIb/IIIa inhibitor,
and a thienopyridine (i.e., clopidogrel; initiation may be
deferred until a revascularization decision is made).
Critical decisions are required regarding the angiographic
(invasive) strategy. One option is a routine angiographic
approach in which coronary angiography and revascular-
ization are performed unless a contraindication exists.
Within this approach, a common past strategy has called
for a period of medical stabilization. Increasingly, physi-
cians are taking a more aggressive approach, with coro-
nary angiography and revascularization performed within
24 h of admission; the rationale for the more aggressive
approach is the protective effect of carefully administered
anticoagulant and antiplatelet therapy on procedural
outcome. The alternative approach, commonly referred
to as the “initial conservative strategy” (see Section 3.3),
is guided by ischemia, with angiography reserved for
patients with recurrent ischemia or a high-risk stress test
despite medical therapy. Regardless of the angiographic
strategy, an assessment of LV function is recommended
in patients with documented ischemia because of the
imperative to treat patients who have impaired LV
function with ACE inhibitors, beta blockers, and, when
HF or diabetes mellitus is present, aldosterone antago-
nists; when the coronary anatomy is appropriate (e.g.,
3-vessel coronary disease), CABG is appropriate (see
Section 4). When the coronary angiogram is obtained, a
left ventriculogram may be obtained at the same time.
When coronary angiography is not scheduled, echocar-
diography, nuclear ventriculography, or magnetic reso-
nance imaging or CT angiography can be used to evaluate
LV function.
3.1. Anti-Ischemic and Analgesic Therapy
RECOMMENDATIONS FOR ANTI-ISCHEMIC THERAPY
CLASS I
1. Bed/chair rest with continuous ECGmonitoring is recommended for
all UA/NSTEMI patients during the early hospital phase. (Level of
Evidence: C)
2. Supplemental oxygen should be administered to patients with
UA/NSTEMI with an arterial saturation less than 90%, respiratory
distress, or other high-risk features for hypoxemia. (Pulse oxime-
try is useful for continuous measurement of SaO2.) (Level of
Evidence: B)
3. Patients with UA/NSTEMI with ongoing ischemic discomfort should
receive sublingual NTG (0.4 mg) every 5 min for a total of 3 doses,
after which assessment should be made about the need for intra-
venous NTG, if not contraindicated. (Level of Evidence: C)
4. Intravenous NTG is indicated in the ﬁrst 48 h after UA/NSTEMI for
treatment of persistent ischemia, HF, or hypertension. The decision
to administer intravenous NTG and the dose used should not
preclude therapy with other proven mortality-reducing interventions
such as beta blockers or ACE inhibitors. (Level of Evidence: B)
5. Oral beta-blocker therapy should be initiated within the ﬁrst 24 h for
patients who do not have 1 or more of the following: 1) signs of HF,
2) evidence of a low-output state, 3) increased risk* for cardiogenic
shock, or 4) other relative contraindications to beta blockade (PR
interval greater than 0.24 s, second or third degree heart block,
active asthma, or reactive airway disease). (Level of Evidence: B)
6. In UA/NSTEMI patients with continuing or frequently recurring isch-
emia and in whom beta blockers are contraindicated, a nondihydro-
pyridine calcium channel blocker (e.g., verapamil or diltiazem)
should be given as initial therapy in the absence of clinically
signiﬁcant LV dysfunction or other contraindications. (Level of Evi-
dence: B)
7. An ACE inhibitor should be administered orally within the ﬁrst 24 h
to UA/NSTEMI patients with pulmonary congestion or LV ejection
fraction (LVEF) less than or equal to 0.40, in the absence of
hypotension (systolic blood pressure less than 100 mm Hg or less
than 30 mm Hg below baseline) or known contraindications to that
class of medications. (Level of Evidence: A)
8. An angiotensin receptor blocker should be administered to UA/
NSTEMI patients who are intolerant of ACE inhibitors and have
either clinical or radiological signs of HF or LVEF less than or equal
to 0.40. (Level of Evidence: A)
9. Because of the increased risks of mortality, reinfarction, hyperten-
sion, HF, and myocardial rupture associated with their use, nonste-
roidal anti-inﬂammatory drugs (NSAIDs), except for ASA, whether
nonselective or cyclooxygenase (COX)-2–selective agents, should be
discontinued at the time a patient presents with UA/NSTEMI. (Level
of Evidence: C)
*Risk factors for cardiogenic shock (the greater the number of risk factors present, the
higher the risk of developing cardiogenic shock): age greater than 70 years, systolic
blood pressure less than 120 mmHg, sinus tachycardia greater than 110 or heart rate
less than 60, increased time since onset of symptoms of UA/NSTEMI.
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CLASS IIa
1. It is reasonable to administer supplemental oxygen to all patients
with UA/NSTEMI during the ﬁrst 6 h after presentation. (Level of
Evidence: C)
2. In the absence of contradictions to its use, it is reasonable to
administer morphine sulfate intravenously to UA/NSTEMI patients if
there is uncontrolled ischemic chest discomfort despite NTG, pro-
vided that additional therapy is used to manage the underlying
ischemia. (Level of Evidence: B)
3. It is reasonable to administer intravenous (IV) beta blockers at the
time of presentation for hypertension to UA/NSTEMI patients who
do not have 1 or more of the following: 1) signs of HF, 2) evidence of
a low-output state, 3) increased risk* for cardiogenic shock, or 4)
other relative contraindications to beta blockade (PR interval
greater than 0.24 s, second or third degree heart block, active
asthma, or reactive airway disease). (Level of Evidence: B)
4. Oral long-acting nondihydropyridine calcium channel blockers are
reasonable for use in UA/NSTEMI patients for recurrent ischemia in
the absence of contraindications after beta blockers and nitrates
have been fully used. (Level of Evidence: C)
5. An ACE inhibitor administered orally within the ﬁrst 24 h of UA/
NSTEMI can be useful in patients without pulmonary congestion or
LVEF less than or equal to 0.40 in the absence of hypotension
(systolic blood pressure less than 100 mm Hg or less than 30 mm
Hg below baseline) or known contraindications to that class of
medications. (Level of Evidence: B)
6. Intra-aortic balloon pump (IABP) counterpulsation is reasonable in
UA/NSTEMI patients for severe ischemia that is continuing or recurs
frequently despite intensive medical therapy, for hemodynamic
instability in patients before or after coronary angiography, and for
mechanical complications of MI. (Level of Evidence: C)
CLASS IIb
1. The use of extended-release forms of nondihydropyridine calcium
channel blockers instead of a beta blocker may be considered in
patients with UA/NSTEMI. (Level of Evidence: B)
2. Immediate-release dihydropyridine calcium channel blockers in the
presence of adequate beta blockade may be considered in patients
with UA/NSTEMI with ongoing ischemic symptoms or hypertension.
(Level of Evidence: B)
CLASS III
1. Nitrates should not be administered to UA/NSTEMI patients with
systolic blood pressure less than 90 mm Hg or greater than or equal
to 30 mm Hg below baseline, severe bradycardia (less than 50
beats per minute), tachycardia (more than 100 beats per minute) in
the absence of symptomatic HF, or right ventricular infarction.
(Level of Evidence: C)
2. Nitroglycerin or other nitrates should not be administered to pa-
tients with UA/NSTEMI who had received a phosphodiesterase
inhibitor for erectile dysfunction within 24 h of sildenaﬁl or 48 h of
tadalaﬁl use. The suitable time for the administration of nitrates
after vardenaﬁl has not been determined. (Level of Evidence: C)
3. Immediate-release dihydropyridine calcium channel blockers
should not be administered to patients with UA/NSTEMI in the
absence of a beta blocker. (Level of Evidence: A)
4. An intravenous ACE inhibitor should not be given to patients within
the ﬁrst 24 h of UA/NSTEMI because of the increased risk of
hypotension. (A possible exception may be patients with refractory
hypertension.) (Level of Evidence: B)
5. It may be harmful to administer intravenous beta blockers to
UA/NSTEMI patients who have contraindications to beta blockade,
signs of HF or low-output state, or other risk factors* for cardiogenic
shock. (Level of Evidence: A)
6. Nonsteroidal anti-inﬂammatory drugs (except for ASA), whether non-
selective or COX-2–selective agents, should not be administered during
hospitalization for UA/NSTEMI because of the increased risks of mor-
tality, reinfarction, hypertension, HF, and myocardial rupture associ-
ated with their use. (Level of Evidence: C)
The optimal management of UA/NSTEMI has the
twin goals of the immediate relief of ischemia and the
prevention of serious adverse outcomes (i.e., death or
myocardial [re]infarction). This is best accomplished
with an approach that includes anti-ischemic therapy
(Table 12), antithrombotic therapy (Table 13), ongoing
risk stratiﬁcation, and the use of invasive procedures.
Patients who are at intermediate or high risk for adverse
outcomes, including those with ongoing ischemia refrac-
tory to initial medical therapy and those with evidence of
hemodynamic instability, should be admitted whenever
possible to a critical care environment with ready access
*Risk factors for cardiogenic shock (the greater the number of risk factors present, the
higher the risk of developing cardiogenic shock): age greater than 70 years, systolic
blood pressure less than 120 mmHg, sinus tachycardia greater than 110 or heart rate
less than 60, increased time since onset of symptoms of UA/NSTEMI.
Table 12. Class I Recommendations for Anti-Ischemic
Therapy: Continuing Ischemia/Other Clinical High-Risk
Features Present*
Bed/chair rest with continuous ECG monitoring
Supplemental oxygen with an arterial saturation less than 90%, respiratory
distress, or other high-risk features for hypoxemia. Pulse oximetry can be
useful for continuous measurement of SaO2.
NTG 0.4 mg sublingually every 5 min for a total of 3 doses; afterward, assess
need for IV NTG
NTG IV for ﬁrst 48 h after UA/NSTEMI for treatment of persistent ischemia, HF,
or hypertension
Decision to administer NTG IV and dose should not preclude therapy with other
mortality-reducing interventions such as beta blockers or ACE inhibitors
Beta blockers (via oral route) within 24 h without a contraindication (e.g., HF)
irrespective of concomitant performance of PCI
When beta blockers are contraindicated, a nondihydropyridine calcium channel
blocker (e.g., verapamil or diltiazem) should be given as initial therapy in the
absence of severe LV dysfunction or other contraindications
ACE inhibitor (via oral route) within ﬁrst 24 h with pulmonary congestion, or
LVEF less than or equal to 0.40, in the absence of hypotension (systolic
blood pressure less than 100 mm Hg or less than 30 mm Hg below
baseline) or known contraindications to that class of medications
ARB should be administered to UA/NSTEMI patients who are intolerant of ACE
inhibitors and have either clinical or radiological signs of heart failure or
LVEF less than or equal to 0.40.
*Recurrent angina and/or ischemia-related ECG changes (0.05 mV or greater ST-segment
depression or bundle-branch block) at rest or with low-level activity; or ischemia associated with
HF symptoms, S3 gallop, or new or worsening mitral regurgitation; or hemodynamic instability or
depressed LV function (LVEF less than 0.40 on noninvasive study); or serious ventricular
arrhythmia.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; HF heart failure;
IV  intravenous; LV  left ventricular; LVEF  left ventricular ejection fraction; NTG 
nitroglycerin; MI  myocardial infarction; PCI  percutaneous coronary intervention; UA/NSTEMI
 unstable angina/non–ST-elevation myocardial infarction.
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Table 13. Dosing Table for Antiplatelet and Anticoagulant Therapy in Patients With UA/NSTEMI
Drug* Initial Medical Treatment
During PCI
After PCI At Hospital Discharge
Patient Received
Initial Medical
Treatment
Patient Did Not
Receive Initial
Medical Treatment
Oral Antiplatelet Therapy
Aspirin 162 to 325 mg nonenteric
formulation, orally or
chewed
No additional treatment 162 to 325 mg
nonenteric
formulation orally
or chewed
162 to 325 mg daily should
be given† for at least
1 month after BMS
implantation, 3 months
after SES implantation,
and 6 months after PES
implantation, after which
daily chronic aspirin
should be continued
indeﬁnitely at a dose of
75 to 162 mg
162 to 325 mg daily should
be given† for at least
1 month after BMS
implantation, 3 months
after SES implantation,
and 6 months after PES
implantation, after which
daily chronic aspirin
should be continued
indeﬁnitely at a dose of
75 to 162 mg
Clopidogrel LD of 300 to 600 mg
orally
MD of 75 mg orally per
day
A second LD of 300 mg
orally may be given
to supplement a
prior LD of 300 mg
LD of 300 to 600 mg
orally
For BMS: 75 mg daily for at
least 1 month and ideally
up to 1 year. For DES, 75
mg daily for at least 1
year (in patients who are
not at high risk of
bleeding) (See Fig. 11)
For BMS: 75 mg daily for at
least 1 month and
ideally up to 1 year. For
DES, 75 mg daily for at
least 1 year (in patients
who are not at high risk
of bleeding) (See Fig. 11)
Ticlopidine LD of 500 mg orally
MD of 250 mg orally twice
daily
No additional treatment LD of 500 mg orally MD of 250 mg orally twice
daily (duration same as
clopidogrel)
MD of 250 mg orally twice
daily (duration same as
clopidogrel)
Anticoagulants
Bivalirudin 0.1 mg per kg bolus,
0.25 mg per kg per h
infusion
0.5 mg per kg bolus,
increase infusion to
1.75 mg per kg per h
0.75 mg per kg
bolus, 1.75 mg
per kg per h
infusion
No additional treatment or
continue infusion for up
to 4 h
Dalteparin 120 IU per kg SC every
12 h (maximum 10,000
IU twice daily)‡
IV GP IIb/IIIa planned:
target ACT 200 s
using UFH
IV GP IIb/IIIa
planned: 60 to 70
U per kg§ of UFH
No additional treatment
No IV GP IIb/IIIa
planned: target ACT
250 to 300 s for
HemoTec; 300 to
350 s for Hemochron
using UFH
No IV GP IIb/IIIa
planned: 100 to
140 U per kg of
UFH
Enoxaparin LD of 30 mg IV bolus may
be given
MD  1 mg per kg SC
every 12 h; extend
dosing interval to 1 mg
per kg every 24 h if
estimated creatinine
clearance less than
30 mL per min
Last SC dose less than
8 h: no additional
therapy
Last SC dose greater
than 8 h: 0.3 mg per
kg IV bolus
0.5 to 0.75 mg per
kg IV bolus
No additional treatment
Fondaparinux 2.5 mg SC once daily.
Avoid for creatinine
clearance less than 30
mL per min
50 to 60 U per kg IV
bolus of UFH is
recommended by the
OASIS 5
Investigators¶
50 to 60 U per kg IV
bolus of UFH is
recommended by
the OASIS 5
Investigators¶
No additional treatment
Unfractionated
heparin
LD of 60 U per kg (max
4,000 U) as IV bolus
MD of IV infusion of 12 U
per kg per h (max
1,000 U per h) to
maintain aPTT at 1.5 to
2.0 times control
(approximately 50 to
70 s)
IV GP IIb/IIIa planned:
target ACT 200 s
No IV GP IIb/IIIa
planned: target ACT
250 to 300 s for
HemoTec; 300 to
350 s for Hemochron
IV GP IIb/IIIa
planned: 60 to 70
U per kg§
No IV GP IIb/IIIa
planned: 100 to
140 U per kg
No additional treatment
Continued on next page
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to invasive cardiovascular diagnosis and therapeutic pro-
cedures. Ready access is deﬁned as ensured, timely access
to a cardiac catheterization laboratory with personnel
who have appropriate credentials and experience in inva-
sive coronary procedures, as well as to emergency or
urgent cardiovascular surgery and cardiac anesthesia
(2,300).
The approach to the achievement of the twin goals
described here includes the initiation of pharmacological
management and planning of a deﬁnitive treatment strategy
for the underlying disease process. Most patients are stable
at presentation or stabilize after a brief period of intensive
pharmacological management and, after appropriate coun-
seling, will be able to participate in the choice of an
approach for deﬁnitive therapy (see Section 3.3 for a full
discussion of conservative vs. invasive strategy selection). A
few patients will require prompt triage to emergency or
urgent cardiac catheterization and/or the placement of an
IABP.
3.1.1. General Care
The severity of symptoms dictates some of the general care
that should be given during the initial treatment. Patients
should be placed on bed rest while ischemia is ongoing but
Table 13. Continued
Drug* Initial Medical Treatment
During PCI
After PCI At Hospital Discharge
Patient Received
Initial Medical
Treatment
Patient Did Not
Receive Initial
Medical Treatment
Intravenous Antiplatelet Therapy
Abciximab Not applicable Not applicable LD of 0.25 mg per kg
IV bolus
MD of 0.125 mcg per
kg per min (max
10 mcg per min)
Continue MD infusion for
12 h
Eptiﬁbatide LD of IV bolus of 180 mcg
per kg
MD of IV infusion of 2.0
mcg per kg per min;
reduce infusion by 50%
in patients with
estimated creatinine
clearance less than 50
mL per min
Continue infusion LD of IV bolus of 180
mcg per kg
followed 10 min
later by second IV
bolus of 180 mcg
per kg
MD of 2.0 mcg per
kg per min; reduce
infusion by 50% in
patients with
estimated
creatinine
clearance less
than 50 mL per
min
Continue MD infusion for
18 to 24 h
Tiroﬁban LD of IV infusion of 0.4
mcg per kg per min for
30 min
MD of IV infusion of 0.1
mcg per kg per min;
reduce rate of infusion
by 50% in patients with
estimated creatinine
clearance less than 30
mL per min
Continue infusion LD of IV infusion of
0.4 mcg per kg
per min for 30
min
MD of IV infusion of
0.1 mcg per kg
per min; reduce
rate of infusion by
50% in patients
with estimated
creatinine
clearance less
than 30 mL per
min
Continue MD infusion for
18 to 24 h
Additional considerations include the possibility that a conservatively managed patient may develop a need for PCI, in which case an intravenous bolus of 50 to 60 U per kg of UFH is recommended
if fondaparinux was given for initial medical treatment; the safety of this drug combination is not well established. For conservatively managed patients in whom enoxaparin was the initial medical
treatment, as noted in the table, additional intravenous enoxaparin is an acceptable option. *This list is in alphabetical order and is not meant to indicate a particular therapy preference. †In patients
in whom the physician is concerned about the risk of bleeding, a lower initial ASA dose after PCI of 75 to 162 mg/d is reasonable (Class IIa, LOE: C). ‡Dalteparin was evaluated for management of
patients with UA/NSTEMI in an era before the widespread use of important therapies such as stents, clopidogrel, and GP IIb/IIIa inhibitors. Its relative efﬁcacy and safety in the contemporary
management era is not well established. §Some operators use less than 60 U per kg of UFH with GP IIb/IIIa blockade, although no clinical trial data exist to demonstrate the efﬁcacy of doses below
60 U per kg in this setting. For patients managed by an initial conservative strategy, agents such as enoxaparin and fondaparinux offer the convenience advantage of SC administration compared with
an intravenous infusion of UFH. They are also less likely to provoke heparin-induced thrombocytopenia than UFH. Available data suggest fondaparinux is associated with less bleeding than enoxaparin
in conservatively managed patients using the regimens listed. ¶Personal communication, OASIS 5 Investigators, July 7, 2006. Note that this regimen has not been rigorously tested in prospective
randomized trials.
ACT  activated clotting time; BMS  bare-metal stent; GP  glycoprotein; h  hour; IU  international unit; IV  intravenous; LD  loading dose; MD  maintenance dose; PCI  percutaneous
coronary intervention; PES  paclitaxel-eluting stent; SC  subcutaneous; SES  sirolimus-eluting stent; U  units; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction; UFH 
unfractionated heparin.
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can be mobilized to a chair and use a bedside commode
when symptom free. Subsequent activity should not be
inappropriately restrictive; instead, it should be focused on
the prevention of recurrent symptoms and liberalized as
judged appropriate when response to treatment occurs.
Patients with cyanosis, respiratory distress, or other high-
risk features should receive supplemental oxygen. Adequate
arterial oxygen saturation should be conﬁrmed with direct
measurement (especially with respiratory distress or cyano-
sis) or pulse oximetry. No evidence is available to support
the administration of oxygen to all patients with ACS in the
absence of signs of respiratory distress or arterial hypoxemia.
Its use based on the evidence base can be limited to those
with questionable respiratory status and documented hypox-
emia. Nevertheless, it is the opinion of the Writing Com-
mittee that a short period of initial routine oxygen supple-
mentation is reasonable during initial stabilization of the
patient, given its safety and the potential for underrecogni-
tion of hypoxemia. Inhaled oxygen should be administered
if the arterial oxygen saturation (SaO2) declines to less than
90%. Finger pulse oximetry is useful for the continuous
monitoring of SaO2 but is not mandatory in patients who
do not appear to be at risk of hypoxemia. Patients should
undergo continuous ECG monitoring during their ED
evaluation and early hospital phase, because sudden, unex-
pected ventricular ﬁbrillation is the major preventable cause
of death in this early period. Furthermore, monitoring for
the recurrence of ST-segment shifts provides useful diag-
nostic and prognostic information, although the system of
monitoring for ST-segment shifts must include speciﬁc
methods intended to provide stable and accurate recordings.
3.1.2. Use of Anti-Ischemic Therapies
3.1.2.1. NITRATES
Nitroglycerin reduces myocardial oxygen demand while
enhancing myocardial oxygen delivery. Nitroglycerin, an
endothelium-independent vasodilator, has both peripheral
and coronary vascular effects. By dilating the capacitance
vessels (i.e., the venous bed), it increases venous pooling to
decrease myocardial preload, thereby reducing ventricular
wall tension, a determinant of myocardial oxygen demand
(MVO2). More modest effects on the arterial circulation
decrease systolic wall stress (afterload), which contributes to
further reductions in MVO2. This decrease in myocardial
oxygen demand is in part offset by reﬂex increases in heart
rate and contractility, which counteract the reductions in
MVO2 unless a beta blocker is concurrently administered.
Nitroglycerin dilates normal and atherosclerotic epicardial
coronary arteries and smaller arteries that constrict with
certain stressors (e.g., cold, mental or physical exercise).
With severe atherosclerotic coronary obstruction and with
less severely obstructed vessels with endothelial dysfunction,
physiological responses to changes in myocardial blood ﬂow
are often impaired (i.e., loss of ﬂow-mediated dilation), so
maximal dilation does not occur unless a direct-acting
vasodilator like NTG is administered. Thus, NTG pro-
motes the dilation of large coronary arteries, as well as
collateral ﬂow and redistribution of coronary blood ﬂow to
ischemic regions. Inhibition of platelet aggregation also
occurs with NTG (300), but the clinical signiﬁcance of this
action is not well deﬁned.
Intravenous NTG can beneﬁt patients whose symptoms
are not relieved in the hospital with three 0.4-mg sublingual
NTG tablets taken 5 min apart (Tables 12 and 14) and with
the initiation of an oral or intravenous beta blocker (when
there are no contraindications), as well as those with HF or
hypertension. Note that NTG is contraindicated after the
use of sildenaﬁl within the previous 24 h or tadalaﬁl within
48 h or with hypotension (301–303). The suitable delay
before nitrate administration after the use of vardenaﬁl has
not been determined, although blood pressure had generally
returned to baseline by 24 h (304). These drugs inhibit the
phosphodiesterase that degrades cyclic guanosine mono-
phosphate, and cyclic guanosine monophosphate mediates
vascular smooth muscle relaxation by nitric oxide. Thus,
NTG-mediated vasodilatation is markedly exaggerated and
prolonged in the presence of phosphodiesterase inhibitors.
Nitrate use within 24 h after sildenaﬁl or the administration
of sildenaﬁl in a patient who has received a nitrate within
24 h has been associated with profound hypotension, MI,
Table 14. NTG and Nitrates in Angina
Compound Route Dose/Dosage Duration of Effect
NTG Sublingual tablets 0.3 to 0.6 mg up to 1.5 mg 1 to 7 min
Spray 0.4 mg as needed Similar to sublingual tablets
Transdermal 0.2 to 0.8 mg per h every 12 h 8 to 12 h during intermittent therapy
Intravenous 5 to 200 mcg per min Tolerance in 7 to 8 h
Isosorbide dinitrate Oral 5 to 80 mg, 2 or 3 times daily Up to 8 h
Oral, slow release 40 mg 1 or 2 times daily Up to 8 h
Isosorbide mononitrate Oral 20 mg twice daily 12 to 24 h
Oral, slow release 60 to 240 mg once daily
Pentaerythritol tetranitrate Sublingual 10 mg as needed Not known
Erythritol tetranitrate Sublingual 5 to 10 mg as needed Not known
Oral 10 to 30 mg 3 times daily Not known
Adapted from Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. Available at: http://www.acc.org/qualityandscience (4).
NTG  nitroglycerin.
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and even death (303). Similar concerns apply to tadalaﬁl and
vardenaﬁl (301,304).
Intravenous NTG may be initiated at a rate of 10 mcg per
min through continuous infusion via nonabsorbing tubing
and increased by 10 mcg per min every 3 to 5 min until
some relief of symptoms or blood pressure response is noted.
If no response is seen at 20 mcg per min, increments of 10
and, later, 20 mcg per min can be used. If symptoms and
signs of ischemia are relieved, there is no need to continue
to increase the dose to effect a blood pressure response. If
symptoms and signs of ischemia are not relieved, the dose
should be increased until a blood pressure response is
observed. Once a partial blood pressure response is ob-
served, the dosage increase should be reduced and the
interval between increments lengthened. Side effects of
NTG include headache and hypotension. Systolic blood
pressure generally should not be titrated to less than 110
mm Hg in previously normotensive patients or to greater
than 25% below the starting mean arterial blood pressure if
hypertension was present. Nitroglycerin should be avoided
in patients with initial systolic blood pressure less than 90
mm Hg or 30 mm Hg or more below baseline or with
marked bradycardia or tachycardia. Although recommenda-
tions for a maximal dose are not available, a ceiling of 200
mcg per min is commonly used. Even prolonged (2 to 4
weeks) infusion at 300 to 400 mcg per min does not increase
methemoglobin levels (306).
Topical or oral nitrates are acceptable alternatives for
patients who require antianginal therapy but who do not
have ongoing refractory ischemic symptoms. Tolerance to
the hemodynamic effects of nitrates is dose and duration
dependent and typically becomes important after 24 h of
continuous therapy with any formulation. Patients who
require continued intravenous NTG beyond 24 h may
require periodic increases in infusion rate to maintain
efﬁcacy. An effort must be made to use non–tolerance-
producing nitrate regimens (lower doses and intermittent
dosing). When patients have been free of ischemic discom-
fort and other manifestations of ischemia for 12 to 24 h, an
attempt should be made to reduce the dose of intravenous
NTG and to switch to oral or topical nitrates. It is not
appropriate to continue intravenous NTG in patients who
remain free of signs and symptoms of ischemia. When
ischemia recurs during continuous intravenous NTG ther-
apy, responsiveness to nitrates can often be restored by
increasing the dose and, after symptoms have been con-
trolled for several hours, attempting to add a nitrate-free
interval. This strategy should be pursued as long as symp-
toms are not adequately controlled. In stabilized patients,
intravenous NTG should generally be converted within 24 h
to a nonparenteral alternative (Table 14) administered in a
non–tolerance-producing regimen to avoid the potential
reactivation of symptoms. A practical method for converting
intravenous to topical NTG has been published (307).
Most studies of nitrate treatment in UA/NSTEMI have
been small and uncontrolled, and there are no randomized,
placebo-controlled trials that address either symptom relief
or reduction in cardiac events. One small randomized trial
compared intravenous NTG with buccal NTG and found
no signiﬁcant difference in the control of ischemia (308). An
overview of small studies of NTG in MI from the preﬁ-
brinolytic era suggested a 35% reduction in mortality rates
(309); in contrast, both the Fourth International Study of
Infarct Survival (ISIS-4) (310) and Gruppo Italiano per lo
Studio della Sopravvivenza nell’infarto Miocardico
(GISSI-3) (311) trials formally tested this hypothesis in
patients with suspected MI in the reperfusion era and failed
to conﬁrm this magnitude of beneﬁt. However, these large
trials are confounded by frequent prehospital and hospital
use of NTG in the “control” groups. Nevertheless, a strategy
of routine as opposed to selective use of nitrates did not
reduce mortality. The abrupt cessation of intravenous NTG
has been associated with exacerbation of ischemic changes
on the ECG (312), and a graded reduction in the dose of
intravenous NTG is advisable. Thus, the rationale for NTG
use in UA/NSTEMI is extrapolated from pathophysiolog-
ical principles and extensive, although uncontrolled, clinical
observations (300).
3.1.2.2. MORPHINE SULFATE
Morphine sulfate (1 to 5 mg IV) is reasonable for patients
whose symptoms are not relieved despite NTG (e.g., after
3 serial sublingual NTG tablets) or whose symptoms
recur despite adequate anti-ischemic therapy. Unless
contraindicated by hypotension or intolerance, morphine
may be administered with intravenous NTG, with careful
blood pressure monitoring, and may be repeated every 5
to 30 min as needed to relieve symptoms and maintain
patient comfort.
Morphine sulfate has potent analgesic and anxiolytic
effects, as well as hemodynamic effects, that are potentially
beneﬁcial in UA/NSTEMI. No randomized trials have
deﬁned the unique contribution of morphine to the initial
therapeutic regimen or its optimal administration schedule.
Morphine causes venodilation and can produce modest
reductions in heart rate (through increased vagal tone) and
systolic blood pressure to further reduce myocardial oxygen
demand. The major adverse reaction to morphine is an
exaggeration of its therapeutic effect, causing hypotension,
especially in the presence of volume depletion and/or
vasodilator therapy. This reaction usually responds to supine
or Trendelenburg positioning or intravenous saline boluses
and atropine when accompanied by bradycardia; it rarely
requires pressors or naloxone to restore blood pressure.
Nausea and vomiting occur in approximately 20% of pa-
tients. Respiratory depression is the most serious complica-
tion of morphine; severe hypoventilation that requires in-
tubation occurs very rarely in patients with UA/NSTEMI
treated with morphine. Naloxone (0.4 to 2.0 mg IV) may be
administered for morphine overdose with respiratory or
circulatory depression. Other narcotics may be considered in
patients allergic to morphine. A cautionary note on mor-
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phine use has been raised by data from a large observational
registry (n  443 hospitals) that enrolled patients with
UA/NSTEMI (n  57,039) (313). Those receiving mor-
phine (30%) had a higher adjusted likelihood of death
(propensity-adjusted OR  1.41, 95% CI 1.26 to 1.57),
which persisted across all subgroups (313). Although subject
to uncontrolled selection biases, these results raise a safety
concern and suggest the need for a randomized trial.
Meanwhile, the Writing Committee has downgraded the
recommendation for morphine use for uncontrolled isch-
emic chest discomfort from a Class I to a Class IIa
recommendation.
3.1.2.3. BETA-ADRENERGIC BLOCKERS
Beta blockers competitively block the effects of cat-
echolamines on cell membrane beta receptors. Beta-1 ad-
renergic receptors are located primarily in the myocardium;
inhibition of catecholamine action at these sites reduces
myocardial contractility, sinus node rate, and AV node
conduction velocity. Through these actions, they blunt the
heart rate and contractility responses to chest pain, exertion,
and other stimuli. They also decrease systolic blood pres-
sure. All of these effects reduce MVO2. Beta-2 adrenergic
receptors are located primarily in vascular and bronchial
smooth muscle; the inhibition of catecholamine action at
these sites produces vasoconstriction and bronchoconstric-
tion (300). In UA/NSTEMI, the primary beneﬁts of beta
blockers are due to inhibition of beta-1 adrenergic receptors,
which results in a decrease in cardiac work and myocardial
oxygen demand. Slowing of the heart rate also has a
favorable effect, acting not only to reduce MVO2 but also to
increase the duration of diastole and diastolic pressure-time,
a determinant of forward coronary ﬂow and collateral ﬂow.
Beta blockers, administered orally, should be started early
in the absence of contraindications. Intravenous adminis-
tration may be warranted in patients with ongoing rest pain,
especially with tachycardia or hypertension, in the absence
of contraindications (see below) (Table 12).
The beneﬁts of routine early intravenous use of beta
blockers in the ﬁbrinolytic era have been challenged by 2
later randomized trials of intravenous beta blockade
(314,315) and by a post hoc analysis of the use of atenolol
in the GUSTO-I trial (316). A subsequent systematic
review of early beta-blocker therapy in STEMI found no
signiﬁcant reduction in mortality (27). Most recently, the
utility of early intravenous followed by oral beta blockade
(metoprolol) was tested in 45,852 patients with MI (93%
had STEMI, 7% had NSTEMI) in the COMMIT study
(317). Neither the composite of death, reinfarction, or
cardiac arrest nor death alone was reduced for up to 28 d in
the hospital. Overall, a modest reduction in reinfarction and
ventricular ﬁbrillation (which was seen after day 1) was
counterbalanced by an increase in cardiogenic shock, which
occurred early (ﬁrst day) and primarily in those who were
hemodynamically compromised or in HF or who were
stable but at high risk of development of shock. Thus, early
aggressive beta blockade poses a substantial net hazard in
hemodynamically unstable patients and should be avoided.
Risk factors for shock were older age, female sex, time delay,
higher Killip class, lower blood pressure, higher heart rate,
ECG abnormality, and previous hypertension. There was a
moderate net beneﬁt for those who were relatively stable
and at low risk of shock. Whether to start beta blockade
intravenously or orally in these latter stable patients is
unclear, and patterns of use vary. In an attempt to balance
the evidence base overall for UA/NSTEMI patients, beta
blockers are recommended in these guidelines to be initiated
orally, in the absence of contraindications (e.g., HF), within
the ﬁrst 24 h. Greater caution is now suggested in the early
use of intravenous beta blockers, which should be targeted
to speciﬁc indications and should be avoided with HF,
hypotension, and hemodynamic instability.
The choice of beta blocker for an individual patient is
based primarily on pharmacokinetic and side effect criteria,
as well as on physician familiarity (Table 15). There are no
comparative studies between members of this class in the
Table 15. Properties of Beta Blockers in Clinical Use
Drugs Selectivity Partial Agonist Activity Usual Dose for Angina
Propranolol None No 20 to 80 mg twice daily
Metoprolol Beta1 No 50 to 200 mg twice daily
Atenolol Beta1 No 50 to 200 mg per d
Nadolol None No 40 to 80 mg per d
Timolol None No 10 mg twice daily
Acebutolol Beta1 Yes 200 to 600 mg twice daily
Betaxolol Beta1 No 10 to 20 mg per d
Bisoprolol Beta1 No 10 mg per d
Esmolol (intravenous) Beta1 No 50 to 300 mcg per kg per min
Labetalol* None Yes 200 to 600 mg twice daily
Pindolol None Yes 2.5 to 7.5 mg 3 times daily
Carvedilol None Yes 6.25 mg twice daily, uptitrated to a maximum of 25 mg twice daily
*Labetalol and carvedilol are combined alpha and beta blockers. Adapted from Table 25, Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients
with chronic stable angina. Available at: http://www.acc.org/qualityandscience (4).
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acute setting. Beta blockers without intrinsic sympathomi-
metic activity are preferred, however. Agents studied in the
acute setting include metoprolol, propranolol, and atenolol.
Carvedilol may be added to the list of agents studied for
post-MI use. Comparative studies among different beta
blockers in the chronic setting after UA/NSTEMI also are
not available to establish a preference among agents. In
patients with HF, 1 study suggested greater beneﬁt with
carvedilol, with mixed beta-blocking and alpha-adrenergic-
blocking effects, than metoprolol, a relatively selective
beta-1 blocker (318). In patients with hypertension, the
relative cardiovascular beneﬁt of atenolol has been ques-
tioned on the basis of recent clinical trial analyses (319,320).
Patients with marked ﬁrst-degree AV block (i.e., ECG
PR interval greater than 0.24 s), any form of second- or
third-degree AV block in the absence of a functioning
implanted pacemaker, a history of asthma, severe LV
dysfunction or HF (e.g., rales or S3 gallop) or at high risk for
shock (see above) should not receive beta blockers on an
acute basis (4). Patients with evidence of a low-output state
(e.g., oliguria) or sinus tachycardia, which often reﬂects low
stroke volume, signiﬁcant sinus bradycardia (heart rate less
than 50 beats per min), or hypotension (systolic blood
pressure less than 90 mm Hg) should not receive acute
beta-blocker therapy until these conditions have resolved.
Patients at highest risk for cardiogenic shock due to intra-
venous beta blockade in the COMMIT trial were those
with tachycardia or in Killip Class II or III (317). However,
beta blockers are strongly recommended before discharge in
those with compensated HF or LV systolic dysfunction for
secondary prevention (321). Patients with signiﬁcant
chronic obstructive pulmonary disease who may have a
component of reactive airway disease should be given beta
blockers very cautiously; initially, low doses of a beta-1–
selective agent should be used. If there are concerns about
possible intolerance to beta blockers, initial selection should
favor a short-acting beta-1–speciﬁc drug such as metoprolol
or esmolol. Mild wheezing or a history of chronic obstruc-
tive pulmonary disease mandates a short-acting cardioselec-
tive agent at a reduced dose (e.g., 12.5 mg of metoprolol
orally) rather than the complete avoidance of a beta blocker.
In the absence of these concerns, previously studied
regimens may be used. Intravenous metoprolol may be given
in 5-mg increments by slow intravenous administration (5
mg over 1 to 2 min), repeated every 5 min for a total initial
dose of 15 mg. In patients who tolerate the total 15-mg IV
dose, oral therapy can be initiated 15 min after the last
intravenous dose at 25 to 50 mg every 6 h for 48 h.
Thereafter, patients should receive a maintenance dose of up
to 100 mg twice daily. Alternatively, intravenous propran-
olol may be administered as an initial dose of 0.5 to 1.0 mg,
followed in 1 to 2 h by 40 to 80 mg by mouth every 6 to 8 h.
Monitoring during intravenous beta-blocker therapy should
include frequent checks of heart rate and blood pressure and
continuous ECG monitoring, as well as auscultation for
rales and bronchospasm. Beta blockade also may be started
orally, in smaller initial doses if appropriate, within the ﬁrst
24 h, in cases in which a speciﬁc clinical indication for
intravenous initiation is absent or the safety of aggressive
early beta blockade is a concern. Carvedilol, 6.25 mg by
mouth twice daily, uptitrated individually at 3- to 10-d
intervals to a maximum of 25 mg twice daily, can reduce
mortality and reinfarction when given to patients with
recent (3 to 21 d) MI and LV dysfunction (321). After the
initial intravenous load, if given, patients without limiting
side effects may be converted to an oral regimen. The target
resting heart rate is 50 to 60 beats per minute unless a
limiting side effect is reached. Selection of the oral agent
should include the clinician’s familiarity with the agent.
Maintenance doses are given in Table 15.
Initial studies of beta-blocker beneﬁts in ACS were small
and uncontrolled. An overview of double-blind, randomized
trials in patients with threatening or evolving MI suggests
an approximately 13% reduction in the risk of progression to
MI (322). These trials were conducted prior to the routine
use of ASA, heparin, clopidogrel, GP IIb/IIIa inhibitors,
and revascularization. These trials lack sufﬁcient power to
assess the effects of these drugs on mortality rates for UA.
Pooled results from the Evaluation of c7E3 for the Preven-
tion of Ischemic Complications (EPIC), Evaluation of
PTCA and Improve Long-term Outcome by c7E3 GP
IIb/IIIa receptor blockade (EPILOG), Evaluation of Plate-
let IIb/IIIa Inhibitor for STENTing (EPISTENT), CAP-
TURE, and ReoPro in Acute myocardial infarction and
Primary PTCA Organization and Randomization Trial
(RAPPORT) studies were used to evaluate the efﬁcacy of
beta-blocker therapy in patients with ACS who were
undergoing PCI (323). At 30 d, death occurred in 0.6% of
patients receiving beta-blocker therapy versus 2.0% of pa-
tients not receiving such therapy (p less than 0.001). At 6
months, death occurred in 1.7% of patients receiving beta-
blocker therapy versus 3.7% not receiving this therapy (p less
than 0.001). Thus, patients receiving beta-blocker therapy
who undergo PCI for UA or MI have a lower short-term
mortality (323).
Overall, the rationale for beta-blocker use in all forms of
CAD, including UA, is generally favorable, with the excep-
tion of initial HF. In the absence of contraindications, the
new evidence appears sufﬁcient to make beta blockers a
routine part of care. A related group shown to beneﬁt are
high- or intermediate-risk patients who are scheduled to
undergo cardiac or noncardiac surgery (324). A recent
exception to beta-blocker beneﬁt was COMMIT, a large
trial of mostly STEMI patients, which showed no overall
mortality effect. Subgroup analysis suggested this to be due
to an increased risk in those with initial HF or risk factors
for cardiogenic shock (317). In contrast to this adverse
experience with early, aggressive beta blockade, carvedilol,
begun in low doses 3 to 10 d after MI in patients with LV
dysfunction (ejection fraction of 0.40 or less) and gradually
uptitrated, decreased subsequent death or nonfatal recurrent
MI when given in conjunction with modern ACS therapies
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in the most contemporary oral beta blocker post-MI trial,
CAPRICORN (Carvedilol Post-Infarct Survival Control in
LV Dysfunction) (321).
In conclusion, evidence for the beneﬁcial effects of the use
of beta blockers in patients with UA is based on limited
randomized trial data along with pathophysiological con-
siderations and extrapolation from experience with CAD
patients who have other types of ischemic syndromes (stable
angina or compensated chronic HF). The duration of
beneﬁt with long-term oral therapy is uncertain and likely
varies with the extent of revascularization.
3.1.2.4. CALCIUM CHANNEL BLOCKERS
Calcium channel blockers (CCBs) reduce cell transmem-
brane inward calcium ﬂux, which inhibits both myocardial
and vascular smooth muscle contraction; some also slow AV
conduction and depress sinus node impulse formation.
Agents in this class vary in the degree to which they produce
vasodilation, decreased myocardial contractility, AV block,
and sinus node slowing. Nifedipine and amlodipine have the
most peripheral arterial dilatory effects but few or no AV or
sinus node effects, whereas verapamil and diltiazem have
prominent AV and sinus node effects and some peripheral
arterial dilatory effects as well. All 4 of these agents, as well
as other approved agents, have coronary dilatory properties
that appear to be similar. Although different CCBs are
structurally and, potentially, therapeutically diverse, superi-
ority of 1 agent over another in UA/NSTEMI has not been
demonstrated, except for the increased risks posed by
rapid-release, short-acting dihydropyridines such as nifedi-
pine (Table 16). Beneﬁcial effects in UA/NSTEMI are
believed to be due to variable combinations of decreased
myocardial oxygen demand (related to decreased afterload,
contractility, and heart rate) and improved myocardial ﬂow
(related to coronary arterial and arteriolar dilation)
(300,325). These agents also have theoretically beneﬁcial
effects on LV relaxation and arterial compliance. Major side
effects include hypotension, worsening HF, bradycardia,
and AV block.
Calcium channel blockers may be used to control ongoing
or recurring ischemia-related symptoms in patients who
already are receiving adequate doses of nitrates and beta
blockers, in patients who are unable to tolerate adequate
doses of 1 or both of these agents, and in patients with
variant angina (see Section 6.7). In addition, these drugs
have been used for the management of hypertension in
patients with recurrent UA (325). Rapid-release, short-
acting dihydropyridines (e.g., nifedipine) must be avoided in
the absence of concomitant beta blockade because of in-
creased adverse potential (326,327,328). Verapamil and
diltiazem should be avoided in patients with pulmonary
edema or evidence of severe LV dysfunction (329–331).
Amlodipine and felodipine are reasonably well tolerated by
patients with mild LV dysfunction (329–331,332–334),
although their use in UA/NSTEMI has not been studied.
The CCB evidence base in UA/NSTEMI is greatest for
verapamil and diltiazem (328,331).
Several randomized trials during the 1980s tested CCBs
in UA/NSTEMI and found that they relieve or prevent
signs and symptoms of ischemia to a degree similar to the
beta blockers. The Danish Study Group on Verapamil in
Myocardial Infarction (DAVIT) (332,333) studied 3,447
patients with suspected UA/NSTEMI. A beneﬁt was not
proved, but death or nonfatal MI tended to be reduced. The
Diltiazem Reinfarction Study (DRS) studied 576 patients
with UA/NSTEMI (329). Diltiazem reduced reinfarction
and refractory angina at 14 d without an increase in
Table 16. Properties of Calcium Channel Blockers in Clinical Use
Drug Usual Dose
Duration of
Action Side Effects
Dihydropyridines
Nifedipine* Immediate release: 30 to 90 mg daily orally Short Hypotension, dizziness, ﬂushing, nausea, constipation,
edema
Slow release: 30 to 180 mg orally
Amlodipine 5 to 10 mg once daily Long Headache, edema
Felodipine 5 to 10 mg once daily Long Headache, edema
Isradipine 2.5 to 10 mg twice daily Medium Headache, fatigue
Nicardipine 20 to 40 mg 3 times daily Short Headache, dizziness, ﬂushing, edema
Nisoldipine 20 to 40 mg once daily Short Similar to nifedipine
Nitrendipine 20 mg once or twice daily Medium Similar to nifedipine
Miscellaneous
Diltiazem Immediate release: 30 to 90 mg 4 times
daily
Short Hypotension, dizziness, ﬂushing, bradycardia, edema
Slow release: 120 to 360 mg once daily Long
Verapamil Immediate release: 80 to 160 mg 3 times
daily
Short Hypotension, myocardial depression, heart failure,
edema, bradycardia
Slow release: 120 to 480 mg once daily Long
*Immediate-release nifedipine not recommended for UA/NSTEMI except with concomitant beta blockade. Modiﬁed from Table 27 in Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline
update for the management of patients with chronic stable angina. Available at: http://www.acc.org/qualityandscience (4).
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mortality rates. Retrospective analysis of the non–Q-wave
MI subset of patients in the Multicenter Diltiazem Postin-
farction Trial (MDPIT) suggested similar ﬁndings (334).
The Holland Interuniversity Nifedipine/metoprolol Trial
(HINT), tested nifedipine and metoprolol in a 2  2
factorial design in 515 patients (327). The study was
stopped early because of concern for harm with the use of
nifedipine alone. In contrast, patients already taking a beta
blocker appeared to beneﬁt from the addition of nifedipine
(risk ratio [RR] 0.68) (335).
Meta-analyses combining UA/NSTEMI studies of all
CCBs have suggested no overall beneﬁt (322,336), whereas
those excluding nifedipine (e.g., for verapamil alone) have
reported favorable effects on outcomes (332). Retrospective
analyses of DAVIT and MDPIT suggested that verapamil
and diltiazem can have a detrimental effect on mortality
rates in patients with LV dysfunction (329,330). In contrast,
verapamil reduced diuretic use in DAVIT-2, (333). Fur-
thermore, subsequent prospective trials with verapamil ad-
ministered to MI patients with HF who were receiving an
ACE inhibitor suggested a beneﬁt (330,337). The Dilti-
azem as Adjunctive Therapy to Activase (DATA) trial also
suggested that intravenous diltiazem in MI patients can be
safe; death, MI, and recurrent ischemia were decreased at 35
d and 6 months (338).
In summary, deﬁnitive evidence for a beneﬁt of CCBs in
UA/NSTEMI is predominantly limited to symptom con-
trol. For immediate-release nifedipine, an increase in serious
events is suggested when administered early without a beta
blocker. The heart rate–slowing CCB drugs (verapamil and
diltiazem) can be administered early to patients with UA/
NSTEMI without HF without overall harm and with
trends toward a beneﬁt. Therefore, when beta blockers
cannot be used, and in the absence of clinically signiﬁcant
LV dysfunction, heart rate–slowing CCBs are preferred.
Greater caution is indicated when combining a beta blocker
and CCB for refractory ischemic symptoms, because they
may act in synergy to depress LV function and sinus and AV
node conduction. The risks and beneﬁts in UA/NSTEMI
of newer CCBs, such as the dihydropyridines amlodipine
and felodipine, relative to the older agents in this class that
have been reviewed here, remain undeﬁned, which suggests
a cautious approach, especially in the absence of beta
blockade.
3.1.2.5. INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Angiotensin-converting enzyme inhibitors have been shown
to reduce mortality rates in patients with MI or who
recently had an MI and have LV systolic dysfunction
(339–341), in patients with diabetes mellitus with LV
dysfunction (342), and in a broad spectrum of patients with
high-risk chronic CAD, including patients with normal LV
function (343). Follow-up of patients with LV dysfunction
after MI in the TRACE (TRAndolapril Cardiac Evalua-
tion) trial showed that the beneﬁcial effect of trandolapril on
mortality and hospitalization rate was maintained for at
least 10 to 12 years (344). A systematic review assessing
potential ASA–ACE inhibitor interactions showed clini-
cally important beneﬁts with ACE inhibitor therapy, irre-
spective of whether concomitant ASA was used, and only
weak evidence of a reduction in the beneﬁt of ACE
inhibitor therapy added to ASA (345); these data did not
solely involve patients with MI. Accordingly, ACE inhibi-
tors should be used in patients receiving ASA and in those
with hypertension that is not controlled with beta blockers.
Recent data on ACE inhibitor patients with stable CAD are
summarized in the section on long-term medical therapy
(see Section 5.2.3).
In patients with MI complicated by LV systolic dys-
function, HF, or both, the angiotensin receptor blocker
valsartan was as effective as captopril in patients at high
risk for cardiovascular events after MI. The combination
of valsartan and captopril increased adverse events and
did not improve survival (346). Although not in the acute
care setting, treatment of patients with chronic HF with
candesartan (at least half of whom had an MI) in the
CHARM (Candesartan in Heart failure Assessment in
Reduction of Mortality)-Overall program showed a re-
duction in cardiovascular deaths and hospital admissions
for HF, independent of ejection fraction or baseline
treatment (347).
The selective aldosterone receptor blocker eplerenone,
used in patients with MI complicated by LV dysfunction
and either HF or diabetes mellitus, reduced morbidity and
mortality in the Eplerenone Post-acute myocardial infarc-
tion Heart failure Efﬁcacy and SUrvival Study (EPHESUS)
(348). This complements data from the earlier Randomized
ALdactone Evaluation Study (RALES), in which aldoste-
rone receptor blockade with spironolactone decreased mor-
bidity and death in patients with severe HF, half of whom
had an ischemic origin (349). Indications for long-term use
of aldosterone receptor blockers are given in Section 5.2.3.
3.1.2.6. OTHER ANTI-ISCHEMIC THERAPIES
Other less extensively studied therapies for the relief of
ischemia, such as spinal cord stimulation (350) and pro-
longed external counterpulsation (351,352), are under eval-
uation. Most experience has been gathered with spinal cord
stimulation in “intractable angina” (353), in which anginal
relief has been described. They have not been applied in the
acute setting for UA/NSTEMI.
The KATP channel openers have hemodynamic and
cardioprotective effects that could be useful in UA/
NSTEMI. Nicorandil is such an agent that has been
approved in a number of countries but not in the United
States. In a pilot double-blind, placebo-controlled study
of 245 patients with UA, the addition of this drug to
conventional treatment signiﬁcantly reduced the number
of episodes of transient myocardial ischemia (mostly silent)
and of ventricular and supraventricular tachycardia (354).
Further evaluation of this class of agents is underway.
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Ranolazine is a newly approved (January 2006) agent that
exerts antianginal effects without reducing heart rate or
blood pressure (355). Currently, ranolazine is indicated
alone or in combination with amlodipine, beta-blockers, or
nitrates for the treatment of chronic angina that has failed to
respond to standard antianginal therapy. The recommended
initial dose is 500 mg orally twice daily, which can be
escalated as needed to a maximum of 1000 mg twice daily.
The mechanism of action of ranolazine has not been fully
characterized but appears to depend on membrane ion-
channel effects (similar to those after chronic amiodarone)
(356). It is contraindicated in patients with QT-prolonging
conditions. Preliminary results of a large (N  6,560)
patient trial of ranolazine, begun within 48 h of UA/
NSTEMI, suggested safety and symptom relief (reduction
in angina) but did not achieve the primary efﬁcacy end point
of a reduction in the composite of cardiovascular death, MI,
or recurrent ischemia (hazard ratio [HR] 0.92, 95% CI 0.83
to 1.02) (357,357a). Thus, ranolazine may be safely admin-
istered for symptom relief after UA/NSTEMI, but it does
not appear to signiﬁcantly improve the underlying disease
substrate.
3.1.2.7. INTRA-AORTIC BALLOON PUMP COUNTERPULSATION
Experience with IABP for refractory ischemia dates back
more than 30 years. In a prospective registry of 22,663
IABP patients, 5,495 of whom had acute MI, placement
of an IABP in MI patients primarily was performed for
cardiogenic shock, for hemodynamic support during
catheterization and/or angioplasty, before high-risk sur-
gery, for mechanical complications of MI, or for refrac-
tory post-MI UA. Balloon insertions were successful in
97.7% of patients, and major complications occurred in
2.7% of patients during a median use of 3 d (358). The
placement of an IABP could be useful in patients with
recurrent ischemia despite maximal medical management
and in those with hemodynamic instability until coronary
angiography and revascularization can be completed.
3.1.2.8. ANALGESIC THERAPY
Because of the known increased risk of cardiovascular events
among patients taking COX-2 inhibitors and NSAIDs
(359–361), patients who are taking them at the time of
UA/NSTEMI should discontinue them immediately (see
Section 5.2.16 for additional discussion). A secondary anal-
ysis of the Enoxaparin and Thrombolysis Reperfusion for
Acute Myocardial Infarction Treatment (EXTRACT)-
TIMI-25 data (362) demonstrated an increased risk of
death, reinfarction, HF, or shock among patients who were
taking NSAIDs within 7 d of enrollment. Longer term
management is considered in Section 5.2.16.
3.2. Recommendations for
Antiplatelet/Anticoagulant Therapy in Patients for
Whom Diagnosis of UA/NSTEMI Is Likely or Deﬁnite
Recommendations are written as the reader follows the
algorithms for antiplatelet/anticoagulant therapy and triage
for angiography (Figs. 7, 8, and 9). Letters after recommen-
dations refer to the speciﬁc box in the algorithm. See Table
13 for dosing recommendations.
3.2.1. Antiplatelet Therapy Recommendations
CLASS I
1. Aspirin should be administered to UA/NSTEMI patients as soon as
possible after hospital presentation and continued indeﬁnitely in
patients not known to be intolerant of that medication. (Level of
Evidence: A) (Figs. 7 and 8; Box A)
2. Clopidogrel (loading dose followed by daily maintenance dose)*
should be administered to UA/NSTEMI patients who are unable to
take ASA because of hypersensitivity or major gastrointestinal
intolerance. (Level of Evidence: A) (Figs. 7 and 8; Box A)
3. In UA/NSTEMI patients with a history of gastrointestinal bleeding,
when ASA and clopidogrel are administered alone or in combina-
tion, drugs to minimize the risk of recurrent gastrointestinal bleed-
ing (e.g., proton-pump inhibitors) should be prescribed concomi-
tantly. (Level of Evidence: B)
4. For UA/NSTEMI patients in whom an initial invasive strategy is
selected, antiplatelet therapy in addition to aspirin should be
initiated before diagnostic angiography (upstream) with either clo-
pidogrel (loading dose followed by daily maintenance dose)* or an
intravenous GP IIb/IIIa inhibitor. (Level of Evidence: A) Abciximab
as the choice for upstream GP IIb/IIIa therapy is indicated only if
there is no appreciable delay to angiography and PCI is likely to be
performed; otherwise, IV eptiﬁbatide or tiroﬁban is the preferred
choice of GP IIb/IIIa inhibitor. (Level of Evidence: B)
5. For UA/NSTEMI patients in whom an initial conservative (i.e.,
noninvasive) strategy is selected (see Section 3.3), clopidogrel
(loading dose followed by daily maintenance dose)* should be
added to ASA and anticoagulant therapy as soon as possible after
admission and administered for at least 1 month (Level of Evi-
dence: A) and ideally up to 1 year. (Level of Evidence: B) (Fig. 8; Box C2)
6. For UA/NSTEMI patients in whom an initial conservative strategy is
selected, if recurrent symptoms/ischemia, HF, or serious arrhyth-
mias subsequently appear, then diagnostic angiography should be
performed. (Level of Evidence: A) (Fig. 8; Box D) Either an intrave-
nous GP IIb/IIIa inhibitor (eptiﬁbatide or tiroﬁban; Level of Evi-
dence: A) or clopidogrel (loading dose followed by daily mainte-
nance dose; Level of Evidence: A)* should be added to ASA and
anticoagulant therapy before diagnostic angiography (upstream).
(Level of Evidence: C)
CLASS IIa
1. For UA/NSTEMI patients in whom an initial conservative strategy is
selected and who have recurrent ischemic discomfort with clopi-
dogrel, ASA, and anticoagulant therapy, it is reasonable to add a GP
IIb/IIIa antagonist before diagnostic angiography. (Level of Evi-
dence: C)
2. For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to initiate antiplatelet therapy with both
*Some uncertainty exists about optimum dosing of clopidogrel. Randomized trials
establishing its efﬁcacy and providing data on bleeding risks used a loading dose of 300
mg orally followed by a daily oral maintenance dose of 75 mg. Higher oral loading
doses such as 600 or 900 mg of clopidogrel more rapidly inhibit platelet aggregation
and achieve a higher absolute level of inhibition of platelet aggregation, but the
additive clinical efﬁcacy and the safety of higher oral loading doses have not been
rigorously established.
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clopidogrel (loading dose followed by daily maintenance dose)* and
an intravenous GP IIb/IIIa inhibitor. (Level of Evidence: B) Abciximab
as the choice for upstream GP IIb/IIIa therapy is indicated only if
there is no appreciable delay to angiography and PCI is likely to be
performed; otherwise, IV eptiﬁbatide or tiroﬁban is the preferred
choice of GP IIb/IIIa inhibitor.† (Level of Evidence: B)
3. For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to omit upstream administration of an
intravenous GP IIb/IIIa antagonist before diagnostic angiography if
bivalirudin is selected as the anticoagulant and at least 300 mg of
clopidogrel was administered at least 6 h earlier than planned
catheterization or PCI. (Level of Evidence: B)
CLASS IIb
For UA/NSTEMI patients in whom an initial conservative (i.e., noninva-
sive) strategy is selected, it may be reasonable to add eptiﬁbatide or
tiroﬁban to anticoagulant and oral antiplatelet therapy. (Level of Evi-
dence: B) (Fig. 8; Box C2)
CLASS III
Abciximab should not be administered to patients in whom PCI is not
planned. (Level of Evidence: A)
3.2.2. Anticoagulant Therapy Recommendations
CLASS I
Anticoagulant therapy should be added to antiplatelet therapy in
UA/NSTEMI patients as soon as possible after presentation.
a. For patients in whom an invasive strategy is selected, regimens with
established efﬁcacy at a Level of Evidence: A include enoxaparin and
UFH (Fig. 7; Box B1), and those with established efﬁcacy at a Level of
Evidence: B include bivalirudin and fondaparinux (Fig. 7; Box B1).
b. For patients in whom a conservative strategy is selected, regimens
using either enoxaparin‡ or UFH (Level of Evidence: A) or fondapa-
rinux (Level of Evidence: B) have established efﬁcacy. (Fig. 8; Box
C1) ‡See also Class IIa recommendation below.
c. In patients in whom a conservative strategy is selected and who
have an increased risk of bleeding, fondaparinux is preferable.
(Level of Evidence: B) (Fig. 8; Box C1)
CLASS IIa
For UA/NSTEMI patients in whom an initial conservative strategy is se-
lected, enoxaparin‡ or fondaparinux is preferable to UFH as anticoagulant
therapy, unless CABG is planned within 24 h. (Level of Evidence: B)
*Some uncertainty exists about optimum dosing of clopidogrel. Randomized trials
establishing its efﬁcacy and providing data on bleeding risks used a loading dose of 300 mg
orally followed by a daily oral maintenance dose of 75 mg. Higher oral loading doses such
as 600 or 900 mg of clopidogrel may more rapidly inhibit platelet aggregation and achieve
a higher absolute level of inhibition of platelet aggregation, but the additive efﬁcacy and
the safety of higher oral loading doses have not been rigorously established.
†Factors favoring administration of both clopidogrel and GP IIb/IIIa inhibitor
include: delay to angiography, high-risk features, and early recurrent ischemic
discomfort.
‡Limited data are available for the use of other LMWHs (e.g., dalteparin; see Tables
13 and 17) in UA/NSTEMI.
Figure 7. Algorithm for Patients With UA/NSTEMI Managed by an Initial Invasive Strategy
When multiple drugs are listed, they are in alphabetical order and not in order of preference (e.g., Boxes B1 and B2). *See dosing Table 13. †See Table 11 for selection of
management strategy. ‡Evidence exists that GP IIb/IIIa inhibitors may not be necessary if the patient received a preloading dose of at least 300 mg of clopidogrel at least
6 h earlier (Class I, Level of Evidence B for clopidogrel administration) and bivalirudin is selected as the anticoagulant (Class IIa, Level of Evidence B). ASA  aspirin; GP 
glycoprotein; IV  intravenous; LOE  level of evidence; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction; UFH  unfractionated heparin.
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3.2.3. Additional Management Considerations for
Antiplatelet and Anticoagulant Therapy
CLASS I
1. For UA/NSTEMI patients in whom an initial conservative strategy is
selected and no subsequent features appear that would necessi-
tate diagnostic angiography (recurrent symptoms/ischemia, HF, or
serious arrhythmias), a stress test should be performed. (Level of
Evidence: B) (Fig. 8; Box O)
a. If, after stress testing, the patient is classiﬁed as not at low risk,
diagnostic angiography should be performed. (Level of Evi-
dence: A) (Fig. 8; Box E1)
b. If, after stress testing, the patient is classiﬁed as being at low
risk (Fig. 8; Box E2), the instructions noted below should be
followed in preparation for discharge (Fig. 8; Box K) (Level of
Evidence: A):
1. Continue ASA indeﬁnitely. (Level of Evidence: A)
2. Continue clopidogrel for at least 1month (Level of Evidence:
A) and ideally up to 1 year. (Level of Evidence: B)
3. Discontinue intravenous GP IIb/IIIa inhibitor if started pre-
viously. (Level of Evidence: A)
4. Continue UFH for 48 h or administer enoxaparin or fondapa-
rinux for the duration of hospitalization, up to 8 d, and then
discontinue anticoagulant therapy. (Level of Evidence: A)
2. For UA/NSTEMI patients in whom CABG is selected as a postan-
giography management strategy, the instructions noted below
should be followed (Fig. 9; Box G).
Figure 8. Algorithm for Patients With UA/NSTEMI Managed by an Initial Conservative Strategy
When multiple drugs are listed, they are in alphabetical order and not in order of preference (e.g., Boxes C1 and C2). *See dosing Table 13. †See Table 11 for selection of
management strategy. ‡Recurrent symptoms/ischemia, heart failure, serious arrhythmia. ASA  aspirin; EF  ejection fraction; GP  glycoprotein; IV  intravenous; LOE 
level of evidence; LVEF  left ventricular ejection fraction; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction; UFH  unfractionated heparin.
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a. Continue ASA. (Level of Evidence: A)
b. Discontinue clopidogrel 5 to 7 d before elective CABG. (Level of
Evidence: B) More urgent surgery, if necessary, may be per-
formed by experienced surgeons if the incremental bleeding
risk is considered acceptable. (Level of Evidence: C)
c. Discontinue intravenous GP IIb/IIIa inhibitor (eptiﬁbatide or
tiroﬁban) 4 h before CABG. (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue UFH. (Level of Evidence: B)
2. Discontinue enoxaparin* 12 to 24 h before CABG and dose
with UFH per institutional practice. (Level of Evidence: B)
3. Discontinue fondaparinux 24 h before CABG and dose with
UFH per institutional practice. (Level of Evidence: B)
4. Discontinue bivalirudin 3 h before CABG and dose with UFH
per institutional practice. (Level of Evidence: B)
3. For UA/NSTEMI patients in whom PCI has been selected as a
postangiography management strategy, the instructions noted be-
low should be followed (Fig. 9; Box H):
a. Continue ASA. (Level of Evidence: A)
b. Administer a loading dose of clopidogrel† if not started before
diagnostic angiography. (Level of Evidence: A)
c. Administer an intravenous GP IIb/IIIa inhibitor (abciximab,
eptiﬁbatide, or tiroﬁban) if not started before diagnostic
angiography for troponin-positive and other high-risk pa-
tients (Level of Evidence: A). See Class IIa recommendation
below if bivalirudin was selected as the anticoagulant.
d. Discontinue anticoagulant therapy after PCI for uncomplicated
cases. (Level of Evidence: B)
4. For UA/NSTEMI patients in whom medical therapy is selected as a
postangiography management strategy and in whom no signiﬁcant
obstructive CAD on angiography was found, antiplatelet and anticoag-
ulant therapy should be administered at the discretion of the clinician.
(Level of Evidence: C) For patients in whom evidence of coronary
atherosclerosis is present (e.g., luminal irregularities or intravascular
ultrasound-demonstrated lesions), albeit without ﬂow-limiting steno-
ses, long-term treatment with ASA and other secondary prevention
measures should be prescribed. (Fig. 9; Box I) (Level of Evidence: C)
5. For UA/NSTEMI patients in whom medical therapy is selected as a
postangiography management strategy and in whom CAD was found
on angiography, the following approach is recommended (Fig. 9; Box J):
a. Continue ASA. (Level of Evidence: A)
b. Administer a loading dose of clopidogrel† if not given before
diagnostic angiography. (Level of Evidence: A)
c. Discontinue intravenous GP IIb/IIIa inhibitor if started previ-
ously. (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue intravenous UFH for at least 48 h or until discharge if
given before diagnostic angiography. (Level of Evidence: A)
*Limited data are available for the use of other LMWHs (e.g., dalteparin; see Tables
13 and 17) in UA/NSTEMI.
†Some uncertainty exists about optimum dosing of clopidogrel. Randomized trials
establishing its efﬁcacy and providing data on bleeding risks used a loading dose of 300 mg
orally followed by a daily oral maintenance dose of 75 mg. Higher oral loading doses such
as 600 or 900 mg of clopidogrel more rapidly inhibit platelet aggregation and achieve a
higher absolute level of inhibition of platelet aggregation, but the additive clinical efﬁcacy
and the safety of higher oral loading doses have not been rigorously established.
Figure 9. Management After Diagnostic Angiography in Patients With UA/NSTEMI
*See dosing Table 13. †Evidence exists that GP IIb/IIIa inhibitors may not be necessary if the patient received a preloading dose of at least 300 mg of clopidogrel at least
6 h earlier (Class I, Level of Evidence B for clopidogrel administration) and bivalirudin is selected as the anticoagulant (Class IIa, Level of Evidence B). ‡Additional bolus of
UFH is recommended if fondaparinux is selected as the anticoagulant (see dosing Table 13). §For patients in whom the clinician believes coronary atherosclerosis is
present, albeit without any signiﬁcant, ﬂow-limiting stenoses, long-term treatment with antiplatelet agents and other secondary prevention measures should be considered.
ASA  aspirin; CABG  coronary artery bypass graft; CAD  coronary artery disease; GP  glycoprotein; IV  intravenous; LD  loading dose; PCI  percutaneous coronary
intervention; pre angio  before angiography; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction; UFH  unfractionated heparin.
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2. Continue enoxaparin for duration of hospitalization, up to 8 d,
if given before diagnostic angiography. (Level of Evidence: A)
3. Continue fondaparinux for duration of hospitalization, up to 8
d, if given before diagnostic angiography. (Level of Evidence: B)
4. Either discontinue bivalirudin or continue at a dose of 0.25mg
per kg per h for up to 72 h at the physician’s discretion, if given
before diagnostic angiography. (Level of Evidence: B)
6. For UA/NSTEMI patients in whom a conservative strategy is se-
lected and who do not undergo angiography or stress testing, the
instructions noted below should be followed (Fig. 8; Box K):
a. Continue ASA indeﬁnitely. (Level of Evidence: A)
b. Continue clopidogrel for at least 1 month (Level of Evidence: A)
and ideally up to 1 year. (Level of Evidence: B)
c. Discontinue IV GP IIb/IIIa inhibitor if started previously. (Level of
Evidence: A)
d. Continue UFH for 48 h or administer enoxaparin or fondapa-
rinux for the duration of hospitalization, up to 8 d, and then
discontinue anticoagulant therapy. (Level of Evidence: A)
7. For UA/NSTEMI patients in whom an initial conservative strategy is
selected and in whom no subsequent features appear that would
necessitate diagnostic angiography (recurrent symptoms/isch-
emia, HF, or serious arrhythmias), LVEF should be measured. (Level
of Evidence: B) (Fig. 8; Box L)
CLASS IIa
1. For UA/NSTEMI patients in whom PCI is selected as a postangiog-
raphy management strategy, it is reasonable to omit administra-
tion of an intravenous GP IIb/IIIa antagonist if bivalirudin was
selected as the anticoagulant and at least 300 mg of clopidogrel
was administered at least 6 h earlier. (Level of Evidence: B) (Fig. 9)
2. If LVEF is less than or equal to 0.40, it is reasonable to perform
diagnostic angiography. (Level of Evidence: B) (Fig. 8; Box M)
3. If LVEF is greater than 0.40, it is reasonable to perform a stress test.
(Level of Evidence: B) (Fig. 8; Box N)
CLASS IIb
For UA/NSTEMI patients in whom PCI is selected as a postangiography
management strategy, it may be reasonable to omit an intravenous GP
IIb/IIIa inhibitor if not started before diagnostic angiography for
troponin-negative patients without other clinical or angiographic high-
risk features. (Level of Evidence: C)
CLASS III
Intravenous ﬁbrinolytic therapy is not indicated in patients without
acute ST-segment elevation, a true posterior MI, or a presumed new left
bundle-branch block. (Level of Evidence: A)
Antithrombotic therapy is essential to modify the disease
process and its progression to death, MI, or recurrent MI in
the majority of patients who have ACS due to thrombosis on
a plaque. A combination of ASA, an anticoagulant, and
additional antiplatelet therapy represents the most effective
therapy. The intensity of treatment is tailored to individual
risk, and triple-antithrombotic treatment is used in patients
with continuing ischemia or with other high-risk features and
in patients oriented to an early invasive strategy (Table 11;
Figs. 7, 8, and 9). Table 13 shows the recommended doses of
the various agents. A problematic group of patients are those
who present with UA/NSTEMI but who are therapeutically
anticoagulated with warfarin. In such patients, clinical judg-
ment is needed with respect to initiation of the antiplatelet and
anticoagulant therapy recommended in this section. A general
guide is not to initiate anticoagulant therapy until the interna-
tional normalized ratio (INR) is less than 2.0. However,
antiplatelet therapy should be initiated even in patients thera-
peutically anticoagulated with warfarin, especially if an invasive
strategy is planned and implantation of a stent is anticipated. In
situations where the INR is supratherapeutic, the bleeding risk
is unacceptably high, or urgent surgical treatment is necessary,
reversal of the anticoagulant effect of warfarin may be consid-
ered with either vitamin K or fresh-frozen plasma as deemed
clinically appropriate on the basis of physician judgment.
3.2.4. Antiplatelet Agents and Trials (Aspirin,
Ticlopidine, Clopidogrel)
3.2.4.1. ASPIRIN
Some of the strongest evidence available about the long-
term prognostic effects of therapy in patients with coronary
disease pertains to ASA (363). By irreversibly inhibiting
COX-1 within platelets, ASA prevents the formation of
thromboxane A2, thereby diminishing platelet aggregation
promoted by this pathway but not by others. This platelet
inhibition is the plausible mechanism for the clinical beneﬁt
of ASA, both because it is fully present with low doses of
ASA and because platelets represent one of the principal
participants in thrombus formation after plaque disruption.
Alternative or additional mechanisms of action for ASA are
possible, such as an anti-inﬂammatory effect (364), but they
are unlikely to be important at the low doses of ASA that
are effective in UA/NSTEMI. Among all clinical investi-
gations with ASA, trials in UA/NSTEMI have consistently
documented a striking beneﬁt of ASA compared with
placebo independent of the differences in study design, such
as time of entry after the acute phase, duration of follow-up,
and dose used (365–368) (Fig. 10).
No trial has directly compared the efﬁcacy of different
doses of ASA in patients who present with UA/NSTEMI;
however, information can be gleaned from a collaborative
meta-analysis of randomized trials of antiplatelet therapy for
prevention of death, MI, and stroke in high-risk patients
(i.e., acute or previous vascular disease or other predisposing
conditions) (375). This collaborative meta-analysis pooled
data from 195 trials involving more than 143,000 patients
and demonstrated a 22% reduction in the odds of vascular
death, MI, or stroke with antiplatelet therapy across a broad
spectrum of clinical presentations that included patients
presenting with UA/NSTEMI. Indirect comparisons of the
proportional effects of different doses of ASA ranging from
less than 75 mg to up to 1500 mg daily showed similar
reductions in the odds of vascular events with doses between
75 and 1500 mg daily; when less than 75 mg was admin-
istered daily, the proportional beneﬁt of ASA was reduced
by at least one half compared with the higher doses. An
analysis from the CURE trial suggested that there was no
difference in the rate of thrombotic events according to ASA
dose, but there was a dose-dependent increase in bleeding in
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patients receiving ASA (plus placebo): the major bleeding
rate was 2.0% in patients taking less than 100 mg of ASA,
2.3% with 100 to 200 mg, and 4.0% with greater than 200
mg per d (243,376). Therefore, maintenance doses of 75 to
162 mg of ASA are preferred.
The prompt action of ASA and its ability to reduce
mortality rates in patients with suspected MI enrolled in the
Second International Study of Infarct Survival (ISIS-2) trial
led to the recommendation that ASA be initiated immediately
in the ED once the diagnosis of ACS is made or suspected.
Aspirin therapy also can be started in the prehospital setting
when ACS is suspected. On the basis of prior randomized trial
protocols and clinical experience, the initial dose of ASA
should be between 162 and 325 mg. Although some trials have
used enteric-coated ASA for initial dosing, more rapid buccal
absorption occurs with non–enteric-coated formulations (377).
After stenting, a higher initial maintenance dose of ASA of
325 mg per d has been recommended for 1 month after
bare-metal stent implantation and 3 to 6 months after drug-
eluting stent (DES) implantation (2). This was based
primarily on clinical trials that led to approval of these
stents, which used the higher doses initially. However, a
dosage change to a range of 162 to 325 mg per d initially has
been subsequently recommended, based on risk of excess
bleeding and an update of current evidence for ASA dosing
(Table 13; Fig. 11).
In patients who are already receiving ASA, it should be
continued. The protective effect of ASA has been sustained
for at least 1 to 2 years in clinical trials in UA/NSTEMI.
Longer term follow-up data in this population are lacking.
Long-term efﬁcacy can be extrapolated from other studies of
ASA therapy in CAD. Studies in patients with prior MI,
stroke, or transient ischemic attack have shown statistically
signiﬁcant beneﬁt during the ﬁrst 2 years and some addi-
tional but not statistically signiﬁcant beneﬁt during the third
year (363). In the absence of large comparison trials of
different durations of antiplatelet treatment in patients with
CVD or in primary prevention, it seems prudent to continue
ASA indeﬁnitely unless side effects are present (1,4,365).
Thus, patients should be informed of the evidence that
Figure 10. Older Trials of Antiplatelet and Anticoagulant Therapy in UA/NSTEMI
*Best results group. †GPIIb/IIIa with no heparin. ‡All trials except PRISM compared GP IIb-IIIa with UFH versus UFH. Meta-analysis of randomized trials in UA/NSTEMI that
have compared ASA with placebo, the combination of UFH and ASA with ASA alone, the combination of an LMWH and ASA with ASA alone, and the combination of a platelet
GP IIb/IIIa antagonist, UFH, and ASA with UFH plus ASA. The risk ratio values, 95% CIs, and probability value for each trial are shown. The timing of the end point (death or
MI) varied. Results with the platelet GP IIb/IIIa antagonists are reported at the 30-d time point. Incremental gain is observed from single therapy with ASA to double therapy
with ASA and UFH and to triple antithrombotic therapy with ASA, UFH, and a platelet GP IIb/IIIa antagonist. In the CAPTURE trial, nearly all patients underwent PCI after 20 to
24 h per study design. Data are taken from PURSUIT (128), PRISM-PLUS (130), Lewis et al. (365), Cairns et al. (366), Théroux et al. (367), RISC group (368), ATACS group
(369), Gurﬁnkel et al. (370), FRISC group (371), CAPTURE (372), PARAGON (373), and PRISM (374). anta.  antagonist; ASA  aspirin; ATACS  Antithrombotic Therapy in
Acute Coronary Syndromes; CAPTURE  c7E3 Fab AntiPlatelet Therapy in Unstable REfractory angina; CI  conﬁdence interval; FRISC  FRagmin during InStability in Coro-
nary artery disease; GP  glycoprotein; hep.  heparin; LMWH  low-molecular-weight heparin; MI  myocardial infarction; NA  not applicable; PARAGON  Platelet IIb/IIIa
Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network; PCI  percutaneous coronary intervention; PRISM  Platelet Receptor
Inhibition in ischemic Syndrome Management; PRISM-PLUS  Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Signs and
symptoms; PURSUIT  Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy; RISC  Research on InStability in Coronary artery dis-
ease; UA/NSTEMI  unstable angina/non--ST-elevation myocardial infarction; UFH  unfractionated heparin; VA  Veterans Affairs.
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supports the use of ASA in UA/NSTEMI and CAD in
general and instructed to continue the drug indeﬁnitely,
unless a contraindication develops. It is important to em-
phasize to patients that there is a sound rationale for
concomitant use of ASA even if other antithrombotic drugs,
such as clopidogrel or warfarin, are administered concur-
rently (Fig. 11) and that withdrawal or discontinuation of
ASA or clopidogrel has been associated with recurrent
episodes of ACS, including stent thrombosis (378–380).
Finally, because of a drug interaction between ibuprofen and
ASA, patients should be advised to use an alternative
NSAID or to take their ibuprofen dose at least 30 min after
ingestion of immediate-release ASA or at least 8 h before
ASA ingestion to avoid any potential diminution of the
protective effects of ASA. No recommendations about the
concomitant use of ibuprofen and enteric-coated low-dose
ASA can be made on the basis of available data (381).
Contraindications to ASA include intolerance and allergy
(primarily manifested as asthma with nasal polyps), active
bleeding, hemophilia, active retinal bleeding, severe un-
treated hypertension, an active peptic ulcer, or another
serious source of gastrointestinal or genitourinary bleeding.
Gastrointestinal side effects such as dyspepsia and nausea
are infrequent with the low doses. Primary prevention trials
have reported a small excess in intracranial bleeding, which
is offset in secondary prevention trials by the prevention of
ischemic stroke. It has been proposed that there is a negative
interaction between ACE inhibitors and ASA, with a
reduction in the vasodilatory effects of ACE inhibitors,
presumably because ASA inhibits ACE inhibitor–induced
prostaglandin synthesis. This interaction does not appear to
interfere importantly with the clinical beneﬁts of therapy
with either agent (382). Therefore, unless there are speciﬁc
contraindications, ASA should be administered to all pa-
tients with UA/NSTEMI.
3.2.4.2. ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS AND OTHER
ANTIPLATELET AGENTS
Two thienopyridines—ticlopidine and clopidogrel—are ADP
receptor (P2Y12) antagonists that are approved for anti-
platelet therapy (383). The platelet effects of ticlopidine and
clopidogrel are irreversible but take several days to achieve
Figure 11. Long-Term Anticoagulant Therapy at Hospital Discharge After UA/NSTEMI
*For aspirin (ASA) allergic patients, use clopidogrel alone (indeﬁnitely), or try aspirin desensitization. †For clopidogrel allergic patients, use ticlopidine, 250 mg by mouth
twice daily. ‡Continue ASA indeﬁnitely and warfarin longer term as indicated for speciﬁc conditions such as atrial ﬁbrillation; LV thrombus; cerebral, venous, or pulmonary
emboli. §When warfarin is added to aspirin plus clopidogrel, an INR of 2.0 to 2.5 is recommended. INR  international normalized ratio; LOE  level of evidence; LV  left
ventricular; UA/NSTEMI  unstable angina/non–ST-elevated myocardial infarction.
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maximal effect in the absence of a loading dose. The
administration of a loading dose can shorten the time to
achievement of effective levels of antiplatelet therapy. Be-
cause the mechanisms of the antiplatelet effects of ASA and
ADP antagonists differ, a potential exists for additive
beneﬁt with the combination. In patients with a history of
gastrointestinal bleeding, when ASA or a thienopyridine is
administered alone or in combination, drugs to minimize the
risk of recurrent gastrointestinal bleeding (e.g., proton-pump
inhibitors) should be prescribed concomitantly (384–386).
Ticlopidine has been used successfully for the secondary
prevention of stroke and MI and for the prevention of stent
closure and graft occlusion (387). The adverse effects of
ticlopidine limit its usefulness: gastrointestinal problems
(diarrhea, abdominal pain, nausea, and vomiting), neutro-
penia in approximately 2.4% of patients, severe neutropenia
in 0.8% of patients, and, rarely, thrombotic thrombocytopenia
purpura (388). Neutropenia usually resolves within 1 to 3
weeks of discontinuation of therapy but very rarely may be
fatal. Thrombotic thrombocytopenia purpura, which is a very
uncommon, life-threatening complication, requires immediate
plasma exchange. Monitoring of ticlopidine therapy requires a
complete blood count that includes a differential count every 2
weeks for the ﬁrst 3 months of therapy.
Extensive clinical experience with clopidogrel is derived
in part from the Clopidogrel versus Aspirin in Patients at
Risk of Ischaemic Events (CAPRIE) trial (389). A total of
19,185 patients were randomized to receive ASA 325 mg
per d or clopidogrel 75 mg per d. Entry criteria consisted of
atherosclerotic vascular disease manifested as recent isch-
emic stroke, recent MI, or symptomatic peripheral arterial
disease. Follow-up extended for 1 to 3 years. The RR of
ischemic stroke, MI, or vascular death was reduced by 8.7%
in favor of clopidogrel from 5.8% to 5.3% (p  0.04). The
beneﬁt was greatest for patients with peripheral arterial
disease. This group had a 24% relative risk reduction (p 
0.03). There was a slightly increased, but minimal, inci-
dence of rash and diarrhea with clopidogrel treatment and
slightly more bleeding with ASA. There was no excess
neutropenia with clopidogrel, which contrasts with ticlopi-
dine. The results provide evidence that clopidogrel is at least
as effective as ASA and appears to be modestly more
effective. In 1 report, 11 severe cases of thrombotic throm-
bocytopenia purpura were described as occurring within 14
d after the initiation of clopidogrel; plasma exchange was
required in 10 of the patients, and 1 patient died (390).
These cases occurred among more than 3 million patients
treated with clopidogrel.
Clopidogrel is reasonable antiplatelet therapy for second-
ary prevention, with an efﬁcacy at least similar to that of
ASA. Clopidogrel is indicated in patients with UA/
NSTEMI who are unable to tolerate ASA due to either
hypersensitivity or major gastrointestinal contraindications,
principally recent signiﬁcant bleeding from a peptic ulcer or
gastritis. In patients with a history of gastrointestinal bleed-
ing while taking ASA, when a thienopyridine is adminis-
tered, drugs to minimize the risk of recurrent gastrointesti-
nal bleeding (e.g., proton-pump inhibitors) should be
prescribed concomitantly (384–386). When treatment with
thienopyridines is considered during the acute phase, it
should be recognized that there is a delay before attainment
of the full antiplatelet effect. Clopidogrel is preferred to
ticlopidine because it more rapidly inhibits platelets and
appears to have a more favorable safety proﬁle.
An oral loading dose (300 mg) of clopidogrel is typically
used to achieve more rapid platelet inhibition. The optimal
loading dose with clopidogrel has not been rigorously
established. The greatest amount of general clinical experi-
ence and randomized trial data exist for a clopidogrel
loading dose of 300 mg, which is the approved loading dose.
Higher loading doses (600 to 900 mg) have been evaluated
(391,392). They appear to be safe and more rapidly acting;
however, it must be recognized that the database for such
higher loading doses is not sufﬁciently robust to formulate
deﬁnitive recommendations. Most studies to date with
higher loading doses of clopidogrel have examined surro-
gates for clinical outcomes, such as measurements of 1 or
more markers of platelet aggregation or function. When
groups of patients are studied, a general dose response is
observed with increasing magnitude and speed of onset of
inhibition of platelet aggregation in response to agonists
such as ADP as the loading dose increases. However,
considerable interindividual variation in antiplatelet effect
also is observed with all loading doses of clopidogrel, which
makes it difﬁcult to predict the impact of different loading
doses of clopidogrel in a speciﬁc patient. Small to moderate-
sized trials have reported favorable outcomes with a 600-mg
versus a 300-mg loading dose in patients undergoing PCI
(393); however, large-scale randomized trials are still
needed to deﬁnitively compare the efﬁcacy and safety of
different loading regimens of clopidogrel. This is of partic-
ular importance because it is known that patients undergo-
ing CABG surgery shortly after receiving 300 mg of
clopidogrel have an increased risk of bleeding (394); the
relative risk of bleeding associated with higher loading doses
of clopidogrel remains to be established. The Writing
Committee endorses the performance of appropriately de-
signed clinical trials to identify the optimal loading dose of
clopidogrel.
Two randomized trials compared clopidogrel with ticlo-
pidine. In 1 study, 700 patients who successfully received a
stent were randomized to receive 500 mg of ticlopidine or
75 mg of clopidogrel, in addition to 100 mg of ASA, for 4
weeks (395). Cardiac death, urgent target-vessel revascular-
ization, angiographically documented thrombotic stent oc-
clusion, or nonfatal MI within 30 d occurred in 3.1% of
patients who received clopidogrel and 1.7% of patients who
received ticlopidine (p  0.24), and noncardiac death,
stroke, severe peripheral vascular hemorrhagic events, or any
adverse event that resulted in the discontinuation of the
study medication occurred in 4.5% and 9.6% of patients,
respectively (p  0.01). The CLopidogrel ASpirin Stent
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International Cooperative Study (CLASSICS) (396) was
conducted in 1,020 patients. A loading dose of 300 mg of
clopidogrel followed by 75 mg per d was compared to a daily
dose of 75 mg without a loading dose and with a loading
dose of 150 mg of ticlopidine followed by 150 mg twice per
day (patients in each of the 3 arms also received ASA). The
ﬁrst dose was administered 1 to 6 h after stent implantation;
the treatment duration was 28 d. The trial showed better
tolerance to clopidogrel with or without a loading dose than
to ticlopidine. Stent thrombosis or major complications
occurred at the same frequency in the 3 groups.
The CURE trial randomized 12,562 patients with UA
and NSTEMI presenting within 24 h to placebo or clopi-
dogrel (loading dose of 300 mg followed by 75 mg daily)
and followed them for 3 to 12 months (243). All patients
received ASA. Cardiovascular death, MI, or stroke occurred
in 11.5% of patients assigned to placebo and 9.3% assigned
to clopidogrel (RR  0.80, p less than 0.001). In addition,
clopidogrel was associated with signiﬁcant reductions in the
rate of in-hospital severe ischemia and revascularization, as well
as the need for ﬁbrinolytic therapy or intravenous GP IIb/IIIa
receptor antagonists. These results were observed across a wide
variety of subgroups. A reduction in recurrent ischemia was
noted within the ﬁrst few hours after randomization.
There was an excess of major bleeding (2.7% in the
placebo group vs. 3.7% in the clopidogrel group, p  0.003)
and of minor bleeding but not of life-threatening bleeding.
The risk of bleeding was increased in patients undergoing
CABG surgery within the ﬁrst 5 d of stopping clopidogrel.
The CURE study was conducted at centers in which there
was no routine policy regarding early invasive procedures;
revascularization was performed during the initial admission in
only 23% of the patients. Although the addition of a platelet
GP IIb/IIIa inhibitor in patients receiving ASA, clopidogrel,
and heparin in CURE was well tolerated, fewer than 10% of
patients received this combination. Therefore, additional in-
formation on the safety of an anticoagulant and a GP IIb/IIIa
inhibitor in patients already receiving ASA and clopidogrel
should be obtained. Accurate estimates of the treatment
beneﬁt of clopidogrel in patients who received GP IIb/IIIa
antagonists remain ill-deﬁned.
The CURE trial also provides strong evidence for the
addition of clopidogrel to ASA on admission in the man-
agement of patients with UA and NSTEMI in whom a
noninterventional approach is intended, an especially useful
approach in hospitals that do not have a routine policy about
early invasive procedures. The event curves for the 2 groups
separate early. The optimal duration of therapy with clopi-
dogrel in patients who have been managed exclusively
medically has not been determined, but the favorable results
in CURE were observed over a period averaging 9 months
and for up to 1 year.
The PCI-CURE study was an observational substudy of
the patients undergoing PCI within the larger CURE trial
(397). In the PCI-CURE study, 2,658 patients had previ-
ously been randomly assigned to double-blind treatment
with clopidogrel (n  1313) as per the CURE protocol or
placebo (n  1,345). Patients were pretreated with ASA
and the study drug for a median of 10 d. After PCI, most
patients received open-label thienopyridine for approxi-
mately 4 weeks, after which the blinded study drug was
restarted for a mean of 8 months. Fifty-nine patients (4.5%)
in the clopidogrel group had the primary end point (a
composite of cardiovascular death, MI, or urgent target-
vessel revascularization) within 30 d of PCI compared with
86 (6.4%) in the placebo group (RR 0.70, 95% CI 0.50 to
0.97, p  0.03). Overall, including events before and after
PCI, there was a 31% reduction in cardiovascular death or
MI (p  0.002). Thus, in patients with UA and NSTEMI
receiving ASA and undergoing PCI, a strategy of clopi-
dogrel pretreatment followed by up to 1 year of clopidogrel
use (and probably at least 1 year in those with DES; see
below) is beneﬁcial in reducing major cardiovascular events
compared with placebo and appears to be cost-effective (the
incremental cost-effectiveness ratio for clopidogrel plus ASA
compared with ASA alone was $15,400 per quality-adjusted
life-year) (398). Therefore, clopidogrel should be used rou-
tinely in patients who undergo PCI.
Pathological and clinical evidence particularly highlights
the need for longer-term ADP-receptor blockade in pa-
tients who receive DES (399). DESs consistently have been
shown to reduce stent restenosis. However, this same
antiproliferative action can delay endothelialization, predis-
posing to stent thrombosis including late (beyond 3–6
months) or very late (after 1 year) thrombosis after stent
placement (399,399a,400). These concerns have raised
questions about the ideal duration of dual antiplatelet
therapy (DAT) and the overall balance of beneﬁt/risk of
DES compared with bare-metal stents (401). A number of
comparisons of outcomes up to 4 years after DES and
bare-metal stent implantation, including the initial FDA
approval trials, have been published (400,402–404,404a–
404f). These conﬁrm a marked reduction in restenosis and
consequent repeat revascularization procedures with DES
(404c). However, although results have varied, they also
suggest a small incremental risk (of about 0.5%) of stent
thrombosis (404a–404c). Reassuringly, they have not
shown an overall increase in death or MI after DES versus
bare-metal stents, suggesting offsetting advantages of im-
proved revascularization versus increased stent thrombosis
risk. These observations also emphasize the need for a
continued search for more biocompatible stents that mini-
mize restenosis without increasing the risks of thrombosis.
In the ISAR-REACT-2 trial, patients undergoing PCI
were assigned to receive either abciximab (bolus of 0.25 mg
per kg of body weight, followed by a 0.125-mg per kg per
min [maximum, 10 mg per min] infusion for 12 h, plus
heparin 70 U per kg of body weight) or placebo (placebo
bolus and infusion of 12 h, plus heparin bolus, 140 U per kg)
(244). All patients received 600 mg of clopidogrel at least
2 h before the procedure, as well as 500 mg of oral or
intravenous ASA. Of 2,022 patients enrolled, 1,012 were
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assigned to abciximab and 1,010 to placebo. The primary
end point was reached in 90 patients (8.9%) assigned to
abciximab versus 120 patients (11.9%) assigned to placebo,
a 25% reduction in risk with abciximab (RR 0.75, 95% CI
0.58 to 0.97, p  0.03) (244). Among patients without an
elevated cTn level, there was no difference in the incidence
of primary end-point events between the abciximab group
(23 [4.6%] of 499 patients) and the placebo group (22
[4.6%] of 474 patients; RR  0.99, 95% CI 0.56 to 1.76, p
 0.98), whereas among patients with an elevated cTn level,
the incidence of events was signiﬁcantly lower in the
abciximab group (67 [13.1%] of 513 patients) than in the
placebo group (98 [18.3%] of 536 patients), which corre-
sponds to an RR of 0.71 (95% CI 0.54 to 0.95, p  0.02; p
 0.07 for interaction). There were no signiﬁcant differ-
ences between the 2 groups with regard to the risk of major
or minor bleeding or the need for transfusion. Thus, it
appears beneﬁcial to add an intravenous GP IIb/IIIa inhib-
itor to thienopyridine treatment if an invasive strategy is
planned in patients with high-risk features (e.g., elevated
cTn level; Figs. 7, 8, and 9).
The optimal timing of administration of the loading dose
of clopidogrel for those who are managed with an early
invasive strategy cannot be determined with certainty from
PCI-CURE because there was no comparison of adminis-
tration of the loading dose before diagnostic angiography
(“upstream treatment”) versus at the time of PCI (“in-lab
treatment”). However, based on the early separation of the
curves, when there is delay to coronary angiography, pa-
tients should receive clopidogrel as initial therapy (Figs. 7, 8,
and 9). The Clopidogrel for the Reduction of Events
During Observation (CREDO) trial (405), albeit not de-
signed speciﬁcally to study UA/NSTEMI patients, provides
partially relevant information on the question of timing of
the loading dose. Patients with symptomatic CAD and
evidence of ischemia who were referred for PCI and those
who were thought to be highly likely to require PCI were
randomized to receive clopidogrel (300 mg) or matching
placebo 3 to 24 h before PCI. All subjects received a
maintenance dose of clopidogrel (75 mg daily) for 28 d.
Thus, CREDO is really a comparison of the administration
of a loading dose before PCI versus not administering a
loading dose at all. There is no explicit comparison within
CREDO of a pre-PCI loading dose versus a loading dose in
the catheterization laboratory. In CREDO, the relative risk
for the composite end point of death/MI/urgent target-
vessel revascularization was 0.82, in favor of the group who
received a loading dose before PCI compared with the
opposite arm that did not receive a loading dose, but this did
not reach statistical signiﬁcance (p  0.23). Subgroup
analyses within CREDO suggest that if the loading dose is
given at least 6 or preferably 15 h before PCI, fewer events
occur compared with no loading dose being administered
(406). One study from the Netherlands that compared
pretreatment with clopidogrel before PCI versus adminis-
tration of a loading dose at the time of PCI in patients
undergoing elective PCI showed no difference in biomarker
release or clinical end points (407).
Thus, there now appears to be an important role for
clopidogrel in patients with UA/NSTEMI, both in those
who are managed conservatively and in those who undergo
PCI, especially stenting, or who ultimately undergo CABG
surgery (408). However, it is not entirely clear how long
therapy should be maintained (409,410). Whereas increased
hazard is clearly associated with premature discontinuation
of dual antiplatelet therapy after DES (405,411,412), the
beneﬁt of extended therapy beyond 1 year is uncertain
(401,403d,403e). Hence, the minimum requirements for
DAT duration should be vigorously applied for each DES
type. However, 1 year of DAT may be ideal for all
UA/NSTEMI patients who are not at high risk of bleeding
given the secondary preventive effects of DAT, perhaps
especially after DES. On the other hand, the limited
database at this point in time does not support a recom-
mendation for DAT beyond 1 year for all DES-treated
patients (401,403d,403e). For patients with clinical features
associated with an increased risk of stent thrombosis, such
as diabetes or renal insufﬁciency or procedural characteristics
such as multiple stents or a treated bifurcation lesion,
extended DAT may be reasonable. Data on the relative
merits of DES versus bare-metal stents in “off-label” patients
(such as multivessel disease or MI), who are at higher risk and
experience higher event rates, and of the ideal duration of
DAT in these patients, are limited and are currently insufﬁ-
cient to draw separate conclusions (401,403d,403e).
Because of the importance of dual-antiplatelet therapy
with ASA and a thienopyridine after implantation of a
stent, especially if a DES is being considered, clinicians
should ascertain whether the patient can comply with 1 year
of dual-antiplatelet therapy. Patients should also be in-
structed to contact their treating cardiologist before stop-
ping any antiplatelet therapy, because abrupt discontinua-
tion of antiplatelet therapy can put the patient at risk of
stent thrombosis, an event that may result in MI or even
death (411). Health care providers should postpone elective
surgical procedures until beyond 12 months after DES
implantation (411). If a surgical procedure must be per-
formed sooner than 12 months, an effort should be made to
maintain the patient on ASA and minimize the period of
time of discontinuation of a thienopyridine (411).
In the CURE study, which predominantly involved
medical management of patients with UA/NSTEMI, the
relative risk reduction in events was of a similar magnitude
(approximately 20%) during the ﬁrst 30 d after randomiza-
tion as during the ensuing cumulative 8 months (413). In
contrast, clopidogrel was not beneﬁcial in a large trial of
high-risk primary prevention patients (414).
Because clopidogrel, when added to ASA, increases the
risk of bleeding during major surgery, it has been recom-
mended that clopidogrel be withheld for at least 5 d (243)
and up to 7 d before surgery in patients who are scheduled
for elective CABG (376,415). In many hospitals in which
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patients with UA/NSTEMI undergo rapid diagnostic cath-
eterization within 24 h of admission, clopidogrel is not
started until it is clear that CABG will not be scheduled
within the next several days. However, unstable patients
should receive clopidogrel or be taken for immediate an-
giography (Figs. 7, 8, and 9). A loading dose of clopidogrel
can be given to a patient on the catheterization table if a
PCI is to be performed immediately. If PCI is not per-
formed, clopidogrel can be given after the catheterization.
However, when clopidogrel is given before catheterization
and urgent surgical intervention is indicated, some experi-
ence suggests that “early” bypass surgery may be undertaken
by experienced surgeons at acceptable incremental bleeding
risk. Among 2,858 UA/NSTEMI patients in the CRU-
SADE (Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Imple-
mentation of the American College of Cardiology/
American Heart Association Guidelines) Registry undergo-
ing CABG, 30% received acute clopidogrel therapy, the
majority of these (87%) within 5 d of surgery. “Early”
CABG after clopidogrel was associated with a signiﬁcant
increase in any blood transfusion (OR 1.36, 95% CI 1.10 to
1.68) and the need for 4 or more units of blood (OR 1.70,
95% CI 1.32 to 2.1). In-hospital rates of death were low (3%
to 4%), and no difference was noted in rates of death,
reinfarction, or stroke with “early” CABG in patients treated
with versus without acute clopidogrel (394). The Writing
Committee believes that more data on the overall relative
beneﬁts versus risks of proceeding with early bypass surgery in
the presence of clopidogrel therapy are desirable and necessary
in order to formulate better-informed recommendations for
the timing of surgery in the UA/NSTEMI patient.
Sulﬁnpyrazone, dipyridamole, prostacyclin, and prostacy-
clin analogs have not been demonstrated to be of beneﬁt in
UA or NSTEMI and are not recommended. The throm-
boxane synthase blockers and thromboxane A2 receptor
antagonists have been evaluated in ACS and have not
shown any advantage over ASA. A number of other
antiplatelet drugs are currently available, and still others are
under active investigation. Clopidogrel is currently the
preferred thienopyridine because of its extensive evidence
base, its more rapid onset of action, especially after a loading
dose (417,418), and its better safety proﬁle than ticlopidine
(396).
Evidence has emerged that there is considerable interpa-
tient variability in the response to clopidogrel, with a wide
range of inhibition of platelet aggregation after a given dose
(419). Patients with diminished responsiveness to clopi-
dogrel appear to be at increased risk of ischemic events
(420,421). The reasons for the large interpatient variability
in responsiveness to clopidogrel are under investigation, but
variation in absorption, generation of the active metabolite,
and drug interactions are leading possibilities. Maneuvers to
overcome poor responsiveness to clopidogrel may involve an
increase in the dose (422). However, techniques for moni-
toring for poor response to clopidogrel and the appropriate
dosing strategy when it is uncovered remain to be
established.
3.2.5. Anticoagulant Agents and Trials
A number of drugs are available to clinicians for manage-
ment of patients with UA/NSTEMI. Although the medical
literature sometimes refers to such drugs as “antithrombins,”
the Writing Committee has chosen to refer to them as
anticoagulants because they often inhibit 1 or more proteins
in the coagulation cascade before thrombin. Evaluation of
anticoagulant strategies is an active area of investigation. It
is difﬁcult to draw conclusions that 1 anticoagulant strategy
is to be preferred over another given the uncertainty of
whether equipotent doses were administered, the different
durations of treatment studied across the trials, and the fact
that many patients were already receiving 1 open-label
anticoagulant before they were randomized in a trial to
another anticoagulant (which makes it uncertain what
residual effect the open-label anticoagulant had in the trial).
Other aspects of the data set that confound interpretation of
the impact of speciﬁc anticoagulant strategies include a
range of antiplatelet strategies administered concomitantly
with the anticoagulant and the addition of a second anti-
coagulant, either because of clinician preference or as part of
protocol design (423–425) as patients moved from the
medical management phase to the interventional manage-
ment phase of treatment for UA/NSTEMI.
The Writing Committee also wishes to draw attention to
the fact that active-control noninferiority trials are being
performed with increasing frequency as it becomes ethically
increasingly difﬁcult to perform placebo-controlled trials. In
this update, for example, noninferiority (“equivalence”)
comparisons on primary or major secondary end points were
important in the Acute Catheterization and Urgent Inter-
vention Triage strategy (ACUITY) (425), Organization to
Assess Strategies for Ischaemic Syndromes (OASIS-5)
(424), and Randomized Evaluation of PCI Linking Angio-
max to reduced Clinical Events (REPLACE-2) (426)
studies. Although practically useful, noninferiority analyses
depend on assumptions not inherent in classic superiority
analytical designs and thus present additional limitations
and interpretative challenges (427–429). Noninferiority tri-
als require an a priori choice of a “noninferiority margin,”
typically deﬁned in terms of a fraction of standard treatment
effect to be preserved compared with a putative placebo
(e.g., 0.5) and which rests on clinical judgment and statis-
tical issues (428). Because noninferiority trials do not have a
placebo control, these assumptions cannot be easily veriﬁed.
Thus, whether the new therapy indeed is therapeutically
“equivalent” is less certain than in a superiority trial. Hence,
additional caution in weighing and applying the results of
noninferiority trials is appropriate.
The Writing Committee believes that a number of
acceptable anticoagulant strategies can be recommended
with a Class I status but emphasizes the fact that a
preference for a particular strategy is far from clear (Figs. 7,
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8, and 9). It is suggested that each institution agree on a
consistent approach to minimize the chance of medication
errors and double anticoagulation when personal prefer-
ences are superimposed on an already-initiated treatment
plan. Factors that should be weighed when one considers an
anticoagulant strategy (or set of strategies to cover the range
of patient scenarios) include established efﬁcacy, risk of
bleeding in a given patient, cost, local familiarity with
dosing regimens (particularly if PCI is planned), anticipated
need for surgery, and the desire to promptly reverse the
anticoagulant effect if bleeding occurs.
Unfractionated heparin exerts its anticoagulant effect by
accelerating the action of circulating antithrombin, a pro-
teolytic enzyme that inactivates factor IIa (thrombin), factor
IXa, and factor Xa. It prevents thrombus propagation but
does not lyse existing thrombi (430). Unfractionated hepa-
rin is a heterogeneous mixture of polysaccharide chains of
molecular weights that range from 5,000 to 30,000 Daltons
and have varying effects on anticoagulant activity. Unfrac-
tionated heparin binds to a number of plasma proteins,
blood cells, and endothelial cells. The LMWHs are ob-
tained through chemical or enzymatic depolymerization of
the polysaccharide chains of heparin to provide chains with
different molecular weight distributions. Approximately
25% to 50% of the pentasaccharide-containing chains of
LMWH preparations contain more than 18 saccharide
units, and these are able to inactivate both thrombin and
factor Xa. Low-molecular-weight heparin chains that are
fewer than 18 saccharide units retain their ability to inacti-
vate factor Xa but not thrombin. Therefore, LMWHs are
relatively more potent in facilitating inhibition of factor Xa
than in the inactivation of thrombin. Distinct advantages of
LMWH over UFH include decreased binding to plasma
proteins and endothelial cells and dose-independent clear-
ance, with a longer half-life that results in more predictable
and sustained anticoagulation with once- or twice-a-day
subcutaneous administration. An advantage of LMWHs is
that they do not usually require laboratory monitoring of
activity. The pharmacodynamic and pharmacokinetic pro-
ﬁles of the different commercial preparations of LMWHs
vary, with their mean molecular weights ranging from 4,200
to 6,000 Daltons. Accordingly, their ratios of anti–factor Xa
to anti–factor IIa vary, ranging from 1.9 to 3.8 (431). By
contrast, the direct thrombin inhibitors speciﬁcally block
thrombin without the need for a cofactor. Hirudin binds
directly to the anion binding site and the catalytic sites of
thrombin to produce potent and predictable anticoagulation
(432).
Bivalirudin is a synthetic analog of hirudin that binds
reversibly to thrombin and inhibits clot-bound thrombin.
More upstream in the coagulation cascade are factor Xa
inhibitors, such as the synthetic pentasaccharide fondapa-
rinux, that act proximally to inhibit the multiplier effects of
the downstream coagulation reactions and thereby reduce
the amount of thrombin that is generated. Advantages of
fondaparinux compared with UFH include decreased bind-
ing to plasma proteins and endothelial cells and dose-
independent clearance, with a longer half-life that results in
more predictable and sustained anticoagulation with ﬁxed-
dose, once-a-day subcutaneous administration. An advan-
tage of these agents over UFH is that like the LMWHs,
fondaparinux does not require laboratory monitoring of
activity. Fondaparinux is cleared renally, as is the anti–Xa
activity of enoxaparin. The factor Xa inhibitors do not have
any action against thrombin that is already formed or that is
generated despite their administration, which possibly con-
tributes to the observation of an increased rate of catheter
thrombosis when factor Xa inhibitors such as fondaparinux
are used alone to support PCI procedures. In the case of
both the direct thrombin inhibitors and fondaparinux, it is
not possible to reverse the effect with protamine because
they lack a protamine-binding domain; reversal of their
action in the event of bleeding requires discontinuation of
their administration and, if needed, transfusion of coagula-
tion factors (e.g., fresh-frozen plasma).
In summary, whereas anticoagulant therapy forms a basic
element of UA/NSTEMI therapy, recommendation of an
anticoagulant regimen has become more complicated by a
number of new choices suggested by contemporary trials,
some of which do not provide adequate comparative infor-
mation for common practice settings. The Writing Com-
mittee believes that inadequate unconfounded comparative
information is available to recommend a preferred regimen
when an early, invasive strategy is used for UA/NSTEMI,
and physician and health care system preference, together
with individualized patient application, is advised. Addi-
tional experience may change this viewpoint in the future.
On the other hand, these available trials are less confounded
for the large number of patients treated with an initial
noninvasive or delayed invasive strategy: they suggest an
anticoagulant preference for these patients treated with a
noninvasive strategy in the order of fondaparinux, enoxapa-
rin, and UFH (least preferred), using the speciﬁc regimens
tested in these trials. Bivalirudin has not been tested in a
noninvasive strategy and hence cannot be recommended
currently. Even in this group, the order of preference often
depends on a single, albeit large, trial, so that additional
clinical trial information will be welcomed.
The optimal duration of anticoagulation therapy remains
undeﬁned. Evidence for recurrence of events after cessation
of short-duration intravenous UFH and results of studies in
STEMI patients demonstrating superiority of anticoagulant
agents that are administered for the duration of the hospital
stay suggest that anticoagulation duration of more than 2 d
for those who are managed with a conservative strategy may
be beneﬁcial, but this requires further study (433,434).
3.2.5.1. UNFRACTIONATED HEPARIN
Six relatively small randomized, placebo-controlled trials
with UFH have been reported (435–440). The results of
studies that compared the combination of ASA and heparin
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with ASA alone are shown in Figure 10. In the trials that
used UFH, the reduction in the rate of death or MI during
the ﬁrst week was 54% (p  0.016), and in the trials that
used either UFH or LMWH, the reduction was 63%. Two
published meta-analyses have included different studies. In
1 meta-analysis, which involved 3 randomized trials and an
early end point (less than 5 d) (369), the risk of death or MI
with the combination of ASA and heparin was reduced by
56% (p  0.03). In the second meta-analysis, which
involved 6 trials and end points that ranged from 2 to 12
weeks, the RR was reduced by 33% (p  0.06) (441). Most
of the beneﬁts of the various anticoagulants are short term,
however, and are not maintained on a long-term basis.
Reactivation of the disease process after the discontinuation
of anticoagulants may contribute to this loss of early gain
among medically treated patients that has been described
with UFH (442), dalteparin (371), and hirudin (443,444).
The combination of UFH and ASA appears to mitigate this
reactivation in part (442,445), although there is hematologic
evidence of increased thrombin activity after the cessation of
intravenous UFH (“rebound”) even in the presence of ASA
(446). Uncontrolled observations suggested a reduction in
the “heparin rebound” by switching from intravenous to
subcutaneous UFH for several days before the drug is
stopped.
Unfractionated heparin has important pharmacokinetic
limitations that are related to its nonspeciﬁc binding to
proteins and cells. These pharmacokinetic limitations of
UFH translate into poor bioavailability, especially at low
doses, and marked variability in anticoagulant response
among patients (447). As a consequence of these pharma-
cokinetic limitations, the anticoagulant effect of heparin
requires monitoring with the activated partial thromboplas-
tin time (aPTT), a test that is sensitive to the inhibitory
effects of UFH on thrombin (factor IIa), factor Xa, and
factor IXa. Many clinicians have traditionally prescribed a
ﬁxed initial dose of UFH (e.g., 5,000 U bolus, 1,000 U per
h initial infusion); clinical trials have indicated that a
weight-adjusted dosing regimen can provide more predict-
able anticoagulation than the ﬁxed-dose regimen (448–
450). The weight-adjusted regimen recommended is an
initial bolus of 60 U per kg (maximum 4,000 U) and an
initial infusion of 12 U per kg per h (maximum 1,000 U per
h). The therapeutic range of the various nomograms differs
due to variation in the laboratory methods used to deter-
mine aPTT. The American College of Chest Physicians
consensus conference (451) has therefore recommended
dosage adjustments of the nomograms to correspond to a
therapeutic range equivalent to heparin levels of 0.3 to 0.7 U
per ml by anti–factor Xa determinations, which correlates
with aPTT values between 60 and 80 s. In addition to body
weight, other clinical factors that affect the response to
UFH include age and sex, which are associated with higher
aPTT values, and smoking history and diabetes mellitus,
which are associated with lower aPTT values (447,452). At
high doses, heparin is cleared renally (451).
Even though weight-based UFH dosing regimens are
used, the aPTT should be monitored for adjustment of
UFH dosing. Because of variation among hospitals in the
control aPTT values, nomograms should be established at
each institution that are designed to achieve aPTT values in
the target range (e.g., for a control aPTT of 30 s, the target
range [1.5 to 2.5 times control] would be 45 to 75 s). Delays
in laboratory turnaround time for aPPT results also can be
a source of variability in care, resulting in over- or under-
anticoagulation for prolonged time periods, and should be
avoided. Measurements should be made 6 h after any dosage
change and used to adjust UFH infusion until the aPTT
exhibits a therapeutic level. When 2 consecutive aPTT
values are therapeutic, the measurements may be made every
24 h and, if necessary, dose adjustment performed. In
addition, a signiﬁcant change in the patient’s clinical con-
dition (e.g., recurrent ischemia, bleeding, or hypotension)
should prompt an immediate aPTT determination, fol-
lowed by dose adjustment, if necessary.
Serial hemoglobin/hematocrit and platelet measurements
are recommended at least daily during UFH therapy. In
addition, any clinically signiﬁcant bleeding, recurrent symp-
toms, or hemodynamic instability should prompt their
immediate determination. Serial platelet counts are neces-
sary to monitor for heparin-induced thrombocytopenia.
Mild thrombocytopenia may occur in 10% to 20% of
patients who are receiving heparin, whereas signiﬁcant
thrombocytopenia (platelet count less than 100,000) occurs
in 1% to 5% of patients and typically appears after 4 to 14
d of therapy (453–457). A rare but dangerous complication
(less than 0.2% incidence) is autoimmune UFH-induced
thrombocytopenia with thrombosis, which can occur both
shortly after initiation of UFH or, rarely, in a delayed (i.e.,
after 5 to 19 d or more), often unrecognized form (458–
460). A high clinical suspicion mandates the immediate
cessation of all heparin therapy (including that used to ﬂush
intravenous lines).
Most of the trials that evaluated the use of UFH in
UA/NSTEMI have continued therapy for 2 to 5 d. The
optimal duration of therapy remains undeﬁned.
3.2.5.2. LOW-MOLECULAR-WEIGHT HEPARIN
In a pilot open-label study, 219 patients with UA were
randomized to receive ASA (200 mg per d), ASA plus
UFH, or ASA plus nadroparin (an LMWH) (370). The
combination of ASA and LMWH signiﬁcantly reduced the
total ischemic event rate, the rate of recurrent angina, and
the number of patients requiring interventional procedures.
The FRISC study (371) randomized 1,506 patients with
UA or non–Q-wave MI to receive subcutaneous adminis-
tration of the LMWH dalteparin (120 IU per kg twice
daily) or placebo for 6 d and then once a day for the next 35
to 45 d. Dalteparin was associated with a 63% risk reduction
in death or MI during the ﬁrst 6 d (4.8% vs. 1.8%, p 
0.001), which matched the favorable experience observed
with UFH. Although an excess of events was observed after
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the dose reduction to once daily after 6 d, a signiﬁcant
decrease was observed at 40 d with dalteparin in the
composite outcome of death, MI, or revascularization
(23.7% vs. 18.0%, p 0.005), and a trend was noted toward
a reduction in rates of death or MI (10.7% vs. 8.0%, p 
0.07).
Because the level of anticoagulant activity cannot be easily
measured in patients receiving LMWH (e.g., aPTT or
activated clotting time [ACT]), interventional cardiologists
have expressed concern about the substitution of LMWH
for UFH in patients scheduled for catheterization with
possible PCI. However, in a study involving 293 patients
with UA/NSTEMI who received the usual dose of enox-
aparin, Collett et al. (461) showed that PCI can be
performed safely.
An alternative approach is to use LMWH during the
period of initial stabilization. The dose can be withheld on
the morning of the procedure, and if an intervention is
required and more than 8 h has elapsed since the last dose
of LMWH, UFH can be used for PCI according to usual
practice patterns. Because the anticoagulant effect of UFH
can be more readily reversed than that of LMWH, UFH is
preferred in patients likely to undergo CABG within 24 h.
3.2.5.3. LMWH VERSUS UFH
Nine randomized trials have directly compared LMWH
with UFH (Table 17). Two trials evaluated dalteparin,
another evaluated nadroparin, and 6 evaluated enoxaparin.
Heterogeneity of trial results has been observed. Trials with
dalteparin and nadroparin reported similar rates of death or
nonfatal MI compared with UFH, whereas 5 of 6 trials of
enoxaparin found point estimates for death or nonfatal MI
that favored enoxaparin over UFH; the pooled OR was 0.91
(95% CI 0.83 to 0.99). The beneﬁt of enoxaparin appeared
to be driven largely by a reduction in nonfatal MI, especially
in the cohort of patients who had not received any open-
label anticoagulant therapy before randomization.
There are few data to assess whether the heterogeneous
results are explained by different populations, study designs,
various heparin dose regimens, properties of the various
LMWHs (more speciﬁcally, different molecular weights
and anti–factor Xa/anti–factor IIa ratios), concomitant ther-
apies, or other unrecognized inﬂuences. Although it is
tempting to compare the relative treatment effects of the
different LMWH compounds, the limitations of such indi-
rect comparisons must be recognized. The only reliable
method of comparing 2 treatments is through a direct
comparison in a well-designed clinical trial or series of trials.
The comparison of different therapies (e.g., different LM-
WHs) with a common therapy (e.g., UFH) in different
trials does not allow a conclusion to be made about the
relative effectiveness of the different LMWHs because of
the variability in both control group and experimental group
event rates due to protocol differences, differences in con-
comitant therapies due to geographic and time variability,
and the play of chance. Similar considerations apply to
comparisons among platelet GP IIb/IIIa inhibitors.
In the Enoxaparin Versus Tinzaparin (EVET) trial, 2
LMWHs, enoxaparin and tinzaparin, administered for 7 d,
were compared in 436 patients with UA/NSTEMI. Enox-
aparin was associated with a lower rate of death/MI/
recurrent angina at 7 and 30 d compared with tinzaparin
(467,468). Bleeding rates were similar with the 2 LMWHs.
The advantages of LMWH preparations are the ease of
subcutaneous administration and the absence of a need for
monitoring. Furthermore, the LMWHs stimulate platelets
less than UFH (469) and are less frequently associated with
heparin-induced thrombocytopenia (456). In the ES-
SENCE trial, minor bleeding occurred in 11.9% of enox-
aparin patients and 7.2% of UFH patients (p less than
0.001), and major bleeding occurred in 6.5% and 7.0%,
respectively (169). In TIMI 11B, the rates of minor bleed-
ing in hospital were 9.1% and 2.5%, respectively (p less than
0.001), and the rates of major bleeding were 1.5% and 1.0%
(p  0.14) (180). In the FRISC study, major bleeding
occurred in 0.8% of patients given dalteparin and in 0.5% of
patients given placebo, and minor bleeding occurred in 61
(8.2%) of 746 patients and 2 (0.3%) of 760 patients,
respectively (371).
The anticoagulant effect of LMWH is less effectively
reversed with protamine than that of UFH. In addition,
LMWH administered during PCI does not permit moni-
toring of the ACT to titrate the level of anticoagulation. In
the ESSENCE and TIMI 11B trials, special rules were set
to discontinue enoxaparin before PCI and CABG. Because
of limited experience with enoxaparin at the time the
ESSENCE and TIMI 11B trials were conducted, UFH was
administered during PCI to achieve ACT values of greater
than 350 s. In the Superior Yield of the New Strategy of
Enoxaparin, Revascularization and Glycoprotein IIb/IIIa
Inhibitors (SYNERGY) trial, enoxaparin was compared to
UFH during PCI in patients with high-risk UA/NSTEMI
(423) (Fig. 12). More bleeding was observed with enoxaparin,
with a statistically signiﬁcant increase in TIMI-deﬁned major
bleeding (9.1% vs. 7.6%, p 0.008) but a nonsigniﬁcant excess
in GUSTO-deﬁned severe bleeding (2.7% vs. 2.2%, p 0.08)
and transfusions (17.0% vs. 16.0%, p  0.16). A post hoc
analysis from SYNERGY suggested that some of the excess
bleeding seen with enoxaparin could be explained by crossover
to UFH at the time of PCI (470). This remains to be validated
prospectively, but at the present time, it appears reasonable
to minimize the risk of excessive anticoagulation during
PCI by avoiding crossover of anticoagulants (i.e., maintain
consistent anticoagulant therapy from the pre-PCI phase
throughout the procedure itself).
An economic analysis of the ESSENCE trial suggested
cost savings with enoxaparin (471). For patients who are
receiving subcutaneous LMWH and in whom CABG is
planned, it is recommended that LMWH be discontinued
and UFH be used during the operation. Additional experi-
ence with regard to the safety and efﬁcacy of the concom-
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Table 17. Trials of LMWH Versus UFH in UA/NSTEMI
Trial
(Reference) n LMWH/Dose UFH
End Point/
Drug Effect Analysis 95% CI p
Major Bleeding
(p)
FRISC (371) 1,506 (a) 6 d*: dalteparin
120 IU per kg†
SC twice daily (max-
imum 10,000 IU)
(b) During ﬁrst 40 d:
dalteparin 7,500 IU
SC once per day
(a) 6 d: placebo
(b) During ﬁrst 40
d: placebo
(a) Death or new
MI (6 d):
LMWH 1.8%,
Placebo 4.8%
(b) Death or new
MI (during ﬁrst
40 d‡): LMWH
8%, placebo
10.7%
(a) RR 0.37
ARR 3%
(b) RR 0.75
ARR 2.7%
(a) 0.20 to
0.68
(b) 0.54 to
1.03
(a) 0.001
(b) 0.07
(a) LMWH 0.8%,
placebo 0.5%;
ARR 0.3%
(p  NR)
(b) During ﬁrst
40 d:
LMWH 0.3%,
placebo 0.3%;
ARR 0%
(p  NR)
ESSENCE
(169)
3,171 Enoxaparin 1 mg per
kg SC twice daily
(minimum 48 h,
maximum 8 d)
UFH IV bolus
(usually 5,000
units) and
continued IV
infusion
(a) Death, MI, or
recurrent
angina at
14 d:
LMWH 16.6%,
UFH 19.8%
(b) Death, MI, or
recurrent
angina at
30 d:
LMWH 19.8%,
UFH 23.3%
(a) OR at 14 d 
0.80
ARR 3.2%
(b) OR at 30 d 
0.81
ARR 3.5%
(a) 0.67 to
0.96
(b) 0.68 to
0.96
(a) 0.019
(b) 0.016
At 30 d:
LMWH 6.5%,
UFH 7%;
ARR 0.5%
(p  0.57)
FRIC (462) 1,482 (a) Days 1 to 6:
dalteparin 120 IU
per kg SC twice
daily
(b) Days 6 to 45§:
dalteparin 7,500 IU
SC once per day
(a) Days 1 to 6:
UFH 5,000 units
IV bolus and IV
infusion of
1,000 units per
h for 48 h
(b) Days 6 to 45:
placebo SC once
daily
(a) Death, MI, or
recurrence of
angina (Days
1 to 6):
LMWH 9.3%,
UFH 7.6%
(b) Death, MI, or
recurrence of
angina (Days
6 to 45):
12.3% in both
the LMWH and
UFH groups
(a) Death or MI
(Days 1 to 6):
LMWH 3.9%,
UFH 3.6%
(b) Death or MI
(Days 6 to 45):
LMWH 4.3%,
placebo 4.7%
(a) RR 1.18
ARR 1.7%
(b) RR 1.01
ARR 0%
(a) RR 1.07
ARR 0.3%
(b) RR 0.92
ARR 0.4%
(a) 0.84 to
1.66
(b) 0.74 to
1.38
(a) 0.63 to
1.80
(b) 0.54 to
1.57
(a) 0.33
(b) 0.96
(a) 0.80
(b) 0.76
(a) Days 1 to 6:
LMWH 1.1%,
UFH 1.0%;
ARR 0.1%
(p  NR)
(b) Days 6 to 45:
LMWH 0.5%,
placebo 0.4%;
ARR 0.1%
(p  NR)
FRAX.I.S.
(463)
3,468 (a) Nadroparin 6 d:
nadroparin 86 anti-
Xa IU per kg IV
bolus, followed by
nadroparin 86 anti-
Xa IU per kg SC
twice daily for 6 d
(b) Nadroparin 14 d:
nadroparin 86 anti-
Xa IU per kg IV
bolus, followed by
nadroparin 86 anti-
Xa IU per kg SC
twice daily for 14 d
(a)  (b) UFH
5,000 units IV
bolus and UFH
infusion at
1,250 units per
h IV for 6 d (plus
or minus 2 d)
Cardiac death,
MI, refractory
angina,
recurrence of
UA at Day 14:
LMWH 6 d
17.8%,
LMWH 14 d
20.0%,
UFH 18.1%
(a) ARR 0.3%
(b) ARR 1.9%
(a) 2.8
to 3.4
(b) 5.1
to 1.3
(a) 0.85
(b) 0.24
At 6 d:
UFH 1.6%,
LMWH 1.5%,
ARR 0.1%
At 14 d:
UFH 1.6%,
LMWH 3.5%,
ARR 1.9%
(p  0.0035)
Continued on next page
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Table 17. Continued
Trial
(Reference) n LMWH/Dose UFH
End Point/
Drug Effect Analysis 95% CI p
Major Bleeding
(p)
TIMI 11B
(180)
3,910 (a) Inpatient:
enoxaparin 30mg IV
bolus immediately
followed by 1mg per
kg SC every 12 h
(b) Outpatient:
enoxaparin 40mg
SC twice per day
(patients weighing
less than 65 kg) or
60mg SC twice per
day (patients
weighing at least 65
kg)
(a) Inpatient: UFH
70 units per kg
bolus and
infusion at 15
units per h
titrated to aPTT
(treatment
maintained for a
minimum of 3
and maximum
of 8 d at
physician’s
discretion)
(b) Outpatient:
placebo SC
twice per day
Death, MI,
urgent
revascularization
(a) At 48 h:
LMWH 5.5%,
UFH 7.3%
(b) 8 d:
LMWH 12.4%,
UFH 14.5%
(c) 14 d:
LMWH 14.2%,
UFH 16.7%
(d) 43 d:
LMWH 17.3%,
UFH 19.7%
(a) OR 0.75
ARR 1.8%
(b) OR 0.83
ARR 2.1%
(c) OR 0.82
ARR 2.5%
(d) OR 0.85
ARR 2.4%
(a) 0.58 to
0.97
(b) 0.69 to
1.00
(c) 0.69 to
0.98
(d) 0.72 to
1.00
(a) 0.026
(b) 0.048
(c) 0.029
(d) 0.048
At 48 h:
LMWH 0.8%,
UFH 0.7%;
ARR 0.1%
(p  0.14)
End of initial
hospitalization:
LMWH 1.5%,
UFH 1%;
ARR 0.5%
(p  0.143)
Between Day 8
and Day 43:
LMWH 2.9%,
placebo 2.9%;
ARR 0%
(p  0.021)
ACUTE II
(464)
525 Enoxaparin 1 mg per
kg SC every 12 h
UFH 5,000 units IV
bolus and
maintenance
infusion at
1,000 units per
h IV adjusted to
aPTT
(a) Death or (b)
MI at 30 d
(a) LMWH 2.5%,
UFH 1.9%
(b) LMWH 6.7%,
UFH 7.1%
(a) RR 1.3
ARR 0.6%
(b) RR 0.94
ARR 0.4%
(a) 0.06 to
3.93
(b) 0.45 to
2.56
(a) 0.77
(b) 0.86
LMWH 0.3%;
UFH 1%;
ARR 0.7%
(p  0.57)
INTERACT¶
(465)
746 Enoxaparin 1 mg per
kg SC every 12 h
UFH 70 units per
kg IV bolus
followed by
continuous
infusion at 15
units per kg per h
Death or MI at
30 d:
LMWH 5.0%,
UFH 9.0%
RR 0.55
ARR 4%
0.30 to
0.96
0.031 At 96 h:
LMWH 1.8%;
UFH 4.6%;
ARR 2.8%
(p  0.03)
A to Z
(466)
3,987 Enoxaparin 1 mg per
kg SC every 12 h
UFH 4,000 units IV
bolus followed
by 900 units per
h IV infusion for
patients
weighing equal
to or greater
than 70 kg
UFH 60 units per
kg (maximum
4,000 units) IV
bolus followed
by 12 units per
kg per h IV
infusion for
patients
weighing less
than 70 kg
All-cause death,
MI, or
refractory
ischemia
within 7 d of
tiroﬁban
initiation:
LMWH 8.4%,
UFH 9.4%
HR 0.88
ARR 1%
0.71 to
1.08
NR LMWH 0.9%;
UFH 0.4%;
ARR 0.5%
(p  0.05)
Continued on next page
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itant administration of LMWHs with GP IIb/IIIa antago-
nists and ﬁbrinolytic agents is currently being acquired.
3.2.5.3.1. EXTENDED THERAPY WITH LMWHs. The FRISC,
Fragmin in unstable coronary artery disease study (FRIC),
TIMI 11B, and Fast Revascularization during InStability in
Coronary artery disease-II (FRISC-II) trials evaluated the
potential beneﬁt of the prolonged administration of
LMWH after hospital discharge (Table 17). In the FRISC
trial, doses of dalteparin were administered between 6 d and
35 to 45 d; in FRIC, patients were rerandomized after the
initial 6-d treatment period to receive dalteparin for an
additional 40 d, and the outpatient treatment period lasted
5 to 6 weeks in TIMI 11B and 1 week in the FRAXiparine
in Ischaemic Syndromes (FRAXIS) trial. The FRISC-II
trial used a different study design. Dalteparin was adminis-
tered to all patients for a minimum of 5 d (472). Patients
were subsequently randomized to receive placebo or the
continued administration of dalteparin twice per day for up
to 90 d. Analysis of the results from the time of random-
ization showed a signiﬁcant reduction with dalteparin in the
composite end point of death or MI at 30 d (3.1% vs. 5.9%,
p  0.002) but not at 3 months (6.7% vs. 8.0%, p  0.17).
The composite of death, MI, or revascularization during the
total treatment period was reduced at 3 months (29.1% vs.
33.4%, p  0.031). The beneﬁts of prolonged dalteparin
administration were limited to patients who were managed
medically and to those with elevated TnT levels at baseline.
Although these results make a case for the prolonged use of
an LMWH in selected patients who are managed medically
or in whom angiography is delayed, their relevance to
contemporary practice is less clear now that clopidogrel is
used more frequently and there is a much greater tendency
to proceed to an early invasive strategy.
3.2.5.4. DIRECT THROMBIN INHIBITORS
Hirudin, the prototype of the direct thrombin inhibitors, has
been extensively studied but with mixed results. The GUSTO-
IIb trial randomly assigned 12,142 patients with suspected MI
to 72 h of therapy with either intravenous hirudin or UFH
(473). Patients were stratiﬁed according to the presence of
ST-segment elevation on the baseline ECG (4,131 patients) or
its absence (8,011 patients). The primary end point of death,
nonfatal MI, or reinfarction at 30 d occurred in 9.8% of the
UFH group versus 8.9% of the hirudin group (OR 0.89, p 
0.058). For patients without ST-segment elevation, the rates
were 9.1% and 8.3%, respectively (OR 0.90, p  0.22). At
24 h, the risk of death or MI was signiﬁcantly lower in the
patients who received hirudin than in those who received UFH
(2.1% vs. 1.3%, p  0.001). However, the Thrombolysis and
Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
of hirudin as adjunctive therapy to thrombolytic therapy in
patients with STEMI showed no beneﬁt of the drug over
UFH either during study drug infusion or later (474). The
GUSTO-IIb and TIMI 9B trials used hirudin doses of 0.1 mg
Table 17. Continued
Trial
(Reference) n LMWH/Dose UFH
End Point/
Drug Effect Analysis 95% CI p
Major Bleeding
(p)
SYNERGY††
(423)
9,978 Enoxaparin 1 mg per
kg SC every 12 h
UFH 60 units per
kg IV bolus
(maximum of
5,000 units) and
followed by IV
infusion of 12
units per kg per
h (maximum of
1,000 units per
h initially
Death or
nonfatal MI
during ﬁrst 30
d after
randomization
LMWH 14.0%,
UFH 14.5%,
HR 0.96
ARR 0.5%
0.86 to
1.06
0.40 TIMI minor:
LMWH 12.5%,
UFH 12.3%;
ARR 0.2%
(p  0.80)
TIMI major:
LMWH 9.1%,
UFH 7.6%
ARR 1.5%
(p  0.008)
GUSTO severe:
LMWH 2.7%,
UFH 2.2%;
ARR 0.5%
(p  0.08)
For speciﬁc interventions and additional medications during the study, see individual study references. Major bleeding was classiﬁed as follows in the various trials: A to Z: decrease in hemoglobin of more
than 5 mg per dL or intracranial or pericardial bleeding. ESSENCE: Major hemorrhage was deﬁned as bleeding resulting in death, transfusion of at least 2 U of blood, a fall in hemoglobin of 30 g per liter
or more, or a retroperitoneal, intracranial, or intraocular hemorrhage. TIMI 11B: Overt bleed resulting in death; a bleed in a retroperitoneal, intracranial, or intraocular location; a hemoglobin drop of greater
than or equal to 3 g per dL; or the requirement of transfusion of at least 2 U of blood. SYNERGY: TIMI and GUSTO criteria. ACUTE II: Severity was recorded on the basis of the TIMI trial bleeding criteria. TIMI
major bleeding involved a hemoglobin drop greater than 5 g per dL (with or without an identiﬁed site, not associated with coronary artery bypass grafting) or intracranial hemorrhage or cardiac tamponade.
INTERACT: Major bleeding included bleeding resulting in death, or retroperitoneal hemorrhage, or bleeding at a speciﬁc site accompanied by a drop in hemoglobin greater than or equal to 3 g per dL. FRIC:
A bleeding event was classiﬁed as major if it led to a fall in the hemoglobin level of at least 20 g per liter, required transfusion, was intracranial, or caused death or cessation of the study treatment. *Primary
study end point was ﬁrst 6 d. †Initial trial dose of 150 IU per kg SC twice daily decreased to 120 IU per kg SC twice daily due to increased bleeding during ﬁrst 6 d (4 patients or 6% major bleeding episodes
and 9 patients or 14% minor episodes among 63 actively treated patients). ‡Follow-up incomplete in 13 patients (8 dalteparin, 5 placebo) at their request. §Primary study outcome was Days 6 to 45. All
patients in ACUTE II received a tiroﬁban loading dose of 0.4 mcg per kg per min over 30 min, followed by a maintenance infusion at 0.1 mcg per kg per min. ¶All patients in INTERACT received eptiﬁbatide
180 mcg per kg bolus followed by a 2.0 mcg per kg per min infusion for 48 h. All patients enrolled in the A to Z Trial received aspirin and tiroﬁban. ††Patients also received glycoprotein IIb/IIIa inhibitors,
aspirin, clopidogrel; patients eligible for enrollment even if LMWH or UFH given before enrollment, adjustments made to enoxaparin and UFH during percutaneous coronary intervention.
A to Z Aggrastat to Zocor study; ACUTE II Antithrombotic Combination Using Tiroﬁban and Enoxaparin; aPTT activated partial thromboplastin time; ARR absolute risk reduction; CI conﬁdence
interval; ESSENCE  Efﬁcacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave Myocardial Infarction; FRIC  FRagmin In unstable Coronary disease; HR  hazard ratio; INTERACT 
Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment; IU international units; IV intravenous; LD loading dose; MDmaintenance dose; N number of patients; LMWH
 low-molecular-weight heparin; MI  myocardial infarction; NR  not reported; RR  relative risk; SC  subcutaneous; SYNERGY  Superior Yield of the New strategy of Enoxaparin, Revascularization and
Glycoprotein IIb/IIIA Inhibitors; TIMI 11B  Thrombolysis In Myocardial Infarction 11B; U unit; UA  unstable angina; UFH  unfractionated heparin.
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per kg bolus and 0.1 mg per kg per h infusion for 3 to 5 d after
the documentation of excess bleeding with higher doses used in
the GUSTO-IIA and TIMI 9A trials (0.6 mg per kg bolus
and 0.2 mg per kg per h infusion) (473,475).
The OASIS program evaluated hirudin in patients with
UA/NSTEMI. OASIS 1 (476) was a pilot trial of 909
patients that compared the low hirudin dose of 0.1 mg per
kg per h infusion and the medium hirudin dose of 0.15 mg
per h infusion with UFH. The latter dose provided the best
results, with a reduction in the rate of death, MI, or
refractory angina at 7 d (6.5% with UFH vs. 3.3% with
hirudin, p  0.047). This medium dose was used in the
large OASIS 2 (477) trial that consisted of 10,141 patients
with UA/NSTEMI who were randomized to receive UFH
(5,000 IU bolus plus 15 U per kg per h) or recombinant
hirudin (0.4 mg per kg bolus and 0.15 mg per kg per h)
infusion for 72 h. The primary end point of cardiovascular
death or new MI at 7 d occurred in 4.2% in the UFH group
versus 3.6% patients in the hirudin group (RR 0.84, p 
0.064). A secondary end point of cardiovascular death, new
MI, or refractory angina at 7 d was signiﬁcantly reduced
with hirudin (6.7% vs. 5.6%, RR 0.83, p  0.011). There
was an excess of major bleeding incidents that required
transfusion with hirudin (1.2% vs. 0.7% with heparin, p 
0.014) but no excess in life-threatening bleeding incidents
or strokes. A meta-analysis of the GUSTO-IIB, TIMI 9B,
OASIS 1, and OASIS 2 trials showed a relative risk of
death or MI of 0.90 (p  0.015) with hirudin compared
with UFH at 35 d after randomization; RR values were
similar for patients receiving thrombolytic agents (0.88) and
not receiving thrombolytic agents (0.90) (477).
The relative beneﬁts of hirudin versus UFH in ACS
patients undergoing PCI were evaluated in the 1,410-
patient subset in GUSTO-IIb who underwent PCI during
the initial drug infusion. A reduction in nonfatal MI and the
composite of death and MI was observed with hirudin that
was associated with a slightly higher bleeding rate (478).
Hirudin (lepirudin) is presently indicated by the US Food
and Drug Administration only for anticoagulation in pa-
tients with heparin-induced thrombocytopenia (456) and
for the prophylaxis of deep vein thrombosis in patients
undergoing hip replacement surgery. It should be adminis-
tered as a 0.4 mg per kg IV bolus over 15 to 20 s followed
by a continuous intravenous infusion of 0.15 mg per kg per
h, with adjustment of the infusion to a target range of 1.5 to
2.5 times the control aPTT values. Argatroban is another
direct thrombin inhibitor that is approved for the manage-
ment of patients with heparin-induced thrombocytopenia
(479). However, in ACS, the monovalent direct thrombin
inhibitors (including argatroban) are ineffective antithrom-
botic agents compared with UFH, and thus, argatroban
should generally not be used in management of ACS (480).
The recommended initial dose of argatroban is an intrave-
nous infusion of 2 mcg per kg per min, with subsequent
adjustments to be guided by the aPTT (medical manage-
ment) or ACT (interventional management).
The REPLACE 2 investigators compared bivalirudin
(bolus 0.75 mg per kg followed by infusion of 1.75 mg per
kg per h with provisional GP IIb/IIIa inhibition) with UFH
65 U per kg bolus with planned GP IIb/IIIa inhibition in
patients undergoing urgent or elective PCI (426). Only 14%
had been treated for UA within 48 h before enrollment.
Figure 12. SYNERGY Primary Outcomes at 30 d
CI  conﬁdence interval; MI  myocardial infarction; SYNERGY  Superior Yield of the New strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors
(423); UFH  unfractionated heparin.
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Prespeciﬁed deﬁnitions of noninferiority were satisﬁed for
bivalirudin, with the beneﬁts of a signiﬁcantly lower bleed-
ing rate (481). Follow-up through 1 year also suggested
similar mortality for the 2 approaches (482).
Bivalirudin was investigated further in the ACUITY trial
(425) (Figs. 13 and 14). The ACUITY trial used a 2  2
factorial design to compare a heparin (UFH or enoxaparin)
with or without upstream GP IIb/IIIa inhibition versus
bivalirudin with or without upstream GP IIb/IIIa inhibi-
tion; a third arm tested bivalirudin alone and provisional GP
IIb/IIIa inhibition. The study was randomized but open-
label (unblinded). The main comparisons in the ACUITY
trial were of heparin with GP IIb/IIIa inhibition versus
bivalirudin with GP IIb/IIIa inhibition versus bivalirudin
Figure 13. ACUITY Clinical Outcomes at 30 d
*p for noninferiority. ACUITY  Acute Catheterization and Urgent Intervention Triage strategY; CI  conﬁdence interval; GP  glycoprotein; UFH  unfractionated heparin.
Figure 14. ACUITY Composite Ischemia and Bleeding Outcomes
ACUITY  Acute Catheterization and Urgent Intervention Triage strategY; CI  conﬁdence interval; GP  glycoprotein; PCI  percutaneous coronary intervention; UFH 
unfractionated heparin.
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with provisional GP IIb/IIIa inhibition. Three primary
30-d end points were prespeciﬁed: composite ischemia,
major bleeding, and net clinical outcomes (composite isch-
emia or major bleeding). Bivalirudin plus GP IIb/IIIa
inhibitors compared with heparin plus GP IIb/IIIa inhibi-
tors resulted in noninferior 30-d rates of composite ischemia
(7.7% vs. 7.3%), major bleeding (5.3% vs. 5.7%), and net
clinical outcomes (11.8% vs. 11.7%) (Fig. 13). Bivalirudin
alone compared with heparin plus GP IIb/IIIa inhibitors
resulted in noninferior rates of composite ischemia (7.8% vs.
7.3%, p 0.32, RR 1.08, 95% CI 0.93 to 1.42), signiﬁcantly
reduced major bleeding (3.0% vs. 5.7%, p less than 0.001,
RR 0.53, 95% CI 0.43 to 0.65), and superior 30-d net
clinical outcomes (10.1% vs. 11.7% respectively, p  0.015,
RR 0.86, 95% CI 0.77 to 0.97). For the subgroup of 5,753
patients who did receive a thienopyridine before angiogra-
phy or PCI, the composite ischemic end point occurred in
7.0% in the bivalirudin-alone group versus 7.3% in the
group that received heparin plus GP IIb/IIIa inhibition (RR
0.97, 95% CI 0.80 to 1.17), whereas in the 3,304 patients
who did not receive a thienopyridine before angiography or
PCI, the composite ischemic event rate was 9.1% in the
bivalirudin-alone group versus 7.1% in the heparin plus GP
IIb/IIIa inhibition group (RR 1.29, 95% CI 1.03 to 1.63; p
for interaction 0.054) (Fig. 14) (425). The Writing Com-
mittee believes that this observation introduces a note of
caution about the use of bivalirudin alone, especially when
there is a delay to angiography when high-risk patients who
may not be represented by the ACUITY trial population are
being managed, or if early ischemic discomfort occurs after
the initial antithrombotic strategy has been implemented
(Figs. 7, 8, and 9). The Writing Committee therefore
recommends that patients meeting these criteria be treated
with concomitant GP IIb/IIIa inhibitors or a thienopyri-
dine, administered before angiography to optimize out-
comes whether a bivalirudin-based or heparin-based anti-
coagulant strategy is used. This approach is also supported
by the ﬁndings of the ACUITY timing study that showed a
trend toward higher rates of ischemic events, which did not
meet inferiority criteria, in the deferred GP IIb/IIIa inhib-
itor group compared with the upstream GP IIb/IIIa inhib-
itor. Death/MI/unplanned revascularization for ischemia
occurred in 7.1% of routine upstream GP IIb/IIIa inhibitor
group versus 7.9% of deferred selective inhibitor group; RR
1.12 (95% CI 0.97 to 1.29) (482a,482b). Similarly, in the
ACUITY PCI substudy (482c,482d), subjects who did not
receive a thienopyridine pre-PCI had higher rates of the
composite ischemic end point in the bivalirudin-alone
group compared with the heparin plus GP IIb/IIIa group.
In both the REPLACE 2 and ACUITY trials, bivalirudin
with provisional GP IIb/IIIa blockade was associated with a
lower risk of bleeding, whereas this was not the case in
ACUITY with the combination of bivalirudin and planned
GP IIb/IIIa blockade, suggesting that dosing regimens and
concomitant GP IIb/IIIa blockade plays an important role
in bleeding risk (483). The impact of switching anticoagu-
lants after randomization, which has been associated with
excess bleeding (423,484), is unclear for bivalirudin. It
should be noted that the ACUITY protocol called for
angiography within 24 to 48 h of randomization and that
the median time to catheterization (from the time the study
drug was started) was approximately 4 h; thus, the study
results of this trial cannot be extrapolated beyond the group
of patients treated in an early invasive fashion.
3.2.5.5. FACTOR XA INHIBITORS
The OASIS 5 investigators evaluated the use of fondapa-
rinux in UA/NSTEMI (424) (Fig. 15). OASIS 5 compared
2 anticoagulant strategies given for a mean of 6 d; one of
which was amended during the conduct of the trial. In
OASIS 5, patients with UA/NSTEMI were randomized to
a control strategy of enoxaparin 1.0 mg per kg SC twice
daily (reduced to 1.0 mg per kg once daily for patients with
an estimated creatinine clearance less than 30 ml per min)
coupled with UFH when PCI was performed (no additional
UFH if the last dose of enoxaparin was less than 6 h before).
If the last dose of enoxaparin was given more than 6 h
before, the recommendation was that an intravenous bolus
of UFH 65 U per kg be administered if a GP IIb/IIIa
inhibitor was to be used and 100 U per kg if no GP IIb/IIIa
inhibitor was to be used. The opposite arm was a strategy of
fondaparinux 2.5 mg SC once daily to be supplemented as
follows if PCI was performed: within 6 h of the last
subcutaneous dose of fondaparinux, no additional study
drug was given if a GP IIb/IIIa inhibitor was used, and 2.5
mg of fondaparinux was given intravenously if no GP
IIb/IIIa inhibitor was used; more than 6 h since the last dose
of fondaparinux, an additional intravenous dose of fondapa-
rinux 2.5 mg was recommended if a GP IIb/IIIa inhibitor
was used or 5.0 mg IV if no GP IIb/IIIa inhibitor was used.
As explained by the OASIS 5 investigators, the rationale for
the recommendation to use UFH during PCI in the
enoxaparin arm was based on lack of approval for enoxapa-
rin for PCI in the US by the Food and Drug Administra-
tion, lack of available trial data on the use of enoxaparin
during PCI when OASIS 5 was designed, and lack of any
recommendations about the use of enoxaparin in the avail-
able ACC/AHA or ESC PCI guidelines (personal commu-
nication, OASIS 5 Investigators, July 7, 2006). The UFH
dosing recommendation in the enoxaparin arm was formu-
lated in consultation with the maker of enoxaparin and was
not altered when the SYNERGY trial did not show
superiority of enoxaparin over UFH (423). Of note, during
the conduct of the trial, catheter-associated thrombus was
reported 3 times more frequently with the fondaparinux
strategy (0.9% vs. 0.3%). After approximately 12,000 of the
20,078 patients ultimately enrolled in the trial had been
randomized, the protocol was amended to remind the
investigators to be certain that the intravenous dose of
fondaparinux was properly ﬂushed in the line and to permit
the use of open-label UFH. As described by the OASIS 5
investigators (personal communication, OASIS 5 Investi-
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gators, July 7, 2006), investigators gave open-label UFH
both before and during PCI, with the dose being deter-
mined at their discretion.
The number of patients with primary outcome events at
9 d (death, MI, or refractory ischemia) was similar in the 2
groups (579 with fondaparinux [5.8%] vs. 573 with enox-
aparin [5.7%]; HR in the fondaparinux group 1.01; 95% CI
0.90 to 1.13), which satisﬁed prespeciﬁed noninferiority
criteria. The number of events that met this combined
primary efﬁcacy outcome showed a nonsigniﬁcant trend
toward a lower value in the fondaparinux group at 30 d (805
vs. 864, p  0.13) and at the end of the study (180 d; 1,222
vs. 1,308, p  0.06; Fig. 12). The rate of major bleeding at
9 d was lower with fondaparinux than with enoxaparin (217
events [2.2%] vs. 412 events [4.1%]; HR 0.52; p less than
0.001). The composite of the primary outcome and major
bleeding at 9 d favored fondaparinux (737 events [7.3%] vs.
905 events [9.0%]; HR 0.81; p less than 0.001) (Fig. 15).
Fondaparinux was associated with a signiﬁcantly reduced
number of deaths at 30 d (295 vs. 352, p 0.02) and at 180
d (574 vs. 638, p  0.05). Fondaparinux also was associated
with signiﬁcant reductions in death, MI, and stroke (p 
0.007) at 180 d.
Thus, fondaparinux is another anticoagulant that has
been given a Class I recommendation in the management of
UA/NSTEMI, as noted in Figures 7, 8, and 9. As tested in
OASIS 5, the fondaparinux (plus UFH) strategy was
associated with lower bleeding rates, clearly an attractive
feature given the relationship between bleeding events and
increased risk of death and ischemic events (486). The excess
bleeding in the enoxaparin arm may have been in part a result
of the combination of enoxaparin and UFH during PCI.
At present, based on experience in both OASIS 5 and
OASIS 6 (433), it appears that patients receiving fondapa-
rinux before PCI should receive an additional anticoagulant
with anti–IIa activity to support PCI (see Table 13). To
date, the only anticoagulant that has been evaluated with
fondaparinux during PCI is UFH, and based on limited
experience, the OASIS investigators recommend an UFH
dose of 50 to 60 U per kg IV when fondaparinux-treated
patients are taken to PCI (personal communication, OASIS
5 Investigators, July 7, 2006). However, a cautionary note is
that this UFH recommendation is not fully evidence-based,
given its inconsistent and uncontrolled use in OASIS 5.
Hence, additional clinical trial information is needed to
establish more rigorously the safety of intravenous UFH at
the time of PCI in patients receiving fondaparinux as initial
medical treatment (Table 13). Because the anticoagulant
effect of UFH can be more readily reversed than that of
fondaparinux, UFH is preferred over fondaparinux in pa-
tients likely to undergo CABG within 24 h.
3.2.5.6. LONG-TERM ANTICOAGULATION
The long-term administration of warfarin has been evalu-
ated in a few, mostly small studies. Williams et al. (436)
randomized 102 patients with UA to UFH for 48 h
followed by open-label warfarin for 6 months and reported
a 65% risk reduction in the rate of MI or recurrent UA. The
Antithrombotic Therapy in Acute Coronary Syndromes
(ATACS) trial (369) randomized 214 patients with UA/
NSTEMI to ASA alone or to the combination of ASA plus
UFH followed by warfarin. At 14 d, there was a reduction
in the composite end point of death, MI, and recurrent
ischemia with the combination therapy (27.0% vs. 10.5%, p
Figure 15. OASIS 5 Cumulative Risks of Death, MI, or Refractory Ischemia
*p for noninferiority. †p for superiority. CI  conﬁdence interval; MI  myocardial infarction; OASIS 5  Fifth Organization to Assess Strategies for Ischemic Syndromes.
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 0.004). In a small randomized pilot study of 57 patients
allocated to warfarin or placebo in addition to ASA, less
evidence was noted of angiographic progression in the
culprit lesion after 10 weeks of treatment with warfarin
(33% for placebo vs. 4% for warfarin) and more regression
was observed (487). The OASIS pilot study (488) compared
a ﬁxed dosage of warfarin 3 mg per d or a moderate dose
titrated to an INR of 2.0 to 2.5 in 197 patients and given for
7 months after the acute phase. Low-intensity warfarin had
no beneﬁt, whereas the moderate-intensity regimen reduced
the risk of death, MI, or refractory angina by 58% and the
need for rehospitalization for UA by 58%. However, these
results were not reproduced in the larger OASIS 2 trial
(477) of 3,712 patients randomized to the moderate-
intensity regimen of warfarin or standard therapy, with all
patients receiving ASA. The rate of cardiovascular death,
MI, or stroke after 5 months was 7.7% with the anticoag-
ulant and 8.4% without (p  0.37) (489). Thus, the role, if
any, of long-term warfarin in patients with UA/NSTEMI
remains to be deﬁned.
The Coumadin Aspirin Reinfarction Study (CARS)
conducted in post-MI patients was discontinued prema-
turely owing to a lack of evidence of a beneﬁt of reduced-
dose ASA (80 mg per d) combined with either 1 or 3 mg of
warfarin daily compared with 160 mg per d of ASA alone
(490). The Combination Hemotherapy And Mortality Pre-
vention study found no beneﬁt to the use of warfarin (to an
INR of 1.5 to 2.5) plus 81 mg per d of ASA versus 162 mg
per d of ASA alone with respect to total mortality (the
primary end point), cardiovascular mortality, stroke, or
nonfatal MI (mean follow-up of 2.7 years) after an index MI
(491). Low- or moderate-intensity anticoagulation with
ﬁxed-dose warfarin thus is not recommended for routine use
after hospitalization for UA/NSTEMI. Warfarin should be
prescribed, however, for UA/NSTEMI patients with estab-
lished indications for warfarin, such as atrial ﬁbrillation, left
ventricular thrombus, and mechanical prosthetic heart
valves.
The Antithrombotics in the Secondary Prevention of
Events in Coronary Thrombosis-2 (ASPECT-2) open-
label trial randomized 999 patients after ACS to low-dose
ASA, high-intensity oral anticoagulation (INR 3.0 to 4.0),
or combined low-dose ASA and moderate intensity oral
anticoagulation (INR 2.0 to 2.5) (492). After a median of 12
months, the primary end point of MI, stroke, or death was
reached in 9% receiving ASA, 5% given anticoagulants (p
0.048), and 5% receiving combination therapy (p  0.03).
Major and minor bleeding events occurred in 1% and 5%,
1% and 8%, and 2% and 15% of patients, respectively.
Similarly, a large (n  3,630) Norwegian open-label
study (WARIS-2) compared ASA (160 mg per d), high-
intensity warfarin (INR target 2.8 to 4.2), or ASA (75 mg
per d) combined with moderate-intensity warfarin (INR 2.0
to 2.5) over a mean of 4 years after MI (41% with
non–Q-wave MI) (493). One third of patients underwent
an intervention over the study period. The primary outcome
of death, nonfatal MI, or thromboembolic stroke occurred
in 20% of ASA patients, 16.7% of warfarin patients, and
15% of combination therapy patients (p  0.03). The
annual major bleeding rate was 0.62% in both warfarin arms
and 0.17% with ASA alone (p less than 0.001). Thus,
moderate-intensity warfarin with low-dose ASA appears to
be more effective than ASA alone when applied to MI
patients treated primarily with a noninterventional ap-
proach, but it is associated with a higher bleeding risk.
An indication for warfarin (e.g., for atrial ﬁbrillation,
mechanical prosthetic valve, or left ventricular thrombus) in
addition to ASA and clopidogrel, which are indicated for
most high-risk patients, arises occasionally after UA/
NSTEMI. There are no prospective trials and few observa-
tional data to establish the beneﬁt and risk of such “triple
antithrombotic” therapy (494,495). In the 2004 STEMI
guidelines (1), a Class IIb, Level of Evidence: C recom-
mendation was given for the use of warfarin (INR 2.0 to
3.0) in combination with ASA (75 to 162 mg) and clopi-
dogrel (75 mg per d) for patients with a stent implanted and
concomitant indications for anticoagulation. Similarly, the
2005 PCI guidelines (2) stated that warfarin in combination
with clopidogrel and low-dose ASA should be used with
great caution and only when INR is carefully regulated (2.0
to 3.0). Despite a limited amount of subsequent observa-
tional data (495), the evidence base remains small, which
leaves this recommendation at the Class IIb, Level of
Evidence: C. When triple-combination therapy is selected
for clear indications and is based on clinical judgment that
beneﬁt will outweigh the incremental risk of bleeding, then
therapy should be given for the minimum time and at the
minimally effective doses necessary to achieve protection.
An expanded evidence base on this issue is strongly needed.
Figure 11 provides recommendations for long-term man-
agement of dual- and triple-antithrombotic therapy after
UA/NSTEMI.
3.2.6. Platelet GP IIb/IIIa Receptor Antagonists
The GP IIb/IIIa receptor is abundant on the platelet
surface. When platelets are activated, this receptor under-
goes a change in conformation that increases its afﬁnity for
binding to ﬁbrinogen and other ligands. The binding of
molecules of ﬁbrinogen to receptors on different platelets
results in platelet aggregation. This mechanism is indepen-
dent of the stimulus for platelet aggregation and represents
the ﬁnal and obligatory pathway for platelet aggregation
(496). The platelet GP IIb/IIIa receptor antagonists act by
occupying the receptors, preventing ﬁbrinogen from bind-
ing, and thereby preventing platelet aggregation. Experi-
mental and clinical studies have suggested that occupancy of
at least 80% of the receptor population and inhibition of
platelet aggregation to ADP (5 to 20 micromoles per liter)
by at least 80% results in potent antithrombotic effects
(497). The various GP IIb/IIIa antagonists, however, pos-
sess signiﬁcantly different pharmacokinetic and pharmaco-
dynamic properties (498).
Anderson et al ACC/AHA UA/NSTEMI Guideline Revision e213
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
Abciximab is a Fab fragment of a humanized murine
antibody that has a short plasma half-life but strong afﬁnity
for the receptor, which results in some receptor occupancy
that persists in part for weeks. Platelet aggregation gradually
returns to normal 24 to 48 h after discontinuation of the
drug. Abciximab also inhibits the vitronectin receptor (al-
phavbeta3) on endothelial cells and the MAC-1 receptor on
leukocytes (499,500). The clinical relevance of occupancy of
these receptors is unknown.
Eptiﬁbatide is a cyclic heptapeptide that contains the
KGD (Lys-Gly-Asp) sequence; tiroﬁban is a nonpeptide
mimetic of the RGD (Arg-Gly-Asp) sequence of ﬁbrinogen
(498,501–503). Receptor occupancy with these 2 synthetic
antagonists is, in general, in equilibrium with plasma levels.
They have half-lives of 2 to 3 h and are highly speciﬁc for
the GP IIb/IIIa receptor. Platelet aggregation returns to
normal in 4 to 8 h after discontinuation of these drugs, a
ﬁnding that is consistent with their relatively short half-lives
(504). Glycoprotein IIb/IIIa antagonists can bind to differ-
ent sites on the receptor, which results in somewhat differ-
ent binding properties that can modify their platelet effects
and, potentially and paradoxically, activate the receptor
(505). Oral antagonists to the receptor, previously under
investigation, have been abandoned because of negative
results of 5 large trials of 4 of these compounds (506–509).
The efﬁcacy of GP IIb/IIIa antagonists in prevention of
the complications associated with percutaneous interven-
tions has been documented in numerous trials, many of
them composed totally or largely of patients with UA
(372,510–512) (Table 18). Two trials with tiroﬁban and 1
trial with eptiﬁbatide have also documented their efﬁcacy in
UA/NSTEMI patients, only some of whom underwent
interventions (128,130). Two trials were completed with the
experimental drug lamiﬁban (373,513) and 1 with abcix-
imab (514). Few direct comparative data are available for
these various antiplatelet agents. The TARGET study (Do
Tiroﬁban and ReoPro Give Similar Efﬁcacy Trial) assessed
differences in safety and efﬁcacy of tiroﬁban and abciximab
in 4,809 patients undergoing PCI with intended stenting
(515). The composite of death, nonfatal MI, or urgent
target-vessel revascularization at 30 d occurred more fre-
quently in the tiroﬁban group (7.6% vs. 6.0%). The advan-
tage of abciximab was observed exclusively among patients
presenting with UA/NSTEMI (63% of the population)
(515). A possible explanation for the inferior performance of
in-laboratory initiation of tiroﬁban for PCI in the setting of
ACS was an insufﬁcient loading dose of tiroﬁban to achieve
optimal early (periprocedural) antiplatelet effect (516).
Abciximab has been studied primarily in PCI trials, in
which its administration consistently resulted in reductions
in rates of MI and the need for urgent revascularization
(Table 18). In subgroups of patients within those trials who
had ACS, the risk of ischemic complications within the ﬁrst
30 d after PCI was reduced by 60% to 80% with abciximab
therapy. Two trials with abciximab speciﬁcally studied
patients with acute ischemic syndromes. The CAPTURE
trial enrolled patients with refractory UA (372). After
angiographic identiﬁcation of a culprit lesion suitable for
angioplasty, patients were randomized to either abciximab
or placebo administered for 20 to 24 h before angioplasty
and for 1 h thereafter. The rate of death, MI, or urgent
revascularization within 30 d (primary outcome) was re-
duced from 15.9% with placebo to 11.3% with abciximab
(RR 0.71, p  0.012). At 6 months, death or MI had
occurred in 10.6% of the placebo-treated patients versus
9.0% of the abciximab-treated patients (p  0.19). Abcix-
imab is approved for the treatment of UA/NSTEMI as an
adjunct to PCI or when PCI is planned within 24 h.
The GUSTO IV-ACS trial (514) enrolled 7,800 patients
with UA/NSTEMI who were admitted to the hospital with
more than 5 min of chest pain and either ST-segment
depression and/or elevated TnT or TnI concentration. All
received ASA and either UFH or LMWH. They were
randomized to an abciximab bolus and a 24-h infusion, an
abciximab bolus and a 48-h infusion, or placebo. In contrast
to other trials with GP IIb/IIIa antagonists, GUSTO
IV-ACS enrolled patients in whom early (less than 48 h)
revascularization was not intended. At 30 d, death or MI
occurred in 8.0% of patients taking placebo, 8.2% of patients
taking 24-h abciximab, and 9.1% of patients taking 48-h
abciximab, differences that were not statistically signiﬁcant.
At 48 h, death occurred in 0.3%, 0.7%, and 0.9% of patients
in these groups, respectively (placebo vs. abciximab 48 h, p 
0.008). The lack of beneﬁt of abciximab was observed in most
subgroups, including patients with elevated concentrations of
troponin who were at higher risk. Although the explanation for
these results is not clear, they indicate that abciximab at the
dosing regimen used in GUSTO IV-ACS is not indicated in
the management of patients with UA or NSTEMI in whom
an early invasive management strategy is not planned.
Tiroﬁban was studied in the Platelet Receptor Inhibition
in Ischemic Syndrome Management (PRISM) (374) and
Platelet Receptor Inhibition in Ischemic Syndrome Man-
agement in Patients Limited by Unstable Signs and Symp-
toms (PRISM-PLUS) (130) trials. PRISM directly com-
pared tiroﬁban with heparin in 3,232 patients with
accelerating angina or angina at rest and ST-segment or
T-wave changes and with cardiac marker elevation, a
previous MI, or a positive stress test or angiographically
documented coronary disease (374). The primary composite
outcome (death, MI, or refractory ischemia at the end of a
48-h infusion period) was reduced from 5.6% with UFH to
3.8% with tiroﬁban (RR 0.67, p  0.01). At 30 d, the
frequency of the composite outcome was similar in the 2
groups (17.1% for UFH vs. 15.9% for tiroﬁban, p  0.34),
but a trend toward reduction in the rate of death or MI was
present with tiroﬁban (7.1% vs. 5.8%, p  0.11), and a
signiﬁcant reduction in mortality rates was observed (3.6%
vs. 2.3%, p  0.02). The beneﬁt of tiroﬁban was mainly
present in patients with an elevated TnI or TnT concen-
tration at baseline.
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The PRISM-PLUS trial enrolled 1,915 patients with
clinical features of UA/NSTEMI within the previous 12 h
and the presence of ischemic ST-T changes or CK and
CK-MB elevation (130). Patients were randomized to
tiroﬁban alone, UFH alone, or the combination for a period
varying from 48 to 108 h. The tiroﬁban-alone arm was
dropped during the trial because of an excess mortality rate.
The combination of tiroﬁban and UFH compared with
UFH alone reduced the primary composite end point of
death, MI, or refractory ischemia at 7 d from 17.9% to
12.9% (RR 0.68, p  0.004). This composite outcome also
was signiﬁcantly reduced at 30 d (22%, p  0.03) and at 6
months (19%, p 0.02). The end point of death or nonfatal
MI was reduced at 7 d (43%, p  0.006), at 30 d (30%, p 
0.03), and at 6 months (22%, p  0.06). A high rate of
angiography in this trial could have contributed to the
important reduction in event rates. Computer-assisted anal-
ysis of coronary angiograms obtained after 48 h of treatment
in PRISM-PLUS also showed a reduction in the thrombus
load at the site of the culprit lesion and improved coronary
ﬂow in patients who received the combination of tiroﬁban
and UFH (134). Tiroﬁban, in combination with heparin,
has been approved for the treatment of patients with ACS,
including patients who are managed medically and those
undergoing PCI.
Eptiﬁbatide was studied in the PURSUIT trial, which
enrolled 10,948 patients who had chest pain at rest within
the previous 24 h and ST-T changes or CK-MB elevation
(128). The study drug was added to standard management
until hospital discharge or for 72 h, although patients with
normal coronary arteries or other mitigating circumstances
had shorter infusions. The infusion could be continued for
an additional 24 h if an intervention was performed near the
end of the 72-h infusion period. The primary outcome rate
of death or nonfatal MI at 30 d was reduced from 15.7% to
14.2% with eptiﬁbatide (RR 0.91, p  0.042). Within the
ﬁrst 96 h, a substantial treatment effect was seen (9.1% vs.
7.6%, p  0.01). The beneﬁts were maintained at 6-month
follow-up. Eptiﬁbatide has been approved for the treatment of
patients with ACS (UA/NSTEMI) who are treated medically
or with PCI. It is usually administered with ASA and heparin.
The cumulative event rates observed during the phase of
medical management and at the time of PCI in the
CAPTURE, PRISM-PLUS, and PURSUIT trials are
shown in Figure 16 (523). By protocol design, almost all
patients underwent PCI in CAPTURE. In PRISM-PLUS,
angiography was recommended. A percutaneous revascular-
ization was performed in 31% of patients in PRISM-PLUS
and in 13% of patients in PURSUIT. Each trial showed a
statistically signiﬁcant reduction in the rate of death or MI
during the phase of medical management; the reduction in
event rates was magniﬁed at the time of the intervention.
Although it is tempting to evaluate the drug effect by
comparing patients who had intervention with those who
did not, such an analysis is inappropriate. Patients who do
not undergo intervention include many low-risk patients,
patients who died before having the opportunity for inter-
vention, patients with contraindications, and patients with
uncomplicated courses in countries and practices that use
the ischemia-guided approach; there is no way to adjust for
these imbalances. Accordingly, the analysis in Figure 16
includes the event rates for all patients during the time when
they were treated medically. It then begins the analysis anew
in patients who underwent PCI at the time of angiography
while taking drug or placebo. In the PRISM-PLUS trial,
1,069 patients did not undergo early PCI. Although tiroﬁ-
ban treatment was associated with a lower incidence of
death, MI or death, or MI or refractory ischemia at 30 d,
these reductions were not statistically signiﬁcant (130). In a
high-risk subgroup of these patients not undergoing PCI
(TIMI risk score greater than or equal to 4) (159), tiroﬁban
appeared to be beneﬁcial whether patients underwent PCI
(OR 0.60, 95% CI 0.35 to 1.01) or not (OR 0.69, 95% CI
0.49 to 0.99); however, no beneﬁt was observed in patients
at lower risk (181,525). In the PURSUIT trial, the impact
of eptiﬁbatide on the incidence of death or MI in the
subgroup of patients who did not undergo revascularization
within the ﬁrst 72 h was modest and consistent with the
overall trial result, although not individually signiﬁcant
(15.6% vs. 14.5%, p  0.23) (128).
Boersma et al. performed a meta-analysis of GP IIb/IIIa
antagonists of all 6 large, randomized, placebo-controlled
trials (including GUSTO IV; [514]) involving 31,402 pa-
tients with UA/NSTEMI not routinely scheduled to un-
dergo coronary revascularization (526). In the overall pop-
ulation, the risk of death or MI by 30 d was modestly
reduced in the active treatment arms (11.8% vs. 10.8%, OR
0.91, 95% CI 0.84 to 0.98, p  0.015). Treatment effect
appeared to be greater among higher-risk patients with
troponin elevations or ECG ST-segment depressions. Un-
expectedly, no beneﬁt was observed in women, but there
was no evidence of a sex difference in treatment effect once
patients were stratiﬁed by troponin concentrations (a risk
reduction was seen in both men and women with elevated
cTn levels). These and other data have elevated troponin
level to a major factor in decision making for the use of these
agents in UA/NSTEMI. Major bleeding complications
were increased in the GP IIb/IIIa antagonist-treated group
compared with those who received placebo (2.4% vs. 1.4%,
p less than 0.0001). For special considerations about the use
of GP IIb/IIIa antagonists in women, see Section 6.1.2.1.
A relationship was observed between revascularization
procedures and the apparent treatment effect of GP IIb/IIIa
blockade in the meta-analysis by Boersma et al. (526).
Revascularization strategies were not speciﬁed by trial pro-
tocols or randomized, but 5,847 (19%) of the 31,402
patients underwent PCI or CABG within 5 d, and 11,965
patients (38%) did so within 30 d. Signiﬁcant reductions in
the risk of death or MI with GP IIb/IIIa blockade were
observed in these subgroups (OR 0.79, 95% CI 0.68 to 0.91
for patients revascularized within 5 d; OR  0.89, 95% CI
0.80 to 0.98 for patients revascularized within 30 d),
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whereas no signiﬁcant treatment effect was present in the
other 19,416 patients who did not undergo coronary revas-
cularization within 30 d (OR for death or MI 0.95, 95% CI
0.86 to 1.05). The authors concluded that the beneﬁt of GP
IIb/IIIa blockade in patients with UA/NSTEMI was “clin-
ically most meaningful in patients at high risk of thrombotic
complications” (526). The ﬁndings of this meta-analysis in
the context of other trials of GP IIb/IIIa blockade during
PCI suggest that GP IIb/IIIa inhibitors are of substantial
beneﬁt in patients with UA/NSTEMI who undergo PCI,
are of modest beneﬁt in patients who are not routinely
scheduled to undergo revascularization (but who may do
so), and are of questionable beneﬁt in patients who do not
undergo revascularization.
Although there is a temptation to use the comparison of
each of these GP IIb/IIIa inhibitors with placebo to draw
conclusions about relative efﬁcacy, such an exercise could be
misleading. Each trial had different entry criteria, different
approaches to angiographic evaluation, and different criteria
for end-point measurement and took place in different
Figure 16. Kaplan-Meier Curves Showing Cumulative Incidence of Death or MI
Incidence is shown in patients randomly assigned to platelet GP IIb/IIIa receptor antagonist (bold line) or placebo. Data are derived from the CAPTURE, PURSUIT, and PRISM-PLUS
trials. Left: events during the initial period of medical treatment until the moment of PCI or CABG. In the CAPTURE trial, abciximab was administered for 18 to 24 h before the PCI
was performed in almost all patients as per study design; abciximab was discontinued 1 h after the intervention. In PURSUIT, a PCI was performed in 11.2% of patients during a
period of medical therapy with eptiﬁbatide that lasted 72 h and for 24 h after the intervention. In PRISM-PLUS, an intervention was performed in 30.2% of patients after a 48-h
period of medical therapy with tiroﬁban, and the drug infusion was maintained for 12 to 24 h after an intervention. Right: events occurring at the time of PCI and the next 48 h, with
the event rates reset to 0% before the intervention. Creatine kinase or creatine kinase-MB elevations exceeding 2 times the upper limit of normal were considered as infarction dur-
ing medical management and exceeding 3 times the upper limit of normal for PCI-related events. Adapted from Boersma E, Akkerhuis KM, Théroux P, et al. Platelet glycoprotein IIb/
IIIa receptor inhibition in non–ST-elevation acute coronary syndromes. Circulation 1999;100:2045–8 (523), CAPTURE (240), PURSUIT (172), and PRISM-PLUS (134). © Lippincott,
Williams & Wilkins. CABG  coronary artery bypass graft; CAPTURE  c7E3 Fab AntiPlatelet Therapy in Unstable REfractory angina; GP  glycoprotein; MI  myocardial infarction; N
 number of patients; OR  odds ratio; PCI  percutaneous coronary intervention; PRISM-PLUS  Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Lim-
ited by Unstable Signs and symptoms; PURSUIT  Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
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locations in different time periods. The effects of these
differences cannot be accounted for in an indirect compar-
ison. Head-to-head (direct) comparisons are required to
draw reliable conclusions about the relative efﬁcacy of these
different molecules. As noted earlier, 1 trial (TARGET)
demonstrated an advantage to in-laboratory initiation of
abciximab over tiroﬁban for UA/NSTEMI patients under-
going PCI with stenting (515). An explanation offered for
this difference was an insufﬁcient loading dose of tiroﬁban to
achieve optimal periprocedural antiplatelet effect (516).
Treatment with a GP IIb/IIIa antagonist increases the risk
of bleeding, which is typically mucocutaneous or involves the
access site of vascular intervention. Unfortunately, each trial
also used a different deﬁnition of bleeding and reported
bleeding related to CABG differently. In the PRISM trial,
with no interventions (including CABG) on treatment, major
bleeding (excluding CABG) occurred in 0.4% of patients who
received tiroﬁban and 0.4% of patients who received UFH
(374). In the PRISM-PLUS trial, major bleeding according to
the TIMI criteria was reported in 1.4% of patients who
received tiroﬁban and 0.8% of patients who received placebo (p
 0.23), whereas PURSUIT reported major bleeding in 10.6%
of patients who received eptiﬁbatide and 9.1% of patients who
received placebo (p 0.02) (134,172). In the PURSUIT trial,
with the exclusion of patients who underwent CABG, the
rates were 3.0% with eptiﬁbatide and 1.3% with placebo (p less
than 0.001). No trials have shown an excess of intracranial
bleeding with a GP IIb/IIIa inhibitor. As with the efﬁcacy
data, the temptation to make indirect comparisons should be
tempered by the variability in protocol, circumstances, and
deﬁnitions of the trial.
Aspirin has been used with the intravenous GP IIb/IIIa
receptor blockers in all trials. A strong case also can be made
for the concomitant use of heparin with GP IIb/IIIa
receptor blockers. The tiroﬁban arm without UFH in the
PRISM-PLUS trial was discontinued early because of an
excess of deaths. In addition, the PURSUIT trial reported a
higher event rate in the 11% of patients who were not
treated with concomitant heparin (128). In a randomized
comparison, a lower-dose regimen of the GP IIb/IIIa
inhibitor lamiﬁban gave a more favorable outcome trend
when combined with heparin than when administered
without heparin (373). Current recommendations call for
the concomitant use of heparin with GP IIb/IIIa inhibitors.
Glycoprotein IIb/IIIa inhibitors can increase the ACT
when combined with heparin, which means that lower doses
of heparin are required to achieve a target level of antico-
agulation. Moreover, trial data indicate that lower heparin
doses diminish the bleeding risk associated with GP IIb/
IIIa blockade in the setting of PCI, ﬁndings that likely can
be extrapolated to the medical phase of management in
patients with UA/NSTEMI.
Blood hemoglobin and platelet counts should be monitored
and patient surveillance for bleeding should be performed daily
during the administration of GP IIb/IIIa receptor blockers.
Thrombocytopenia is an unusual complication of this class of
agents. Severe thrombocytopenia, deﬁned by nadir platelet
counts of less than 50,000 per ml, is observed in 0.5% of
patients, and profound thrombocytopenia, deﬁned by nadir
platelet counts of less than 20,000 per ml, is observed in 0.2%
of patients. Although reversible, thrombocytopenia is associ-
ated with an increased risk of bleeding (527,528).
Several trials have demonstrated that GP IIb/IIIa inhib-
itors can be used with LMWH among patients with
unstable ischemic syndromes. In the Antithrombotic Com-
bination Using Tiroﬁban and Enoxaparin (ACUTE II)
study (529), UFH and enoxaparin were compared in pa-
tients with UA/NSTEMI receiving tiroﬁban. The inci-
dence of major and minor bleeding was similar, and there
was a trend to fewer adverse events in patients receiving
enoxaparin. More recently, 2 large-scale, randomized trials
have examined the relative efﬁcacy of enoxaparin versus
UFH among patients with ACS. One of these, the A to Z
Trial (Aggrastat to Zocor), randomized 3,987 patients who
were treated with concomitant ASA and tiroﬁban (466).
Coronary angiography was performed in 60% of patients.
Nonsigniﬁcant trends toward fewer ischemic end points but
more frequent bleeding events were observed with enoxapa-
rin than with UFH therapy (466). In the larger SYNERGY
trial, 10,027 patients with high-risk ACS were randomized
to receive either UFH or enoxaparin (423) (Fig. 12).
Glycoprotein IIb/IIIa antagonists were administered to 57% of
patients, and 92% underwent coronary angiography. No ad-
vantage of enoxaparin over heparin was observed for the
primary end point of death or myocardial infarction by 30 d
(14.0% vs. 14.5%), but the 2 randomized therapies offered
similar protection against ischemic events during PCI. Enox-
aparin was associated, however, with an excess risk of TIMI
major bleeding (9.1% vs. 7.6%, p  0.008) (423).
The ACUITY trial investigated the combination of a GP
IIb/IIIa inhibitor with bivalirudin, a direct thrombin inhib-
itor (see Section 3.2.2.4 and Fig. 13) (425). Glycoprotein
IIb/IIIa inhibition with bivalirudin resulted in similar (non-
inferior) clinical outcomes compared with GP IIb/IIIa
inhibition with UFH or enoxaparin.
A challenge for the current guidelines is integrating the GP
IIb/IIIa studies from the 1990s with more recent studies using
preangiography clopidogrel loading, newer anticoagulants, and
varying degrees of patient acuity and risk/beneﬁt. The current
evidence base and expert opinion suggest that for UA/
NSTEMI patients in whom an initial invasive strategy is
selected, either an intravenous GP IIb/IIIa inhibitor or clopi-
dogrel should be added to ASA and anticoagulant therapy
before diagnostic angiography (upstream) for lower-risk,
troponin-negative patients and that both should be given
before angiography for high-risk, troponin-positive patients
(Class I recommendations). For UA/NSTEMI patients in
whom an initial conservative (i.e., noninvasive) strategy is
selected, the evidence for beneﬁt is less; for this strategy, the
addition of eptiﬁbatide or tiroﬁban to anticoagulant and oral
antiplatelet therapy may be reasonable for high-risk UA/
NSTEMI patients (Class IIb recommendation).
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3.2.7. Fibrinolysis
The failure of intravenous ﬁbrinolytic therapy to improve
clinical outcomes in the absence of MI with ST-segment
elevation or bundle-branch block was clearly demonstrated in
the TIMI 11B, ISIS-2, and GISSI 1 trials (129,530,531). A
meta-analysis of ﬁbrinolytic therapy in UA/NSTEMI patients
showed no beneﬁt of ﬁbrinolysis versus standard therapy
(531a). Fibrinolytic agents had no signiﬁcant beneﬁcial effect
and actually increased the risk of MI (531a). Consequently,
such therapy is not recommended for the management of
patients with an ACS without ST-segment elevation, a
posterior-wall MI, or a presumably new left bundle-branch
block (see ACC/AHA Guidelines for the Management of
Patients With ST-Elevation Myocardial Infarction [1]).
3.3. Initial Conservative Versus Initial Invasive
Strategies
RECOMMENDATIONS
CLASS I
1. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in UA/NSTEMI patients who
have refractory angina or hemodynamic or electrical instability
(without serious comorbidities or contraindications to such proce-
dures). (Level of Evidence: B)
2. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in initially stabilized UA/
NSTEMI patients (without serious comorbidities or contraindications
to such procedures) who have an elevated risk for clinical events
(see Table 11 and Sections 2.2.6 and 3.4.3). (Level of Evidence: A)
CLASS IIb
1. In initially stabilized patients, an initially conservative (i.e., a selectively
invasive) strategy may be considered as a treatment strategy for UA/
NSTEMI patients (without serious comorbidities or contraindications to
such procedures) who have an elevated risk for clinical events (see Table
11 and Sections 2.2.6 and 3.4.3) including those who are troponin posi-
tive. (Level of Evidence: B) The decision to implement an initial conserva-
tive (vs. initial invasive) strategy in these patients may be made by
considering physician and patient preference. (Level of Evidence: C)
2. An invasive strategy may be reasonable in patients with chronic
renal insufﬁciency. (Level of Evidence: C)
CLASS III
1. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is not recommended in patients with exten-
sive comorbidities (e.g., liver or pulmonary failure, cancer), in whom the
risks of revascularization and comorbid conditions are likely to out-
weigh the beneﬁts of revascularization. (Level of Evidence: C)
2. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is not recommended in patients with
acute chest pain and a low likelihood of ACS. (Level of Evidence: C)
3. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) should not be performed in patients who
will not consent to revascularization regardless of the ﬁndings. (Level of
Evidence: C)
3.3.1. General Principles
In addition to aggressive medical therapy, 2 treatment
pathways have emerged for treating ACS patients. The
“initial” or “early” invasive strategy, now known simply as
the “invasive” strategy, triages patients to undergo an inva-
sive diagnostic evaluation without ﬁrst getting a noninvasive
stress test or without failing medical treatment (i.e., an
initial conservative diagnostic strategy, or sometimes now
known as the “selective invasive strategy”; see below and de
Winter et al. [532]). Patients treated with an invasive
strategy generally will undergo coronary angiography within
4 to 24 h of admission; however, these patients also are
treated with the usual UA/NSTEMI medications, includ-
ing appropriate anti-ischemic, antiplatelet, and anticoagu-
lant therapy, as outlined in Sections 3.1 and 3.2. These
drugs generally are not withheld until after angiography.
Within the invasive strategy, there is a subgroup of patients
presenting to the ED who require urgent catheterization
and revascularization in the absence of ST deviation because
of ongoing ischemic symptoms or hemodynamic or rhythm
instability. These patients are often rushed off to the
catheterization laboratory within minutes to a few hours of
arrival and are not considered appropriate candidates for a
conservative strategy. Even here, appropriate medical ther-
apy is considered; however, with these patients, the admin-
istration of GP IIb/IIIa inhibitors or clopidogrel may be
delayed until the time of angiography, at a physician’s
discretion (Figs. 7, 8, and 9). On the other hand, the longer
the interval between presentation and angiography in pa-
tients, the greater the incremental beneﬁt of “upstream”
antiplatelet therapy. In summary, the invasive strategy can
be subdivided into: 1) those patients requiring urgent
angiography/revascularization very soon after arrival at the
ED, and 2) those with a UA/NSTEMI presentation who
are designated either by patient/physician discretion or after
risk assessment to beneﬁt from “early” but nonurgent
angiography/intervention.
In contrast, the “initial conservative strategy” (also referred
to as “selective invasive management”) calls for proceeding with
an invasive evaluation only for those patients who fail medical
therapy (refractory angina or angina at rest or with minimal
activity despite vigorous medical therapy) or in whom objective
evidence of ischemia (dynamic ECG changes, high-risk stress
test) is identiﬁed. Estimating the risk for an adverse outcome is
paramount for determining which strategy is best applied to an
individual ACS patient. Several risk tools have been validated
that are useful in guiding the type and intensity of therapy by
identifying patients most likely to beneﬁt from aggressive
treatment.
One such valuable tool for risk determination is based on
data from the TIMI 11B and ESSENCE trials (159) and is
discussed in Section 2.2.6 and Table 8. The TIMI risk
calculator is available at http://www.timi.org/.
Another simple risk-prediction tool has been validated by
data from GRACE (168) (Fig. 4; Section 2.2.6). The
GRACE calculator can estimate short and intermediate
mortality and is useful when making diagnostic and treat-
ment decisions for ACS patients. The GRACE clinical
application tool can be downloaded to a handheld PDA to
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be used at the bedside and is available at http://
www.outcomes-umassmed.org/grace.
The PURSUIT, TIMI, and GRACE risk scores dem-
onstrate good predictive accuracy for death and MI. They
provide valuable information that can be used to identify
patients likely to beneﬁt from early, aggressive therapy,
including intravenous GP platelet inhibitors and early cor-
onary revascularization (174).
3.3.2. Rationale for the Initial Conservative Strategy
A few multicenter trials have shown similar outcomes with
initial conservative and invasive therapeutic strategies
(129,533,534). Some trials (534,535) have emphasized the
early risk associated with revascularization procedures. The
conservative strategy seeks to avoid the routine early use of
invasive procedures unless patients experience refractory or
recurrent ischemic symptoms or develop hemodynamic
instability. When the conservative strategy is chosen, a plan
for noninvasive evaluation is required to detect severe
ischemia that occurs spontaneously or at a low threshold of
stress and to promptly refer these patients for coronary
angiography and revascularization when possible. In addi-
tion, as in STEMI (536), an early echocardiogram should be
considered to identify patients with signiﬁcant LV dysfunc-
tion (e.g., LVEF less than 0.40). Such a ﬁnding prompts
consideration for angiography to identify left main or
multivessel CAD, because patients with multivessel disease
and LV dysfunction are at high risk and could accrue a
survival beneﬁt from CABG (537,538). In addition, a stress
test (e.g., exercise or pharmacological stress) for the assess-
ment of ischemia is recommended before discharge or
shortly thereafter to identify patients who may also beneﬁt
from revascularization. The use of aggressive anticoagulant
and antiplatelet agents has reduced the incidence of adverse
outcomes in patients managed conservatively (see Section
3.3) (128,134,169,180,372,374,523,539). An advantage of-
fered by the conservative strategy is that many patients
stabilize on medical therapy and will not require coronary
angiography. Consequently, the conservative strategy limits
the use of in-hospital cardiac catheterization and may avoid
costly and possibly unnecessary invasive procedures.
3.3.3. Rationale for the Invasive Strategy
For patients with UA/NSTEMI without recurrent ischemia
in the ﬁrst 24 h, the use of angiography provides an invasive
approach to risk stratiﬁcation. It can identify the 10% to
20% of patients with no signiﬁcant coronary stenoses and
the approximately 20% with 3-vessel disease with LV
dysfunction or left main CAD. This latter group can derive
a survival beneﬁt from CABG (see Section 4). In addition,
PCI of the culprit lesion has the potential to reduce the risk
for subsequent hospitalization and the need for multiple
antianginal drugs compared with the early conservative
strategy (TIMI IIIB) (129). Just as the use of improved
anticoagulant therapy and/or a platelet GP IIb/IIIa receptor
blocker has improved the outcome in patients managed
according to the conservative strategy, the availability of
these agents also makes the invasive approach more attrac-
tive, particularly because the early hazard of PCI is lessened.
The availability of GP IIb/IIIa receptor blockers also has led
to 2 alternatives for the routine invasive approach: imme-
diate angiography or deferred angiography.
3.3.4. Immediate Angiography
Excluding those in need of urgent intervention, 2 alterna-
tives for the invasive approach have emerged: early (“imme-
diate”) or deferred angiography (i.e., with respect to a 12- to
48-h window). Some believe that proceeding immediately
to angiography is an efﬁcient approach for the ACS patient.
Patients found not to have CAD may be discharged rapidly
or shifted to a different management strategy. Patients with
obvious culprit lesions amenable to PCI can have a proce-
dure performed immediately, hastening discharge. Patients
with left main CAD and those with multivessel disease and
LV dysfunction can be sent expeditiously to undergo bypass
surgery, thereby avoiding a risky waiting period. Support for
immediate angiography comes from the Intracoronary
Stenting with Antithrombotic Regimen Cooling-off Study
(ISAR-COOL) (540). All ACS patients were treated with
intensive medical therapy (including oral and intravenous
antiplatelet therapy). They were randomized to immediate
angiography (median time 2.4 h) or a prolonged “cooling
off” period for a median of 86 h before undergoing cathe-
terization. Patients randomized to immediate angiography
had signiﬁcantly fewer deaths or MIs at 30 d. Importantly,
this difference in outcome was attributed to events that
occurred before catheterization in the “cooling off” group,
which supports the rationale for intensive medical therapy
and very early angiography. Data supporting this approach
are limited, but additional clinical trial results are expected
in the future.
3.3.5. Deferred Angiography
In most reports that involve use of the invasive strategy,
angiography has been deferred for 12 to 48 h while antithrom-
botic and anti-ischemic therapies are intensiﬁed. Several ob-
servational studies, as summarized in Smith et al (541) have
found a lower rate of complications in patients undergoing PCI
more than 48 h after admission, during which heparin and
ASA were administered, than with early intervention; how-
ever, the value of medical stabilization before angiography has
never been assessed formally or proven.
3.3.6. Comparison of Early Invasive and Initial
Conservative Strategies
Prior meta-analyses have concluded that routine invasive
therapy is better than an initial conservative or selectively
invasive approach (542–544). Mehta et al. (543) concluded
that the routine invasive strategy resulted in an 18% relative
reduction in death or MI, including a signiﬁcant reduction
in MI alone. The routine invasive arm was associated with
higher in-hospital mortality (1.8% vs. 1.1%), but this
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disadvantage was more than compensated for by a signiﬁ-
cant reduction in mortality between discharge and the end
of follow-up (3.8% vs. 4.9%). The invasive strategy also was
associated with less angina and fewer rehospitalizations than
with the conservative pathway. Patients undergoing routine
invasive treatment also had improved quality of life.
In contrast to these ﬁnding, other studies, most recently
ICTUS (Invasive versus Conservative Treatment in Unsta-
ble coronary Syndromes) (532), have favorably highlighted a
strategy of selective invasive therapy (532). In ICTUS,
1,200 high-risk ACS patients were randomized to routine
invasive versus selective invasive management and followed
up for 1 year with respect to the combined incidence of
death, MI, and ischemic rehospitalization. All patients were
treated with optimal medical therapy that included ASA,
clopidogrel, LMWH, and lipid-lowering therapy; abcix-
imab was given to those undergoing revascularization. At
the end of 1 year, there was no signiﬁcant difference in the
composite end point between groups. This study suggests
that a selective invasive strategy could be reasonable in ACS
patients. A possible explanation for the lack of beneﬁt of the
invasive approach in this trial (and other trials) (545) could
be related to the relatively high rate of revascularization
actually performed in patients treated in the selective inva-
sive arm (47%), thereby reducing observed differences be-
tween treatment strategies (174), and to the lower event rate
(lower-risk population) than in other studies. Results were
unchanged during longer term follow-up (545a,545b). Nev-
ertheless, ICTUS required troponin positivity for entry. Thus
troponin alone might no longer be an adequate criterion for
strategy selection, especially with increasingly sensitive tropo-
nin assays. The degree of troponin elevation and other high-
risk clinical factors taken together should be considered in
selecting a treatment strategy.
Other criticisms of ICTUS have included that it was
relatively underpowered for hard end points and that it used a
controversial deﬁnition for post-procedural MI (i.e., even
minimal, asymptomatic CK-MB elevation) (532,545a,545b).
Additionally, 1-year follow-up may be inadequate to fully
realize the long-term impact and beneﬁt of the routine
invasive strategy. In the RITA-3 trial (Third Randomized
Intervention Treatment of Angina), 5-year but not 1-year
event rates favored the early invasive arm (see Fig. 17 and
text below) (546). In ICTUS, however, results were main-
tained during a 3-year follow-up (546a).
Thus, these guidelines recommend that in initially stabi-
lized UA/NSTEMI patients, an initial conservative (selec-
tive invasive) strategy may be considered as a treatment
option. The Writing Committee also believes that addi-
tional comparative trials of the selective invasive with the
routine initial invasive strategies are indicated using aggres-
sive contemporary medical therapies in both arms, including
routine dual antiplatelet therapy in medically treated pa-
tients (as recommended in Section 5.2.1) as well as aggres-
sive lipid lowering and other updated secondary prevention
measures (as summarized in Section 5.2). Further study
could provide a stronger evidence base for an initial conser-
vative/selective invasive strategy in initially stabilized pa-
tients, as it has for stable angina patients (546a).
Nevertheless, a meta-analysis of contemporary random-
ized trials in NSTEMI, including ICTUS, currently sup-
ports a long-term mortality and morbidity beneﬁt of an
early invasive as compared with an initial conservative
strategy (547). Nonfatal MI at 2 years (7.6% vs. 9.1%,
respectively; RR 0.83, 95% CI 0.72 to 0.96, p  0.012) and
hospitalization (at 13 months; RR  0.69, 95% CI 0.65 to
0.74, p less than 0.0001) also were reduced by an early
invasive strategy (Fig. 18). A separate review of contempo-
rary randomized trials in the stent era using the Cochrane
database arrived at similar conclusions (548). Details of
selected contemporary trials of invasive versus conservative
strategies follow.
In the FRISC-II study, 3,048 ACS patients were treated
with dalteparin for 5 to 7 d (245). Of these patients, 2,457
who qualiﬁed were then randomized (2 2 factorial design)
Figure 17. Cumulative Risk of Death or Myocardial Infarction or
Death in RITA-3
Cumulative risk of death or myocardial infarction (top) or of death (bottom) in the
RITA 3 trial of patients with non-ST acute coronary syndromes. Reprinted from The
Lancet, 366, Fox KAA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an
interventional strategy in non-ST-elevation acute coronary syndrome: the British
Heart Foundation RITA 3 randomised trial, 914–20. Copyright 2005, with permis-
sion from Elsevier (546). RITA-3  Third Randomized Intervention Treatment of
Angina trial.
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Figure 18. Relative Risk of Outcomes With Early Invasive Versus Conservative Therapy in UA/NSTEMI
A: Relative risk of all-cause mortality for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. B: Relative risk of recurrent nonfatal myocardial
infarction for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. C: Relative risk of recurrent unstable angina resulting in rehospitalization for
early invasive therapy compared with conservative therapy at a mean follow-up of 13 months. Modiﬁed from the Journal of the American College of Cardiology, 48, Bavry AA, Kumb-
hani DJ, Rassi AN, Bhatt DL, Askari AT. Beneﬁt of early invasive therapy in acute coronary syndromes a meta-analysis of contemporary randomized clinical trials, 1319–25. Copyright
2006, with permission from Elsevier (547). CI  conﬁdence interval; FRISC-II  FRagmin and fast Revascularization during InStability in Coronary artery disease; ICTUS  Invasive
versus Conservative Treatment in Unstable coronary Syndromes; ISAR-COOL  Intracoronary Stenting with Antithrombotic Regimen COOLing-off study; RITA-3  Third Randomized
Intervention Treatment of Angina trial; RR  relative risk; TIMI-18  Thrombolysis In Myocardial Infarction-18; TRUCS  Treatment of Refractory Unstable angina in geographically
isolated areas without Cardiac Surgery; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction; VINO  Value of ﬁrst day angiography/angioplasty In evolving Non-ST
segment elevation myocardial infarction: Open multicenter randomized trial.
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to continue to receive dalteparin or placebo (double blind)
and to receive either a noninvasive or an invasive treatment
strategy, with coronary angiography and revascularization, if
appropriate, performed within 7 d of admission. At 6
months, there were no differences between continued dalte-
parin compared with placebo. However, death or MI
occurred in 9.4% of patients assigned to the invasive strategy
versus 12.1% of those assigned to the noninvasive strategy (p
less than 0.03). At 1 year, the mortality rate in the invasive
strategy group was 2.2% compared with 3.9% in the
noninvasive strategy group (p  0.016) (549). It may be
concluded from FRISC-II that patients with UA/NSTEMI
who are not at very high risk for revascularization and who
ﬁrst receive an average of 6 d of treatment with LMWH,
ASA, nitrates, and beta blockers have a better outcome at 6
months with a (delayed) routine invasive approach than
with a routine conservative approach, with very low revas-
cularization rates. Long-term outcomes of the FRISC-II
trial have been published recently (550). At 5 years, the
invasive strategy was favored for the primary end point of
death or nonfatal MI (HR 0.81, p  0.009). Beneﬁt was
conﬁned to men, nonsmokers, and patients with 2 or more
risk factors.
In the TACTICS-TIMI 18 trial (182), 2,220 patients
with UA or NSTEMI were treated with ASA, heparin, and
the GP IIb/IIIa inhibitor tiroﬁban. They were randomized
to an early invasive strategy with routine coronary angiog-
raphy within 48 h followed by revascularization if the
coronary anatomy was deemed suitable or to a more
conservative strategy. In the latter group, catheterization
was performed only if the patient had recurrent ischemia or
a positive stress test. Death, MI, or rehospitalization for
ACS at 6 months occurred in 15.9% of patients assigned to
the invasive strategy versus 19.4% assigned to the more
conservative strategy (p  0.025). Death or MI (182) was
also reduced at 6 months (7.3% vs. 9.5%, p less than 0.05).
The beneﬁcial effects on outcome were observed in
medium- and high-risk patients, as deﬁned by an elevation
of TnT greater than 0.01 ng per ml, the presence of
ST-segment deviation, or a TIMI risk score greater than 3
(159). In the absence of these high-risk features, outcomes
in patients assigned to the 2 strategies were similar, which
emphasizes the critical importance of appropriate risk strat-
iﬁcation. Rates of major bleeding were similar, and lengths
of hospital stay were reduced in patients assigned to the
invasive strategy. The beneﬁts of the invasive strategy were
achieved at no signiﬁcant increase in the costs of care over
the 6-month follow-up period.
Thus, both the FRISC-II (245) and TACTICS-TIMI
18 (182) trials showed a beneﬁt in patients assigned to the
invasive strategy. In contrast to earlier trials, a large majority
of patients undergoing PCI in these 2 trials received
coronary stenting as opposed to balloon angioplasty alone.
Also, there was a differential rate of thienopyridine use
between the 2 arms; only stented patients were treated. In
FRISC-II, the invasive strategy involved treatment for an
average of 6 d in the hospital with LMWH, ASA, nitrates,
and beta blockers before coronary angiography, an approach
that would be difﬁcult to adopt in US hospitals. In
TACTICS-TIMI 18, treatment included the GP IIb/IIIa
antagonist tiroﬁban, which was administered for an average
of 22 h before coronary angiography. The routine use of the
GP IIb/IIIa inhibitor in this trial may have eliminated the
excess risk of early (within 7 d) MI in the invasive arm, an
excess risk that was observed in FRISC-II and other trials in
which there was no routine “upstream” use of a GP IIb/IIIa
blocker. Therefore, an invasive strategy is associated with a
better outcome in UA/NSTEMI patients at high risk as
deﬁned in Table 11 and as demonstrated in TACTICS-
TIMI 18 when a GP IIb/IIIa inhibitor is used (182).
Although the beneﬁt of intravenous GP IIb/IIIa inhibitors
is established for UA/NSTEMI patients undergoing PCI,
the optimal time to commence these drugs before the
procedure has not been established. In the PURSUIT trial
(128), in patients with UA/NSTEMI who were admitted to
community hospitals, the administration of eptiﬁbatide was
associated with a reduced need for transfer to tertiary
referral centers and improved outcomes (551).
The RITA-3 trial (546) compared early and conservative
therapy in 1,810 moderate-risk patients with ACS. Patients
with positive cardiac biomarkers (CK-MB greater than 2 times
the upper limit of normal at randomization) were excluded
from randomization, as were those with new Q waves, MI
within 1 month, PCI within 1 year, and any prior CABG. The
combined end point of death, nonfatal MI, and refractory
angina was reduced from 14.5% to 9.6% by early invasive
treatment. The beneﬁt was driven primarily by a reduction in
refractory angina. There was a late divergence of the curves,
with reduced 5-year death and MI in the early invasive arm
(Fig. 17).
In the VINO trial (Value of ﬁrst day angiography/
angioplasty In evolving Non-ST segment elevation myocar-
dial infarction: Open multicenter randomized trial) (522),
131 patients with NSTEMI were randomized to cardiac
catheterization on the day of admission versus conservative
therapy. Despite the fact that 40% of the conservatively
treated patients crossed over to revascularization by the time
of the 6-month follow-up, there was a signiﬁcant reduction
in death or reinfarction for patients assigned to early
angiography and revascularization (6% vs. 22%).
The ISAR-COOL trial (540) randomized 410 intermediate-
to high-risk patients to very early angiography and revascular-
ization versus a delayed invasive strategy. All patients were
treated with intensive medical therapy that included ASA,
heparin, clopidogrel (600-mg loading dose), and the intrave-
nous GP IIb/IIIa receptor inhibitor tiroﬁban. In the very early
arm, patients underwent cardiac catheterization at a mean time
of 2.4 h versus 86 h in the delayed invasive arm. The very early
invasive strategy was associated with signiﬁcantly better out-
come at 30 d, measured by reduction in death and large MI
(5.9% vs. 11.6%). More importantly, the beneﬁt seen was
attributable to a reduction in events before cardiac catheteriza-
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tion, which raises the possibility that there is a hazard associ-
ated with a ”cooling-down” period.
3.3.7. Subgroups
TACTICS-TIMI 18 demonstrated a reduction in the
6-month end point of death or MI in older adult ACS
patients. With respect to gender, controversy exists over
revascularization treatment differences between men and
women with ACS. The FRISC-II trial showed a beneﬁt of
early revascularization in men for death or MI that was not
observed for women (552). In contrast, death, MI, or
rehospitalization rates were reduced for both men and
women in TACTICS-TIMI 18 (182). Furthermore, an
observational study reported that women actually did better
than men with early interventional therapy for UA/
NSTEMI (553). Finally, RITA-3 (546) showed that the
routine strategy of invasive evaluation resulted in a beneﬁcial
effect in men that was not seen in women. Additional
research is required to further clarify these diverse observa-
tions (554).
3.3.8. Care Objectives
The objective is to provide a strategy that has the most
potential to yield the best clinical outcome and improve
long-term prognosis. The purpose of coronary angiography
is to provide detailed information about the size and
distribution of coronary vessels, the location and extent of
atherosclerotic obstruction, and the suitability for revascu-
larization. The LV angiogram, which is usually performed
along with coronary angiography, provides an assessment of
the extent of focal and global LV dysfunction and of the
presence and severity of coexisting disorders (e.g., valvular
or congenital lesions). A detailed discussion of revascular-
ization is presented in Section 4 of these guidelines, as well
as in the ACC/AHA Guidelines for Percutaneous Coro-
nary Intervention (2) and the ACC/AHA Guideline Up-
date for Coronary Artery Bypass Graft Surgery (555).
Although general guidelines can be offered, the selection of
appropriate procedures and the decision to refer patients for
revascularization require both clinical judgment and coun-
seling with the patient and the patient’s family regarding
expected risks and beneﬁts.
Although not conducted in patients with UA/NSTEMI,
the following studies have addressed the value of stress
testing in guiding therapy. The DANish trial in Acute
Myocardial Infarction (DANAMI) studied 503 patients
with inducible ischemia (i.e., a positive exercise stress test)
after ﬁbrinolytic therapy for ﬁrst MI and compared an
ischemia-guided invasive strategy with a conservative strat-
egy (556). The invasive strategy in the post-MI patients
with inducible ischemia resulted in a reduction in the
incidence of reinfarction, hospitalizations for UA, and stable
angina. Similarly, in the Asymptomatic Cardiac Ischemia
Pilot (ACIP) study (557,558), 558 clinically stable patients
with ischemia on stress testing and during daily life (ST-
segment depression on exercise treadmill testing or perfu-
sion abnormality on radionuclide pharmacological stress test
if unable to exercise, in addition to ST-segment depression
on ambulatory ECG monitoring), most of whom had
angina in the previous 6 weeks, were randomized to 1 of 3
initial treatment strategies: symptom-guided medical care,
ischemia-guided medical care, or revascularization. More
than one third of these patients had “complex” stenoses on
angiography. Those randomized to early revascularization
experienced less ambulatory ischemia at 12 weeks than did
those randomized to initial medical care in whom revascu-
larization was delayed and symptom driven.
After either STEMI or NSTEMI, the SWISSI II (Swiss
Interventional Study of Silent Ischemia Type II) study,
which randomized 201 patients with silent ischemia, dem-
onstrated by stress imaging, to either revascularization with
PCI or anti-ischemic drug therapy and followed them for an
average of 10 years. Survival free of cardiac death, nonfatal
MI, or symptom-driven revascularization was signiﬁcantly
reduced in the PCI group. Though relatively small, the
study supports the use of stress testing after UA/NSTEMI
for guiding the selection of invasive evaluation in UA/
NSTEMI patients treated with an initial conservative strat-
egy (558a).
In ACS patients with UA/NSTEMI, the purpose of
noninvasive testing is both to identify ischemia and to
identify candidates at high risk for adverse outcomes and to
direct them to coronary angiography and revascularization
when possible. However, neither randomized trials
(129,245,533,534) nor observational data (559) uniformly
support an inherent superiority for the routine use of
coronary angiography and revascularization (see Section 4).
Accordingly, the decision regarding which strategy to pur-
sue for a given patient should be based on the patient’s
estimated outcome risk assisted by clinical and noninvasive
test results, available facilities, previous outcome of revas-
cularization by the team available in the institution in which
the patient is hospitalized, and patient preference.
Coronary angiography can enhance prognostic stratiﬁca-
tion. This information can be used to guide medical therapy
and to plan revascularization therapy, but it is important to
emphasize that an adverse outcome in ACS is very time
dependent and that after 1 to 2 months, the risk for adverse
outcome is essentially the same as that for low-risk chronic
stable angina (Fig. 17). Several older studies in patients with
stable angina, including the Second Randomized Interven-
tion Treatment of Angina (RITA-2) trial (535), have found
a higher early risk of death or MI with an interventional
strategy than with medical management alone. Thus, the
timing of coronary angiography and revascularization is
critically important if patients at high risk are to beneﬁt.
Unfortunately, the total number of operative complications
is increased when revascularization procedures are per-
formed routinely, because some patients who are not in need
of revascularization will be exposed to its hazards. However,
contemporary use of aggressive medical therapy in UA/
NSTEMI, including oral and intravenous antiplatelet
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agents and anticoagulant agents, has lessened the early
hazard and risk for ischemic complications in patients
undergoing early invasive procedures.
Patients with UA/NSTEMI often can be divided into
different risk groups on the basis of their initial clinical
presentation. The TIMI, PURSUIT, and GRACE scores
are useful clinical tools for assigning risk to patients pre-
senting with UA/NSTEMI (Table 8; Fig. 4; see Section
2.2.6.).
Risk stratiﬁcation in turn identiﬁes patients who are most
likely to beneﬁt from subsequent revascularization. For
example, patients with left main disease or multivessel CAD
with reduced LV function are at high risk for adverse
outcomes and are likely to beneﬁt from surgical bypass.
Clinical evaluation and noninvasive testing will aid in the
identiﬁcation of most patients in the high-risk subset,
because they often have 1 or more of the following high-risk
features: advanced age (greater than 70 years), prior MI,
revascularization, ST-segment deviation, HF or depressed
resting LV function (i.e., LVEF less than or equal to 0.40)
on noninvasive study, or noninvasive stress test ﬁndings.
The presence of any of these risk factors or of diabetes
mellitus aids in the identiﬁcation of high-risk patients who
could beneﬁt from an invasive strategy.
The majority of patients presenting with UA/NSTEMI,
however, do not fall into the very high-risk group and do
not have ﬁndings that typically portend a high risk for
adverse outcomes. Accordingly, they are not likely to receive
the same degree of beneﬁt from routine revascularization
afforded to high-risk patients, and an invasive study is
optional for those at lower risk and can be safely deferred
pending further clinical developments. Decisions regarding
coronary angiography in patients who are not high risk
according to ﬁndings on clinical examination and noninva-
sive testing can be individualized on the basis of patient
preferences and the degree to which they are affected by
clinical symptoms.
The data on which recommendations for invasive or
conservative strategy recommendations are based come from
several randomized trials. Older trials included TIMI IIIB
(129,561), Veterans Affairs Non-Q-Wave Infarction Strat-
egies in Hospital (VANQWISH) (534), and Medicine
versus Angiography in Thrombolytic Exclusion (MATE)
(533). More recent trials, relevant to contemporary practice,
include FRISC-II (245), TACTICS-TIMI 18 (182),
VINO (522), RITA-3 (546), ISAR-COOL (540), and
ICTUS (532); a large, prospective, multinational registry,
the OASIS registry (559); and several meta-analyses (542–
544). See Section 3.3.1.5 for a detailed description of these
trials and the more recent meta-analyses (543,547).
Some selected areas require additional comment. In a
patient with UA, a history of prior PCI within the past 6
months suggests the presence of restenosis, which often can
be treated effectively with repeat PCI. Coronary angiogra-
phy without preceding functional testing is generally indi-
cated. Patients with prior CABG represent another sub-
group for whom a strategy of early coronary angiography is
usually indicated. The complex interplay between the pro-
gression of native coronary disease and the development of
graft atherosclerosis with ulceration and embolization is
difﬁcult to untangle noninvasively; these considerations
argue for early coronary angiography. In addition, patients
with known or suspected reduced LV systolic function,
including patients with prior anterior Q-wave MIs, those
with known depressed LV function, and those who present
with HF, have sufﬁcient risk that the possibility of beneﬁt
from revascularization procedures merits early coronary
angiography without preceding functional testing.
In patients with UA/NSTEMI, coronary angiography
typically shows the following proﬁle: 1) no severe epicardial
stenosis in 10% to 20% with a sex differential, 2) 1-vessel
stenosis in 30% to 35%, 3) multivessel stenosis in 40% to
50%, and 4) signiﬁcant (greater than 50%) left main stenosis
in 4% to 10%. In the early invasive strategy in TIMI IIIB,
no critical obstruction (less than 60% diameter stenosis) was
found in 19% of patients, 1-vessel stenosis in 38%, 2-vessel
stenosis in 29%, 3-vessel stenosis in 15%, and left main
stenosis (greater than 50%) in 4% (564). Complex plaques
are usually believed to be responsible for the culprit lesions.
These usually are eccentric and sometimes have irregular
borders and correlate with intracoronary thrombi and an
increased risk of recurrent ischemia at rest, MI, and cardiac
death (563). Similar ﬁndings were noted in more than 80%
of the patients in the VANQWISH trial, and more than 1
complex lesion was found in most patients (534). Interest-
ingly, in TIMI IIIB, many of the patients without severe
stenosis had reduced contrast clearance, which suggests
microvascular dysfunction (564), which can contribute to
impaired myocardial perfusion.
Appropriate treatment for women presenting with ACS
might be different from that in men (see also Section 6.1).
In FRISC-II and RITA-3, an improved outcome in the
early invasive arm was seen only in men, whereas the beneﬁt
of early revascularization was equivalent in men and women
in the TACTICS-TIMI 18 (182) trial provided that the
troponin level was elevated. In contrast, low-risk women
tended to have worse outcomes, including a higher risk of
major bleeding, with early revascularization therapy,
whereas low-risk men were neither harmed nor beneﬁted by
this strategy (565). Most studies showed that women were
more likely than men to have either normal vessels or
noncritical stenoses. High-risk women also were more likely
to have elevation of CRP and BNP and less often had
elevated troponin (182,565). Women with any positive
biomarker beneﬁted from invasive therapy, whereas those
without elevated CRP, BNP, or troponin did better with a
conservative approach (see Section 6.1).
Patients with severe 3-vessel stenosis and reduced LV
function and those with left main stenosis should be
considered for early CABG (see Section 4). In low-risk
patients, quality of life and patient preferences should be
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given considerable weight in the selection of a treatment
strategy. Low-risk patients whose symptoms do not respond
well to maximal medical therapy and who experience poor
quality of life and functional status and are prepared to
accept the risks of revascularization should be considered for
revascularization.
The discovery that a patient does not have signiﬁcant
obstructive CAD should prompt consideration of whether
the symptoms represent another cause of cardiac ischemia
(e.g., syndrome X, coronary spasm, coronary embolism, or
coronary artery dissection; see Section 6) or pericarditis/
myocarditis or are noncardiac in origin. There is a distinc-
tion between normal coronaries and vessels with less than
50% stenoses but with atherosclerotic plaque present, which
might be demonstrated to be extensive on coronary intra-
vascular ultrasound. The latter can include visualization of a
culprit ulcerated plaque. Noncardiac syndromes should
prompt a search for the true cause of symptoms. Unfortu-
nately, many such patients continue to have recurrent
symptoms, are readmitted to the hospital, can become
disabled, and continue to consume health care resources
even with repeated coronary angiography (566,567).
It is not presently possible to deﬁne the extent of
comorbidity that would, in every case, make referral for
coronary angiography and revascularization inappropriate.
The high-risk patient with signiﬁcant comorbidities re-
quires thoughtful discussion among the physician, patient,
and family and/or patient advocate. A decision for or against
revascularization must be made on a case-by-case basis.
Examples of extensive comorbidity that usually preclude
revascularization include 1) advanced or metastatic malig-
nancy with a projected life expectancy of 1 year or less, 2)
intracranial pathology that contraindicates the use of sys-
temic anticoagulation or causes severe cognitive disturbance
(e.g., Alzheimer’s disease) or advanced physical limitations,
3) end-stage cirrhosis with symptomatic portal hypertension
(e.g., encephalopathy, visceral bleeding), and 4) CAD that
is known from previous angiography not to be amenable to
revascularization. This list is not meant to be all-inclusive.
More difﬁcult decisions involve patients with signiﬁcant
comorbidities that are not as serious as those listed here;
examples include patients who have moderate or severe
renal failure but are stable with dialysis.
Consultation with an interventional cardiologist and a
cardiac surgeon before coronary angiography is advised to
deﬁne technical options and likely risks and beneﬁts. The
operators who perform coronary angiography and revascu-
larization and the facility in which these procedures are
performed are important considerations, because the avail-
ability of interventional cardiologists and cardiac surgeons
who are experienced in high-risk and complex patients is
essential. As a general principle, the potential beneﬁts of
coronary angiography and revascularization must be care-
fully weighed against the risks and the conﬂicting results of
the clinical trials and registries. The Writing Committee
endorses further research into techniques that could reduce
bleeding (e.g., radial access and smaller sheath sizes) (568)
and the proper selection and dosing of drugs to minimize
bleeding in patients with UA/NSTEMI.
3.4. Risk Stratiﬁcation Before Discharge
RECOMMENDATIONS
CLASS I
1. Noninvasive stress testing is recommended in low-risk patients
(Table 7) who have been free of ischemia at rest or with low-level
activity and of HF for a minimum of 12 to 24 h. (Level of Evidence: C)
2. Noninvasive stress testing is recommended in patients at interme-
diate risk (Table 7) who have been free of ischemia at rest or with
low-level activity and of HF for a minimum of 12 to 24 h. (Level of
Evidence: C)
3. Choice of stress test is based on the resting ECG, ability to perform
exercise, local expertise, and technologies available. Treadmill ex-
ercise is useful in patients able to exercise in whom the ECG is free
of baseline ST-segment abnormalities, bundle-branch block, LV
hypertrophy, intraventricular conduction defect, paced rhythm, pre-
excitation, and digoxin effect. (Level of Evidence: C)
4. An imaging modality should be added in patients with resting
ST-segment depression (greater than or equal to 0.10 mV), LV
hypertrophy, bundle-branch block, intraventricular conduction de-
fect, preexcitation, or digoxin who are able to exercise. In patients
undergoing a low-level exercise test, an imaging modality can add
sensitivity. (Level of Evidence: B)
5. Pharmacological stress testing with imaging is recommended when
physical limitations (e.g., arthritis, amputation, severe peripheral vas-
cular disease, severe chronic obstructive pulmonary disease, or gen-
eral debility) preclude adequate exercise stress. (Level of Evidence: B)
6. Prompt angiography without noninvasive risk stratiﬁcation should
be performed for failure of stabilization with intensive medical
treatment. (Level of Evidence: B)
7. A noninvasive test (echocardiogram or radionuclide angiogram) is
recommended to evaluate LV function in patients with deﬁnite ACS
who are not scheduled for coronary angiography and left ventricu-
lography. (Level of Evidence: B)
The management of ACS patients requires continuous
risk stratiﬁcation. Important prognostic information is de-
rived from careful initial assessment, the patient’s course
during the ﬁrst few days of management, and the patient’s
response to anti-ischemic and antithrombotic therapy. The
Braunwald classiﬁcation (14,260) has been validated pro-
spectively and represents an appropriate clinical instrument
to help predict outcome (569). Angina at rest, within 48 h
in the absence of an extracardiac condition (primary UA;
Braunwald Class III), and UA in the early postinfarction
period (Braunwald class C), along with age, male sex,
hypertension, and maximal intravenous antianginal/anti-
ischemic therapy, were independent predictors for death or
nonfatal MI. The baseline ECG on presentation was also
found to be extremely useful for risk stratiﬁcation in the
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TIMI III registry (199), as discussed in Section 2.2.6.2, and
in the RISC (Research on InStability in Coronary artery
disease) study group (570). In a more recent database of
12,142 patients presenting within 12 h of the onset of
ischemic symptoms, the ECG at presentation allowed
individualized risk stratiﬁcation across the spectrum of ACS
(127) (Fig. 19). In many cases, noninvasive stress testing
provides a very useful supplement to such clinically based
risk assessment. In addition, as pointed out previously,
troponins are very helpful in risk assessment. Some patients,
however, are at such high risk for an adverse outcome that
noninvasive risk stratiﬁcation would not be likely to identify
a subgroup with sufﬁciently low risk to avoid coronary
angiography to determine whether revascularization is pos-
sible. These patients include those who, despite intensive
medical therapy, manifest recurrent rest angina, hemody-
namic compromise, or severe LV dysfunction. Such patients
should be considered directly for early coronary angiography
without noninvasive stress testing; however, referral for
coronary angiography is not reasonable if they are unwilling
to consider revascularization or have severe complicating
illnesses that preclude revascularization. Other patients may
have such a low likelihood of CAD after initial clinical
evaluation that even an abnormal test ﬁnding is unlikely to
prompt additional therapy that would further reduce risk
(e.g., a 35-year-old woman without CAD risk factors). Such
patients would ordinarily not be considered for coronary
angiography and revascularization unless the diagnosis of
UA/NSTEMI is unclear. The majority of patients present-
ing with UA/NSTEMI do not fall into these categories and
are accordingly reasonable candidates for risk stratiﬁcation
with noninvasive testing.
Determination of patient risk on the basis of a validated
scoring algorithm (e.g., from the TIMI, GRACE, or
PURSUIT trial data) can be valuable for identifying high-
risk patients (see Section 2.2.6 and Table 8). They also can
assist in selecting those who can beneﬁt most from more
aggressive therapies, such as LMWH or an invasive treat-
ment strategy (see Section 3.4.1).
3.4.1. Care Objectives
The goals of noninvasive testing are to 1) determine the
presence or absence of ischemia in patients with a low or
intermediate likelihood of CAD and 2) estimate prognosis.
This information is key for the development of further
diagnostic steps and therapeutic measures.
A detailed discussion of noninvasive stress testing in
CAD is presented in the ACC/AHA Guidelines for Exer-
cise Testing, ACC/AHA Guidelines for the Clinical Use of
Cardiac Radionuclide Imaging, and ACC/AHA Guidelines
for the Clinical Application of Echocardiography (4,571–
573) (Tables 19, 20, and 21). Brieﬂy, the provocation of
ischemia at a low workload (574) or a high-risk treadmill
score (i.e., greater than or equal to 11) (575) implies severe
limitation in the ability to increase coronary blood ﬂow.
This is usually the result of severe coronary artery obstruction
and is associated with a high risk for an adverse outcome
and/or severe angina after discharge. Unless there are contra-
indications to revascularization, such patients generally merit
referral for early coronary angiography to direct a revascular-
ization procedure, if appropriate. On the other hand, the
attainment of a higher workload (e.g., greater than 6.5 meta-
bolic equivalents [METS]) without evidence of ischemia
(low-risk treadmill score greater than or equal to 5) (575) is
Figure 19. Kaplan-Meier Estimates of Probability of Death Based
on Admission Electrocardiogram
Modiﬁed with permission from Savonitto S, Ardissino D, Granger CB, et al. Prognos-
tic value of the admission electrocardiogram in acute coronary syndromes. JAMA
1999;281:707–13 (127). Copyright © 1999 American Medical Association.
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associated with functionally less severe coronary artery obstruc-
tion. Such patients have a better prognosis and can often be
safely managed conservatively. Ischemia that develops at
greater than 6.5 METS can be associated with severe coronary
artery obstruction, but unless other high-risk markers are
present (greater than 0.2-mV ST-segment depression or ele-
vation, fall in blood pressure, ST-segment shifts in multiple
leads reﬂecting multiple coronary regions, or prolonged ST-
segment shifts [greater than 6 min] in recovery), these patients
also may be safely managed conservatively (Table 20).
Stress radionuclide ventriculography or stress echocardi-
ography (Table 20) provides an important alternative to
exercise electrocardiography testing. Myocardial perfusion
imaging with pharmacological stress (Table 21) is particu-
larly useful in patients who are unable to exercise. The
prognostic value of pharmacological stress testing appears
similar to that of exercise testing with imaging, although
there are few direct comparisons.
As noted earlier (Section 2.3.2.), CMR is a newer
imaging modality that can effectively assess cardiac function,
perfusion (e.g., with adenosine stress), and viability at the
same study. The combination of these features has been
reported to yield excellent predictive information in sus-
pected CAD/ACS patients (296).
3.4.2. Noninvasive Test Selection
There are no conclusive data that either LV function or
myocardial perfusion at rest and during exercise or pharmaco-
logical stress is superior in the assessment of prognosis. Both
the extent of CAD and the degree of LV dysfunction are
important in the selection of the appropriate therapy. Studies
that directly compare prognostic information from multiple
noninvasive tests for ischemia in patients after the stabilization
of UA/NSTEMI are hampered by small sample size. Dobut-
amine stress echocardiography measures both resting LV
function and the functional consequences of a coronary steno-
sis (571). An ischemic response is characterized by initially
improved LV function at low-stress doses, followed by dete-
rioration with increasing dobutamine doses (571). However,
UA and MI are listed as contraindications for dobutamine
stress echocardiography (578).
The RISC study evaluated predischarge symptom-limited
bicycle exercise testing in 740 men with UA/NSTEMI (579).
Multivariate analysis showed that the extent of ST-segment
depression, expressed as the number of leads with ischemic
changes at a low maximal workload, was negatively correlated
independently with infarct-free survival rates at 1 year. This
and other smaller studies permit a comparison of the effective-
ness of exercise ECG with exercise or dipyridamole thallium-
201 study for risk stratiﬁcation. All of these noninvasive tests
Table 19. Noninvasive Risk Stratiﬁcation
High risk (greater than 3% annual mortality rate)
Severe resting LV dysfunction (LVEF less than 0.35)
High-risk treadmill score (score 11 or less)
Severe exercise LV dysfunction (exercise LVEF less than 0.35)
Stress-induced large perfusion defect (particularly if anterior)
Stress-induced multiple perfusion defects of moderate size
Large, ﬁxed perfusion defect with LV dilation or increased lung uptake
(thallium-201)
Stress-induced moderate perfusion defect with LV dilation or increased lung
uptake (thallium-201)
Echocardiographic wall-motion abnormality (involving more than 2
segments) developing at low dose of dobutamine (10 mcg per kg per min
or less) or at a low heart rate (less than 120 beats per min)
Stress echocardiographic evidence of extensive ischemia
Intermediate risk (1% to 3% annual mortality rate)
Mild/moderate resting LV dysfunction (LVEF  0.35 to 0.49)
Intermediate-risk treadmill score (11 to 5)
Stress-induced moderate perfusion defect without LV dilation or increased
lung intake (thallium-201)
Limited stress echocardiographic ischemia with a wall-motion abnormality
only at higher doses of dobutamine involving less than or equal to 2
segments
Low risk (less than 1% annual mortality rate)
Low-risk treadmill score (score 5 or greater)
Normal or small myocardial perfusion defect at rest or with stress*
Normal stress echocardiographic wall motion or no change of limited resting
wall-motion abnormalities during stress*
*Although the published data are limited, patients with these ﬁndings will probably not be at low
risk in the presence of either a high-risk treadmill score or severe resting LV dysfunction (LVEF
less than 0.35). Reproduced from Table 23 in Gibbons RJ, Abrams J, Chatterjee K, et al.
ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a
report of the American College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients With
Chronic Stable Angina). 2002. Available at: www.acc.org/qualityandscience/clinical/
statements.htm (4).
LV  left ventricular; LVEF  left ventricular ejection fraction.
Table 20. Noninvasive Test Results That Predict
High Risk for Adverse Outcome (Left Ventricular Imaging)
Stress Radionuclide
Ventriculography Stress Echocardiography
Exercise EF 0.50 or less Rest EF 0.35 or less
Rest EF 0.35 or less Wall-motion score index greater than 1
Fall in EF 0.10 or greater
Adapted from O’Rourke RA, Chatterjee K, Dodge HT, et al. Guidelines for clinical use of cardiac
radionuclide imaging, December 1986: a report of the American College of Cardiology/American
Heart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on
Nuclear Imaging). J Am Coll Cardiol 1986;8:1471–83 (576); and Cheitlin MD, Alpert JS,
Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography.
Circulation 1997;95:1686–744 (577).
EF  ejection fraction.
Table 21. Noninvasive Test Results That Predict High Risk for
Adverse Outcome on Stress Radionuclide Myocardial
Perfusion Imaging
Abnormal myocardial tracer distribution in more than 1 coronary artery region
at rest or with stress or a large anterior defect that reperfuses
Abnormal myocardial distribution with increased lung uptake
Cardiac enlargement
Adapted from O’Rourke RA, Chatterjee K, Dodge HT, et al. Guidelines for clinical use of cardiac
radionuclide imaging, December 1986: a report of the American College of Cardiology/American
Heart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on
Nuclear Imaging). J Am Coll Cardiol 1986;8:1471–83 (576).
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show similar accuracy in dichotomization of the total popula-
tion into low- and high-risk subgroups.
Selection of the noninvasive stress test should be based
primarily on patient characteristics, local availability, and ex-
pertise in interpretation (580). Because of simplicity, lower
cost, and widespread familiarity with performance and inter-
pretation, the standard low-level exercise ECG stress test
remains the most reasonable test in patients who are able to
exercise and who have a resting ECG that is interpretable for
ST-segment shifts. Patients with an ECG pattern that would
interfere with interpretation of the ST segment should have an
exercise test with imaging. Patients who are unable to exercise
should have a pharmacological stress test with imaging. Low-
and intermediate-risk patients admitted with ACS may un-
dergo symptom-limited stress testing provided they have been
asymptomatic and clinically stable for 12 to 24 h.
The optimal testing strategy in women is less well deﬁned
than in men (see Section 6.1), but there is evidence that
imaging studies are superior to exercise ECG evaluation in
women (580,581). Exercise testing has been reported to be less
accurate for diagnosis in women. At least a portion of the lower
reported accuracy derives from a lower pretest likelihood of
CAD in women than in men; the higher prevalence of
ischemia secondary to vascular dysfunction (coronary endothe-
lial and/or microvascular dysfunction) in the absence of ob-
structive CAD also is a likely contributor to this.
Results of a symptom-limited exercise test performed 3
to 7 d after UA/NSTEMI were compared with results of
a test conducted 1 month later in 189 patients (534,582).
The diagnostic and prognostic values of the tests were
similar, but the earlier test identiﬁed patients who developed
adverse events during the ﬁrst month, and this represented
approximately one half of all events that occurred during the
ﬁrst year. These data illustrate the importance of early nonin-
vasive testing for risk stratiﬁcation.
The VANQWISH trial used symptom-limited thallium
exercise treadmill testing at 3 to 5 d to direct the need for
angiography in the 442 non–Q-wave MI patients randomized
to an early conservative strategy (534). Among subjects in the
conservative arm meeting VANQWISH stress test criteria to
cross over to coronary angiography, 51% were found to have
surgical CAD and showed favorable outcomes after revascu-
larization (583). These ﬁndings support the concept that
noninvasive stress testing can be used successfully to identify a
high-risk subset of patients who can be directed to coronary
angiography. It is unlikely that any angiographically directed
early revascularization strategy could alter the very low early
event rates observed in patients without a high-risk stress test.
Noninvasive tests are most useful for management decisions
when risk can be stated in terms of events over time. A large
population of patients must be studied to derive and test the
equations needed to accurately predict individual patient risk.
No noninvasive study has been reported in a sufﬁcient number
of patients after the stabilization of UA/NSTEMI to develop
and test the accuracy of a multivariable equation to report test
results in terms of absolute risk. Therefore, data from studies of
stable angina patients must be used for risk, reported as events
over time. Although the pathological process that evokes
ischemia may be different in the 2 forms of angina, it is likely
that the use of prognostic nomograms derived from patients
with stable angina also are predictive of risk in patients with
recent UA/NSTEMI after stabilization. With this untested
assumption, the much larger literature derived from popula-
tions that include patients with both stable angina and UA/
NSTEMI provides equations for risk stratiﬁcation that convert
physiological changes observed during noninvasive testing into
statements of risk expressed as events over time.
3.4.3. Selection for Coronary Angiography
In contrast to the noninvasive tests, coronary angiography
provides detailed structural information to allow an assessment
of prognosis and to provide direction for appropriate manage-
ment. When combined with LV angiography, it also allows an
assessment of global and regional LV function. Indications for
coronary angiography are interwoven with indications for
possible therapeutic plans, such as PCI or CABG.
Coronary angiography is usually indicated in patients with
UA/NSTEMI who either have recurrent symptoms or isch-
emia despite adequate medical therapy or are at high risk as
categorized by clinical ﬁndings (HF, serious ventricular ar-
rhythmias) or noninvasive test ﬁndings (signiﬁcant LV dys-
function: ejection fraction less than 0.35, large anterior or
multiple perfusion defects; Tables 19, 20, and 21), as discussed
in Section 3.4.2. Patients with UA/NSTEMI who have had
previous PCI or CABG also should generally be considered for
early coronary angiography, unless prior coronary angiography
data indicate that no further revascularization is likely to be
possible. The placement of an IABP may allow coronary
angiography and revascularization in those with hemodynamic
instability (see Section 3.1.2.7). Patients with suspected Prinz-
metal’s variant angina also are candidates for coronary angiog-
raphy (see Section 6.7).
In all cases, the general indications for coronary angiog-
raphy and revascularization are tempered by individual
patient characteristics and preferences. Patient and physi-
cian judgments regarding risks and beneﬁts are particularly
important for patients who might not be candidates for
coronary revascularization, such as very frail older adults and
those with serious comorbid conditions (i.e., severe hepatic,
pulmonary, or renal failure; active or inoperable cancer).
3.4.4. Patient Counseling
Results of testing should be discussed with the patient, the
patient’s family, and/or the patient’s advocate in a language
that is understood by them. Test results should be used to
help determine the advisability of coronary angiography, the
need for adjustments in the medical regimen, and the need
for secondary prevention measures (see Section 5).
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4. Coronary Revascularization
4.1. Recommendations for Revascularization With
PCI and CABG in Patients With UA/NSTEMI
(See Fig. 20 for details of the decision tree.)
4.1.1. Recommendations for PCI
CLASS I
1. An early invasive PCI strategy is indicated for patients with UA/
NSTEMI who have no serious comorbidity and who have coronary
lesions amenable to PCI and any of the high-risk features listed in
Section 3.3. (See Section 3.3 for speciﬁc recommendations and
their Level of Evidence.)
2. Percutaneous coronary intervention (or CABG) is recommended for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a large area of
viable myocardium and high-risk criteria on noninvasive testing.
(Level of Evidence: B)
3. Percutaneous coronary intervention (or CABG) is recommended for
UA/NSTEMI patients with multivessel coronary disease with suit-
able coronary anatomy, with normal LV function, and without dia-
betes mellitus. (Level of Evidence: A)
4. An intravenous platelet GP IIb/IIIa inhibitor is generally recom-
mended in UA/NSTEMI patients undergoing PCI. (Level of Evidence:
A) See Section 3.2.3 and Figures 7, 8, and 9 for details on timing
and dosing recommendations (see Table 13).
CLASS IIa
1. Percutaneous coronary intervention is reasonable for focal saphe-
nous vein graft (SVG) lesions or multiple stenoses in UA/NSTEMI
patients who are undergoing medical therapy and who are poor
candidates for reoperative surgery. (Level of Evidence: C)
2. Percutaneous coronary intervention (or CABG) is reasonable for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a moderate
area of viable myocardium and ischemia on noninvasive testing.
(Level of Evidence: B)
3. Percutaneous coronary intervention (or CABG) can be beneﬁcial
compared with medical therapy for UA/NSTEMI patients with
1-vessel disease with signiﬁcant proximal left anterior descending
CAD. (Level of Evidence: B)
4. Use of PCI is reasonable in patients with UA/NSTEMI with signiﬁcant
left main CAD (greater than 50% diameter stenosis) who are
candidates for revascularization but are not eligible for CABG or who
require emergent intervention at angiography for hemodynamic
instability. (Level of Evidence: B)
CLASS IIb
1. In the absence of high-risk features associated with UA/NSTEMI, PCI
may be considered in patients with single-vessel or multivessel CAD
who are undergoing medical therapy and who have 1 or more lesions
to be dilatedwith a reduced likelihood of success. (Level of Evidence: B)
2. Percutaneous coronary intervention may be considered for UA/
NSTEMI patients who are undergoing medical therapy who have 2-
or 3-vessel disease, signiﬁcant proximal left anterior descending
CAD, and treated diabetes or abnormal LV function, with anatomy
suitable for catheter-based therapy. (Level of Evidence: B)
CLASS III
1. Percutaneous coronary intervention (or CABG) is not recommended
for patients with 1- or 2-vessel CAD without signiﬁcant proximal left
anterior descending CAD with no current symptoms or symptoms
that are unlikely to be due to myocardial ischemia and who have no
ischemia on noninvasive testing. (Level of Evidence: C)
2. In the absence of high-risk features associated with UA/NSTEMI, PCI
is not recommended for patients with UA/NSTEMI who have single-
vessel or multivessel CAD and no trial of medical therapy, or who
have 1 or more of the following:
a. Only a small area of myocardium at risk. (Level of Evidence: C)
b. All lesions or the culprit lesion to be dilated with morphology that
conveys a low likelihood of success. (Level of Evidence: C)
c. A high risk of procedure-related morbidity or mortality. (Level of
Evidence: C)
d. Insigniﬁcant disease (less than 50% coronary stenosis). (Level of
Evidence: C)
e. Signiﬁcant left main CAD and candidacy for CABG. (Level of
Evidence: B)
3. A PCI strategy in stable patients with persistently occluded infarct-
related coronary arteries after NSTEMI is not indicated. (Level of
Evidence: B)
4.1.2. Recommendations for CABG
CLASS I
1. Coronary artery bypass graft surgery is recommended for UA/NSTEMI
patients with signiﬁcant left main CAD (greater than 50% stenosis).
(Level of Evidence: A)
2. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI patients with 3-vessel disease; the survival beneﬁt is
greater in patients with abnormal LV function (LVEF less than 0.50).
(Level of Evidence: A)
3. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI patients with 2-vessel disease with signiﬁcant proximal
left anterior descending CAD and either abnormal LV function
(LVEF less than 0.50) or ischemia on noninvasive testing. (Level
of Evidence: A)
4. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI patients in whom percutaneous revascularization is not
optimal or possible and who have ongoing ischemia not responsive
to maximal nonsurgical therapy. (Level of Evidence: B)
5. Coronary artery bypass graft surgery (or PCI) is recommended for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a large area of
viable myocardium and high-risk criteria on noninvasive testing.
(Level of Evidence: B)
6. Coronary artery bypass graft surgery (or PCI) is recommended for
UA/NSTEMI patients with multivessel coronary disease with suit-
able coronary anatomy, with normal LV function, and without dia-
betes mellitus. (Level of Evidence: A)
CLASS IIa
1. For patients with UA/NSTEMI and multivessel disease, CABG with
use of the internal mammary arteries can be beneﬁcial over PCI in
patients being treated for diabetes. (Level of Evidence: B)
2. It is reasonable to perform CABG with the internal mammary artery
for UA/NSTEMI patients with multivessel disease and treated dia-
betes mellitus. (Level of Evidence: B)
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3. Repeat CABG is reasonable for UA/NSTEMI patients with multiple
SVG stenoses, especially when there is signiﬁcant stenosis of a graft
that supplies the LAD. (Level of Evidence: C)
4. Coronary artery bypass graft surgery (or PCI) is reasonable for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a moderate
area of viable myocardium and ischemia on noninvasive testing.
(Level of Evidence: B)
5. Coronary artery bypass graft surgery (or PCI) can be beneﬁcial
compared with medical therapy for UA/NSTEMI patients with
1-vessel disease with signiﬁcant proximal left anterior descending
CAD. (Level of Evidence: B)
6. Coronary artery bypass surgery (or PCI with stenting) is reasonable
for patients with multivessel disease and symptomatic myocardial
ischemia. (Level of Evidence: B)
CLASS IIb
Coronary artery bypass graft surgery may be considered in patients
with UA/NSTEMI who have 1- or 2-vessel disease not involving the
proximal LAD with a modest area of ischemic myocardium when
percutaneous revascularization is not optimal or possible. (If there is a
large area of viable myocardium and high-risk criteria on noninvasive
testing, this recommendation becomes a Class I recommendation.)
(Level of Evidence: B)
CLASS III
Coronary artery bypass graft surgery (or PCI) is not recommended for
patients with 1- or 2-vessel CAD without signiﬁcant proximal left
anterior descending CAD with no current symptoms or symptoms that
are unlikely to be due to myocardial ischemia and who have no
ischemia on noninvasive testing. (Level of Evidence: C)
4.2. General Principles
As discussed in Section 3.4.3, coronary angiography is
useful for deﬁning the coronary artery anatomy in patients
with UA/NSTEMI and for identifying subsets of high-risk
patients who can beneﬁt from early revascularization. Cor-
onary revascularization (PCI or CABG) is performed to
improve prognosis, relieve symptoms, prevent ischemic
complications, and improve functional capacity. The deci-
sion to proceed from diagnostic angiography to revascular-
ization is inﬂuenced not only by the coronary anatomy but
also by a number of additional factors, including anticipated
life expectancy, ventricular function, comorbidity, func-
tional capacity, severity of symptoms, and quantity of viable
myocardium at risk. These are all important variables that
must be considered before revascularization is recom-
mended. For example, patients with distal obstructive cor-
Figure 20. Revascularization Strategy in UA/NSTEMI
*There is conﬂicting information about these patients. Most consider CABG to be preferable to PCI. CABG  coronary artery bypass graft; LAD  left anterior descending cor-
onary artery; PCI  percutaneous coronary intervention UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.
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onary lesions or those who have large quantities of irrevers-
ibly damaged myocardium are unlikely to beneﬁt from
revascularization, particularly if they can be stabilized with
medical therapy. Patients with high-risk coronary anatomy
are likely to beneﬁt from revascularization in terms of both
symptom improvement and long-term survival (Fig. 20).
The indications for coronary revascularization in patients
with UA/NSTEMI are similar to those for patients with
chronic stable angina and are presented in greater detail in
the ACC/AHA Guidelines for the Management of Patients
With Chronic Stable Angina (4), the ACC/AHA Guide-
lines for Coronary Artery Bypass Graft Surgery (555), and
the 2005 ACC/AHA/SCAI Guidelines Update for Percu-
taneous Coronary Intervention (2).
Plaque rupture with subsequent platelet aggregation and
thrombus formation is most often the underlying patho-
physiological cause of UA/NSTEMI (124,126). The man-
agement of many patients with UA/NSTEMI often in-
volves revascularization of the underlying CAD with either
PCI or CABG. Selection of the appropriate revasculariza-
tion strategy depends on clinical factors, operator experi-
ence, and extent of the underlying CAD. Many patients
with UA/NSTEMI have coronary disease that is amenable
to either form of therapy; however, some patients have
high-risk features, such as reduced LV function, that place
them in a group of patients who experience improved
long-term survival rates with CABG. In other patients,
adequate revascularization with PCI might not be optimal
or even possible, and CABG would be the better revascu-
larization choice. In still other patients who are poor
surgical candidates, PCI is preferred.
Findings in large registries of patients with CAD suggest
that the mode of clinical presentation should have little
bearing on the subsequent revascularization strategy
(7,9,13,124,126). In a series of 9,263 patients with CAD, an
admission diagnosis of UA (vs. chronic stable angina) had
no inﬂuence on 5-year survival rates after CABG, percuta-
neous transluminal coronary angioplasty (PTCA), or med-
ical treatment (584). An initial diagnosis of UA also did not
inﬂuence survival 3 years after either CABG or PTCA in
59,576 patients treated in the state of New York (585).
Moreover, long-term survival rates after CABG are similar
for UA patients who present with rest angina, increasing
angina, new-onset angina, or post-MI angina (586). These
observations suggest that published data that compare
deﬁnitive treatments for patients who initially present with
multiple clinical manifestations of CAD can be used to
guide management decisions for patients who present with
UA/NSTEMI. Consequently, the indications for coronary
revascularization in patients with UA/NSTEMI are, in
general, similar to those for patients with stable angina. The
principal difference is that the impetus for some form of
revascularization is stronger in patients with UA/NSTEMI
by the very nature of the presenting symptoms (586).
Moreover, revascularization in patients with UA/NSTEMI,
particularly those with high-risk characteristics, appears to
be of most beneﬁt if performed early in the hospital course
(see Section 3.3).
4.3. Percutaneous Coronary Intervention
In recent years, technological advances coupled with high
acute success rates and low complication rates have in-
creased the use of percutaneous catheterization in patients
with UA/NSTEMI. Stenting and the use of adjunctive
platelet GP IIb/IIIa inhibitors have further broadened the
use of PCI by improving both the safety and durability of
these procedures. Percutaneous coronary revascularization
(intervention) strategies are referred to in these guidelines as
“PCI.” This term refers to a family of percutaneous tech-
niques, including standard balloon angioplasty (PTCA),
intracoronary stenting, and atheroablative technologies
(e.g., atherectomy, thrombectomy, or laser angioplasty).
“Percutaneous transluminal coronary angioplasty” some-
times is used to refer to studies in which this was the
dominant form of PCI, before the widespread use of
stenting. The majority of current PCIs involve balloon
dilation and coronary stenting. Stenting has contributed
greatly to catheter-based revascularization by reducing the
risks of both acute vessel closure and late restenosis. Drug-
eluting stents have been demonstrated to markedly reduce
the risk of restenosis compared with bare-metal stents.
Although stenting has become the most widely used percu-
taneous technique, with most laboratories in the United
States employing stents in 80% to 85% of their PCI
procedures, other devices continue to be used for speciﬁc
lesions and patient subsets. Although the technical safety
and efﬁcacy of atheroablative and thrombectomy devices
have been described, few data exist to demonstrate incre-
mental beneﬁt with regard to clinical outcomes, and even
less information is available that describes the use of these
strategies speciﬁcally in patients with UA/NSTEMI (587).
The need to continue with the development of safer, more
effective PCI techniques is emphasized by recently raised
concerns about delayed endothelialization over DES and
consequent increases in late coronary thrombotic events,
potentially leading to death or MI (399,400,402,403,411).
Other techniques and devices, such as the AngioJet
thrombectomy catheter, have been tested for the treatment
of thrombi that are visible within a coronary artery (588).
Experience with these devices has indicated that the angio-
graphic appearance of a coronary stenosis can be improved,
but few comparative data exist to substantiate improvements
in clinical outcome.
The reported clinical efﬁcacy of PCI in UA/NSTEMI
has varied. This is likely attributable to differences in study
design, treatment strategies, patient selection, and operator
experience. Nevertheless, the success rate of PCI in patients
with UA/NSTEMI overall is quite high. In TIMI IIIB, for
example, angiographic success was achieved in 96% of
patients with UA/NSTEMI who underwent balloon angio-
plasty. With clinical criteria, periprocedural MI occurred in
2.7% of patients, emergency CABG surgery was required in
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1.4% of patients, and the death rate due to the procedure
was 0.5% (129,589).
The use of balloon angioplasty has been evaluated in
several other trials of patients with UA versus stable angina
(590–595). A large retrospective study compared the results
of angioplasty in patients with stable angina to that in
patients with UA (591). After an effort to manage patients
with UA with medical therapy, PTCA was performed an
average of 15 d after hospital admission. Compared with
patients with stable angina, UA patients showed no signif-
icant differences with respect to primary clinical success
(92% for UA vs. 94% for stable angina), in-hospital mor-
tality rates (0.3% vs. 0.1%), or the number of adverse events
at 6-month follow-up (591). These ﬁndings suggest that
results in immediate and 6-month outcomes are comparable
in patients with stable angina and UA. In addition, in a
retrospective analysis, the results in UA patients were
similar regardless of whether the procedure was performed
early (less than 48 h) or late (greater than 48 h) after hospital
presentation (590).
Although other earlier studies (predominantly from the
1980s) had suggested that patients with UA who undergo
balloon PTCA have higher rates of MI and restenosis than
patients with stable angina (592–596), contemporary cath-
eter revascularization differs by often involving coronary
stenting, DES, and adjunctive use of platelet GP IIb/IIIa
receptor inhibitors, which are likely to affect not only
immediate- but also long-term outcomes (512). Histori-
cally, PTCA had been limited by acute vessel closure, which
occurs in approximately 5% of patients, and by coronary
restenosis, which occurred in approximately 35% to 45% of
treated lesions during a 6-month period. Coronary stenting
has offered an important alternative to PTCA because of its
association with both a marked reduction in acute closure
and lower rates of restenosis. By preventing acute or
threatened closure, stenting reduces the incidence of
procedure-related STEMI and need for emergency CABG
surgery and can also prevent other ischemic complications.
In a comparison of the use of the Palmaz-Schatz coronary
stent in patients with stable angina and patients with UA,
no signiﬁcant differences were found with respect to in-
hospital outcome or restenosis rates (597). Another study
found similar rates of initial angiographic success and
in-hospital major complications in stented patients with UA
compared with those with stable angina (598). Major
adverse cardiac events at 6 months were also similar between
the 2 groups, whereas the need for repeat PCI and target-
vessel revascularization was actually less in the UA group.
On the other hand, other data have suggested that UA
increases the incidence of adverse ischemic outcomes in
patients undergoing coronary stent deployment despite
therapy with ticlopidine and ASA, which suggests the need
for more potent antiplatelet therapy in this patient popula-
tion (599).
Drug-eluting stent use for UA/NSTEMI has increased
dramatically in recent years. Kandzari et al. evaluated
patterns of DES utilization in 8,852 high-risk UA/
NSTEMI patients who underwent PCI between 2003 and
2004 in 262 hospitals in the CRUSADE Quality Improve-
ment Initiative (601). During a 9-month period, DES use
increased from 52.6% to 78.5% of cases. Differences in
selection of DES compared with bare bare-metal stents
were noted, but adjusted rates of death and recurrent
infarction were favorable for DES.
The open artery hypothesis suggested that late patency of
an infarct artery is associated with improved LV function,
increased electrical stability, and the provision of collateral
vessels to other coronary beds for protection against future
events. The Occluded Artery Trial (OAT) (602, 603) tested
the hypothesis that routine PCI for total occlusion 3 to 28
d after MI would reduce the composite of death, reinfarc-
tion, or Class IV heart failure. Stable patients (n  2166)
with an occluded infarct artery after MI were randomized to
optimal medical therapy and PCI with stenting or optimal
medical therapy alone. The qualifying period of 3 to 28 d
was based on calendar days, thus the minimal time from
symptom onset to angiography was just over 24 h. Inclusion
criteria included absence of angina or heart failure at rest
and LVEF less than 50% or proximal occlusion of a major
epicardial artery with a large risk region. Exclusion criteria
included NYHA Class III or IV heart failure, serum creatinine
greater than 2.5 mg/dL, left main or 3-vessel disease, clinical
instability, or severe inducible ischemia on stress testing if the
infarct zone was not akinetic or dyskinetic.
Percutaneous coronary intervention did not reduce death,
reinfarction, or HF, and there was a trend toward excess
reinfarction during 4 years of follow-up. Findings in the
295-patient NSTEMI subgroup were similar to those in the
overall group (n  2,166) and the larger STEMI groups.
Thus, a routine PCI strategy in OAT-type patients with
persistently occluded infarct-related coronary arteries after
NSTEMI is not indicated.
4.3.1. Platelet Inhibitors and Percutaneous
Revascularization
An important advance in the treatment of patients with
UA/NSTEMI who are undergoing PCI was the introduc-
tion of platelet GP IIb/IIIa receptor inhibitors in the 1990s
(see Section 3.2) (126,128,130,510–512,604–606). This
therapy takes advantage of the fact that platelets play an
important role in the development of ischemic complica-
tions that can occur in patients with UA/NSTEMI or
during coronary revascularization procedures. Currently, 3
platelet GP IIb/IIIa inhibitors are approved by the Food
and Drug Administration on the basis of the outcomes of a
variety of placebo-controlled clinical trials: abciximab, tiro-
ﬁban, and eptiﬁbatide. The EPIC (510), EPILOG (511),
CAPTURE (372), and EPISTENT (512) trials investi-
gated the use of abciximab; the PRISM (374), PRISM-
PLUS (130), and Randomized Efﬁcacy Study of Tiroﬁban
for Outcomes and REstenosis (RESTORE) (518) trials
evaluated tiroﬁban; and the Integrilin to Minimize Platelet
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Aggregation and Coronary Thrombosis (IMPACT) (517),
PURSUIT (128), and Enhanced Suppression of Platelet
Receptor GP IIb/IIIa using Integrilin Therapy (ESPRIT)
(519) trials studied the use of eptiﬁbatide (Table 18). All 3
of these agents interfere with the ﬁnal common pathway for
platelet aggregation. All have shown efﬁcacy in reducing the
incidence of ischemic complications in patients with UA/
NSTEMI (Fig. 16).
In the only head-to-head comparison of 2 GP IIb/IIIa
inhibitors, the TARGET trial randomized 5,308 patients to
tiroﬁban or abciximab before undergoing PCI with the
intent to perform stenting (515). The primary end point, a
composite of death, nonfatal MI, or urgent target-vessel
revascularization at 30 d, occurred less frequently in those
receiving abciximab than in those given tiroﬁban (6.0% vs.
7.6%, p  0.038). There was a similar direction and
magnitude for each component of the end point. Differ-
ences in outcome between the 2 randomized treatment
groups were particularly marked among patients with UA/
NSTEMI (63% of patients), in whom 30-d composite end
point event rates were 9.3% with tiroﬁban versus 6.3% with
abciximab (p  0.002). Although this ﬁnding is subject to
the limitations of subgroup analysis, it suggests that any
differences in efﬁcacy between GP IIb/IIIa inhibitors might
be most apparent among patients undergoing PCI in the
setting of UA/NSTEMI. Inferior efﬁcacy observed with
tiroﬁban in this trial might have been related to inadequate
initial (loading) dosing, which was subsequently demon-
strated to result in platelet inhibition that was inadequate
(only 28% to 33% early platelet inhibition) and less than
that achieved with abciximab (65% to 81%) (516). A
subsequent study evaluating a higher bolus dose of tiroﬁban
(25 mcg per kg) during PCI was unfortunately discontinued
prematurely because of funding issues. Eptiﬁbatide has not
been compared directly to either abciximab or tiroﬁban.
The question of whether GP IIb/IIIa inhibition is still
useful in UA/NSTEMI patients undergoing PCI who have
received a high loading dose (600 mg) of clopidogrel was
raised by a study in CAD patients treated in an elective
setting (607). To address this, 2,022 patients with UA/
NSTEMI undergoing PCI were loaded with clopidogrel,
600 mg, at least 2 h before the procedure and then
randomized to receive either abciximab or placebo (ISAR-
REACT 2) (244). The primary end point of death, nonfatal
reinfarction, or urgent target-vessel revascularization within
30 d was reached in 8.9% of patients assigned to abciximab
versus 11.9% assigned to placebo, a 25% difference, and was
limited entirely to patients with an elevated troponin level,
in whom the incidence of a primary event was 13.1% in the
abciximab group compared with 18.3% in the placebo group
(p  0.02). Bleeding risks were similar in the 2 groups.
Thus, GP IIb/IIIa inhibition provides incremental beneﬁt
beyond high-oral-dose clopidogrel loading for NSTEMI
patients with elevated cardiac biomarker levels but not for
UA patients with normal levels who are undergoing PCI.
In summary, data from both retrospective observations
and randomized clinical trials indicate that PCI can lead to
angiographic success in most patients with UA/NSTEMI
(Table 18). The safety of these procedures in these patients
is enhanced by the addition of intravenous platelet GP
IIb/IIIa receptor inhibitors to the standard regimen of ASA,
anticoagulants, clopidogrel, and anti-ischemic medications.
4.4. Surgical Revascularization
A meta-analysis of 6 trials conducted during the early years
of CABG (between 1972 and 1978) documented a clear
survival advantage for CABG over medical therapy in
symptomatic patients with left main and 3-vessel coronary
disease that was independent of LV function (322). No
survival difference was documented between the 2 therapies
for patients with 1- or 2-vessel coronary disease. However,
dramatic changes in both surgical technique (including
internal thoracic artery grafting to the LAD) and in medical
therapy (e.g., potent anticoagulant and antiplatelet thera-
pies) have subsequently occurred. Pocock et al. (608) per-
formed a meta-analysis on the results of 8 randomized trials
completed between 1986 and 1993 and compared the
outcomes of CABG and PTCA in 3,371 patients with
multivessel CAD before widespread stent use. Many of
these patients presented with UA. At 1-year follow-up, no
difference was documented between the 2 therapies in
cardiac death or MI, but a lower incidence of angina and
need for revascularization was associated with CABG.
The Bypass Angioplasty Revascularization Investigation
(BARI) trial, the largest randomized comparison of CABG
and PTCA, was performed in 1,829 patients with 2- or
3-vessel CAD (609,610). Unstable angina was the admit-
ting diagnosis in 64% of these patients, and 19% had treated
diabetes mellitus. A statistically signiﬁcant advantage in
survival without MI independent of the severity of present-
ing symptoms was observed for CABG over PCI at 7 years
(84.4% vs. 80.9%, p  0.04) (611). Subgroup analysis
demonstrated that the survival beneﬁt was conﬁned to
patients with treated diabetes mellitus (76.4% with CABG
compared with 55.7% for patients treated with PTCA, p 
0.001). The Coronary Angioplasty versus Bypass Revascu-
larization Investigation (CABRI) trial also showed a sur-
vival beneﬁt for CABG in patients with diabetes mellitus
with multivessel CAD (612). A conﬁrmatory study from
Emory University showed that with correction for baseline
differences, patients requiring insulin with multivessel dis-
ease had improved survival with CABG versus PTCA (613)
(see Section 6.2).
A large patient registry of consecutive CAD compared
the 5-year survival rates for medical treatment, PTCA, and
CABG between 1984 and 1990 (584). Patients with 3- or
2-vessel disease with a proximal severe (greater than or equal
to 95%) LAD stenosis treated with CABG had signiﬁcantly
better 5-year survival rates than did those who received
medical treatment or PTCA. In patients with less severe
2-vessel CAD or with 1-vessel CAD, either form of
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revascularization improved survival relative to medical ther-
apy. The 2 revascularization treatments were equivalent for
patients with nonsevere 2-vessel disease. Percutaneous
transluminal coronary angioplasty provided better survival
rates than CABG in patients with 1-vessel disease, except
for those with severe proximal LAD stenosis, for whom the
2 revascularization strategies were equivalent. However, in
patients with single-vessel disease, all therapies were asso-
ciated with high 5-year survival rates, and the differences
among the treatment groups were very small.
Hannan et al. (585) compared 3-year risk-adjusted sur-
vival rates in 29,646 CABG patients and 29,930 PTCA
patients undergoing revascularization in the state of New
York in 1993, adjusted for differences in baseline and
angiographic characteristics. The anatomic extent of disease
was the only variable that interacted with the speciﬁc
revascularization therapy that inﬂuenced long-term survival.
Unstable angina or diabetes mellitus did not result in
treatment-related differences in long-term survival rates.
Patients with single-vessel disease not involving the LAD or
with less than 70% LAD stenosis had higher adjusted
3-year survival rates with PTCA (95.3%) than with CABG
(92.4%). Patients with proximal LAD stenosis of at least
70% had higher adjusted 3-year survival rates with CABG
than with PTCA regardless of the number of diseased
coronary vessels. Patients with 3-vessel disease had higher
adjusted 3-year survival rates with CABG regardless of
proximal LAD disease. Patients with other 1- or 2-vessel
disease had no treatment-related difference in survival rates.
The 3-year reintervention rate was signiﬁcantly higher in
the PCI group than in the CABG group both for subse-
quent CABG (10.4% vs. 0.5%) and for subsequent PCI
(26.6% vs. 2.8%).
Hannan et al. performed a follow-up study using the
same New York State cardiac registries to compare the
outcomes of 37,212 patients who underwent CABG with
22,102 patients who underwent PCI using stents (614). The
maximum follow-up was more than 3 years in each group.
Patients were divided into 5 anatomic groups; 2-vessel
disease without LAD disease; 2-vessel disease with proximal
LAD disease; 2-vessel disease with nonproximal LAD
disease; 3-vessel disease with proximal LAD disease; and
3-vessel disease with nonproximal LAD disease. Patients
with single-vessel disease were generally treated with PCI.
The unanticipated ﬁnding was that the risk-adjusted long-
term mortality of patients in all 5 subsets was lower in the
CABG group. The HR for death after CABG compared
with stent implantation ranged from a low of 0.64 (95% CI
0.56 to 0.74) for patients with 3-vessel disease and proximal
LAD disease to a high of 0.76 (95% CI 0.60 to 0.96) for
patients with 2-vessel disease with involvement of the
nonproximal LAD. The risk of long-term mortality also
was lower with CABG for patients with diabetes in each of
these anatomic subsets, with HRs ranging from 0.59 to
0.69. In all but the subset of patients with 2-vessel disease
without LAD disease, the increase in mortality associated
with PCI compared with CABG was signiﬁcant for patients
with diabetes. The lack of signiﬁcance in this subset likely
reﬂected smaller numbers of patients (CABG plus PCI
combined). In this study (614), as in the earlier study by
Hannan et al. (585), the 3-year reintervention rate was
signiﬁcantly higher in the PCI group than in the CABG
group for both subsequent CABG (7.8% vs. 0.3%) and
subsequent PCI (27.3% vs. 4.6%). In contrast, the random-
ized trials of multivessel disease have shown no differences
in patients without diabetes. These disparate results could
be due to adverse selection biases for PCI. On the other
hand, the registry is very large and included a broad range of
angiographic characteristics not included in the randomized
trials. Consistently, however, the location of a coronary
stenosis in the LAD, especially if severe and proximal, is a
characteristic associated with higher mortality rates and
with a favorable outcome with CABG.
The BARI and CABRI randomized trials appeared to
identify a subset of diabetic patients who had a better
outcome with CABG than with PTCA, a ﬁnding not
observed in earlier cohort studies (609,610,612) but con-
ﬁrmed in a more recent cohort study that exclusively used
stents in the PCI group (614). Analysis of the subgroup
with diabetes was retrospective in both the BARI and
CABRI trials. Moreover, the treatment-related effect was
not reproduced in the BARI registry population (615). A
reasonable explanation for these inconsistent results is that
physicians might be able to recognize characteristics of
CAD in diabetic patients that permit patients to more safely
undergo one or the other revascularization therapy. How-
ever, when all patients with diabetes are randomly assigned
to therapies without the added insight of clinical judgment,
a treatment advantage is apparent for CABG. Given the
combination of data derived from randomized trials and
more recent cohort studies comparing PCI using stents with
CABG, it is reasonable to consider CABG as the preferred
revascularization strategy for most patients with 3-vessel
disease, especially if it involves the proximal LAD, and for
patients with multivessel disease and treated diabetes mel-
litus or LV dysfunction. Alternatively, it would be unwise to
deny the advantages of PCI to a patient with diabetes and
less severe coronary disease on the basis of the current
information. In addition, the use of GP IIb/IIIa inhibitors
together with PCI for UA/NSTEMI in recent years appears
to have resulted in more favorable outcomes (133,616).
An important consideration in a comparison of different
revascularization strategies is that none of the large random-
ized trials reﬂect the current practice of interventional
cardiology that includes the routine use of stents, with an
increasing use of DES, and the increasing use of platelet
receptor inhibitors. Coronary stenting improves procedural
safety, and DES reduce restenosis compared with PTCA or
bare-metal stents. The adjuvant use of platelet inhibitors,
particularly in high-risk patients, is also associated with
improved short- and intermediate-term outcomes. Al-
though the effects of DES and platelet GP IIb/IIIa inhib-
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itors could have improved the PCI results observed, their
added beneﬁt relative to CABG cannot be assumed or
assessed on the basis of the previously reported randomized
trials or large registries. Meanwhile, reﬁnement of surgical
management with right internal mammary artery grafts,
radial artery grafts, improved myocardial protection strate-
gies, and less invasive methodology could have reduced the
morbidity and mortality rates for CABG. In fact, the
risk-adjusted mortality for CABG has declined progres-
sively during the last decade based on data derived from the
STS National Adult Cardiac Database (617).
The most recent comparisons of PCI and CABG surgery,
relevant to current medical practice, can be summarized as
follows: In a randomized study of patients with medically
refractory myocardial ischemia at high risk of adverse
outcomes of CABG surgery (the Angina With Extremely
Serious Operative Mortality Evaluation [AWESOME]
trial), there was comparable survival with traditional CABG
surgery and PCI, which included stenting or atherectomy
(618). A meta-analysis of CABG versus stenting for the
treatment of multivessel disease (619) included patients in
the randomized trials Arterial Revascularization Therapy
Study (ARTS), Stent or Surgery (SoS), Estudio Random-
izado Argentino de Angioplastia vs. CIrugia-II (ERACI-
II), and Multicenter Anti Atherosclerotic Study-II (MASS-
II) (620–624). ERACI-II included a cohort in which 92%
of the patients had UA; patients in the SoS study did not
have apparent recent acute events; patients in MASS-II had
stable angina and preserved ventricular function; and those
in ARTS (with 5-year follow-up data) were not speciﬁcally
described. However, these trials, which enrolled patients
between 1995 and 2000 and primarily used traditional
on-pump CABG surgery and PCI with bare-metal stents,
showed no difference in the primary composite end point of
death, MI, and stroke and no difference in mortality
between the CABG and the stent groups. The ARTS trial,
which included but was not limited to patients with UA,
randomized patients with multivessel disease to coronary
stenting versus CABG. Three-year survival rates without
stroke and MI were identical in both groups.
Nevertheless, evolutionary changes in revascularization
therapy require randomized trials that incorporate the most
contemporary therapies. Off-pump CABG and PCI with
DES are 2 examples. Indeed, not all evolutionary changes in
therapy have shown net incremental clinical beneﬁts. Ran-
domized trial data suggest that coronary graft patency rates
are somewhat lower with off-pump CABG (625). The use
of DES has not decreased the occurrence of death or MI
compared with bare-metal stents, and DES are subject to a
small increase in the rate of late (greater than 6-month,
off-dual-platelet antagonism) stent thrombotic complica-
tions and thrombosis-related clinical events (399,400,402,
403,411,626). Further complicating the picture, ASA and
clopidogrel and other medical therapies are increasingly
utilized in patients after CABG (627), which makes com-
parisons of medical, PCI, and surgical therapy challenging.
The requirement for long-term follow-up and the need for
adequate statistical power add to the difﬁculty in deﬁning
the unique beneﬁts of each of the available forms of therapy
separately. In summary, it cannot be assumed that all
evolutionary changes in these therapies will have a beneﬁcial
impact on long-term outcomes, and clinical judgment in
treatment selection for individual patients and a conserva-
tive approach to new therapies are indicated.
4.5. Conclusions
In general, the indications for PCI and CABG in UA/
NSTEMI are similar to those for stable angina (628–633).
High-risk patients with LV systolic dysfunction, patients with
diabetes mellitus, and those with 2-vessel disease with severe
proximal LAD involvement or severe 3-vessel or left main
disease should be considered for CABG (Fig. 20). Many other
patients will have less severe CAD that does not put them at
high risk for cardiac death. However, even less severe disease
can have a substantial negative impact on the quality of life.
Compared with high-risk patients, low-risk patients will have
negligibly increased chances of long-term survival with CABG
(or PCI) and therefore should be managed medically. How-
ever, in low-risk patients, quality of life and patient preferences
may be considered in addition to strict clinical outcomes in the
selection of a treatment strategy. Low-risk patients whose
symptoms do not respond well to maximal medical therapy
and who experience a signiﬁcant negative impact on their
quality of life and functional status should be considered for
revascularization. Patients in this group who are unwilling to
accept the increased short-term procedural risks to gain long-
term beneﬁts or who are satisﬁed with their existing capabilities
should be managed medically at ﬁrst and followed up carefully
as outpatients. Other patients who are willing to accept the
risks of revascularization and who want to improve their
functional status or to decrease symptoms may be considered
appropriate candidates for early revascularization.
5. Late Hospital Care, Hospital Discharge,
and Post-Hospital Discharge Care
The acute phase of UA/NSTEMI is usually over within 2
months. The risk of progression to MI or the development
of recurrent MI or death is highest during that period. At 1
to 3 months after the acute phase, most patients resume a
clinical course similar to that in patients with chronic stable
coronary disease.
The broad goals during the hospital discharge phase
are 2-fold: 1) to prepare the patient for normal activities
to the extent possible and 2) to use the acute event as an
opportunity to reevaluate the plan of care, particularly
lifestyle and risk factor modiﬁcation. Aggressive risk
factor modiﬁcations that can prolong survival should be
the main goals of long-term management of stable CAD.
Patients who have undergone successful PCI with an
uncomplicated course are usually discharged the next day,
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and patients who undergo uncomplicated CABG are
generally discharged 4 to 7 d after CABG. Medical
management of low-risk patients after noninvasive stress
testing and coronary angiography can typically be accom-
plished rapidly, with discharge soon after testing. Med-
ical management of a high-risk group of patients who are
unsuitable for or unwilling to undergo revascularization
could require vigilant inpatient monitoring in order to
achieve adequate ischemic symptom control with medical
therapy that will minimize future morbidity and mortality
and improve quality of life.
5.1. Medical Regimen and Use of Medications
RECOMMENDATIONS
CLASS I
1. Medications required in the hospital to control ischemia should be
continued after hospital discharge in patients with UA/NSTEMI who
do not undergo coronary revascularization, patients with unsuccess-
ful revascularization, and patients with recurrent symptoms after
revascularization. Upward or downward titration of the doses may
be required. (Level of Evidence: C)
2. All post-UA/NSTEMI patients should be given sublingual or spray
NTG and instructed in its use. (Level of Evidence: C)
3. Before hospital discharge, patients with UA/NSTEMI should be
informed about symptoms of worsening myocardial ischemia and
MI and should be instructed in how and when to seek emergency
care and assistance if such symptoms occur. (Level of Evidence: C)
4. Before hospital discharge, post-UA/NSTEMI patients and/or desig-
nated responsible caregivers should be provided with supportable,
easily understood, and culturally sensitive instructions with respect
to medication type, purpose, dose, frequency, and pertinent side
effects. (Level of Evidence: C)
5. In post-UA/NSTEMI patients, anginal discomfort lasting more than 2
or 3 min should prompt the patient to discontinue physical activity
or remove himself or herself from any stressful event. If pain does
not subside immediately, the patient should be instructed to take 1
dose of NTG sublingually. If the chest discomfort/pain is unim-
proved or worsening 5 min after 1 NTG dose has been taken, it is
recommended that the patient or a family member/friend call 9-1-1
immediately to access EMS. While activating EMS access, addi-
tional NTG (at 5-min intervals 2 times) may be taken while lying
down or sitting. (Level of Evidence: C)
6. If the pattern or severity of anginal symptoms changes, which suggests
worsening myocardial ischemia (e.g., pain is more frequent or severe
or is precipitated by less effort or now occurs at rest), the patient should
contact his or her physician without delay to assess the need for
additional treatment or testing. (Level of Evidence: C)
In most cases, the inpatient anti-ischemic medical regi-
men used in the nonintensive phase (other than intravenous
NTG) should be continued after discharge, and the anti-
platelet/anticoagulant medications should be changed to an
outpatient regimen. The goals for continued medical ther-
apy after discharge relate to potential prognostic beneﬁts
(primarily shown for antiplatelet agents, beta blockers,
low-density cholesterol (LDL-C)-lowering agents, and in-
hibitors of the renin-angiotensin aldosterone system, espe-
cially for ejection fraction of 0.40 or less), control of
ischemic symptoms (nitrates, beta blockers, and CCBs), and
treatment of major risk factors such as hypertension, smok-
ing, dyslipidemia, physical inactivity, and diabetes mellitus
(see Section 5.2). Thus, the selection of a medical regimen
is individualized to the speciﬁc needs of each patient based
on the in-hospital ﬁndings and events, the risk factors for
CAD, drug tolerability, and recent procedural interventions.
The mnemonic ABCDE (Aspirin, antianginals, and ACE
inhibitors; Beta blockers and blood pressure; Cholesterol
and cigarettes; Diet and diabetes; Education and exercise)
has been found to be useful in guiding treatment (4,634).
An effort by the entire multidisciplinary team with special
skills (physicians, nurses, dietitians, pharmacists, rehabilita-
tion specialists, care managers, and physical and occupa-
tional therapists) is often necessary to prepare the patient for
discharge. Both the patient and family should receive
instructions about what to do if ischemic symptoms occur in
the future (74). Face-to-face patient instruction is important
and should be reinforced and documented with written
instruction sheets. Enrollment in a cardiac rehabilitation
program after discharge can enhance patient education and
compliance with the medical regimen (see Section 5.4).
Telephone follow-up can serve to reinforce in-hospital
instruction, provide reassurance, and answer the patient’s
questions (635). If personnel and budget resources are
available, the health care team should establish a follow-up
system in which personnel specially trained to support and
assist clinicians in CAD management call patients on the
telephone. For example, calls might occur weekly for the
ﬁrst 4 weeks after discharge. This structured program can
gauge the progress of the patient’s recovery, reinforce the
CAD education taught in the hospital, address patient
questions and concerns, and monitor progress in meeting
risk factor modiﬁcation goals.
5.2. Long-Term Medical Therapy and Secondary
Prevention
Patients with UA/NSTEMI require secondary prevention
for CAD at discharge. The management of the patient with
stable CAD is of relevance, as detailed in the ACC/AHA/
ACP Guidelines for the Management of Patients With
Chronic Stable Angina (4), as are the secondary prevention
guidelines (3) outlined in the more recent ACC/AHA
Guidelines for the Management of Patients With ST-
Elevation MI (1) and Secondary Prevention (3,38).
A health care team with expertise in aggressively
managing CAD risk factors should work with patients
and their families to educate them in detail regarding
speciﬁc targets for LDL-C and high-density lipoprotein
cholesterol (HDL-C), blood pressure, body mass index
(BMI), physical activity, and other appropriate lifestyle
modiﬁcations (44). These health care teams can be
hospital-, ofﬁce-, or community-based and may include
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chronic disease management or cardiac rehabilitation/
secondary prevention programs. The family should be
instructed on how best to further support the patient by
encouraging reasonable changes in risk behavior (e.g.,
cooking AHA, Mediterranean, or DASH [Dietary Ap-
proach to Stop Hypertension] diet meals for the entire
family; exercising together). This is particularly impor-
tant when screening of family members reveals common
risk factors, such as dyslipidemia, hypertension, second-
hand smoke, and obesity. Of recent concern is the
national trend to obesity, which has increased over the
past decade in all 50 states, and its risk consequences
(636). The combination of evidence-based therapies
provides complementary, added morbidity and mortality
reductions (637,638); prescription of and compliance
with these combination therapies should be stressed.
5.2.1. Antiplatelet Therapy
See Figure 11 for antiplatelet therapy recommendations in
algorithm format.
CLASS I
1. For UA/NSTEMI patients treated medically without stenting, aspi-
rin* (75 to 162 mg per day) should be prescribed indeﬁnitely (Level
of Evidence: A); clopidogrel† (75 mg per day) should be prescribed
for at least 1 month (Level of Evidence: A) and ideally for up to 1
year. (Level of Evidence: B)
2. For UA/NSTEMI patients treated with bare-metal stents, aspirin*
162 to 325 mg per day should be prescribed for at least 1 month
(Level of Evidence: B), then continued indeﬁnitely at a dose of 75 to
162 mg per day (Level of Evidence: A); clopidogrel should be
prescribed at a dose of 75 mg per day for a minimum of 1 month
and ideally for up to 1 year (unless the patient is at increased risk of
bleeding; then it should be given for a minimum of 2 weeks). (Level
of Evidence: B)
3. For UA/NSTEMI patients treated with DES, aspirin* 162 to 325 mg
per day should be prescribed for at least 3 months after sirolimus-
eluting stent implantation and 6 months after paclitaxel-eluting
stent implantation then continued indeﬁnitely at a dose of 75 to
162 mg per day. (Level of Evidence: B) Clopidogrel 75 mg daily
should be given for at least 12 months to all post-PCI patients
receiving DES. (Level of Evidence: B)
4. Clopidogrel 75 mg daily (preferred) or ticlopidine (in the absence of
contraindications) should be given to patients recovering from
UA/NSTEMI when ASA is contraindicated or not tolerated because
of hypersensitivity or gastrointestinal intolerance (but with gastro-
protective agents such as proton-pump inhibitors). (Level of Evi-
dence: A)
CLASS IIa
For UA/NSTEMI patients in whom the physician is concerned about the
risk of bleeding, a lower initial aspirin dose after PCI of 75 to 162 mg
per day is reasonable. (Level of Evidence: C)
CLASS IIb
For UA/NSTEMI patients who have an indication for anticoagulation,
add warfarin‡ to maintain an international normalization ratio of 2.0 to
3.0.§ (Level of Evidence: B)
CLASS III
Dipyridamole is not recommended as an antiplatelet agent in post-UA/
NSTEMI patients because it has not been shown to be effective. (Level
of Evidence: A)
5.2.2. Beta Blockers
CLASS I
1. Beta blockers are indicated for all patients recovering from UA/
NSTEMI unless contraindicated. (For those at low risk, see Class IIa
recommendation below). Treatment should begin within a few days
of the event, if not initiated acutely, and should be continued
indeﬁnitely. (Level of Evidence: B)
2. Patients recovering from UA/NSTEMI with moderate or severe LV
failure should receive beta-blocker therapy with a gradual titration
scheme. (Level of Evidence: B)
CLASS IIa
It is reasonable to prescribe beta blockers to low-risk patients (i.e.,
normal LV function, revascularized, no high-risk features) recovering
from UA/NSTEMI in the absence of absolute contraindications. (Level
of Evidence: B)
5.2.3. Inhibition of the Renin-Angiotensin-Aldosterone
System
CLASS I
1. Angiotensin-converting enzyme inhibitors should be given and con-
tinued indeﬁnitely for patients recovering from UA/NSTEMI with HF,
LV dysfunction (LVEF less than 0.40), hypertension, or diabetes
mellitus, unless contraindicated. (Level of Evidence: A)
2. An angiotensin receptor blocker should be prescribed at discharge
to those UA/NSTEMI patients who are intolerant of an ACE inhibitor
and who have either clinical or radiological signs of HF and LVEF less
than 0.40. (Level of Evidence: A)
3. Long-term aldosterone receptor blockade should be prescribed for
UA/NSTEMI patients without signiﬁcant renal dysfunction (esti-
mated creatinine clearance should be greater than 30 mL per min)
or hyperkalemia (potassium should be less than or equal to 5 mEq
per liter) who are already receiving therapeutic doses of an ACE
inhibitor, have an LVEF less than or equal to 0.40, and have either
symptomatic HF or diabetes mellitus. (Level of Evidence: A)
CLASS IIa
1. Angiotensin-converting enzyme inhibitors are reasonable for pa-
tients recovering from UA/NSTEMI in the absence of LV dysfunction,
hypertension, or diabetes mellitus unless contraindicated. (Level of
Evidence: A)
*For ASA-allergic patients, use clopidogrel alone (indeﬁnitely), or try aspirin
desensitization.
†For clopidogrel-allergic patients, use ticlopidine 250 mg by mouth twice daily.
‡Continue ASA indeﬁnitely and warfarin longer term as indicated for speciﬁc
conditions such as atrial ﬁbrillation; LV thrombus; or cerebral, venous, or pulmonary
emboli.
§An INR of 2.0 to 2.5 is preferable while given with ASA and clopidogrel, especially
in older patients and those with other risk factors for bleeding.
e238 Circulation August 14, 2007
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
2. Angiotensin-converting enzyme inhibitors are reasonable for pa-
tients with HF and LVEF greater than 0.40. (Level of Evidence: A)
3. In UA/NSTEMI patients who do not tolerate ACE inhibitors, an
angiotensin receptor blocker can be useful as an alternative to ACE
inhibitors in long-term management provided there are either clin-
ical or radiological signs of HF and LVEF less than 0.40. (Level of
Evidence: B)
CLASS IIb
The combination of an ACE inhibitor and an angiotensin receptor
blocker may be considered in the long-term management of patients
recovering from UA/NSTEMI with persistent symptomatic HF and LVEF
less than 0.40* despite conventional therapy including an ACE inhibitor
or an angiotensin receptor blocker alone. (Level of Evidence: B)
Data on the utility of ACE inhibitors in stable CAD in the
presence of HF and LV dysfunction have been compelling,
whereas data in their absence have been conﬂicting. A reduc-
tion in the rates of mortality and vascular events was reported
in the Heart Outcomes Prevention Evaluation (HOPE) Study
(343) with the long-term use of an ACE inhibitor (ramipril) in
moderate-risk patients with CAD, many of whom had pre-
served LV function, as well as patients at high risk of
developing CAD. Similar but smaller beneﬁts were reported in
the EUROPA study (EUropean trial on Reduction Of cardiac
events with Perindopril in patients with stable coronary Artery
disease), which observed a signiﬁcant reduction in incidence of
cardiovascular death, MI, or cardiac arrest among moderate-
risk patients with known coronary disease without apparent
HF randomized to perindopril versus placebo (639). Conﬂict-
ing results, however, were observed in the Prevention of Events
with Angiotensin Converting Enzyme Inhibition (PEACE)
trial, which found no signiﬁcant difference in the risk of
cardiovascular death, MI, or coronary revascularization among
low-risk patients with stable CAD and preserved LV function
when an ACE inhibitor (trandolapril) was added to modern
conventional therapy (640); however, a subsequent meta-
analysis of these 3 major trials supported beneﬁt across the risk
spectrum studied (641). These and other data may be harmo-
nized by postulating that ACE inhibitors provide general
beneﬁt in stable CAD but that the absolute beneﬁt is propor-
tional to disease-related risk, with those at lowest risk beneﬁt-
ing least (641,642). These and other agents that may be used
in patients with chronic CAD are listed in Table 22 and are
discussed in detail in the ACC/AHA Guidelines for the
Management of Patients With Chronic Stable Angina (4).
5.2.4. Nitroglycerin
CLASS I
1. Nitroglycerin to treat ischemic symptoms is recommended. (Level of
Evidence: C)
5.2.5. Calcium Channel Blockers
CLASS I
1. Calcium channel blockers† are recommended for ischemic symp-
toms when beta blockers are not successful. (Level of Evidence: B)
2. Calcium channel blockers† are recommended for ischemic symp-
toms when beta blockers are contraindicated or cause unaccept-
able side effects. (Level of Evidence: C)
5.2.6. Warfarin Therapy
CLASS I
Use of warfarin in conjunction with ASA and/or clopidogrel is associ-
ated with an increased risk of bleeding and should be monitored
closely. (Level of Evidence: A)
CLASS IIb
Warfarin either without (INR 2.5 to 3.5) or with low-dose ASA (75 to 81
mg per d; INR 2.0 to 2.5) may be reasonable for patients at high CAD
risk and low bleeding risk who do not require or are intolerant of
clopidogrel. (Level of Evidence: B)
5.2.7. Lipid Management
CLASS I
1. The following lipid recommendations are beneﬁcial:
a. Lipid management should include assessment of a fasting lipid
proﬁle for all patients, within 24 h of hospitalization. (Level of
Evidence: C)
b. Hydroxymethyl glutaryl-coenzyme A reductase inhibitors (st-
atins), in the absence of contraindications, regardless of base-
line LDL-C and diet modiﬁcation, should be given to post-UA/
NSTEMI patients, including postrevascularization patients.
(Level of Evidence: A)
c. For hospitalized patients, lipid-lowering medications should be
initiated before discharge. (Level of Evidence: A)
d. For UA/NSTEMI patients with elevated LDL-C (greater than or
equal to 100 mg per dL), cholesterol-lowering therapy should
be initiated or intensiﬁed to achieve an LDL-C of less than
100 mg per dL. (Level of Evidence: A) Further titration to less than
70 mg per dL is reasonable. (Class IIa, Level of Evidence: A)
e. Therapeuticoptions to reducenon–HDL-C‡are recommended, includ-
ing more intense LDL-C–lowering therapy. (Level of Evidence: B)
f. Dietary therapy for all patients should include reduced intake of
saturated fats (to less than 7% of total calories), cholesterol (to
less than 200 mg per d), and trans fat (to less than 1% of
energy). (Level of Evidence: B)
g. Promoting daily physical activity and weight management
are recommended. (Level of Evidence: B)
2. Treatment of triglycerides and non-HDL-C is useful, including the
following:
a. If triglycerides are 200 to 499 mg per dL, non-HDL-C‡ should be
less than 130 mg per dL. (Level of Evidence: B)
*The safety of this combination has not been proven in patients also on aldosterone
antagonist and is not recommended.
†Short-acting dihydropyridine calcium channel antagonists should be avoided.
‡Non-HDL-C  total cholesterol minus HDL-C.
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b. If triglycerides are greater than or equal to 500 mg per dL*,
therapeutic options to prevent pancreatitis are ﬁbrate† or nia-
cin† before LDL-lowering therapy is recommended. It is also
recommended that LDL-C be treated to goal after triglyceride-
lowering therapy. Achievement of a non-HDL-C‡ less than 130
mg per dL (i.e., 30 mg per dL greater than LDL-C target) if
possible is recommended. (Level of Evidence: C)
CLASS IIa
1. The following lipid management strategies can be beneﬁcial:
a. Further reduction of LDL-C to less than 70 mg per dL is reason-
able. (Level of Evidence: A)
b. If baseline LDL cholesterol is 70 to 100 mg per dL, it is
reasonable to treat LDL-C to less than 70 mg per dL. (Level of
Evidence: B)
c. Further reduction of non-HDL-C‡ to less than 100 mg per dL is
reasonable; if triglycerides are 200 to 499 mg per dL, non-
HDL-C target is less than 130 mg per dL. (Level of Evidence: B)
d. Therapeutic options to reduce non-HDL-C‡ (after LDL-C lower-
ing) include niacin† or ﬁbrate* therapy.
e. Nicotinic acid (niacin)† and ﬁbric acid derivatives (fenoﬁbrate,
gemﬁbrozil)* can be useful as therapeutic options (after LDL-
C–lowering therapy) for HDL-C less than 40 mg per dL. (Level of
Evidence: B)
f. Nicotinic acid (niacin)† and ﬁbric acid derivatives (fenoﬁbrate,
gemﬁbrozil)* can be useful as therapeutic options (after LDL-
C–lowering therapy) for triglycerides greater than 200 mg per
dL. (Level of Evidence: B)
g. The addition of plant stanol/sterols (2 g per d) and/or viscous
ﬁber (more than 10 g per d) is reasonable to further lower LDL-C.
(Level of Evidence: A)
CLASS IIb
Encouraging consumption of omega-3 fatty acids in the form of ﬁsh§ or
in capsule form (1 g per d) for risk reduction may be reasonable. For
treatment of elevated triglycerides, higher doses (2 to 4 g per d) may be
used for risk reduction. (Level of Evidence: B)
There is a wealth of evidence that cholesterol-lowering
therapy for patients with CAD and hypercholesterolemia
(643) or with mild cholesterol elevation (mean 209 to 218
mg per dL) after MI and UA reduces vascular events and
death (644,645). Moreover, recent trials have provided
*Patients with very high triglycerides should not consume alcohol. The use of bile acid
sequestrants is relatively contraindicated when triglycerides are greater than 200 mg
per dL.
†The combination of high-dose statin plus ﬁbrate can increase risk for severe
myopathy. Statin doses should be kept relatively low with this combination. Dietary
supplement niacin must not be used as a substitute for prescription niacin.
‡Non-HDL-C  total cholesterol minus HDL-C.
§Pregnant and lactating women should limit their intake of ﬁsh to minimize exposure
to methylmercury.
Table 22. Medications Used for Stabilized UA/NSTEMI Patients
Anti-Ischemic and Antithrombotic/Antiplatelet
Agents Drug Action Class/Level of Evidence
Aspirin Antiplatelet I/A
Clopidogrel* or ticlopidine Antiplatelet when aspirin is contraindicated I/A
Beta blockers Anti-ischemic I/B
ACEI EF less than 0.40 or HF EF greater than 0.40 I/A IIa/A
Nitrates Antianginal I/C for ischemic symptoms
Calcium channel blockers (short-acting
dihydropyridine antagonists should be avoided)
Antianginal I for ischemic symptoms; when beta blockers are
not successful (B) or contraindicated, or cause
unacceptable side effects (C)
Dipyridamole Antiplatelet III/A
Agents for Secondary Prevention and Other
Indications
Risk Factor Class/Level of Evidence
HMG-CoA reductase inhibitors LDL cholesterol greater than 70 mg per dL Ia
Fibrates HDL cholesterol less than 40 mg per dL IIa/B
Niacin HDL cholesterol less than 40 mg per dL IIa/B
Niacin or ﬁbrate Triglycerides 200 mg per dL IIa/B
Antidepressant Treatment of depression IIb/B
Treatment of hypertension Blood pressure greater than 140/90 mm Hg
or greater than 130/80 mm Hg if kidney
disease or diabetes present
I/A
Hormone therapy (initiation)† Postmenopausal state III/A
Treatment of diabetes HbA1C greater than 7% I/B
Hormone therapy (continuation)† Postmenopausal state III/B
COX-2 inhibitor or NSAID Chronic pain IIa/C, IIb/C or III/C
Vitamins C, E, beta-carotene; folic acid, B6, B12 Antioxidant effect; homocysteine lowering III/A
*Preferred to ticlopidine.†For risk reduction of coronary artery disease.
ACEI  angiotensin-converting enzyme inhibitor; CHF  congestive heart failure; COX-2  cyclooxygenase 2; EF  ejection fraction; HDL  high-density lipoprotein; HMG-CoA  hydroxymethyl glutaryl
coenzyme A; INR international normalized ratio; LDL low-density lipoprotein; NSAID nonsteroidal anti-inﬂammatory drug; NSTEMI non–ST-segment elevation myocardial infarction; UA unstable
angina.
e240 Circulation August 14, 2007
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
mounting evidence that statin therapy is beneﬁcial regard-
less of whether the baseline LDL-C level is elevated
(646–648). More aggressive therapy has resulted in sup-
pression or reversal of coronary atherosclerosis progression
and lower cardiovascular event rates, although the impact on
total mortality remains to be clearly established (649). These
data are discussed more fully elsewhere (3,17,39).
For patients with CHD or CHD equivalents (i.e., ath-
erosclerosis in other vascular territories, diabetes mellitus, or
10-year estimated cardiovascular risk greater than 20%), the
NCEP Adult Treatment Panel III recommended a target
LDL-C level less than 100 mg per dL (17). Therapeutic
lifestyle changes are recommended as well. Therapeutic
lifestyle changes include diet, weight management, and
increased physical activity. Speciﬁc diet recommendations
include restriction of calories from saturated fat to less than
7% of total caloric intake and of cholesterol to less than 200
mg per d. Additionally, increased soluble ﬁber (10 to 25 g
per d) and plant stanols/sterols (2 g per d) are noted as
therapeutic lifestyle change dietary options to enhance
LDL-C lowering. Reduction in trans fat (to less than 1% of
caloric intake) subsequently has been added to prevention
guidelines (3,38). These guidelines also recommend consid-
eration of drug therapy if LDL-C is above goal range, either
simultaneously with therapeutic lifestyle changes or sequen-
tially, after 3 months of therapeutic lifestyle changes.
An update to the Adult Treatment Panel III guidelines
was published in mid 2004 (16). The major change recom-
mended in this update is an LDL-C treatment goal of less
than 70 mg per dL as a reasonable option in very-high-risk
patients (such as after UA/NSTEMI). Furthermore, if a
high-risk patient has high triglycerides (greater than 200 mg
per dL) or low HDL-C (less than 40 mg per dL),
consideration can be given to combining a ﬁbrate or
nicotinic acid with an LDL-lowering drug. For moderately
high-risk patients (2 or more risk factors and 10-year risk of
10% to 20%), the recommended LDL-C goal is less than
130 mg per dL, but an LDL-C goal of less than 100 mg per
dL is a reasonable option. When drug therapy is utilized in
moderate- to high-risk patients, it is advised that the
intensity of the treatment be sufﬁcient to achieve a reduction
in LDL-C levels of at least 30% to 40%. Therapeutic
lifestyle changes to modify existing lifestyle-based risk
factors are strongly urged regardless of LDL-C levels.
Two trials further support early intensive lipid lowering
after ACS. In the PROVE-IT TIMI 22 study (PRavastatin
Or atorVastatin Evaluation and Infection Therapy–
Thrombolysis In Myocardial Infarction 22), 4,162 patients
within 10 d of ACS were randomized to 40 mg of
pravastatin or 80 mg of atorvastatin daily (648). The median
LDL-C achieved in the moderately intensive (standard-
dose) pravastatin group was 95 mg per dL compared with a
median of 62 mg per dL in the aggressive, high-dose
atorvastatin group. A 16% reduction in the HR for the
primary composite end point of all-cause death, MI, UA
requiring rehospitalization, revascularization (performed at
least 30 d after randomization), and stroke was observed in
favor of the high-dose regimen. The second trial, phase Z of
the A to Z Trial (647), compared early initiation of an
intensive statin regimen (simvastatin 40 mg per d for 1
month followed by 80 mg per d thereafter) with a delayed
initiation of a less-intensive regimen (placebo for 4 months
followed by simvastatin 20 mg per d) in patients with ACS.
No difference was observed between the groups during the
ﬁrst 4 months of follow-up for the primary end point
(composite of cardiovascular death, nonfatal MI, readmis-
sion for ACS, and stroke). However, from 4 months
through the end of the study, the primary end point was
signiﬁcantly reduced in the aggressive treatment arm, which
represented a favorable trend toward a reduction of major
cardiovascular events with the early, aggressive statin regi-
men. The incidence of myopathy (CK greater than 10 times
the upper limit of normal, with muscle symptoms) occurred
more frequently in the early/aggressive treatment group,
which reinforces the need for careful monitoring and
follow-up with aggressive treatment.
Observational studies have generally supported initiation
of lipid-lowering therapy before discharge after ACS both
for safety and for early efﬁcacy (event reduction) (650). In
contrast, a meta-analysis of randomized trials of early (less
than 14 d) initiation of lipid lowering after ACS, although
supporting its safety, suggests that efﬁcacy is generally
delayed beyond 4 months (651).
Short- and long-term compliance is a clear beneﬁt of
in-hospital initiation of lipid lowering (652). In a demon-
stration project, the Cardiovascular Hospitalization Athero-
sclerosis Management Program, the in-hospital initiation of
lipid-lowering therapy increased the percentage of patients
treated with statins 1 year later from 10% to 91%, and for
those with an LDL-C less than 100 mg per dL, the
percentage increased from 6% to 58% (653), which suggests
that predischarge initiation of lipid-lowering therapy en-
hances long-term compliance. Thus, there appear to be no
adverse effects and substantial advantages to the initiation of
lipid-lowering therapy before hospital discharge (652,654).
Such early initiation of therapy also has been recommended
in the update of the third report of the NCEP (16).
Adherence to statin therapy was shown to be associated
with improved survival in a large, population-based longi-
tudinal observational study (655).
5.2.8. Blood Pressure Control
CLASS I
Blood pressure control according to JNC 7 guidelines* is recommended
(i.e., blood pressure less than 140/90mmHg or less than 130/80mm
Hg if the patient has diabetes mellitus or chronic kidney disease).
(Level of Evidence: A) Additional measures recommended to treat and
control blood pressure include the following:
*Chobanian AV, Bakris GL, Black HR, et al., for the National High Blood Pressure
Education Program Coordinating Committee. The seventh report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72 (656).
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a. Patients should initiate and/or maintain lifestyle modiﬁcations,
including weight control, increased physical activity, alcohol moder-
ation, sodium reduction, and emphasis on increased consumption
of fresh fruits, vegetables, and low-fat dairy products. (Level of
Evidence: B)
b. For patients with blood pressure greater than or equal to 140/90
mm Hg (or greater than or equal to 130/80 mm Hg for individuals
with chronic kidney disease or diabetes mellitus), it is useful to add
blood pressure medication as tolerated, treating initially with beta
blockers and/or ACE inhibitors, with addition of other drugs such as
thiazides as needed to achieve target blood pressure. (Level of
Evidence: A)
All patients with elevated systolic or diastolic blood pressures
should be educated and motivated to achieve targeted hyper-
tensive control according to JNC 7 guidelines (656) adapted to
patients with ischemic heart disease (656a). Systolic and
diastolic blood pressures should be in the normal range (i.e.,
less than 140/90 mm Hg; 130/80 mm Hg if the patient has
diabetes mellitus or chronic kidney disease).
5.2.9. Diabetes Mellitus
CLASS I
Diabetes management should include lifestyle and pharmacotherapy
measures to achieve a near-normal HbA1c level of less than 7%. (Level
of Evidence: B) Diabetes management should also include the
following:
a. Vigorous modiﬁcation of other risk factors (e.g., physical activity,
weight management, blood pressure control, and cholesterol man-
agement) as recommended should be initiated and maintained.
(Level of Evidence: B)
b. It is useful to coordinate the patient’s diabetic care with the patient’s
primary care physician or endocrinologist. (Level of Evidence: C)
Glycemic control during and after ACS is discussed in
Section 6.2.1.
Overweight patients should be instructed in a weight loss
regimen, with emphasis on the importance of regular
exercise and a lifelong prudent diet to maintain ideal body
mass index. Patients should be informed and encouraged
that even small reductions in weight can have positive
beneﬁts. This can be reassuring to severely obese patients. In
the Diabetes Prevention Program study, 3,234 overweight
subjects with elevated fasting and postload plasma glucose
concentrations were randomized to treatment with met-
formin or a lifestyle modiﬁcation program (657). The goals of
the lifestyle modiﬁcation program were targeted to at least a
7% weight loss and at least 150 min of physical activity per
week. The incidence of diabetes mellitus was reduced by 58%
in the lifestyle modiﬁcation group and 31% in the metformin
group compared with placebo. The study supports the sub-
stantial positive effects of even modest changes in weight and
physical activity on the development of diabetes, a major risk
factor for cardiovascular events (657–659).
5.2.10. Smoking Cessation
CLASS I
Smoking cessation and avoidance of exposure to environmental to-
bacco smoke at work and home are recommended. Follow-up, referral
to special programs, or pharmacotherapy (including nicotine replace-
ment) is useful, as is adopting a stepwise strategy aimed at smoking
cessation (the 5 As are: Ask, Advise, Assess, Assist, and Arrange).
(Level of Evidence: B)
For patients who smoke, persistent smoking cessation
counseling is often successful and has substantial potential
to improve survival. Daly et al. (660) quantiﬁed the long-
term effects of smoking on patients with ACS. Men less
than 60 years old who continued to smoke had a risk of
death due to all causes that was 5.4 times that of men who
stopped smoking (p less than 0.05). Referral to a smoking
cessation program and the use of pharmacological agents
including nicotine patches or gum are recommended (661).
Bupropion, an anxiolytic agent and weak inhibitor of
neuronal uptake of neurotransmitters, has been effective
when added to brief regular counseling sessions in helping
patients to quit smoking. The treatment of 615 study
subjects for 7 weeks resulted in smoking cessation rates of
28.8% for the 100 mg per d dosage and 44.2% for 300 mg
per d compared with 19.6% for placebo-assigned patients (p
less than 0.001) (661). The abstinence rate at 1 year was
23.0% for those treated with bupropion 300 mg per d versus
12.4% for those receiving placebo (661).
Recently, another nonnicotine replacement therapy,
varenicline, was approved to assist in smoking cessation.
Varenicline is a ﬁrst-in-class nicotine acetylcholine receptor
partial agonist, designed to provide some nicotine effects
(easing withdrawal symptoms) and to block the effects of
nicotine from cigarettes, discouraging smoking. Approval
was based on demonstrated effectiveness in 6 clinical trials
involving a total of 3,659 chronic cigarette smokers (32–34).
In 2 of the 5 placebo-controlled trials, varenicline also was
compared to buproprion and found to be more effective.
Varenicline is given for an initial 12-week course. Success-
fully treated patients may continue treatment for an addi-
tional 12 weeks to improve the chances of long-term
abstinence. Family members who live in the same house-
hold should also be encouraged to quit smoking to help
reinforce the patient’s effort and to decrease the risk of
secondhand smoke for everyone.
5.2.11. Weight Management
CLASS I
Weight management, as measured by body mass index and/or waist
circumference, should be assessed on each visit. A body mass index of
18.5 to 24.9 kg per m2 and a waist circumference (measured horizon-
tally at the iliac crest) of less than 40 inches for men and less than 35
inches for women is recommended. (Level of Evidence: B) Additional
weight management practices recommended include the following:
a. On each patient visit, it is useful to consistently encourage weight
maintenance/reduction through an appropriate balance of physical
activity, caloric intake, and formal behavioral programs when indi-
cated to maintain/achieve a body mass index between 18.5 and
24.9 kg per m2. (Level of Evidence: B)
b. If waist circumference is 35 inches ormore inwomenor 40 inches ormore
in men, it is beneﬁcial to initiate lifestyle changes and consider treatment
strategies for metabolic syndrome as indicated. (Level of Evidence: B)
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c. The initial goal of weight loss therapy should be to reduce body
weight by approximately 10% from baseline. With success, further
weight loss can be attempted if indicated through further assess-
ment. (Level of Evidence: B)
5.2.12. Physical Activity
CLASS I
1. The patient’s risk after UA/NSTEMI should be assessed on the basis
of an in-hospital determination of risk. A physical activity history or
an exercise test to guide initial prescription is beneﬁcial. (Level of
Evidence: B)
2. Guided/modiﬁed by an individualized exercise prescription, patients
recovering from UA/NSTEMI generally should be encouraged to
achieve physical activity duration of 30 to 60 min per d, preferably
7 (but at least 5) d per week of moderate aerobic activity, such as
brisk walking, supplemented by an increase in daily lifestyle activi-
ties (e.g., walking breaks at work, gardening, and household work).
(Level of Evidence: B)
3. Cardiac rehabilitation/secondary prevention programs are recom-
mended for patients with UA/NSTEMI, particularly those with mul-
tiple modiﬁable risk factors and/or those moderate- to high-risk
patients in whom supervised exercise training is particularly war-
ranted. (Level of Evidence: B)
CLASS IIb
The expansion of physical activity to include resistance training on 2 d
per week may be reasonable. (Level of Evidence: C)
Federal and ACC/AHA guidelines recommend that all
Americans strive for at least 30 to 60 min of moderate
physical activity most days of the week, preferably daily
(662). The 30 to 60 min can be spread out over 2 or 3
segments during the day. For post-UA/NSTEMI patients,
daily walking can be encouraged immediately after dis-
charge. Excellent resource publications on exercise prescrip-
tion in cardiovascular patients are available (45,663). Phys-
ical activity is important in efforts to lose weight because it
increases energy expenditure and plays an integral role in
weight maintenance. Regular physical activity reduces
symptoms in patients with CVD, improves functional
capacity, and improves other cardiovascular risk factors such
as insulin resistance and glucose intolerance (45). Beyond
the instructions for daily exercise, patients require speciﬁc
instruction on those strenuous activities (e.g., heavy lifting,
climbing stairs, yard work, and household activities) that are
permissible and those they should avoid. Several activity
questionnaires or nomograms, speciﬁc to the cardiac popu-
lation and general population, have been developed to help
guide the patient’s exercise prescription if an exercise test is
not available (664–667). As emphasized by the US Public
Health Service, comprehensive cardiac rehabilitation ser-
vices include long-term programs involving medical evalu-
ation, prescribed exercise, cardiac risk factor modiﬁcation,
education, and counseling (668). These programs are de-
signed to limit the physiological and psychological effects of
cardiac illness, reduce the risk for sudden death or reinfarc-
tion, control cardiac symptoms, and enhance the psychos-
ocial and vocational status of selected patients. Enrollment
in a cardiac rehabilitation program after discharge can
enhance patient education and compliance with the medical
regimen and assist with the implementation of a regular
exercise program (45,47,573,669,670). In addition to aero-
bic training, mild- to moderate-resistance training may be
considered. This can be started 2 to 4 weeks after aerobic
training has begun (671). Expanded physical activity is an
important treatment component for the metabolic syn-
drome, which is becoming increasingly prevalent.
Exercise training can generally begin within 1 to 2 weeks
after UA/NSTEMI treated with PCI or CABG to relieve
ischemia (663). Unsupervised exercise may target a heart rate
range of 60% to 75% of maximum predicted; supervised
training (see Section 5.4) may target a somewhat higher heart
rate (70% to 85% of maximum predicted) (663). Additional
restrictions apply when residual ischemia is present.
5.2.13. Patient Education
CLASS I
Beyond the detailed instructions for daily exercise, patients should be
given speciﬁc instruction on activities (e.g., heavy lifting, climbing
stairs, yard work, and household activities) that are permissible and
those that should be avoided. Speciﬁc mention should be made
regarding resumption of driving, return to work, and sexual activity.
(Level of Evidence: C) Speciﬁc recommendations for physical activity
follow in Section 5.4.
Patients should be educated and motivated to achieve
appropriate target LDL-C and HDL-C goals. Patients who
have undergone PCI or CABG derive beneﬁt from choles-
terol lowering (672) and deserve special counseling lest they
mistakenly believe that revascularization obviates the need
for signiﬁcant lifestyle changes. The NHLBI “Your Guide
to Better Health” series provides useful educational tools for
patients (http://hp2010.nhlbihin.net/yourguide/).
5.2.14. Inﬂuenza
CLASS I
An annual inﬂuenza vaccination is recommended for patients with
cardiovascular disease. (Level of Evidence: B)
5.2.15. Depression
CLASS IIa
It is reasonable to consider screening UA/NSTEMI patients for depres-
sion and refer/treat when indicated. (Level of Evidence: B)
5.2.16. Nonsteroidal Anti-Inﬂammatory Drugs
CLASS I
At the time of preparation for hospital discharge, the patient’s need for
treatment of chronic musculoskeletal discomfort should be assessed,
and a stepped-care approach to treatment should be used for selection
of treatments (Fig. 21). Pain relief should begin with acetaminophen,
small doses of narcotics, or nonacetylated salicylates. (Level of Evi-
dence: C)
CLASS IIa
It is reasonable to use nonselective NSAIDs, such as naproxen, if initial
therapy with acetaminophen, small doses of narcotics, or nonacety-
lated salicylates is insufﬁcient. (Level of Evidence: C)
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CLASS IIb
Nonsteroidal anti-inﬂammatory drugs with increasing degrees of rela-
tive COX-2 selectivity may be considered for pain relief only for situa-
tions in which intolerable discomfort persists despite attempts at
stepped-care therapy with acetaminophen, small doses of narcotics,
nonacetylated salicylates, or nonselective NSAIDs. In all cases, the
lowest effective doses should be used for the shortest possible time.
(Level of Evidence: C)
CLASS III
Nonsteroidal anti-inﬂammatory drugs with increasing degrees of rela-
tive COX-2 selectivity should not be administered to UA/NSTEMI pa-
tients with chronic musculoskeletal discomfort when therapy with
acetaminophen, small doses of narcotics, nonacetylated salicylates, or
nonselective NSAIDs provides acceptable levels of pain relief. (Level of
Evidence: C)
The selective COX-2 inhibitors and other nonselective
NSAIDs have been associated with increased cardiovascular
risk. The risk appears to be ampliﬁed in patients with
established CVD (1,359–362). In a large Danish observa-
tional study of ﬁrst-time MI patients (n 58,432), the HRs
and 95% CIs for death were 2.80 (2.41 to 3.25) for
rofecoxib, 2.57 (2.15 to 3.08) for celecoxib, 1.50 (1.36 to
1.67) for ibuprofen, 2.40 (2.09 to 2.80) for diclofenac, and
1.29 (1.16 to 1.43) for other NSAIDS (361). There were
dose-related increases in risk of death and non–dose-
dependent trends for rehospitalization for MI for all drugs
(360,361). An AHA scientiﬁc statement on the use of
NSAIDS concluded that the risk of cardiovascular events is
proportional to COX-2 selectivity and the underlying risk in
the patient (673). Nonpharmacological approaches were
recommended as the ﬁrst line of treatment, followed by the
stepped-care approach to pharmacological therapy, as
shown in Figure 21.
5.2.17. Hormone Therapy
CLASS III
1. Hormone therapy with estrogen plus progestin, or estrogen alone,
should not be given de novo to postmenopausal women after
UA/NSTEMI for secondary prevention of coronary events. (Level of
Evidence: A)
2. Postmenopausal women who are already taking estrogen plus
progestin, or estrogen alone, at the time of UA/NSTEMI in general
should not continue hormone therapy. However, women who are
more than 1 to 2 years past the initiation of hormone therapy who
wish to continue such therapy for another compelling indication
should weigh the risks and beneﬁts, recognizing the greater risk of
cardiovascular events and breast cancer (combination therapy) or
stroke (estrogen). Hormone therapy should not be continued while
patients are on bedrest in the hospital. (Level of Evidence: B)
Although prior observational data suggested a protective
effect of hormone therapy for coronary events, a randomized
trial of hormone therapy for secondary prevention of death
and MI (Heart and Estrogen/progestin Replacement Study
[HERS]) failed to demonstrate a beneﬁcial effect (674).
Disturbingly, there was an excess risk for death and MI early
after hormone therapy initiation. The Women’s Health
Initiative included randomized primary prevention trials of
estrogen plus progestin and estrogen alone. Both trials were
stopped early owing to an observed increased risk related to
hormone therapy that was believed to outweigh the poten-
tial beneﬁts of further study (675–677). It is recommended
that postmenopausal women receiving hormone therapy at
Figure 21. Stepped-Care Approach to Pharmacological Therapy for Musculoskeletal Symptoms
With Known Cardiovascular Disease or Risk Factors for Ischemic Heart Disease
*Addition of ASA may not be sufﬁcient protection against thrombotic events. Reproduced with permission. American Heart Association Scientiﬁc Statement on the Use of
Nonsteroidal Anti-Inﬂammatory Drugs (NSAIDS)-An Update for Clinicians © 2007, American Heart Association, Inc. (673). ASA  aspirin; COX-2  cyclooxygenase-1; NSAIDs
 nonsteroidal anti-inﬂammatory drugs; PPI  proton-pump inhibitor.
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the time of a cardiovascular event discontinue its use.
Likewise, hormone therapy should not be initiated for
secondary prevention of coronary events. However, there
may be other permissible indications for hormone therapy in
postmenopausal women (e.g., prevention of perimenopausal
symptoms such as ﬂushing, or prevention of osteoporosis) if
the beneﬁts are believed to outweigh the increased cardio-
vascular risk).
5.2.18. Antioxidant Vitamins and Folic Acid
CLASS III
1. Antioxidant vitamin supplements (e.g., vitamins E, C, or beta caro-
tene) should not be used for secondary prevention in UA/NSTEMI
patients. (Level of Evidence: A)
2. Folic acid, with or without B6 and B12, should not be used for
secondary prevention in UA/NSTEMI patients. (Level of Evidence: A)
Although there is an association of elevated homocysteine
blood levels and CAD, a reduction in homocysteine levels
with routine folate supplementation was not demonstrated
to reduce the risk of CAD events in 2 trials (Norwegian
Vitamin Trial [NORVIT] and HOPE) that included
post-MI or high risk, stable patients (678–681). Similarly,
a large clinical trials experience with antioxidant vitamins
has failed to demonstrate beneﬁt for primary or secondary
prevention (38,681a).
5.3. Postdischarge Follow-Up
RECOMMENDATIONS
CLASS I
1. Detailed discharge instructions for post-UA/NSTEMI patients should
include education on medications, diet, exercise, and smoking
cessation counseling (if appropriate), referral to a cardiac rehabili-
tation/secondary prevention program (when appropriate), and the
scheduling of a timely follow-up appointment. Low-risk medically
treated patients and revascularized patients should return in 2 to 6
weeks, and higher risk patients should return within 14 d. (Level of
Evidence: C)
2. Patients with UA/NSTEMI managed initially with a conservative strat-
egy who experience recurrent signs or symptoms of UA or severe
(Canadian Cardiovascular Society class III) chronic stable angina de-
spite medical management who are suitable for revascularization
should undergo timely coronary angiography. (Level of Evidence: B)
3. Patients with UA/NSTEMI who have tolerable stable angina or no
anginal symptoms at follow-up visits should be managed with
long-term medical therapy for stable CAD. (Level of Evidence: B)
4. Care should be taken to establish effective communication between
the post-UA/NSTEMI patient and health care team members to
enhance long-term compliance with prescribed therapies and rec-
ommended lifestyle changes. (Level of Evidence: B)
The risk of death within 1 year can be predicted on the
basis of clinical information and the ECG (see also Section
3.3). In a study of 515 survivors of hospitalization for
NSTEMI, risk factors included persistent ST-segment
depression, HF, advanced age, and ST-segment elevation at
discharge (682). Patients with all high-risk markers present
had a 14-fold greater mortality rate than did patients with
all markers absent. Elevated cardiac TnT levels have also
been demonstrated to provide independent prognostic in-
formation for cardiac events at 1 to 2 years. For patients
with ACS in a GUSTO-IIa substudy, age, ST-segment
elevation on admission, prior CABG, TnT, renal insufﬁ-
ciency, and severe chronic obstructive pulmonary disease
were independently associated with risk of death at 1 year
(683,684). For UA/NSTEMI patients, prior MI, TnT
positivity, accelerated angina before admission, and recur-
rent pain or ECG changes were independently associated
with risk of death at 2 years. Patients managed with an
initial conservative strategy (see Section 3) should be reas-
sessed at the time of return visits for the need for cardiac
catheterization and revascularization. Speciﬁcally, the pres-
ence and severity of angina should be ascertained. Rates of
revascularization during the ﬁrst year have been reported to
be high (685). Long-term (7 years) follow-up of 282
patients with UA demonstrated high event rates during the
ﬁrst year (MI 11%, death 6%, PTCA 30%, and CABG
27%); however, after the ﬁrst year, event rates were low
(685). Independent risk factors for death/MI were age
greater than 70 years, diabetes, and male sex. A predictive
model for the risk of death from discharge to 6 months after
an ACS has been developed and validated using the
17,142-patient GRACE registry database (168). Mortality
averaged 4.8%. Nine predictive variables were identiﬁed:
older age, history of MI, history of HF, increased pulse rate
at presentation, lower systolic blood pressure at presenta-
tion, elevated initial serum creatinine level, elevated initial
serum cardiac biomarker levels, ST-segment depression on
presenting ECG, and not having a PCI performed in the
hospital. The C statistic for the validation cohort was 0.75.
The GRACE tool was suggested to be a simple, robust tool
for clinical use.
Certain patients at high risk of ventricular tachyarrhyth-
mia after UA/NSTEMI may be candidates for an implant-
able cardioverter deﬁbrillator. Indications and timing of an
implantable cardioverter deﬁbrillator in this setting are
presented in the STEMI guidelines (1) and more recently
the Ventricular Arrhythmias and Sudden Cardiac Death
guidelines (686). Indications for testing for atherosclerotic
disease in other vascular beds (i.e., carotid, peripheral
arterial) are also covered elsewhere in recent guidelines
(687).
Major depression has also been reported to be an inde-
pendent risk factor for cardiac events after MI and occurs in
up to 25% of such patients (688). Antidepressant therapy
(with sertraline) was safe and effective for relief of depressive
symptoms in a controlled trial in 369 depressed patients
with ACS, but it did not conclusively demonstrate a
beneﬁcial effect on cardiovascular end points, perhaps be-
cause of limited sample size (689). Cognitive therapy and, in
some cases, sertraline did not affect late survival after MI in
another randomized study (Enhancing Recovery in Coro-
nary Heart Disease [ENRICHD]), but those whose depres-
sion did not improve were at higher risk of late mortality
Anderson et al ACC/AHA UA/NSTEMI Guideline Revision e245
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
(690). The CREATE trial evaluated interpersonal psycho-
therapy (IPT) compared with clinical management and the
selective serotonin reuptake inhibitor citalopram compared
with placebo in a 2 2 factorial design among patients with
CAD and major depression (691). The primary end point of
Hamilton Depression Rating Scale score was improved in
the citalopram group versus placebo (mean reduction 14.9
vs. 11.6, p 0.005) but did not differ for IPT versus clinical
management (mean reduction 12.1 vs. 14.4, p  0.06).
Likewise, the secondary end point of reduction in mean
Beck Depression Inventory score was improved in the
citalopram group but did not differ for IPT.
Patients recognized to be at high risk for a cardiac event
after discharge for any of the above reasons should be seen
for follow-up earlier and more frequently than lower-risk
patients.
The overall long-term risk for death or MI 2 months after
an episode of UA/NSTEMI is similar to that of other CAD
patients with similar characteristics. Van Domburg et al.
(685) reported a good long-term outcome even after a
complicated early course. Based on a median follow-up of
almost 8 years, mortality in the ﬁrst year was 6%, then 2%
to 3% annually in the following years (685). When the
patient has returned to the baseline level, typically 6 to 8
weeks after hospitalization, arrangements should be made
for long-term regular follow-up visits, as for stable CAD.
Cardiac catheterization with coronary angiography is rec-
ommended for any of the following situations: 1) signiﬁcant
increase in anginal symptoms, including recurrent UA; 2)
high-risk pattern (e.g., at least 2 mm of ST-segment
depression, systolic blood pressure decline of at least 10 mm
Hg) on exercise test (see Section 3.4); 3) HF; 4) angina with
mild exertion (inability to complete stage 2 of the Bruce
protocol for angina); and 5) survivors of sudden cardiac
death. Revascularization is recommended based on the
coronary anatomy and ventricular function (see Section 4,
ACC/AHA Guidelines for the Management of Patients
With Chronic Stable Angina [4], and ACC/AHA 2004
Guideline Update for Coronary Artery Bypass Graft Sur-
gery [555]).
Minimizing the risk of recurrent cardiovascular events
requires optimizing patients’ compliance with prescribed
therapies and recommended lifestyle modiﬁcations. Many
studies exploring predictors of compliance have failed to
ﬁnd predictive value in simple demographic or socioeco-
nomic variables. More reliable predictors are the patients’
beliefs and perceptions about their vulnerability to disease
and the efﬁcacy of the prescribed treatments and, impor-
tantly, various aspects of the relationship with their health
care provider (692–694). Development of a therapeutic
relationship with the patient and family is likely to enhance
compliance. Care should be taken to ensure that there is
adequate time spent with the family focused on explanation
of the disease and proposed treatments, the importance of
adhering to the prescribed treatment plan, and exploration
of patient-speciﬁc barriers to compliance. Participation in
cardiac rehabilitation/secondary prevention programs can
help reinforce patient-speciﬁc secondary prevention issues
and can address barriers to compliance. Close communica-
tion between the treating physician and the cardiac rehabil-
itation team is important to maximize effectiveness
(3,47,695,696).
5.4. Cardiac Rehabilitation
CLASS I
Cardiac rehabilitation/secondary prevention programs, when avail-
able, are recommended for patients with UA/NSTEMI, particularly
those with multiple modiﬁable risk factors and those moderate- to
high-risk patients in whom supervised or monitored exercise training is
warranted. (Level of Evidence: B)
Cardiac rehabilitation programs are designed to limit the
physiological and psychological effects of cardiac illness,
reduce the risk for sudden death or reinfarction, control
cardiac symptoms, stabilize or reverse the atherosclerotic
process, and enhance the psychosocial and vocational status
of selected patients (668,695,697). Cardiac rehabilitation is
a comprehensive long-term program that involves medical
evaluation, prescribed exercise, cardiac risk factor modiﬁca-
tion, education, and counseling (668,698). Cardiac rehabil-
itation may occur in a variety of settings, including medi-
cally supervised groups in a hospital, physician’s ofﬁce, or
community facility (696). Exercise may involve a stationary
bicycle, treadmill, calisthenics, walking, or jogging, and
monitoring may include ECG telemetry, depending on a
patient’s risk status and the intensity of exercise training.
Education and counseling concerning risk factor modiﬁca-
tion are individualized, and close communication between
the treating physician and cardiac rehabilitation team may
promote long-term behavioral change (695,696). Alterna-
tive delivery approaches, including home exercise, internet-
based, and transtelephonic monitoring/supervision, can be
implemented effectively and safely for carefully selected
clinically stable patients (668,699).
Witt et al. (700) examined the association of participation
in cardiac rehabilitation with survival in Olmstead County,
Minnesota, and found that participants had a lower risk of
death and recurrent MI at 3 years (p less than 0.001 and p
 0.049, respectively). The survival beneﬁt associated with
participation was stronger in more recent years (700). In this
study, half of the eligible patients participated in cardiac
rehabilitation after MI, although women and older adult
patients were less likely to participate, independent of other
characteristics.
A pooled-effect estimate for total mortality for the
exercise-only intervention demonstrated a reduction in all-
cause mortality (random effects model OR 0.73 [95% CI
0.54 to 0.98]) compared with usual care. Comprehensive
cardiac rehabilitation reduced all-cause mortality, although
to a lesser degree (OR 0.87 [95% CI 0.71 to 1.05]). Neither
of the interventions had an effect on the occurrence of
nonfatal MI. The authors concluded that exercise-based
cardiac rehabilitation appeared to be effective in reducing
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cardiac deaths but that it was still unclear whether an
exercise-only or a comprehensive cardiac rehabilitation in-
tervention was more beneﬁcial. The population studied was
predominantly male, middle-aged, and low risk. The au-
thors suggested that those who could have beneﬁted from
the intervention might have been excluded owing to age,
gender, or comorbidity. The authors cautioned that the
results were of limited reliability because the quality of
reporting in the studies was generally poor, and there were
high losses to follow-up (698).
Cardiac rehabilitation comprising exercise training and
education, counseling, and behavioral interventions yielded
improvements in exercise tolerance with no signiﬁcant
cardiovascular complications, improvements in symptoms
(decreased anginal pain and improved symptoms of HF
such as shortness of breath and fatigue), and improvements
in blood lipid levels; reduced cigarette smoking in conjunc-
tion with a smoking cessation program; decreased stress;
and improved psychosocial well-being (668). In addition to
reductions in total cholesterol and LDL-C, increases in
HDL-C levels occur (701).
Cardiac rehabilitation has been reported to improve
prognosis after MI in a cost-effective manner (702,703). In
current practice, referrals for cardiac rehabilitation are more
frequent after bypass surgery and less frequent after PCI for
UA/NSTEMI (704). Beneﬁts of rehabilitation after un-
complicated UA/NSTEMI with revascularization and
modern medical therapy are less clear in comparison with
STEMI or complicated NSTEMI.
Existing community studies reveal that fewer than one
third of patients with MI receive information or counseling
about cardiac rehabilitation before being discharged from
the hospital (668,705). Only 16% of patients in a study of 5
hospitals in 2 Michigan communities were referred to a
cardiac rehabilitation program at discharge, and only 26% of
the patients later interviewed in the community reported
actual participation in such a program; however, 54% of the
patients referred at discharge did participate at the time of
their follow-up interview (705). Physician referral was the
most powerful predictor of patient participation in a cardiac
rehabilitation program. In a longitudinal study of the use of
inpatient cardiac rehabilitation in 5,204 Worcester, Mass,
residents hospitalized with MI in seven 1-year periods
between 1986 and 1997, patients not referred to inpatient
cardiac rehabilitation were less likely to be prescribed
effective cardiac medications and to undergo risk factor
modiﬁcation counseling before discharge (706).
Patient reasons for nonparticipation and noncompliance
include affordability of service, insurance coverage/
noncoverage, social support from a spouse or other care-
giver, gender-speciﬁc attitudes, patient-speciﬁc internal fac-
tors such as anxiety or poor motivation, and logistical and
ﬁnancial constraints, or a combination of these factors
(688,705). Women and the elderly are referred less fre-
quently to cardiac rehabilitation programs, even though they
derive beneﬁt from them (38,707–710). Health care systems
should consider instituting processes that encourage referral
of appropriate patients to cardiac rehabilitation/secondary
prevention programs (for example, the use of standardized
order sets that facilitate this, such as the AHA “Get with the
Guidelines” tools). In addition, it is important that referring
health care practitioners and cardiac rehabilitation teams
communicate in ways that promote patient participation. Of
note, Medicare coverage for rehabilitation recently was
expanded beyond post-MI, post-CABG, and stable angina
to include PCI (711).
5.5. Return to Work and Disability
Return-to-work rates after MI, which currently range from
63% (712) to 94% (713), are difﬁcult to inﬂuence because
they are confounded by factors such as job satisfaction,
ﬁnancial stability, and company policies (714). In PAMI
(Primary Angioplasty in Myocardial Infarction)-II, a study
of primary PTCA in low-risk patients with MI (i.e., age less
than 70 years, ejection fraction greater than 0.45, 1- or
2-vessel disease, and good PTCA result), patients were
encouraged to return to work at 2 weeks (715). The actual
timing of return to work was not reported, but no adverse
events occurred as a result of this strategy.
Cardiac rehabilitation programs after MI can contribute
to reductions of mortality and improved physical and
emotional well-being (see Section 5.4). Patients whose
expectations for return to work were addressed in rehabili-
tation returned to work at a signiﬁcantly faster rate than the
control group in a prospective study (716).
Lower or absent levels of depressive symptoms before MI
increases the odds of recovery of functional status (717).
Patients with high pre-event functional independence mea-
surement have a shorter length of stay and a greater
likelihood of discharge to home (718). Pre-event peak
aerobic capacity and depression score are the best indepen-
dent predictors of postevent physical function. Women tend
to have lower physical function scores than men of similar
age, depression score, and comorbidity. Resting LVEF is
not a predictor of physical function score.
Patients’ cardiac functional states are not a strong predic-
tor of their probability of returning to work. Diabetes, older
age, Q-wave MI, and preinfarction angina are associated
with failure to resume full employment (719). However,
psychological variables such as trust, job security, patient
feelings about disability, expectations of recovery by both
physician and patient, and degree of somatizing are more
predictive (720,721). Physical requirements of the job play a
role as well (719,721).
To aid occupational physicians in making return-to-work
decisions, Froom et al. (719) studied the incidence of post- MI
events at 1, 2, 4, 6, 9, and 12 months. Events included cardiac
death, recurrent infarction, CHF, and UA. They found that
the incidence of events reached a low steady state at 10 weeks.
Return to work can be determined by employer regulations
rather than by the patient’s medical condition. It behooves the
physician to provide data to prove that the patient’s job does
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not impose a prohibitive risk for a cardiac event. An example is
the case of Canadian bus drivers reported by Kavanagh et al.
(722). These patients were evaluated with a stress test. The
physician and technologist studied the drivers at work and
showed that the cardiac stress values during driving were only
half of the average values obtained in the stress laboratory. The
calculated risk of sudden cardiovascular incidents causing injury
or death to passengers, other road users, and the drivers
themselves in the ﬁrst year after recovery from an MI was 1 in
50,000 driving-years. The bus drivers were allowed to return to
work after they satisﬁed the Canadian Cardiovascular Society
guidelines.
Covinsky et al. (723) performed a mail survey study of
patients with MIs. Three months after discharge, women
reported worse physical and mental health and were more
likely to work less than before the MI. Similarly, women
were less likely to return to work than men. Contemporary
information speciﬁc to UA/NSTEMI on return to work by
gender is needed.
The current aggressive interventional treatment of ACS
will have an impact on mortality, morbidity, and hospital
length of stay (724). It remains to be determined whether
earlier improvement in cardiac condition after ACS will
have an effect on the rate of return to work because of the
multiple noncardiac factors that inﬂuence disability and
return to work.
5.6. Other Activities
In patients who desire to return to physically demanding
activities early, the safety of the activity can be deter-
mined by comparing performance on a graded exercise
test with the MET level required for the desired activity.
Table 23 presents energy levels, expressed in METS,
required to perform a variety of common activities (725).
This and similar tables can be helpful in translating a
patient’s performance on a graded exercise test into daily
activities that can be undertaken with reasonable safety.
The health care provider should provide explicit advice
about when to return to previous levels of physical activity,
sexual activity, and employment. Daily walking can be
encouraged immediately (726). In stable patients without
complications (Class I), sexual activity with the usual
partner can be resumed within 1 week to 10 d. Driving can
begin 1 week after discharge if the patient is judged to be in
compliance with individual state laws. Each state’s Depart-
ment of Motor Vehicles or its equivalent has mandated
certain criteria, which vary from state to state and must be
met before operation of a motor vehicle after serious illness
Table 23. Energy Levels Required to Perform Some Common Activities
Less Than 3 METS 3–5 METS 5–7 METS 7–9 METS More Than 9 METS
Self-Care
Washing
Shaving
Dressing
Desk work
Washing dishes
Driving auto
Light housekeeping
Cleaning windows
Raking
Power lawn mowing
Bed making/stripping
Carrying objects (15 to 30 lb)
Easy digging in garden
Level hand lawn mowing
Climbing stairs (slowly)
Carrying objects (30 to 60 lb)
Sawing wood
Heavy shoveling
Climbing stairs (moderate
speed)
Carrying objects (60 to 90 lb)
Digging vigorously
Carrying loads upstairs
(objects more than
90 lb)
Climbing stairs
(quickly)
Shoveling heavy snow
Occupational
Sitting (clerical/
assembly)
Typing
Desk work
Standing (store
clerk)
Stocking shelves (light
objects)
Auto repair
Light welding/carpentry
Carpentry (exterior)
Shoveling dirt
Sawing wood
Operating pneumatic tools
Digging ditches (pick and
shovel)
Forestry
Farming
Lumber jack
Heavy laborer
Shoveling (heavy)
Recreational
Golf (cart)
Knitting
Hand sewing
Dancing (social)
Golf (walking)
Sailing
Tennis (doubles)
Volleyball (6 persons)
Table tennis
Marital sex
Badminton (competitive)
Tennis (singles)
Snow skiing (downhill)
Light backpacking
Basketball
Football
Stream Fishing
Canoeing
Mountain climbing
Paddle ball
Walking (5 mph)
Running (12 min. mile)
Mountain or rock climbing
Soccer
Handball
Football (competitive)
Squash
Ski touring
Vigorous basketball
(game)
Physical Conditioning
Walking (2 mph)
Stationary bike
Very light
calisthenics
Level walking (3–4 mph)
Level biking (6–8 mph)
Light calisthenics
Level walking (4.5–5.0 mph)
Bicycling (9–10 mph)
Swimming, breast stroke
Level jogging (5 mph)
Swimming (crawl stroke)
Rowing machine
Heavy calisthenics
Bicycling (12 mph)
Running (more than 6
mph)
Bicycling (more than
13 mph)
Rope jumping
Walking uphill (5 mph)
Adapted with permission from Haskell WL. Design and implementation of cardiac conditioning program. In: Wenger NL, Hellerstein HK, editors. Rehabilitation of the Coronary Patient. New York, NY:
Churchill Livingstone, 1978 (725).
METS  metabolic equivalents; mph  miles per hour.
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(727). These include such caveats as the need to be
accompanied and to avoid stressful circumstances such as
rush hour, inclement weather, night driving, heavy trafﬁc,
and high speeds. For patients who have experienced a
complicated MI (one that required CPR or was accompa-
nied by hypotension, serious arrhythmias, high-degree
block, or CHF), driving should be delayed 2 to 3 weeks after
symptoms have resolved.
Most commercial aircraft are pressurized to 7,500 to
8,000 feet and therefore could cause hypoxia due to the
reduced alveolar oxygen tension. The maximum level of
pressurization is limited to 8,000 feet (2440 m) by Federal
Aviation Administration regulation (728). Therefore, air
travel within the ﬁrst 2 weeks of MI should be undertaken
only if there is no angina, dyspnea, or hypoxemia at rest or
fear of ﬂying. The individual must have a companion, must
carry NTG, and must request airport transportation to avoid
rushing and increased cardiac demands. Availability of an
emergency medical kit and automated external deﬁbrillator
has been mandated as of April 12, 2004 (729), in all aircraft
that carry at least approximately 30 passengers and have at
least 1 ﬂight attendant.
Patients with UA (i.e., without infarction) who are
revascularized and otherwise stable may accelerate return to
work, driving, ﬂying, and other normal activities (often,
within a few days).
5.7. Patient Records and Other Information
Systems
Effective medical record systems that document the
course and plan of care should be established or en-
hanced. Both paper-based and electronic systems that
incorporate evidence-based guidelines of care, tools for
developing customized patient care plans and educational
materials, and capture of data for appropriate standard-
ized quality measurements should be implemented and
used routinely. Examples of such tools are the ACC’s
“Guidelines Applied in Practice” and the AHA’s “Get
With the Guidelines.” All computerized provider order
entry (CPOE) systems should incorporate these at-
tributes as well. In some settings, the regular and con-
sistent use of such systems and tools has been shown to
signiﬁcantly improve quality of care and patient safety.
The patient’s medical record from the time of hospital
discharge should indicate the discharge medical regimen,
the major instructions about postdischarge activities and
rehabilitation, and the patient’s understanding and plan
for adherence to the recommendations. After resolution
of the acute phase of UA/NSTEMI, the medical record
should summarize cardiac events, current symptoms, and
medication changes since hospital discharge or the last
outpatient visit and should document the plan for future
care. Processes for effective and timely transfer of relevant
prehospital and postdischarge patient information be-
tween all participating caregivers should be continuously
enhanced in accordance with existing regulatory stan-
dards. This should include providing all patients with the
tools to facilitate access to and understanding of the nature and
importance of their most current plan of care. With the
increasing numbers of patients who have regular access to the
Internet, awareness of online information reﬂecting current
evidence-based and professionally developed standards of care
should be encouraged and promoted. Several sites with reliable
health care information relevant to UA/NSTEMI are available
to patients (http://www.heartauthority.com; http://
www.nhlbi.nih.gov/health/dci/index.html; http://
www.nlm.nih.gov/medlineplus/tutorial.html; and http://
www.fda.gov/hearthealth/index.html).
6. Special Groups
6.1. Women
RECOMMENDATIONS
CLASS I
1. Women with UA/NSTEMI should be managed with the same phar-
macological therapy as men both in the hospital and for secondary
prevention, with attention to antiplatelet and anticoagulant doses
based on weight and renal function; doses of renally cleared medi-
cations should be based on estimated creatinine clearance. (Level
of Evidence: B)
2. Recommended indications for noninvasive testing in women with
UA/NSTEMI are similar to those for men. (Level of Evidence: B)
3. For women with high-risk features, recommendations for invasive
strategy are similar to those of men. See Section 3.3. (Level of
Evidence: B)
4. In women with low-risk features, a conservative strategy is recom-
mended. (Level of Evidence: B)
Although at any age, women have a lower incidence of
CAD than men, they account for a considerable proportion
of UA/NSTEMI patients, and UA/NSTEMI is a serious
and common condition among women. It is important to
overcome long-held notions that severe coronary manifes-
tations are uncommon in this population; however, women
can manifest CAD somewhat differently than men (679).
Women who present with chest discomfort are more likely
than men to have noncardiac causes and cardiac causes other
than ﬁxed obstructive coronary artery stenosis. Other car-
diac causes include coronary vasospasm, abnormal vasodila-
tor reserve, and other mechanisms (679,731–733). Women
with CAD are, on average, older than men and are more
likely to have comorbidities such as hypertension, diabetes
mellitus, and HF with preserved systolic function; to man-
ifest angina rather than MI; and, among angina and MI
patients, to have atypical symptoms (150,734–736).
6.1.1. Proﬁle of UA/NSTEMI in Women
Considerable clinical information about UA/NSTEMI in
women has emerged from many randomized trials and
registries (150,552,554,734,737). As in other forms of
CAD, women are older and have more comorbidities
(diabetes mellitus and hypertension) and stronger family
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histories than men (150,734–736). Women are less likely to
have had a previous MI or cardiac procedures (734), more
likely to have a history of HF, but less likely to have LV
systolic dysfunction. Women present with symptoms of
similar frequency, duration, and pattern, but more often
than men, they have anginal-equivalent symptoms such as
dyspnea or atypical symptoms (72,141,738). The frequency
of ST-segment changes is similar to that for men, but
women more often have T-wave inversion. There are
notable differences in the proﬁles of cardiac biomarkers for
women and men, with a consistent ﬁnding in trials and
registries that women less often have elevated levels of
troponin (552,554,565,737). In an analysis of TACTICS-
TIMI 18, women also less often had elevation of CK-MB;
however, women more often had increased levels of high-
sensitivity CRP or BNP than men. Importantly, the prog-
nostic value of elevated biomarkers is similar in men and
women (739). Coronary angiograms in both trials and
registries revealed less extensive CAD in women, as well as
a higher proportion with nonobstructive CAD. The rate of
nonobstructive CAD can be as high as 37% despite selection
of women according to strict inclusion criteria in clinical
trials (150,554).
A differing symptom pattern in women than men, the
lower frequency of positive cardiac biomarkers despite high
rates of ST-T abnormalities on the ECG, and the higher
frequency of nonobstructive CAD in women make it
challenging to conﬁrm the diagnosis of UA/NSTEMI. This
is a likely cause of underutilization of several therapies in
women compared with men (737). There are important
mechanisms of ischemic chest pain other than platelet/
thrombus aggregates on plaque erosion or ulceration in
women (see Section 6.8). Although some studies report that
female sex is a risk factor for poor outcome in UA/
NSTEMI on the basis of unadjusted event rates, (72,737),
multivariate models have not found female sex to be an
independent risk factor for death, reinfarction, or recurrent
ischemia. This is in contrast to an apparent independent risk
of death for women compared with men with STEMI,
particularly for younger women.
6.1.2. Management
6.1.2.1. PHARMACOLOGICAL THERAPY
In studies that span the spectrum of CAD, women tend to
receive less intensive pharmacological treatment than men
(734,737,740), perhaps in part because of a general percep-
tion of lower frequency and severity of CAD in women.
Although the speciﬁcs vary regarding beta blockers and
other drugs (150,734,741), a consistent (and disturbing)
pattern is that women are prescribed ASA and other
antithrombotic agents less frequently than men (150,737,740).
Women derive the same treatment beneﬁt as men from ASA,
clopidogrel (54), anticoagulants, beta blockers, ACE inhibi-
tors, and statins (54,742). A meta-analysis of GP IIb/IIIa
antagonists in ACS demonstrated an interaction between sex
and treatment effect, with an apparent lack of efﬁcacy in
women (526); however, women with elevated troponin levels
received the same beneﬁcial effect as men treated with GP
IIb/IIIa antagonists. The ﬁndings of a beneﬁcial effect of a
direct invasive strategy in women treated with a GP IIb/IIIa
antagonist in TACTICS-TIMI 18 (see Section 6.1.2.3) fur-
ther supports the similar efﬁcacy of these agents in this cohort
of women and men.
Despite the clear beneﬁt of antiplatelet and anticoagulant
therapy for women with ACS, women are at increased risk
of bleeding. A low maintenance dose of ASA (75 to 162
mg) should be used to reduce the excess bleeding risk,
especially in combination with clopidogrel (54). Estimated
creatinine clearance instead of serum creatinine levels
should guide decisions about dosing and the use of agents
that are renally cleared, e.g., LMWHs and the small-
molecule GP IIb/IIIa antagonists. In a large community-
based registry study, 42% of patients with UA/NSTEMI
received excessive initial dosing of at least 1 antiplatelet or
anticoagulant agent (UFH, LMWH, or GP IIb/IIIa inhib-
itor) (743). Female sex, older age, renal insufﬁciency, low
body weight, and diabetes were predictors of excessive
dosing. Dosing errors predicted an increased risk of major
bleeding (743). The formula used to estimate creatinine
clearance for dose adjustment in clinical studies and labeling
that deﬁnes adjustments for several medications have been
based on the Cockroft-Gault formula for estimating creat-
inine clearance, which is not identical to the Modiﬁcation of
Diet and Renal Disease (MDRD) formula recently recom-
mended for screening for renal disease (744), either in units
or cutpoints for adjustment. Weight-based adjustment of
medication doses also should be applied carefully where
recommended.
The use of hormone therapy in postmenopausal women is
discussed in Section 5.2.17.
6.1.2.2. CORONARY ARTERY REVASCULARIZATION
Contemporary studies have cast doubt on the widely held
belief that women fare worse with PCI and CABG than do
men because of technical factors (e.g., smaller artery size,
greater age, and more comorbidities) (150,735,742,745–
749). In the case of PCI, it has been suggested that
angiographic success and late outcomes are similar in
women and men, although in some series, early complica-
tions occurred more frequently in women (745,746,750–
753). However, the outlook for women undergoing PCI
appears to have improved, as evidenced by the NHLBI
PTCA registry (754). Earlier studies of women undergoing
CABG showed that women were less likely to receive
internal mammary arteries or complete revascularization
and had a higher mortality rate (RR 1.4 to 4.4) than men
(748,749,755). However, more recent studies of CABG in
patients with ACS show a more favorable outlook for
women than previously thought (see Section 6.3)
(756,757,757a).
A Mayo Clinic review of 3,014 patients (941 women)
with UA who underwent PCI reported that women had
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similar early and late results as men (735). The BARI trial
of 1,829 patients compared PTCA and CABG, primarily in
patients with UA, and showed that the results of revascu-
larization were, if anything, better in women than men
when corrected for other factors. At an average 5.4-year
follow-up, mortality rates for men and women were 12%
and 13%, respectively, but when adjusted for baseline
differences (e.g., age, diabetes, and other comorbidities),
there was a lower risk of death (RR 0.60, 95% CI 0.43 to
0.84, p 0.003) but a similar risk of death or MI (RR 0.84,
95% CI 0.66 to 1.07, p  0.16) in women compared with
men (755). The NHLBI Dynamic Registry has reported
improved outcomes for women who underwent PCI in
1997 to 1998 compared with 1985 to 1986. Compared with
men, women had similar procedural success, in-hospital
death, MI, and CABG (754). Although the 1-year event
rate was higher for women, female sex was not indepen-
dently associated with death or MI because women tended
to be older and had more comorbidities. A prospective study
of 1,450 patients with UA/NSTEMI who underwent an
indirect or direct invasive strategy with coronary stenting
reported that female sex was independently associated with
a lower rate of death and MI (HR 0.51, 95% CI 0.28 to
0.95) (553).
6.1.2.3. INITIAL INVASIVE VERSUS INITIAL CONSERVATIVE STRATEGY
In the modern era, clinical trials assessing a direct invasive
strategy compared with an initial conservative strategy for
the management of UA/NSTEMI have consistently dem-
onstrated a beneﬁt for men (552,554,565). Approximately
one third of the cohorts in these trials were women (n 
2,179), and the results on the efﬁcacy and safety of a direct
invasive strategy in women have been conﬂicting. Each trial
was underpowered to evaluate the subgroup of women, and
there were substantial differences among the trials (Table
24). A meta-analysis of trials in the era of stents and GP
IIb/IIIa antagonists has failed to show a survival beneﬁt of
a direct invasive strategy in women at 6 to 12 months (OR
for women 1.07, 95% CI 0.82 to 1.41; OR for men 0.68,
95% CI 0.57 to 0.81) (542).
In TACTICS-TIMI 18, there was a signiﬁcant reduction
in the primary end point of death, nonfatal MI, or rehos-
pitalization for an ACS with a direct invasive strategy (OR
0.45, 95% CI 0.24 to 0.88, p  0.02) (182). All subjects in
this trial (n  754) were treated with an early GP IIb/IIIa
antagonist (tiroﬁban). A similar overall reduction in the
primary composite end point of death, MI, or rehospital-
ization for ACS at 6 months was observed for women and
men (adjusted OR 0.72, 95% CI 0.47 to 1.11 and adjusted
OR 0.64, 95% CI 0.47 to 0.88, respectively). Women were
older, more frequently had hypertension, and less frequently
had previous MI, CABG, and elevated cardiac biomarkers
(p less than 0.001 for all), but there was no signiﬁcant
difference in TIMI risk score distribution by sex (p  0.76)
(565). A similar reduction in composite risk was observed in
women with intermediate (3 to 4) or high (5 to 7) TIMI risk
scores as in men. However, in contrast to men with a low
TIMI risk score who had similar outcomes with an invasive
and conservative strategy, low-risk women had an OR for
events of 1.59 (95% CI 0.69 to 3.67) for the invasive
compared with the conservative strategy (565). However,
the number of events was small (n  26 events), and the p
value for interaction between strategy, TIMI risk score, and
sex on outcome did not achieve signiﬁcance (p  0.09). An
elevated biomarker, including BNP, CRP, CK-MB, and
troponin, also identiﬁed women (and men) who beneﬁted
differentially from a direct invasive strategy. The reduction
in risk was enhanced in women with elevated TnT levels
(adjusted OR 0.47, 95% CI 0.26 to 0.83), with a similar
reduction in the primary end point noted for women and
men with elevated troponin. However, in contrast to the
similar outcome for the invasive versus conservative strategy
in men with a negative TnT marker (OR 1.02, 95% CI 0.64
to 1.62, p  0.04), the primary end point of death, MI, and
rehospitalization occurred signiﬁcantly more frequently in
women with negative troponin randomized to an invasive
strategy (OR 1.46, 95% CI 0.78 to 2.72) (565).
The RITA-3 trial enrolled 682 women (38% of 1,810
patients) (758). There was a signiﬁcant interaction between
sex and treatment strategy (invasive versus conservative) on
outcome in RITA-3 (p  0.042). In contrast to a reduction
in death or MI for men assigned to an invasive strategy, the
HR for women was 1.09. Women assigned to an initial
conservative strategy had a lower rate of death and MI
(5.1%) at 1 year than the women enrolled in TACTICS-
TIMI 18 (9.7% at 6 months). Consistent with this differ-
ence, 37% of women in RITA-3 had no signiﬁcant obstruc-
tive CAD, compared with 17% of women in TACTICS-
TIMI 18 (759). Other notable differences between RITA-3
and TACTICS-TIMI 18 include routine use of GP IIb/
IIIa antagonist in TACTICS-TIMI 18 and different crite-
ria for the MI end point in both the conservative and the
invasive treatment groups. The RITA-3 investigators have
reported that the rates of death and MI for women are
11.1% and 12.7% in the conservative versus invasive strat-
egy, respectively, that is, not signiﬁcantly different, when
there was a lower threshold for cardiac marker diagnosis of
MI among the conservatively treated group (554).
In the only trial that showed an overall survival beneﬁt for
an invasive strategy, FRISC-II, there was a signiﬁcant
interaction in outcome between treatment strategy, which
included a systematic but delayed interventional approach
within 7 d of symptom onset, and sex (549,552). Thirty
percent of the 2,457 enrolled patients were women, and the
death and MI rate at 1 year was nonsigniﬁcantly higher for
invasively treated versus conservatively treated women, in
contrast to a large reduction in death and MI for men.
Female sex was independently associated with events in the
invasively assigned patients. However, the poor outcome of
women was largely driven by a 9.9% death rate at 1 year in
women who underwent CABG. In contrast, the death rate
for women who underwent PCI in the invasive strategy
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group was similar to that of men (1.5% vs. 1.0%; RR 1.50,
95% CI 0.27 to 8.28; p  nonsigniﬁcant [NS]).
In summary, women with UA/NSTEMI and high-risk
features, including elevated cardiac biomarkers, appear to
beneﬁt from an invasive strategy with early intervention and
adjunctive GP IIb/IIIa antagonist use. There is no beneﬁt of
a direct invasive strategy for low-risk women, and the
weight of evidence from the recent randomized clinical trials
suggests that there may be excess risk associated with a
direct invasive strategy in this group. The challenges in the
diagnosis of UA/NSTEMI and the varied pathophysiology
of ischemic pain in women who present with rest discomfort
suggest that perhaps the excess risk of a direct invasive
strategy observed in low-risk women could be due to
intervention on a stable incidental coronary lesion in a
woman with another mechanism for rest pain.
6.1.3. Stress Testing
In general, ECG exercise testing is less predictive in women
than in men, primarily because of the lower pretest proba-
bility of CAD (581,760–762). Perfusion studies using
sestamibi have good sensitivity and speciﬁcity in women
(763). Breast attenuation is less of a problem than previously
with thallium-201 stress testing with new tissue software.
Stress echocardiography (dobutamine or exercise) is there-
fore an accurate and cost-effective technique for CAD
detection in women (581). Newer perfusion methods such
as adenosine-stress CMR also appear to be promising in
women. Cardiac magnetic resonance imaging (for function,
perfusion, and viability) and multislice CCTA are 2 new
diagnostic modalities that could prove particularly useful in
women because of their promise of both greater sensitivity
and speciﬁcity (improved diagnostic accuracy). Evidence of
ischemia by objective measures without obstructive CAD
carries an adverse prognosis (4,764) and is suggestive of
vascular dysfunction (coronary endothelial or microvascular
dysfunction) as an etiological mechanism.
Recommendations for noninvasive testing in women are
the same as in men (see Section 3.4) (733,764). A report of
976 women who underwent treadmill exercise suggests that
the Duke Treadmill Score provides accurate diagnostic and
prognostic estimates in both women and men (765). The
Duke Treadmill Score actually performed better for women
than for men in the exclusion of CAD. There were fewer
low-risk women than men with any signiﬁcant CAD (at
least 1 vessel with greater than 75% stenosis; 20% in women
vs. 47% in men, p less than 0.001).
Regarding dobutamine stress echocardiography, pilot
phase data from the Women’s Ischemia Syndrome Evalu-
ation (WISE) indicated that in women, the test reliably
detects multivessel disease (sensitivity 81.8%, similar to that
in men) but not 1-vessel disease (766). Several studies have
indicated that women with positive stress tests tend not to
be evaluated as aggressively as men (741), which is inappro-
priate given the adverse prognosis of ischemia as demon-
strated in WISE and other studies (733,767–774).
In the TIMI IIIB registry, women underwent exercise
testing in a similar proportion as men (150,734). The
frequencies of stress test positivity were also similar, al-
though women were less likely to have a high-risk stress test
result. Moreover, women were less likely to undergo an-
giography (RR 0.71, p less than 0.001), perhaps because of
the lower percentage with high-risk test results on nonin-
vasive testing.
6.1.4. Conclusions
Women with UA/NSTEMI are older and more frequently
have comorbidities compared with men but have more
atypical presentations and appear to have less severe and less
extensive obstructive CAD. Women receive ASA less fre-
quently than do men, but patients with UA/NSTEMI of
either sex beneﬁt from and should receive this agent, as well
as other Class I recommended agents. Doses should be
adjusted on the basis of weight and estimated creatinine
clearance for renally cleared drugs for all recommended
agents when appropriate. Image-enhanced stress testing has
similar prognostic value in women as in men.
6.2. Diabetes Mellitus
RECOMMENDATIONS
CLASS I
1. Medical treatment in the acute phase of UA/NSTEMI and decisions
on whether to perform stress testing, angiography, and revascular-
ization should be similar in patients with and without diabetes
mellitus. (Level of Evidence: A)
2. In all patients with diabetes mellitus and UA/NSTEMI, attention
should be directed toward aggressive glycemic management in
accordance with current standards of diabetes care endorsed by the
American Diabetes Association and the American College of Endo-
crinology. Goals of therapy should include a preprandial glucose
target of less than 110 mg per dL and a maximum daily target of
less than 180 mg per dL. The postdischarge goal of therapy should
be HbA1C less than 7%, which should be addressed by primary care
and cardiac caregivers at every visit. (Level of Evidence: B)
3. An intravenous platelet GP IIb/IIIa inhibitor should be administered
for patients with diabetes mellitus as recommended for all UA/
NSTEMI patients (Section 3.2). (Level of Evidence: A) The beneﬁt
may be enhanced in patients with diabetes mellitus. (Level of
Evidence: B)
CLASS IIa
1. For patients with UA/NSTEMI and multivessel disease, CABG with
use of the internal mammary arteries can be beneﬁcial over PCI in
patients being treated for diabetes mellitus. (Level of Evidence: B)
2. Percutaneous coronary intervention is reasonable for UA/NSTEMI
patients with diabetesmellitus with single-vessel disease and induc-
ible ischemia. (Level of Evidence: B)
3. In patients with UA/NSTEMI and diabetes mellitus, it is reasonable
to administer aggressive insulin therapy to achieve a glucose less
than 150 mg per dL during the ﬁrst 3 hospital (intensive care unit)
days and between 80 and 110 mg per dL thereafter whenever
possible. (Level of Evidence: B)
Please see Section 4 for further explanation of revascularization
strategies.
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6.2.1. Proﬁle and Initial Management of Diabetic and
Hyperglycemic Patients With UA/NSTEMI
Coronary artery disease accounts for 75% of all deaths in
patients with diabetes mellitus (50,51), and approximately
20% to 25% of all patients with UA/NSTEMI have
diabetes (610,734,775–778). Patients with UA/NSTEMI
and diabetes have more severe CAD (776,779,780), and
diabetes is an important independent predictor for adverse
outcomes (death, MI, or readmission with UA at 1 year; RR
4.9) (781–784). In addition, many patients with diabetes
who present with UA/NSTEMI have already undergone
CABG (785).
Patients with diabetes tend to have more extensive
noncoronary vascular comorbidities, hypertension, LV hy-
pertrophy, cardiomyopathy, and HF. In addition, auto-
nomic dysfunction, which occurs in approximately one third
of patients with diabetes, inﬂuences heart rate and blood
pressure, raises the threshold for the perception of angina,
and may be accompanied by LV dysfunction (786–788). On
coronary angiography, patients with diabetes and UA have
a greater proportion of ulcerated plaques (94% vs. 60%, p 
0.01) and intracoronary thrombi (94% vs. 55%, p  0.004)
than patients without diabetes (789). These ﬁndings suggest
a higher risk of plaque instability.
According to American Diabetes Association standards
of care (790), the relationship of controlled blood glucose
levels and reduced mortality in the setting of MI has been
demonstrated. The American College of Endocrinology has
also emphasized the importance of careful control of blood
glucose targets in the range of 110 mg per dL preprandially
to a maximum of 180 mg per dL. In 1 study (791),
admission blood glucose values were analyzed in consecutive
patients with MI. Analysis revealed an independent associ-
ation of admission blood glucose and mortality. The 1-year
mortality rate was signiﬁcantly lower in subjects with
admission plasma glucose less than 101 mg per dL (5.6
mmol per liter) than in those with plasma glucose 200 mg
per dL (11 mmol per liter). In the ﬁrst Diabetes and
Insulin-Glucose Infusion in Acute Myocardial Infarction
(DIGAMI) study (792,793) insulin-glucose infusion fol-
lowed by subcutaneous insulin treatment in diabetic patients
with MI was examined. Mean blood glucose in the intensive
insulin intervention arm was 172.8 mg per dL (9.5 mmol
per liter) compared with 211 mg per dL (11.6 mmol per
liter) in the “conventional” group. Overall, the intensive
approach reduced long-term relative mortality (at 3.4 years
of follow-up) by 25% in the insulin-treated group. The
broad range of blood glucose levels within each arm limits
the ability to deﬁne speciﬁc blood glucose target thresholds.
In the second DIGAMI study (794), 3 treatment strat-
egies were compared in a randomized trial among 1,253
patients with type 2 diabetes mellitus and suspected MI:
acute insulin-glucose infusion followed by insulin-based
long-term glucose control, insulin-glucose infusion followed
by standard glucose control, and routine metabolic manage-
ment according to local practice. Blood glucose was reduced
more at 24 h in those receiving insulin-glucose infusions,
but long-term glucose control, assessed by HbA1C, did not
differ between the groups, and the fasting glucose in group
1 (8.0 mmol per liter) did not reach target (5 to 7 mmol per
liter). The primary end point of all-cause mortality between
groups 1 and 2 did not differ signiﬁcantly (23.4% vs. 22.6%)
at a median of 2.1 years of follow-up. Morbidity also did not
differ among the 3 groups. Although the DIGAMI-2
regimen of acutely introduced, long-term insulin treatment
in the setting of suspected acute MI was not demonstrated
to incrementally reduce morbidity and mortality, epidemi-
ological analyses still support a strong, independent rela-
tionship between glucose levels and long-term mortality in
patients with ischemic heart disease (794).
Attainment of targeted glucose control in the setting of
cardiac surgery is associated with reduced mortality and risk
of deep sternal wound infections in cardiac surgery patients
with diabetes (795,796). This supports the concept that
perioperative hyperglycemia is an independent predictor of
infection in patients with diabetes mellitus, with the lowest
mortality in patients with blood glucose less than or equal to
150 mg per dL (8.3 mmol per liter) (797).
A mixed group of patients with and without diabetes
admitted to a surgical intensive care unit (ICU) were
randomized to receive intensive insulin therapy (target
blood glucose 80 to 110 mg per dL [4.4 to 6.1 mmol per
liter]). Achievement of a mean blood glucose of 103 mg per
dL (5.7 mmol per liter) reduced mortality during the ICU
stay and decreased overall in-hospital mortality (798). Sub-
sequent analysis demonstrated that for each 20-mg per dL
(1.1-mmol per liter) glucose elevation above 100 mg per dL
(5.5 mmol per liter), the risk of death during the ICU stay
increased. Hospital and ICU survival were linearly associ-
ated with ICU glucose levels, with the highest survival rates
occurring in patients achieving an average blood glucose less
than or equal to 110 mg per dL (6.1 mmol per liter).
Although beta blockers can mask the symptoms of
hypoglycemia or lead to it by blunting the hyperglycemic
response, they nevertheless should be used with appropriate
caution in patients with diabetes mellitus and UA/
NSTEMI. Diuretics that cause hypokalemia can inhibit
insulin release and thereby worsen glucose intolerance.
Elevated blood glucose among critically ill patients even
in the absence of clinical diabetes mellitus has received
recent attention as an important risk factor for mortality
(799). A randomized trial in the surgical ICU setting (800)
found that strict glycemic control with insulin reduced both
morbidity and in-hospital mortality (800). More recently,
the role of intensive insulin therapy in the medical ICU
setting has been studied (801) in 1,200 medical ICU
patients (some with CVD) randomized to conventional
therapy (insulin administered when glucose exceeded 215
mg per dL, tapering infusion when glucose fell below 180
mg per dL) or to intensive insulin therapy (targeting a
glucose of 80 to 110 mg per dL). Overall, intensive insulin
e254 Circulation August 14, 2007
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
did not signiﬁcantly reduce in-hospital mortality, the pri-
mary end point (37.3% in the intensive therapy arm, 40% in
the conventional arm, p 0.33), but secondary outcomes of
acquired kidney injury, time to ventilator weaning, and ICU
and hospital discharge stays were reduced. Hypoglycemia
was more common but often consisted of a single, asymp-
tomatic episode. However, when analysis was restricted to
the intended population of 767 patients whose ICU stay was
at least 3 d, in-hospital death was reduced from 52.5% to
43% (p  0.009) and ICU death from 38.1% to 31.3% (p 
0.005). In addition, secondary outcomes of time to ventila-
tor weaning, days to ICU discharge and to hospital dis-
charge, acquired kidney injury, hyperbilirubinemia, and
CRP levels were reduced. Pending results of additional
randomized clinical trials (802), a reasonable approach is to
apply a less aggressive glucose control strategy during the
ﬁrst 3 ICU days (e.g., goal of less than 150 mg per dL) in
very ill patients (e.g., with ventilators or on parenteral
feeding) (803). Thereafter, and in less ill patients, a more
intensive insulin regimen could be instituted, with a goal of
normoglycemia (80 to 110 mg per dL).
6.2.2. Coronary Revascularization
Approximately 20% of all patients who undergo CABG
(804) and PCI (746,747,750,751,779,780) have diabetes
mellitus. Data regarding outcomes are complex. In the
Coronary Artery Surgery Study (CASS) of CABG, patients
with diabetes had a 57% higher mortality rate than patients
without diabetes. A striking advantage for CABG over PCI
was found in treated patients with diabetes in the BARI trial
(776), a randomized trial of PCI versus CABG in 1,829
stable patients with multivessel disease, of whom 19% were
patients with diabetes (see Section 4). As in other studies,
patients with diabetes mellitus had increased comorbidity
rates. Five years after randomization, patients who required
treatment for diabetes had a lower survival rate than patients
without diabetes (73.1% vs. 91.3%, p less than 0.0001),
whereas survival rates in patients without and with diabetes
who did not require hypoglycemic treatment were similar
(93.3% vs. 91.1%, pNS). Outcomes for CABG in treated
patients with diabetes were far better than those for PCI
(80.6% vs. 65.5% survival, p  0.0003). An interesting
ﬁnding was that the mortality rate during the 5.4 years of
the study in patients with diabetes who received SVGs
(18.2%) was similar to that of patients who underwent PCI
(20.6%); whereas the mortality rate in patients who received
internal mammary arteries was much lower (2.9%). Results
of the Emory Angioplasty versus Surgery Trial (EAST) at 8
years showed a similar trend but were less conclusive (805).
The increased mortality rate noted in randomized trials in
patients with diabetes treated with PTCA has been con-
ﬁrmed in a registry study from Emory University (613).
Uncorrected, there was little difference in long-term mor-
tality rates. The CABG patients had more severe disease,
and with correction for baseline differences, there was an
improved survival rate in insulin-requiring patients with
multivessel disease who were revascularized with CABG
rather than with PCI. That the more severely diseased
patients, in a nonrandomized registry, were selectively sent
more often for CABG than for PCI probably represents
good clinical decision making.
A 9-year follow-up of the NHLBI registry showed a similar
disturbing pattern for patients with diabetes undergoing PCI
(779). Immediate angiographic success and completeness of
revascularization were similar, but compared with patients
without diabetes, patients with diabetes (who, again, had more
severe CAD and comorbidities) had increased rates of hospital
mortality (3.2% vs. 0.5%), nonfatal MI (7.0% vs. 4.1%), death
and MI (10.0% vs. 4.5%), and the combined end point of
death, MI, and CABG (11% vs. 6.7%; p less than 0.01 for all).
At 9 years, rates of mortality (35.9% vs. 17.9%), MI (29% vs.
18.5%), repeat PCI (43.0% vs. 36.5%), and CABG (37.6% vs.
27.4%) were all higher in patients with diabetes than in those
without (779).
However, as discussed in Section 4, other data point to a
lesser differential effect of PCI in patients with diabetes. For
example, data from the BARI registry varied from those of
the BARI trial. In the registry, there was no signiﬁcant
difference in cardiac survival for patients with diabetes
undergoing PCI (92.5%) and CABG (94%; p  NS)
(615,806). In the Duke University registry, patients with
diabetes and PCI or CABG were matched with the BARI
population (807). The outcome in patients with diabetes
was worse than that without diabetes with either CABG or
PCI, but there was no differential effect by therapy. The
5-year survival rate for PCI and CABG adjusted for
baseline characteristics was 86% and 89% in patients with
diabetes and 92% and 93% without diabetes, respectively
(807).
Stents could improve the outcome of patients with
diabetes who undergo PCI. In a study with historical
controls, the outcome after coronary stenting was superior
to that after PTCA in patients with diabetes, and the
restenosis rate after stenting was reduced (63% vs. 36%,
diabetes vs. no diabetes with balloon PTCA at 6 months, p
 0.0002, compared with 25% and 27% with stents, p 
NS) (805). On the other hand, patients with diabetes who
underwent atherectomy had a substantial restenosis rate
(60% over 6 months) (808). Using data derived from the
Northern New England registries, a contemporary BARI-
like comparison of long-term survival after PCI (64% with
at least 1 stent) versus CABG found signiﬁcantly better
risk-adjusted long-term survival in CABG patients with
3-vessel disease (HR 0.60, p less than 0.01) (809). Similar
beneﬁts of CABG over PCI were demonstrated for patients
with diabetes.
Three trials have shown that abciximab considerably
improved the outcome of PCI in patients with diabetes. In
the EPILOG trial, abciximab resulted in a greater decline in
death/MI over 6 months after PCI in patients with diabetes
(HR 0.36, 95% CI 0.21 to 0.61) than in those without
diabetes (HR 0.60, 95% CI 0.44 to 0.83) (810). Similar
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results have been reported for tiroﬁban in the PRISM-
PLUS trial (133,811). EPISTENT was a randomized trial
that compared stent plus placebo with stent plus abciximab
and balloon plus abciximab in 2,399 patients, of whom
20.5% had diabetes and 20.3% had UA (512). The 30-d
event rate (death, MI, and urgent revascularization) in
patients with diabetes declined from 12.1% (stent plus
placebo) to 5.6% (stent plus abciximab; p  0.040). At 6
months, the drug reduced revascularization of target arteries
in patients with diabetes (16.6% vs. 8.1%, p  0.02). Death
or MI was reduced to a similar degree in patients with
diabetes as that in patients without diabetes (812). These
beneﬁts were maintained at 1 year (813). Thus, in the
6-month data, initial GP IIb/IIIa therapy, as well as
stenting, considerably improved the safety of PCI in pa-
tients with diabetes. In a comparative trial of abciximab and
tiroﬁban (TARGET), both agents were associated with
comparable event rates, including similar rates of 6-month
target-vessel revascularization and 1-year mortality (814).
6.2.3. Conclusions
Diabetes occurs in approximately one ﬁfth of patients with
UA/NSTEMI and is an independent predictor of adverse
outcomes. It is associated with more extensive CAD,
unstable lesions, frequent comorbidities, and less favorable
long-term outcomes with coronary revascularization, espe-
cially with PTCA. It is unclear whether these differences are
due to more frequent restenosis and/or severe progression of
the underlying disease (779). The use of stents, particularly
with abciximab, appears to provide more favorable results in
patients with diabetes, although more data are needed,
including with DES. Coronary artery bypass grafting, espe-
cially with 1 or both internal mammary arteries, leads to
more complete revascularization and a decreased need for
reintervention than PCI, even when bare-metal stents are
used in diabetic patients with multivessel disease. Given the
diffuse nature of diabetic coronary disease, the relative
beneﬁts of CABG over PCI may well persist for diabetic
patients, even in the era of DES.
6.3. Post-CABG Patients
RECOMMENDATIONS
CLASS I
1. Medical treatment for UA/NSTEMI patients after CABG should fol-
low the same guidelines as for non–post-CABG patients with UA/
NSTEMI. (Level of Evidence: C)
2. Because of the many anatomic possibilities that might be respon-
sible for recurrent ischemia, there should be a low threshold for
angiography in post-CABG patients with UA/NSTEMI. (Level of Evi-
dence: C)
CLASS IIa
1. Repeat CABG is reasonable for UA/NSTEMI patients with multiple
SVG stenoses, especially when there is signiﬁcant stenosis of a graft
that supplies the LAD. Percutaneous coronary intervention is rea-
sonable for focal saphenous vein stenosis. (Level of Evidence: C)
(Note that an intervention on a native vessel is generally preferable
to that on a vein graft that supplies the same territory, if possible.)
2. Stress testing with imaging in UA/NSTEMI post-CABG patients is
reasonable. (Level of Evidence: C)
Overall, up to 20% of patients presenting with UA/
NSTEMI have previously undergone CABG (785). Con-
versely, approximately 20% of post-CABG patients develop
UA/NSTEMI during an interval of 7.5 years (815), with a
highly variable postoperative time of occurrence (816).
Post-CABG patients who present with UA/NSTEMI are
at higher risk, with more extensive CAD and LV dysfunc-
tion than those patients who have not previously undergone
surgery.
6.3.1. Pathological Findings
Pathologically, intimal hyperplasia or atherosclerosis may
develop in SVGs, and there is a particular tendency for
thrombotic lesions to develop in these vessels (in 72% of
grafts resected in 1 study) (817–820). In addition, post-
CABG patients may develop atherosclerosis in their native
vessels, and this can lead to UA/NSTEMI (820,821).
However, obstructive lesions are more likely to occur in
SVGs (53% within 5 years, 76% at 5 to 10 years, and 92%
at greater than 10 years) (822), and there is a high rate of
early graft failure in current practice (occlusion in up to one
third at 1 year). Spasm in grafts or native vessels (823,824)
and technical complications may also play a role in the
development of UA/NSTEMI during the early postopera-
tive period (815,825). Both angioscopic and angiographic
ﬁndings indicate that SVG disease is a serious and unstable
process. Angioscopically, friable plaques occur uniquely in
SVGs (44% vs. 0% in native coronary arteries), whereas
rough and white plaques occur in both SVGs and native
coronary arteries (826). Angiographically, the SVGs more
frequently have complex lesions (i.e., overhanging edges,
irregular borders, ulcerations, or thrombosis), thrombi (37%
vs. 12%, p  0.04), and total occlusions (49% vs. 24%, p 
0.02) (822).
6.3.2. Clinical Findings and Approach
Compared with UA/NSTEMI patients without prior
CABG, post-CABG patients are more often male (presum-
ably because more men than women have undergone
CABG), older, and more likely to have diabetes. They have
more extensive native-vessel CAD and more previous MIs
and LV dysfunction. Symptomatically, these patients have
more prolonged chest pain than ACS patients without prior
CABG. More than 30% of post-CABG patients have
resting ECG abnormalities, and ECG stress tests are
therefore less conclusive (827); however, a test that becomes
positive after having been negative is helpful in the diagnosis
of ischemia. Myocardial stress perfusion imaging and do-
butamine echocardiography are often helpful diagnostically
(828). Furthermore, a positive imaging test can help to
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deﬁne the area of ischemia in post-CABG patients with
complex disease.
The outcomes of UA/NSTEMI in post-CABG pa-
tients are less favorable than those in patients who have
not undergone CABG. There is a high rate of emboli-
zation of atherosclerotic material from friable grafts at
the time of intervention, which makes these procedures
more difﬁcult and which is associated with higher rates of
complications (829). In one matched case-control study
of UA, the initial course was similar, but post-CABG
patients had twice the incidence of adverse events (death,
MI, or recurrent UA) during the ﬁrst year. This was
attributed to a lower rate of complete revascularization,
which was possible in only 9 of 42 post-CABG patients
compared with 39 of 52 patients who had not previously
undergone CABG (p  0.001) (815). Results were
directionally similar in the TIMI III registry of ACS, in
which 16% of patients were post-CABG. Here again,
early outcomes in post-CABG patients and others were
equivalent, but at 1 year, the rate of adverse events (death,
MI, or recurrent ischemia) was 39.3% for those who had
previously undergone CABG versus 30.2% for those who
had not (p  0.002) (830).
Revascularization with either PCI or reoperation often is
indicated and is possible in post-CABG patients with
UA/NSTEMI. In a randomized controlled trial that com-
pared stents with PTCA of obstructed SVGs, there was no
statistically signiﬁcant difference in restenosis during a
6-month period, although a trend favored stents (34% vs.
46%) (831). Although hemorrhagic complications were
higher in the stent group, clinical outcomes (freedom from
MI or repeat revascularization) were better (73% vs. 58%, p
 0.03) (831).
6.3.3. Conclusions
Post-CABG patients, especially those with only SVGs, are
at high risk of UA/NSTEMI. There is a higher likelihood
of disease in SVGs than in native arteries, and this differ-
ence increases with postoperative time. Pathologically and
angiographically, disease in SVGs has characteristics asso-
ciated with instability. There also are difﬁculties with
treadmill ECG testing and less favorable outcomes with
repeat revascularization than in patients who have not
undergone previous CABG.
6.4. Older Adults
RECOMMENDATIONS
CLASS I
1. Older patients with UA/NSTEMI should be evaluated for appropriate
acute and long-term therapeutic interventions in a similar manner
as younger patients with UA/NSTEMI. (Level of Evidence: A)
2. Decisions onmanagement of older patients with UA/NSTEMI should
not be based solely on chronologic age but should be patient-
centered, with consideration given to general health, functional and
cognitive status, comorbidities, life expectancy, and patient prefer-
ences and goals. (Level of Evidence: B)
3. Attention should be given to appropriate dosing (i.e., adjusted by
weight and estimated creatinine clearance) of pharmacological
agents in older patients with UA/NSTEMI, because they often have
altered pharmacokinetics (due to reduced muscle mass, renal
and/or hepatic dysfunction, and reduced volume of distribution)
and pharmacodynamics (increased risks of hypotension and bleed-
ing). (Level of Evidence: B)
4. Older UA/NSTEMI patients face increased early procedural risks
with revascularization relative to younger patients, yet the overall
beneﬁts from invasive strategies are equal to or perhaps greater in
older adults and are recommended. (Level of Evidence: B)
5. Consideration should be given to patient and family preferences,
quality-of-life issues, end-of-life preferences, and sociocultural dif-
ferences in older patients with UA/NSTEMI. (Level of Evidence: C)
Older adults represent a group of patients in whom
baseline risk is higher (Table 25) and who have more
comorbidities but who derive equivalent or greater ben-
eﬁt (e.g., invasive vs. conservative strategy) compared to
younger patients. Although a precise deﬁnition of “older
patients” or “elderly” has not been established in the
medical literature, many studies have used this term to
refer to those who are 75 years and older. On the basis of
a large national ACS registry, older patients make up a
substantial portion of those presenting with UA/
NSTEMI, with 35% older than 75 years and 11% aged
more than 85 years (832). Older persons also present with
a number of special and complex challenges. First, older
persons who develop UA/NSTEMI are more likely to
present with atypical symptoms, including dyspnea and
Table 25. Impact of Age on Outcomes of Acute Coronary Syndrome: GRACE Risk Model
Age Group
No. of Deaths
(Hospital Mortality Rate)* Crude OR (95% CI) Adjusted OR (95% CI)
Less than 45 y 20 (1.3) Reference Reference
45 to 54 y 79 (2.0) 1.47 (0.90 to 2.41) 1.95 (1.06 to 3.61)
55 to 64 y 171 (3.1) 2.35 (1.47 to 3.74) 2.77 (1.53 to 4.99)
65 to 74 y 373 (5.5) 4.34 (2.76 to 6.83) 4.95 (2.78 to 8.79)
75 to 84 y 439 (9.3) 7.54 (4.80 to 11.8) 8.04 (4.53 to 14.3)
85 y or more 260 (18.4) 16.7 (10.5 to 26.4) 15.7 (8.77 to 28.3)
*All p less than 0.0001. The GRACE risk model includes systolic blood pressure, initial serum creatinine, heart rate, initial cardiac enzyme, Killip class, ST- segment deviation, and cardiac arrest at
hospital arrival. Modiﬁed with permission from Avezum A, Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry
of Acute Coronary Events (GRACE). Am Heart J 2005; 149:67–73 (835).
CI  conﬁdence interval; GRACE  Global Registry of Acute Coronary Events; OR  odds ratio.
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confusion, rather than with the chest pain typically
experienced by younger patients with acute myocardial
ischemia (833). Conversely, noncardiac comorbidities
such as chronic obstructive lung disease, gastroesophageal
reﬂux disease, upper-body musculoskeletal symptoms,
pulmonary embolism, and pneumonia also are more
frequent and may be associated with chest pain at rest
that can mimic classic symptoms of UA/NSTEMI.
Hence, successful recognition of true myocardial isch-
emia in the elderly is often more difﬁcult than in younger
patients. Second, they are more likely than younger
patients to have altered or abnormal cardiovascular anat-
omy and physiology, including a diminished beta-
sympathetic response, increased cardiac afterload due to
decreased arterial compliance and arterial hypertension,
orthostatic hypotension, cardiac hypertrophy, and ven-
tricular dysfunction, especially diastolic dysfunction
(834). Third, older patients typically have developed
signiﬁcant cardiac comorbidities and risk factors, such as
hypertension, prior MI, HF, cardiac conduction abnor-
malities, prior CABG, peripheral and cerebrovascular
disease, diabetes mellitus, renal insufﬁciency, and stroke.
Fourth, because of this larger burden of comorbid dis-
ease, older patients tend to be treated with a greater
number of medications and are at higher risk for drug
interactions and polypharmacy. Hence, among an already
high-risk population, older age is associated with higher
disease severity and higher disease and treatment risk at
presentation (832).
6.4.1. Pharmacological Management
Overall, although the elderly have been generally underrep-
resented in randomized controlled trials, when examined,
older subgroups appear to have relatively similar relative risk
reductions and similar or greater absolute risk reductions in
many end points as younger patients for commonly used
treatments in the management of UA/NSTEMI. In spite of
an increasing number of possible relative contraindications
associated with older age, the rates of serious adverse events
for most older patients generally remain low when evidence-
based treatment for UA/NSTEMI is provided. Despite
generally similar beneﬁts, recent studies such as CRUSADE
(832), TACTICS-TIMI 18 (182), and GRACE (835) have
documented signiﬁcantly lower use of evidence-based ther-
apies in the elderly, including less use of an aggressive, early
invasive strategy and of key pharmacotherapies, including
anticoagulants, beta blockers, clopidogrel, and GP IIb/IIIa
inhibitors.
With this said, precautions need to be taken to person-
alize these therapies (i.e., beginning with lower doses than
in younger patients, whenever appropriate, and providing
careful observation for toxicity). Older persons are particu-
larly vulnerable to adverse events from cardiovascular drugs
due to altered drug metabolism and distribution, as well as
to exaggerated drug effects. Reductions in cardiac output
and in renal and hepatic perfusion and function decrease the
rate of elimination of drugs in the elderly. Additionally,
older patients typically have lower drug distribution volumes
(due to a lower body mass). As a result, drugs need to be
carefully selected and individually adjusted. Current evi-
dence demonstrates that older adults are frequently exces-
sively dosed. In a community-based registry, among treated
patients aged 75 years or older, 38% received an excessive
dose of UFH, 17% received excessive LMWH, and 65%
received an excessive dose of a GP IIb/IIIa antagonist (832).
A subsequent study from the same registry found that 15%
of major bleeding in UA/NSTEMI patients could be
attributed to excessive dosing (743). Mortality and length of
stay also were higher in patients receiving excessive dosing.
In the elderly, drugs such as beta blockers that undergo
ﬁrst-pass hepatic metabolism exhibit increased bioavailabil-
ity (836). Exaggerated pharmacodynamic responses to drugs
often resulted from lower cardiac output, plasma volume,
and vasomotor tone, as well as blunted baroreceptor and
beta-adrenergic responses.
6.4.2. Functional Studies
Older persons can have difﬁculty performing standardized
exercise tolerance tests because of age-related medical prob-
lems, such as general deconditioning, decreased lung capac-
ity, chronic pain, sensory neuropathy, osteoarthritis, and
muscle weakness. Furthermore, the higher prevalence of
preexisting resting ECG abnormalities (782), arrhythmias
(140,837), and cardiac hypertrophy often make the inter-
pretation of a standard stress ECG inconclusive or impos-
sible. In such patients, alternative methods for evoking
evidence of acute myocardial ischemia, such as pharmaco-
logical stress testing with dynamic cardiac imaging, may be
substituted (see also Section 3.4).
6.4.3. Percutaneous Coronary Intervention in Older
Patients
Recent evidence from several major interventional trials has
demonstrated a clear beneﬁt for older patients. A collabo-
rative meta-analysis of several more recently published PCI
trials (FRISC-II, TACTICS, RITA-3, VINO, and
MATE) have suggested that the majority of the beneﬁt
from an invasive strategy in the elderly has accrued from
contemporary strategies used in trials published after 1999
and in patients with positive troponins or their cardiac
biomarkers (543). These trials indicated that compared with
younger patients, the elderly gain important absolute ben-
eﬁts from an early invasive strategy but at a cost of increased
bleeding. Speciﬁcally, a signiﬁcant beneﬁt was seen in
reduction of the combined end point of death and recurrent
MI, but only a trend to reduction in death was noted. A
recent observational analysis in a community population
failed to show an early beneﬁt on in-hospital survival with
an invasive strategy in the older subgroup (75 years or
older), which highlights the need for continued caution in
applying trial results uniformly in older patients (837a).
Thus, selection of older patients for an early invasive
strategy is complex, including risk from disease and risk
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from intervention, but given the absolute beneﬁts observed
in these trials, age should not preclude consideration.
Despite these potential beneﬁts, older patients are also far
less likely to undergo angiography (RR 0.65, p less than 0.001
at 6 weeks) and coronary revascularization (RR 0.79, p 0.002
at 6 weeks) after a UA/NSTEMI episode than younger
patients. This apparent underuse of potentially beneﬁcial in-
terventions might be due in part to practitioner concerns about
the increased risk of complications. Finding the appropriate
balance between beneﬁt and risk of aggressive therapies to
maximize net clinical outcome remains a challenge in the elderly.
6.4.4. Contemporary Revascularization Strategies in
Older Patients
Several studies of PCI in patients aged 65 to 75 years have
shown that success rates with experienced medical profes-
sionals are similar to those in younger patients, but with
even older patients, success rates decline and complication
rates rise. On the other hand, a Mayo Clinic review of PCI
in patients greater than 65 years old (of whom 75% had UA)
revealed an overall success rate of 93.5%, an immediate
in-hospital mortality rate of 1.4%, and a need for emergency
CABG rate of only 0.7% (838). Angiographic outcome
changed little between the 65-to-69-year-old group and the
greater than 75-year-old group, and the 1-year event rate
(death, MI, CABG, repeat PCI, or severe angina) was
45.1% in all patients greater than 65 years old (838).
Predictors of outcomes (i.e., extent and severity of CAD
and comorbidities) after PCI in older patients were the same
as those in younger patients (839). Similarly, a review of
coronary stenting in the elderly reported that procedural
success rates were high (95% to 98%) and periprocedural
complication rates were low (MI 1.2% to 2.8%, urgent
CABG 0.9% to 1.8%, repeat PCI 0% to 0.6%) in the
elderly, with little difference between those greater than 75
years old and those less than 65 years old (840). Subgroup
analyses in both TIMI IIIB (129) and FRISC-II (245)
showed a greater advantage of the invasive strategy in
patients older than 65 years of age. More contemporary
studies have conﬁrmed this advantage, including
TACTICS-TIMI 18 (841). Among patients older than 75
years of age, the early invasive strategy conferred an absolute
reduction of 10.8 percentage points (to 10.8% from 21.6%;
p  0.016) and a relative reduction of 56% in death or MI
at 6 months; however, beneﬁts came with an increased risk
of major bleeding events (16.6% vs. 6.5%; p  0.009).
A review of 15,679 CABG procedures performed in
patients greater than 70 years old from the Toronto Hos-
pital (842) reported encouraging results. Operative mortal-
ity rates declined from 7.2% in 1982 to 1986, to 4.4% in
1987 to 1991 (and from 17.2% to 9.1% for high-risk
patients) but showed little further change in the period of
1992 to 1996. Predictors of operative death (LV dysfunc-
tion, previous CABG, peripheral vascular disease, and
diabetes) were similar to those in younger patients.
Operative morbidity and mortality rates increase for CABG
with advanced age, but outcomes have been favorable com-
pared with medical therapy, and quality of life improves
(843–847). A recent retrospective review of 662,033 patients
who underwent cardiac surgical procedures performed using
the STS National Cardiac Database (848) found a CABG
operative mortality of 2.8% for patients 50 to 79 years of age,
7.1% for patients 80 to 89 years of age, and 11.8% for patients
aged 90 years or more. This study included more than 1,000
patients over 90 years of age and 5 centenarians and docu-
mented that the 57% of nonagenarians without certain risk
factors (renal failure, IABP, emergency surgery, or peripheral
or cerebrovascular disease) constituted a relatively low-risk
group with an operative mortality of only 7.2%, similar to the
overall risk in octogenarians. Thus, with appropriate selection,
CABG surgery can be an appropriate revascularization strategy
in even the oldest patient subgroups.
6.4.5. Conclusions
Older patients with UA/NSTEMI tend to have atypical
presentations of disease, substantial comorbidity, ECG stress
tests that are more difﬁcult to interpret, and different physio-
logical responses to pharmacological agents compared with
younger patients. Although they are at highest risk, guideline-
recommended therapies are used less frequently. Even though
their outcomes with interventions and surgery are not as
favorable as those of younger patients, coronary revasculariza-
tion should be recommended when the same group of prog-
nostic risk factors that play a role in the younger age group are
taken into account. The approach to these patients also must
consider general medical and cognitive status, bleeding risk and
other risk of interventions, anticipated life expectancy, and
patient or family preferences.
6.5. Chronic Kidney Disease
RECOMMENDATIONS
CLASS I
1. Creatinine clearance should be estimated in UA/NSTEMI patients,
and the doses of renally cleared drugs should be adjusted appropri-
ately. (Level of Evidence: B)
2. In chronic kidney disease patients undergoing angiography, isosmo-
lar contrast agents are indicated and are preferred. (Level of Evi-
dence: A)
Chronic kidney disease (CKD) is not only a coronary risk
equivalent for ascertainment of coronary risk but also a risk
factor for the development and progression of CVD (744).
Chronic kidney disease constitutes a risk factor for adverse
outcomes after MI (849), including NSTEMI and other
coronary patient subsets. In the highly validated GRACE
risk score, serum creatinine is 1 of the 8 independent
predictors of death (168,835). In recent study, even early
CKD constituted a signiﬁcant risk factor for cardiovascular
events and death (849,850). Chronic kidney disease also
predicts an increase in recurrent cardiovascular events (851).
Cardiovascular death is 10 to 30 times higher in dialysis
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patients than in the general population. The underrepresen-
tation of patients with renal disease in randomized con-
trolled trials of CVD is of concern (179). Most of the
limited evidence available and current opinion suggest that
when appropriately monitored, cardiovascular medications
and interventional strategies can be applied safely in those
with renal impairment and provide therapeutic beneﬁt
(849). However, not all recent evidence is consistent with
this premise: atorvastatin did not signiﬁcantly reduce the
primary end point of cardiovascular death, nonfatal MI, or
stroke in a prospective randomized trial of patients with
diabetes and end-stage CKD who were undergoing hemo-
dialysis (234). The preference for primary PCI has also been
questioned (235).
Particularly in the setting of ACS, bleeding complications
are higher in this patient subgroup because of platelet
dysfunction and dosing errors; beneﬁts of ﬁbrinolytic ther-
apy, antiplatelet agents, and anticoagulants can be negated
or outweighed by bleeding complications; and renin-
angiotensin-aldosterone inhibitors can impose a greater risk
because of the complications of hyperkalemia and worsen-
ing renal function in the CKD patient. Angiography carries
an increased risk of contrast-induced nephropathy; the usual
beneﬁts of percutaneous interventions can be lessened or
abolished; and PCI in patients with CKD is associated with
a higher rate of early and late complications of bleeding,
restenosis, and death (179). Thus, the identiﬁcation of
CKD is important in that it represents an ACS subgroup
with a far more adverse prognosis but for whom interven-
tions have less certain beneﬁt.
Coronary arteriography is a frequent component of the care
of ACS patients. As such, contrast-induced nephropathy can
constitute a serious complication of diagnostic and interven-
tional procedures. In patients with CKD or CKD and diabe-
tes, isosmolar contrast material lessens the rise in creatinine and
is associated with lower rates of contrast-induced nephropathy
than low-osmolar contrast media. This has been documented
in a randomized clinical trial (RECOVER [Renal Toxicity
Evaluation and Comparison Between Visipaque (Iodixanol)
and Hexabrix (Ioxaglate) in Patients With Renal Insufﬁciency
Undergoing Coronary Angiography]) comparing iodixanol
with ioxaglate (852) and in a meta-analysis of 2,727 patients
from 16 randomized clinical trials (853). Identiﬁcation of
CKD patients as recommended in the AHA science advisory
on detection of chronic kidney disease in patients with or at
increased risk of cardiovascular disease should guide the use of
isosmolar contrast agents (744).
To increase awareness of CKD, an AHA science advisory
for the detection of CKD in patients with or at increased risk
for CVD recently was developed in collaboration with the
National Kidney Foundation (744). The advisory recommen-
dations are that all patients with CVD be screened for evidence
of kidney disease by estimating glomerular ﬁltration rate,
testing for microalbuminuria, and measuring the albumin-to-
creatinine ratio (Class IIa, Level of Evidence: C). A glomerular
ﬁltration rate less than 60 ml per min per 1.73 square meters of
body surface should be regarded as abnormal (Class I, Level of
Evidence: B). Furthermore, the albumin-to-creatinine ratio
should be used to screen for the presence of kidney damage in
adult patients with CVD, with values greater than 30 mg of
albumin per 1 g of creatinine regarded as abnormal (Class IIa,
Level of Evidence: B).
A diagnosis of renal dysfunction is critical to proper medical
therapy of UA/NSTEMI. Many cardiovascular drugs used in
UA/NSTEMI patients are renally cleared; their doses should
be adjusted for estimated creatinine clearance (see also Section
3). In a large community-based registry study, 42% of patients
with UA/NSTEMI received excessive initial dosing of at least
1 antiplatelet or antithrombin agent (UFH, LMWH, or GP
IIb/IIIa inhibitor) (743). Renal insufﬁciency was an indepen-
dent predictor of excessive dosing. Dosing errors predicted an
increased risk of major bleeding. Clinical studies and labeling
that deﬁnes adjustments for several of these drugs have been
based on the Cockroft-Gault formula for estimating creatinine
clearance, which is not identical to the MDRD formula. Use of
the Cockroft-Gault formula to generate dose adjustments is
recommended. The impact of renal dysfunction on biomarkers
of necrosis (i.e., troponin) is discussed in Section 2.2.8.2.1.
To increase the meager evidence base and to optimize care for
this growing high-risk population, the recognition of CKD
patients with or at risk of CVD and the inclusion and reporting of
renal disease in large CVD trials must be increased in the future.
6.6. Cocaine and Methamphetamine Users
RECOMMENDATIONS
CLASS I
1. Administration of sublingual or intravenous NTG and intravenous or
oral calcium channel blockers is recommended for patients with
ST-segment elevation or depression that accompanies ischemic
chest discomfort after cocaine use. (Level of Evidence: C)
2. Immediate coronary angiography, if possible, should be performed in
patients with ischemic chest discomfort after cocaine use whose ST
segments remain elevated after NTG and calcium channel blockers;
PCI is recommended if occlusive thrombus is detected. (Level of
Evidence: C)
3. Fibrinolytic therapy is useful in patients with ischemic chest discom-
fort after cocaine use if ST segments remain elevated despite NTG
and calcium channel blockers, if there are no contraindications, and
if coronary angiography is not possible. (Level of Evidence: C)
CLASS IIa
1. Administration of NTG or oral calcium channel blockers can be
beneﬁcial for patients with normal ECGs or minimal ST-segment
deviation suggestive of ischemia after cocaine use. (Level of Evi-
dence: C)
2. Coronary angiography, if available, is probably recommended for
patients with ischemic chest discomfort after cocaine use with
ST-segment depression or isolated T-wave changes not known to be
previously present and who are unresponsive to NTG and calcium
channel blockers. (Level of Evidence: C)
3. Management of UA/NSTEMI patients with methamphetamine use
similar to that of patients with cocaine use is reasonable. (Level of
Evidence: C)
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CLASS IIb
Administration of combined alpha- and beta-blocking agents (e.g.,
labetalol) may be reasonable for patients after cocaine use with
hypertension (systolic blood pressure greater than 150 mm Hg) or
those with sinus tachycardia (pulse greater than 100 beats per min)
provided that the patient has received a vasodilator, such as NTG or a
calcium channel blocker, within close temporal proximity (i.e., within
the previous hour). (Level of Evidence: C)
CLASS III
Coronary angiography is not recommended in patients with chest pain
after cocaine use without ST-segment or T-wave changes and with a
negative stress test and cardiac biomarkers. (Level of Evidence: C)
The use of cocaine can produce myocardial ischemia,
thereby leading to UA/NSTEMI (854–857). The wide-
spread use of cocaine makes it mandatory to consider this
cause, because its recognition mandates special manage-
ment. Speciﬁcally, initial management recommendations
for cocaine-induced ACS include NTG and calcium chan-
nel antagonists. Assessment for resolution of chest discom-
fort and ECG changes is then undertaken before ﬁbrinolytic
therapy is initiated or angiography is considered. The use of
beta blockers in close proximity (i.e., within 4 to 6 h) of
cocaine exposure is controversial, with some evidence for
harm; thus, when used, the guidelines recommend combi-
nation alpha and beta blockade in addition to a vasodilator.
There are no data to guide recommendations for beta
blockade later after exposure, after cocaine elimination.
The action of cocaine is to block presynaptic reuptake of
neurotransmitters such as norepinephrine and dopamine,
which produces excess concentrations at the postsynaptic
receptors that lead to sympathetic activation and the stim-
ulation of dopaminergic neurons (858). There may also be a
direct contractile effect on vascular smooth muscle (855).
Detoxiﬁcation is accomplished with plasma and liver cho-
linesterases, which form metabolic products that are ex-
creted in the urine. Infants, elderly patients, and patients
with hepatic dysfunction lack sufﬁcient plasma cholinester-
ase to metabolize the drug (859) and therefore are at high
risk of adverse effects with cocaine use.
6.6.1. Coronary Artery Spasm With Cocaine Use
The basis for coronary spasm has been demonstrated in both
in vitro (859) and in vivo (855,860–864) experiments in
animals and humans. Reversible vasoconstriction of rabbit
aortic rings has been demonstrated with cocaine in concen-
trations of 103 to 108 mol per liter. Pretreatment with
calcium channel blockers markedly inhibits cocaine-induced
vasoconstriction. Coronary injection of cocaine produces
vasoconstriction in miniswine with experimentally induced
nonocclusive atherosclerotic lesions (865).
Nademanee et al. (866) performed 24-h ECG monitor-
ing in 21 male cocaine users after admission to a substance
abuse treatment center and found that 8 had frequent
episodes of ST-segment elevation, most during the ﬁrst 2
weeks of withdrawal. In cocaine users with prolonged
myocardial ischemia, coronary arteriography can reveal cor-
onary artery spasm with otherwise normal-appearing coro-
nary arteries or with underlying minimally obstructive cor-
onary atherosclerosis (855,857,860). The cocaine-induced
increase in coronary vascular resistance is reversed with
calcium channel blockers (861,867). Cocaine increases the
response of platelets to arachidonic acid, thus increasing
thromboxane A2 production and platelet aggregation (868).
In addition, reversible combined reduction in protein C and
antithrombin III has been observed in patients with
cocaine-related arterial thrombosis (869). All of these effects
favor coronary thrombosis (855,862,870). Coronary throm-
bosis can also develop as a consequence of coronary spasm.
Cocaine users can develop ischemic chest discomfort that
is indistinguishable from the UA/NSTEMI secondary to
coronary atherosclerosis. The patient who presents with
prolonged myocardial ischemia should be questioned about
the use of cocaine. In a study by Hollander et al. (871), the
presence or absence of cocaine use was assessed in only 13%
of patients who presented to the ED with chest pain. Table
26 lists the clinical characteristics of a typical patient with
cocaine-related chest pain or MI (857).
Most patients who present to the ED with cocaine-
associated chest pain do not develop MI (872). MI development
has been reported to occur only in 6% of such patients (857).
Accelerated coronary atherosclerosis has been reported in
chronic users of cocaine (873,874); coronary artery spasm is
more readily precipitated at sites of atherosclerotic plaques
(860). Cocaine causes sinus tachycardia, as well as an
increase in blood pressure and myocardial contractility,
thereby increasing myocardial oxygen demand (861). These
increases can precipitate myocardial ischemia and UA/
NSTEMI in both the presence and absence of obstructive
coronary atherosclerosis and coronary spasm.
Aortic dissection (875) and coronary artery dissection
(855,875) have been reported as consequences of cocaine
use. Other reported cardiac complications are myocarditis
(874) and cardiomyopathy (876,877).
Table 26. Clinical Characteristics in the Typical Patient With
Cocaine-Related Chest Pain, Unstable Angina, or Myocardial
Infarction
Young age, usually less than 40 years
Male gender
Cigarette smoker, but no other risk factors for atherosclerosis
Chronic or ﬁrst-time cocaine user
Symptom onset minutes or even several hours after cocaine use
Associated with all routes of administration
May occur with small or large doses
Often associated with concomitant use of cigarettes and/or alcohol
Reprinted from Progressive Cardiovascular Disease, 40, Pitts WF, Lange RA, Cigarroa JE, Hillis
LD. Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and
management, 65–76. Copyright 1997, with permission from Elsevier (857).
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6.6.2. Treatment
When a patient with or suspected of cocaine use is seen in the
ED with chest pain compatible with myocardial ischemia and
ST-segment elevation, sublingual NTG or a calcium channel
blockers (e.g., diltiazem 20 mg IV) should be administered
(855,864). If there is no response, immediate coronary angiog-
raphy should be performed, if possible. Fibrinolytic therapy has
been successfully employed in patients with MI after cocaine
use, although these patients frequently have contraindications
to ﬁbrinolysis, including hypertension, seizures, or aortic dis-
section. Thus, PCI may be a preferred method of revascular-
ization in this setting. However, even this therapeutic strategy
is problematic in subjects with cocaine-related MI; those in
whom stents are deployed are at substantial risk of subsequent
in-stent thrombosis unless double-antiplatelet therapy (ASA
and clopidogrel) is ingested regularly and predictably for several
months afterward, and those who partake in substance abuse
often are unreliable in adhering to such a regimen. Thus,
bare-metal stents, which require a shorter duration of dual-
antiplatelet therapy, generally are preferred to DES in cocaine
abusers. If thrombus is present and PCI is unavailable or
ineffective, ﬁbrinolytic agents may be administered if there are
no contraindications (878,879). If catheterization is not avail-
able, intravenous ﬁbrinolytic therapy may be considered in
patients with ST-segment elevation and clinical symptoms
consistent with MI.
If the ECG is normal or shows only minimal T-wave
changes and there is a history of chest pain compatible with
acute myocardial ischemia, the patient should receive sublin-
gual NTG or an oral calcium channel blocker and be observed.
After cocaine use, increased motor activity, skeletal muscle
injury, and rhabdomyolysis can occur, causing CK and even
CK-MB elevation in the absence of MI (880). Troponin I and
TnT are more speciﬁc for myocardial injury and therefore are
preferred. Blood should be drawn twice for serum markers of
myocardial necrosis at 6-h intervals. If the ECG shows
ST-segment changes and the cardiac biochemical markers are
normal, the patient should be observed in the hospital in a
monitored bed for 24 h; most complications will occur within
24 h (881). If the patient’s clinical condition is unchanged and
the ECG remains unchanged after 24 h, the patient can be
discharged (879). A shorter observation period of 9 to 12 h,
with measurement of troponin levels at 3, 6, and 9 h after
presentation, also has been validated (882).
Many observers believe that beta blockers are contrain-
dicated in cocaine-induced coronary spasm because there is
evidence from a single double-blind, randomized, placebo-
controlled trial that beta-adrenergic blockade augments
cocaine-induced coronary artery vasoconstriction (883).
Others believe that if the patient has a high sympathetic
state with sinus tachycardia and hypertension, beta blockers
should be used (855). Labetalol, an alpha and beta blocker,
has been advocated, because it has been shown not to induce
coronary artery vasoconstriction (884) even though its beta-
adrenergic–blocking action predominates over its alpha-
adrenergic–blocking activity in the doses that are commonly
used (884). Therefore, in cocaine-induced myocardial ischemia
and vasoconstriction, NTG and calcium channel blockers are
the preferred drugs. Both NTG and verapamil have been
shown to reverse cocaine-induced hypertension, coronary ar-
terial vasoconstriction (864,883), and tachycardia (verapamil).
6.6.3. Methamphetamine Use and UA/NSTEMI
Given the rapid increase in methamphetamine abuse, recognition
of its cardiovascular risk is ofmounting importance. Currently, the
evidence base for UA/NSTEMI after methamphetamine and its
treatment is limited to a few publications of case reports and small
series (885–888). These suggest that ACS is increasingly
common in patients evaluated in the ED for chest discomfort
after methamphetamine use and that the frequency of other
potentially life-threatening arrhythmias is not negligible (886).
Clinical presentation resembles that of cocaine-associated
ACS. On the basis of the similarities in pathophysiology and
these few clinical observations, therapy similar to that of
cocaine-induced UA/NSTEMI is recommended pending in-
formation more speciﬁc to methamphetamine.
6.7. Variant (Prinzmetal’s) Angina
RECOMMENDATIONS
CLASS I
1. Diagnostic investigation is indicated in patients with a clinical
picture suggestive of coronary spasm, with investigation for the
presence of transient myocardial ischemia and ST-segment eleva-
tion during chest pain. (Level of Evidence: A)
2. Coronary angiography is recommended in patients with episodic
chest pain accompanied by transient ST-segment elevation. (Level
of Evidence: B)
3. Treatment with nitrates and calcium channel blockers is recom-
mended in patients with variant angina whose coronary angiogram
shows no or nonobstructive coronary artery lesions. Risk factor
modiﬁcation is recommended, with patients with atherosclerotic
lesions considered to be at higher risk. (Level of Evidence: B)
CLASS IIb
1. Percutaneous coronary intervention may be considered in patients
with chest pain and transient ST-segment elevation and a signiﬁcant
coronary artery stenosis. (Level of Evidence: B)
2. Provocative testing may be considered in patients with no signiﬁ-
cant angiographic CAD and no documentation of transient ST-
segment elevation when clinically relevant symptoms possibly ex-
plained by coronary artery spasm are present. (Level of Evidence: C)
CLASS III
Provocative testing is not recommended in patients with variant angina
and high-grade obstructive stenosis on coronary angiography. (Level of
Evidence: B)
Variant angina (Prinzmetal’s angina, periodic angina) is a
form of UA that usually occurs spontaneously and is charac-
terized by transient ST-segment elevation that spontaneously
resolves or resolves with NTG use without progression to MI
(889). The earliest stages of MI can also be associated with
cyclic ST-segment elevations, but MI does not possess the
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nature of periodic angina. The spasm is most commonly focal
and can occur simultaneously at more than 1 site (890). Even
coronary segments that are apparently normal on coronary
angiography often have evidence of mural atherosclerosis on
intravascular ultrasound (891). This can result in localized
endothelial dysfunction and coronary spasm.
Patients with Prinzmetal’s angina frequently have coro-
nary artery plaques that can be either nonobstructive or
obstructive (892). Walling et al. (893) reported that coro-
nary arteriography showed 1-vessel disease in 81 (39%) of
217 patients and multivessel disease in 40 (19%). Rovai et al.
(894) found a similar high prevalence of obstructive disease
in 162 patients with variant angina.
6.7.1. Clinical Picture
Although chest discomfort in the patient with variant
angina can be precipitated by exercise, it usually occurs
without any preceding increase in myocardial oxygen de-
mand; the majority of patients have normal exercise toler-
ance, and stress testing may be negative. Because the anginal
discomfort usually occurs at rest without a precipitating
cause, it may simulate UA/NSTEMI secondary to coronary
atherosclerosis. Episodes of Prinzmetal’s angina often occur
in clusters, with prolonged asymptomatic periods of weeks
to months. Attacks can be precipitated by an emotional
stress, hyperventilation (895), exercise (896), or exposure to
cold (897). A circadian variation in the episodes of angina is
most often present, with most attacks occurring in the early
morning (898). Compared with patients with chronic stable
angina, patients with variant angina are younger and, except
for smoking, have fewer coronary risk factors (899,900).
Some studies have shown an association of variant angina
with other vasospastic disorders, such as migraine headache
and Raynaud’s phenomenon (901). The presence of syncope
during an episode of chest pain suggests severe ischemia
related to an acute occlusion, often due to focal spasm.
Most often, the attacks of angina resolve spontaneously
without evidence of MI. However, a prolonged vasospasm may
result in complications such as MI, a high degree of AV block,
life-threatening ventricular tachycardia, or sudden death
(902,903).
6.7.2. Pathogenesis
The pathogenesis of focal coronary spasm in this condi-
tion is not well understood. The probable underlying
defect is the presence of dysfunctional endothelium that
exposes the medial smooth muscle to vasoconstrictors
such as catecholamines, thromboxane A2, serotonin,
histamine, and endothelin (904). Endothelial dysfunction
also can impair coronary ﬂow-dependent vasodilatation
owing to the decreased production and release of nitric
oxide (905) and enhanced phosphorylation of myosin
light chains, an important step in smooth muscle con-
traction (906). There can be an imbalance between
endothelium-produced vasodilator factors (i.e., prostacy-
clin, nitric oxide) and vasoconstrictor factors (i.e., endo-
thelin, angiotensin II) that favors the latter (907). There
also is evidence of involvement of the autonomic nervous
system, with reduced parasympathetic tone and enhanced
reactivity of the alpha-adrenergic vascular receptors
(905,908,909). Regardless of the mechanism, the risk for
focal spasm is transient but recurrent.
6.7.3. Diagnosis
The key to the diagnosis of variant angina is the documenta-
tion of ST-segment elevation in a patient during transient
chest discomfort (which usually occurs at rest, typically in the
early morning hours, and nonreproducibly during exercise) and
that resolves when the chest discomfort abates. Typically,
NTG is exquisitely effective in relieving the spasm. ST-
segment elevation implies transmural focal ischemia associated
with complete or near-complete coronary occlusion of an
epicardial coronary artery in the absence of collateral circula-
tion. In variant angina, the dynamic obstruction can be
superimposed on severe or nonsevere coronary stenosis or
supervene in an angiographically normal coronary artery seg-
ment. Hence, coronary angiography is usually part of the
workup of these patients and can help orient treatment.
It is noteworthy that spasm often develops spontaneously
during angiography, which aids the diagnosis in patients with
no previously documented ST-segment elevation; catheter-
induced spasm is not, however, an indicator of vasospastic
disease. Diagnostic tests for Prinzmetal’s angina are based on
the recording of transient ST-segment elevation during an
episode of chest pain. Continuous 12-lead ECG monitoring
can be performed for this purpose in-hospital or as an outpa-
tient; recording during numerous episodes of pain improves
diagnostic sensitivity. A treadmill exercise test is also useful;
one third of patients will show ST-segment elevation, another
third ST-segment depression, and one third no ST-segment
change. Interestingly, the results may not be reproducible
within the same patients and are more often positive when the
test is performed in the early morning hours. A 2-dimensional
echocardiogram or the injection of a nuclear marker at the time
of chest pain may help document the presence of transmural
ischemia. A number of other provocative tests can be used to
precipitate coronary artery spasm when the diagnosis is sus-
pected but not objectively documented. Nitrates and calcium
channel blockers should be withdrawn well before provocative
testing. These tests are more often used during coronary
angiography; the spasm can then be visualized before the
appearance of chest pain and promptly relieved by the intra-
coronary injection of NTG. The test can also be performed in
a coronary care unit setting while the patient is monitored for
ST-segment elevation, but this is recommended only if the
coronary anatomy is known. Such nonpharmacological tests
include the cold pressor test and hyperventilation performed
for 6 min in the morning, alone or after exercise (910).
Pharmacological tests in general provide a better diagnostic
yield. Ergonovine, methylergonovine, and ergometrin have
been most widely studied and used in the past, but methyler-
gonovine and ergometrin are no longer generally available, and
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the use of ergonovine is limited. Acetylcholine and methacho-
line are now predominantly used for this diagnostic purpose.
Although the spasm is usually promptly relieved with NTG
administered intracoronarily or intravenously, it may at times
be refractory to therapy with NTG and other vasodilators and
may be recurrent in the same segment or in other coronary
artery segments, resulting in prolonged ischemia, MI, or
occasionally, death (911). For these reasons, provocative tests
are now rarely used and are limited to a few indications, such
as patients with suggestive symptoms that could be helped by
an appropriate diagnosis not otherwise reached, patients in
whom treatment with nitrates and calcium channel blockers
has failed, and patients with a life-threatening disease in whom
the physician wants to verify the efﬁcacy of the treatment.
Thus, patients with a positive hyperventilation test are more
likely to have a higher frequency of attacks, multivessel spasm,
or high degree of AV block or ventricular tachycardia than are
patients with a negative hyperventilation test (910), and high-
risk patients whose tests become negative with treatment are
more likely to have a favorable long-term course. The investi-
gation of coronary spasm in patients with coronary artery
lesions of borderline signiﬁcance can be complemented by
other diagnostic procedures such as intravascular ultrasound,
functional ﬂow reverse, and other functional testing to assess
more accurately the signiﬁcance of the obstruction.
6.7.4. Treatment
Coronary spasm is usually very responsive to NTG, long-
acting nitrates, and calcium channel blockers (912–914), which
are considered ﬁrst-line therapies. (Beta-blockers have theo-
retical adverse potential, and their clinical effect is controver-
sial.) Smoking should be discontinued. Usually, a calcium
channel blocker in a moderate to high dose (e.g., verapamil 240
to 480 mg per d, diltiazem 180 to 360 mg per d, or nifedipine
60 to 120 mg per d) is started; patients with very active disease
can require a combination of nitrates and 2 calcium channel
blockers of different classes (i.e., a dihydropyridine with vera-
pamil or diltiazem). Alpha-receptor blockers have been re-
ported to be of beneﬁt, especially in patients who are not
responding completely to calcium channel blockers and nitrates
(906). In patients who develop coronary spasm (with or
without provocation) during coronary angiography, 0.3 mg of
NTG should be infused directly into the coronary artery that is
involved.
6.7.5. Prognosis
The prognosis of variant angina is usually excellent in
patients with variant angina who receive medical therapy,
especially in patients with normal or near-normal coronary
arteries. Yasue et al. (915) reported an 89% to 97% overall
5-year survival rate. In a 7-year follow-up in approximately
300 patients, the incidence of sudden death was 3.6% and
the incidence of MI was 6.5% (915). Patients with coronary
artery vasospasm superimposed on a ﬁxed obstructive CAD
have a worse prognosis. In a study of 162 patients with
variant angina by Rovai et al. (894), patients with normal
coronary arteries and single-vessel disease had a 5-year
survival rate of 95% compared with a rate of 80% for those
with multivessel disease. Almost identical survival rates were
reported in an earlier study by Walling et al. (893). Occa-
sional patients may require instrumentation with a pace-
maker to prevent transient AV block associated with isch-
emia or with a deﬁbrillator to prevent sudden death
associated with ischemia-induced ventricular ﬁbrillation.
Treatment can at times be very frustrating in the occasional
patient refractory to standard medication. Cardiac denerva-
tion has been used in these patients with marginal beneﬁt.
6.8. Cardiovascular “Syndrome X”
RECOMMENDATIONS
CLASS I
1. Medical therapy with nitrates, beta blockers, and calcium channel
blockers, alone or in combination, is recommended in patients with
cardiovascular syndrome X. (Level of Evidence: B)
2. Risk factor reduction is recommended in patients with cardiovascu-
lar syndrome X. (Level of Evidence: B)
CLASS IIb
1. Intracoronary ultrasound to assess the extent of atherosclerosis and
rule out missed obstructive lesions may be considered in patients
with syndrome X. (Level of Evidence: B)
2. If no ECGs during chest pain are available and coronary spasm
cannot be ruled out, coronary angiography and provocative testing
with acetylcholine, adenosine, or methacholine and 24-h ambula-
tory ECG may be considered. (Level of Evidence: C)
3. If coronary angiography is performed and does not reveal a cause of
chest discomfort, and if syndrome X is suspected, invasive physio-
logical assessment (i.e., coronary ﬂow reserve measurement) may
be considered. (Level of Evidence: C)
4. Imipramine or aminophylline may be considered in patients with
syndrome X for continued pain despite implementation of Class I
measures. (Level of Evidence: C)
5. Transcutaneous electrical nerve stimulation and spinal cord stimula-
tion for continued pain despite the implementation of Class Imeasures
may be considered for patients with syndrome X. (Level of Evidence: B)
CLASS III
Medical therapy with nitrates, beta blockers, and calcium channel
blockers for patients with noncardiac chest pain is not recommended.
(Level of Evidence: C)
6.8.1. Deﬁnition and Clinical Picture
Cardiovascular “syndrome X” refers to patients with angina
or angina-like discomfort with exercise, ST-segment de-
pression on exercise testing, and normal or nonobstructed
coronary arteries on arteriography (916). This entity should
be differentiated from the metabolic syndrome X (metabolic
syndrome), which describes patients with insulin resistance,
hyperinsulinemia, dyslipidemia, hypertension, and abdom-
inal obesity. It also should be differentiated from noncardiac
chest pain. Syndrome X is more common in women than in
men (679,916–918). Chest pain can vary from that of
typical angina pectoris to chest pain with atypical features to
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chest pain that simulates UA secondary to CAD (917).
Other atypical features can be prolonged chest pain at rest
and chest pain that is unresponsive to NTG (919). Most
often, the chest pain occurs with activity and simulates
angina pectoris due to stable CAD. However, because chest
pain can accelerate in frequency or intensity or may occur at
rest, the patient can present with the clinical picture of UA.
Therefore, this syndrome is discussed in this guideline.
The cause of the discomfort and ST-segment depression
in patients with syndrome X is not well understood. The
most frequently proposed causes are impaired endothelium-
dependent arterial vasodilatation with decreased nitric oxide
production, impaired microvascular dilation (non–
endothelium-dependent), increased sensitivity to sympa-
thetic stimulation, or coronary vasoconstriction in response
to exercise (731,920,921). Increased levels of plasma endo-
thelin correlate with impaired coronary microvascular dila-
tion (922). There is increasing evidence that these patients
frequently also have an increased responsiveness to pain and
an abnormality in pain perception.
The diagnosis of syndrome X is suggested by the triad of
anginal-type chest discomfort, objective evidence of ischemia,
and absence of obstructive CAD. The diagnosis can be
conﬁrmed by provocative coronary angiographic testing with
acetylcholine for coronary endothelium-dependent function
and adenosine for non–endothelium-dependent microvascular
function. Other causes of angina-like chest discomfort not
associated with cardiac disease, such as esophageal dysmotility,
ﬁbromyalgia, and costochondritis, must also be eliminated. In
addition, in patients with a clinical presentation consistent with
variant angina, coronary spasm must be ruled out by the
absence of ST-segment elevation with the anginal discomfort
or by provocative testing. Myocardial perfusion scanning may
be abnormal owing to a patchy abnormal response to exercise
of the microvasculature that can lead to reduced coronary ﬂow
to different regions of the myocardium (731). Magnetic reso-
nance imaging studies also may suggest myocardial ischemia
(923,924).
The intermediate-term prognosis of patients with syn-
drome X has been reported to be excellent in older studies
(917,919,925). The CASS registry reported a 96% 7-year
survival rate in patients with anginal-type chest pain, normal
coronary arteriograms, and an LVEF greater than 0.50
(926). However, testing for ischemia was not performed in
CASS. More recent data from WISE indicate that the
prognosis in syndrome X, validated by ischemia testing, is
not entirely benign with respect to risk of cardiac death and
nonfatal MI (918,919). The WISE data demonstrate that
the prognosis is related to the extent of angiographic disease
across the range of 20% stenosis to obstructive lesions (918).
Long-term follow-up shows that ventricular function usu-
ally remains normal (919), although there have been reports
of progressive LV dysfunction, and many patients continue
to have chest pain that requires medication (927).
Additional data from WISE (733,767–774) suggest adverse
outcomes in some women with myocardial ischemia on non-
invasive testing and nonobstructive CAD. A number of vari-
ables may be contributory. Intramural lesions, evidence of an
atherosclerotic burden, are evident on intravascular ultrasound.
A decrease in coronary ﬂow reserve appears to independently
predict major coronary events. In addition, there is important
coronary endothelial dysfunction that may be related to hor-
monal inﬂuences, inﬂammatory markers, or oxidative stress
and possibly to a clustering of risk factors as is seen in the
metabolic syndrome. Other microvascular dysfunction may be
present. Although half of the WISE women with myocardial
ischemia documented on noninvasive testing had no ﬂow-
limiting coronary obstructive disease at angiography, not only
were there persisting symptoms, but there was a subsequent
signiﬁcant occurrence of coronary events. Evaluation of the
4-year risk-adjusted freedom from death or MI showed that
women with no or minimal obstructive disease had a total rate
of occurrence of these end points of 9.4% by 4 years. Pending
additional data, aggressive coronary risk factor reduction ap-
pears to be appropriate.
6.8.2. Treatment
Persistence of symptoms is common, and many patients do
not return to work (919). The demonstration of normal
coronary arteries on angiography can be reassuring. In 1
study, after a normal coronary arteriogram, there was a
reduced need for hospitalization and a reduction in the
number of hospital days for cardiac reasons (566). However,
even minimal atherosclerotic disease on angiography war-
rants risk factor modiﬁcation.
Both beta blockers and calcium channel blockers have been
found to be effective in reducing the number of episodes of
chest discomfort (928,929). Beneﬁcial effects with nitrates are
seen in approximately one half of patients (930). The use of
alpha-adrenergic blockers would appear to be a rational ther-
apy, but the results of small trials are inconsistent (931).
Imipramine 50 mg daily has been successful in some chronic
pain syndromes, including syndrome X, reducing the frequency
of chest pain by 50% (932). Transcutaneous electrical nerve
stimulation and spinal cord stimulation can offer good pain
control (933,934). Estrogen in postmenopausal women with
angina and normal coronary arteriograms has been shown to
reverse the acetylcholine-induced coronary arterial vasocon-
striction, presumably by improving endothelium-dependent
coronary vasomotion (935), and to reduce the frequency of
chest pain episodes by 50% (936). However, because of
increased cardiovascular and other risks documented in
randomized controlled trials of primary and secondary
coronary prevention, hormone therapy is not recommended
for chronic conditions (29). Statin therapy and exercise
training have improved exercise capacity, endothelial func-
tion, and symptoms (937,938).
It is recommended that patients be reassured of the excellent
intermediate-term prognosis and treated with long-acting
nitrates. If the patient continues to have episodes of chest pain,
a calcium channel blocker or beta blocker can be started (929).
Finally, 50 mg of imipramine daily has been successful in
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reducing the frequency of chest pain episodes (932). Cognitive
behavioral therapy can be beneﬁcial (939). If symptoms persist,
other causes of chest pain, especially esophageal dysmotility,
should be ruled out.
6.9. Takotsubo Cardiomyopathy
A disorder, or group of disorders, with several names
(stress-induced cardiomyopathy, transient LV apical bal-
looning, Takotsubo cardiomyopathy, and broken heart syn-
drome) is an uncommon but increasingly reported cause of
ACS. Takotsubo cardiomyopathy is noteworthy for the
absence of obstructive coronary artery disease, typical pre-
cipitation by intense psychological or emotional stress, and
predominant occurrence in postmenopausal women. The
characteristic ﬁnding of apical LV ballooning is seen on left
ventriculography or echocardiography, with transient ST
elevation or deep T-wave inversions on the surface ECG.
Despite the presence of positive cardiac biomarkers and
frequent hemodynamic compromise or even cardiogenic
shock, almost all patients recover completely, typically with
normal wall motion within 1 to 4 weeks (730,940,941).
7. Conclusions and Future Directions
The last quarter century has witnessed enormous strides in the
understanding of ACS pathophysiology and its management.
These have included the critical role of coronary thrombosis
(942), the novel concept and suggestion of a therapeutic beneﬁt
of reperfusion therapy (943–946), and ﬁnally, the demonstra-
tion of mortality reductions with ﬁbrinolysis in large, multi-
center trials (531a). However, these trials also uncovered the
paradox that ﬁbrinolysis did not beneﬁt or even harmed
NSTEMI patients (531a). This central management dichot-
omy, together with other differences between STEMI and
UA/NSTEMI (13), has been reﬂected since 2000 in separate
practice guidelines. Despite these differences, more remains in
common than distinct, including the discovery that athero-
thrombosis is an active, inﬂammatory process (947,948). Fur-
ther inquiry has led to the concept of the vulnerable plaque and
the vulnerable patient (949,950).
Whereas the incidence and risk of STEMI have de-
creased over the past 25 years, the relative frequency of
UA/NSTEMI has increased, and its risk has remained
relatively high (now comparable to that of STEMI) (951).
Hence, improving UA/NSTEMI outcomes remains a chal-
lenge for the future.
A contemporary multinational observational study has em-
phasized the beneﬁts of applying evidence-based guidelines in
clinical practice (951a). Between 1999 and 2006, 27,558
patients with UA/NSTEMI in 14 countries were enrolled and
followed for 6 months after discharge. Increases over the 7
years of enrollment were observed in the use of interventional
therapy and of major pharmacological therapies, including beta
blockers, statins, ACE inhibitors (or ARBs), low molecular
weight heparin, GP IIb/IIa inhibitors, and thienopyridines.
These changes were accompanied by marked declines (by one
half) in in-hospital rates of heart failure or cardiogenic shock
and recurrent MI and in 6-month rates of death (from 4.9% to
3.3%) and stroke (1.4% to 0.7%). Improved outcomes occurred
despite an increase in patient risk proﬁle. The future should
emphasize further improvements in evidence-based guideline
applications.
Improving prehospital and ED assessment should aim at
more efﬁcient entry into the health care system (e.g., limiting
delays for NTG-refractory angina before calling 9-1-1), diag-
nosis and risk stratiﬁcation (e.g., using marker changes while
they are still in the normal range; in the future, with the aid of
nontraditional biomarkers), and initiation of therapy. The
future will see the increasing use of new imaging tests to assess
the chest pain patient. By simultaneously assessing cardiac
function, perfusion, and viability, CMR can yield a high
sensitivity and speciﬁcity for diagnosis of CAD/ACS (296).
Multislice cardiac computed tomography, which combines
coronary calcium scoring with noninvasive coronary angiogra-
phy (current resolution 0.5mm), has undergone favorable
initial evaluation for assessment of the low- to intermediate-
risk chest pain patient (297). The current status and appropri-
ate application of CMR and cardiac CT are addressed in recent
ACC/AHA documents (25,294).
The concept of a network of “heart attack centers” has
been proposed as a way to improve MI care in the future
(952–954). These heart attack centers would be organized
and certiﬁed to provide the highest levels of care and would
be geographically readily accessible to virtually all patients.
For high-risk patients, the concept of establishing and
maintaining normal levels of myocardial perfusion mechani-
cally continues to gain support, with evidence favoring inter-
vention at even shorter (e.g., less than 6 to 24 h) rather than
longer (i.e., greater than 48 to 96 h) intervals (540). The future
should bring additional important information on this issue.
In contrast, for low-risk patients, evidence is growing that
an initially noninvasive approach may be preferred (e.g.,
PCI shows beneﬁt in high-risk women, as in men, but
carries adverse risk potential in low-risk women) (532,565).
This dependence of therapeutic beneﬁt on disease risk has
also been shown for antiplatelet and anticoagulant therapies.
Hence, there is an increasing need to optimally stratify risk;
some progress has been made (e.g., with the use of biomar-
kers integrated into an overall clinical risk score; see Section
2.2), but further development of risk assessment algorithms
will be welcome in the future.
Platelets play a critical role UA/NSTEMI, and antiplate-
let therapy continues to undergo testing. Higher (e.g., 600
mg or more of clopidogrel) and earlier loading doses of oral
thienopyridine have been tested since the previous guide-
lines were published (see Section 3.2), with evidence of
earlier antiplatelet activity. However, an incremental beneﬁt
of triple-antiplatelet therapy (ASA, GP IIb/ IIIa inhibitor,
and clopidogrel) over double therapy with clopidogrel plus
ASA (without GP IIb/IIIa inhibition) was recently shown
for PCI in the setting of UA/NSTEMI (244).
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Late thrombosis of DES (400,402,403,955), associated with
delayed endothelialization (399,399a), recently has emerged as
a therapeutic issue (401). Thus, longer periods of dual-
antiplatelet therapy (i.e., at least 1 year) increasingly are
advocated (see Section 3.2). Missing is an individualized
approach to antiplatelet management: the future should bring
efﬁcient, validated platelet function testing to allow titration of
the type, intensity, and duration of antiplatelet therapy. More
choices in antiplatelet therapy can be expected, including
intravenously administered and rapidly acting ADP receptor
antagonists and more potent and/or more readily reversible oral
agents. Biocompatible stents can also be expected looking
forward, including biodegradable stents.
Triple-anticoagulant therapy (e.g., ASA, a thienopyri-
dine, and warfarin) increasingly has a potential indication
(e.g., PCI plus atrial ﬁbrillation, cardiac or vascular throm-
bosis, or mechanical heart valve). Its current Class IIb
recommendation (to be used “with caution” [1,2]; Fig. 11) is
in need of a ﬁrmer evidence base (1,2).
Anticoagulant choices have proliferated since the last guide-
lines were published. Although LMWH (e.g., enoxaparin)
gained recognition as an alternative or preferred anticoagulant
in the previous guidelines, subsequent study in the setting of an
early PCI strategy has suggested that either UFH or LWMH
is acceptable (423). Meanwhile, agents from 2 new classes have
been tested favorably (see Section 3.2) (424,425). Fondapa-
rinux, a synthetic factor Xa inhibitor, was noninferior to
enoxaparin at 9 d, with a lower bleeding risk. However,
catheter-related thrombosis with fondaparinux raises concerns
about its use with PCI, a concern ampliﬁed by its failure with
PCI in STEMI (433). In contrast, fondaparinux is an appeal-
ing choice with a noninvasive approach to UA/NSTEMI,
especially in those at higher risk of bleeding.
The ACUITY study, which tested bivalirudin for UA/
NSTEMI, has led to a guidelines change to allow bivaliru-
din as an anticoagulant option (425). Bivalirudin was found
to be noninferior to UFH/LMWH when given with a GP
IIb/IIIa inhibitor. When given without a GP inhibitor,
bleeding rates were lower but ischemic risk was higher
unless clopidogrel therapy had been given before the pro-
cedure. Bivalirudin use was not tested with a conservative
strategy. These guidelines present several options for anti-
coagulant/antiplatelet regimens, but whether there are clear
preferences must await additional analysis and an enriched
evidence base and could vary depending on the health care
setting, the preferred treatment strategy (e.g., invasive vs.
conservative), and individual patient factors.
This guideline revision recognizes ongoing developments
in prevention (see Section 5.1.1). More aggressive LDL-C
lowering (i.e., to the optimal LDL-C goal of less than 70
mg per dL) further reduces cardiovascular events, although
an incremental mortality beneﬁt remains to be shown (956).
An additional tool for smoking cessation has appeared
(varenicline), and others are in testing (see Section 5.2).
High compliance with recommended secondary prevention
measures has been shown to improve outcomes, but optimal
compliance is still lacking, including at hospitals peer-rated
as top tier (957). The evidence base for therapeutic lifestyle
change continues to grow; the challenge for the future is
more successful implementation (see Section 5.2).
Primary prevention remains a major challenge. Risk is
currently assessed by traditional factors (e.g., Framingham
risk score) and the intensity of treatment by risk score-
determined goals. The majority of coronary events occur in
a large segment of the population whose risk is intermediate
(neither very low nor very high). Routine individual screen-
ing for asymptomatic disease is widely accepted for common
cancers (e.g., colon and breast cancer) but not for athero-
sclerosis. Application of an “atherosclerosis test” (e.g., cor-
onary artery calcium scoring or carotid intima-media thick-
ness assessment) to middle-aged adults at intermediate risk
has been proposed (25,294,949,950). The future will deter-
mine how broadly extended primary screening will be
accepted to identify the “ACS-vulnerable” patient.
Progress in UA/NSTEMI remains uneven, with rapid
evolution in some areas but slow progress in others. Our hope
is that guidelines increasingly become based on levels of
evidence A (or B). Writing these guidelines has highlighted
the many holes in the fabric of the current evidence base.
Academia, regulatory agencies, practicing physicians, profes-
sional organizations, and patient advocacy groups, as well as
industry, must cooperate to achieve the universal goal of a fully
evidence-based management strategy for UA/NSTEMI in the
future. Strategies must include not only innovations in diag-
nosis and treatment but also fresh approaches to motivating
lifestyle changes, leading to improved diet, weight control,
physical activity, and tobacco avoidance, as well as to better
compliance with evidence-based medical therapies (380).
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APPENDIX 3. ABBREVIATIONS
AAFP American Academy of Family Physicians
ACC American College of Cardiology
ACCF American College of Cardiology Foundation
ACE angiotensin converting enzyme
ACEP American College of Emergency Physicians
ACP American College of Physicians
ACS acute coronary syndrome
ACT activated clotting time
ACUITY Acute Catheterization and Urgent Intervention Triage strategy
AHA American Heart Association
AMI acute myocardial infarction
aPTT activated partial thromboplastin time
ARTS Arterial Revascularization Therapy Study
ASA aspirin
AST, SGOT aspartate aminotransferase
AV atrioventricular
BARI Bypass Angioplasty Revascularization Investigation
BNP B-type natriuretic peptide
CABG coronary artery bypass graft
CABRI Coronary Angioplasty versus Bypass Revascularization Investigation
CAD coronary artery disease
CAPTURE c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina trial
CASS Coronary Artery Surgery Study
CCB calcium channel blocker
CCTA coronary computed tomographic angiogram
CHD coronary heart disease
CI conﬁdence interval
CKD chronic kidney disease
CK-MB creatine kinase-myocardial band
CMR cardiac magnetic resonance
COMMIT CIOpidogrel and Metoprolol in Myocardial Infarction Trial
COX cyclooxygenase
CPR cardiopulmonary resuscitation
CREDO Clopidogrel for the Reduction of Events During Observation trial
CRP C-reactive protein
CT computed tomography
cTn cardiac troponin
CURE Clopidogrel in Unstable Angina to Prevent Recurrent Events trial
CVD cardiovascular disease
d day
DAVIT Danish Study Group on Verapamil in Myocardial Infarction
DES drug-eluting stent
DIGAMI Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction
ECG electrocardiogram
ED emergency department
EMS emergency medical services
EPIC Evaluation of c7E3 for the Prevention of Ischemic Complications
EPILOG Evaluation of PTCA and Improve Long-term Outcome by c7E3 GP IIb/IIIa receptor blockade
EPISTENT Evaluation of Platelet IIb/IIIa Inhibitor for STENTing
ERACI-II Estudio Randomizado Argentino de Angioplastia vs. Clrugia-II
ESC European Society of Cardiology
ESSENCE Efﬁcacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q Wave Myocaridal Infarction trial
FRIC FRagmin In ustable Coronary artery disease
FRISC Fast Revascularization During Instability in Coronary Artery Disease
FRISC-II Fast Revascularization During Instability in Coronary Artery Disease-II
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APPENDIX 3. Continued
GISSI Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto-1 1 trial
GISSI-3 Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico
GP glycoprotein
GRACE Global Registry of Acute Coronary Events
GUSTO Global Utilization of Streptokinase and t-PA for Occluded Arteries
GUSTO-II Global Use of Strategies to Open Occluded Coronary Arteries II
h hour
Hb hemoglobin
HDL-C high-density lipoprotein cholesterol
HF heart failure
HOPE Heart Outcomes Prevention Evaluation Study
HR hazard ratio
IABP intra-aortic balloon pump
ICTUS Invasive versus Conservative Treatment in Unstable coronary Syndromes
ICU intensive care unit
IPT interpersonal psychotherapy
INR international normalized ratio
ISAR-REACT Intracoronary stenting and Antithrombotic Regimen- Rapid Early Action for Coronary Treatment
ISIS-2 Second International Study of Infarct Survival
ISIS-4 Fourth International Study of Infarct Survival
IU international unit
IV intravenous
JNC 7 Seventh Joint National Committee on High Blood Pressure
kg kilogram
LAD left anterior descending coronary artery
LDL-C low-density lipoprotein choloesterol
LMWH low-molecular-weight heparin
LV left ventricular
LVEF left ventricular ejection fraction
MASS II Multicenter Anti Atherosclerotic Study II
MATE Medicine versus Angiography in Thrombolytic Exclusion
MDPIT Multicenter Diltiazem Postinfarction Trial
MDRD Modiﬁcation of Diet and Renal Disease
METS metabolic equivalents
MI myocardial infarction
MVO2 myocardial oxygen demand
NCEP National Cholesterol Education Program
NHLBI National Heart, Lung, and Blood Institute
NS nonsigniﬁcant
NSTEMI non–ST-segment elevation myocardial infarction
NTG nitroglycerin
NT-proBNP N-terminal B-type natriuretic peptide
OASIS Organization to Assess Strategies for Ischemic Syndromes
OR odds ratio
PCI percutaneous coronary intervention
PDA personal digital assistant
PRISM Platelet Receptor Inhibition in Ischemic Syndrome Management
PRISM-PLUS Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms
PTCA percutaneous transluminal coronary angioplasty
PURSUIT Platelet Glycoprotein IIb/IIIa in Unstable 16 Angina: Receptor Suppression Using Integrilin Therapy
REACT Rapid Early Action for Coronary Treatment
REPLACE-2 Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events
RITA Research Group in Instability in Coronary Artery Disease trial
RR risk ratio
SaO2 arterial oxygen saturation
SC subcutaneous
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APPENDIX 3. Continued
SCAI Society for Cardiovascular Angiography and Interventions
SHOCK SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK study
SoS Stent or Surgery
STEMI ST-elevation myocardial infarction
STS Society of Thoracic Surgeons
SVG saphenous vein graft
SYNERGY Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors trial
TACTICS-TIMI 18 Treat Angina with Aggrastat and determine Cost of therapy with Invasive or Conservative Strategy (TACTICS) TIMI-18 trial
TARGET Do Tiroﬁban and ReoPro Give Similar Efﬁcacy Outcomes Trial
TIMI Thrombolysis In Myocardial Infarction
TnI troponin I
TnT troponin T
U units
UA unstable angina
UA/NSTEMI unstable angina/non–ST-elevation myocardial infarction
UFH unfractionated heparin
VANQWISH Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital
VINO Value of ﬁrst day angiography/angioplasty In evolving Non-ST-Segment elevation myocardial infarction: Open
randomized trial
WISE Women’s Ischemia Syndrome Evaluation
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